[
  {
    "spl_product_data_elements": [
      "Eptifibatide Eptifibatide EPTIFIBATIDE EPTIFIBATIDE CITRIC ACID MONOHYDRATE SODIUM HYDROXIDE WATER Eptifibatide Eptifibatide EPTIFIBATIDE EPTIFIBATIDE CITRIC ACID MONOHYDRATE SODIUM HYDROXIDE WATER Eptifibatide Eptifibatide EPTIFIBATIDE EPTIFIBATIDE CITRIC ACID MONOHYDRATE SODIUM HYDROXIDE WATER"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Eptifibatide injection is a platelet aggregation inhibitor indicated for: Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI) (1.1) Treatment of patients undergoing PCI (including intracoronary stenting) (1.2) 1.1 Acute Coronary Syndrome (ACS) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). 1.2 Percutaneous Coronary Intervention (PCI) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting [see Clinical Studies (14.1, 14.2) ] ."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION Before infusion of eptifibatide, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured. The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT. ACS or PCI: 180 mcg/kg I.V. bolus as soon as possible after diagnosis followed by infusion at 2 mcg/kg/min. (2.1 , 2.2) PCI: Add a second 180 mcg/kg bolus at 10 minutes. (2.2) In patients with creatinine clearance less than 50 mL/min, reduce the infusion to 1 mcg/kg/min. ( 2.1 , 2.2 , 2.3 ) 2.1 Dosage in Acute Coronary Syndrome (ACS) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with ACS 180 mcg/kg intravenous (I.V.) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min 180 mcg/kg I.V. bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy Aspirin, 160 to 325 mg, should be given daily Eptifibatide injection should be given concomitantly with heparin dosed to achieve the following parameters: During Medical Management : Target aPTT 50 to 70 seconds If weight greater than or equal to 70 kg, 5,000 units bolus followed by infusion of 1,000 units/h. If weight less than 70 kg, 60 units/kg bolus followed by infusion of 12 units/kg/h. During PCI : Target ACT 200 to 300 seconds If heparin is initiated prior to PCI, additional boluses during PCI to maintain an ACT target of 200 to 300 seconds. Heparin infusion after the PCI is discouraged. 2.2 Dosage in Percutaneous Coronary Intervention (PCI) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with PCI 180 mcg/kg I.V. bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) 180 mcg/kg I.V. bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. In patients who undergo CABG surgery, eptifibatide infusion should be discontinued prior to surgery. Aspirin, 160 to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter. Eptifibatide injection should be given concomitantly with heparin to achieve a target ACT of 200 to 300 seconds. Administer 60 units/kg bolus initially in patients not treated with heparin within 6 hours prior to PCI. Additional boluses during PCI to maintain ACT within target. Heparin infusion after the PCI is strongly discouraged. Patients requiring thrombolytic therapy should discontinue eptifibatide injection. 2.3 Important Administration Instructions Inspect eptifibatide injection for particulate matter and discoloration prior to administration, whenever solution and container permit. May administer eptifibatide injection in the same intravenous line as alteplase, atropine, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, or verapamil. Do not administer eptifibatide injection through the same intravenous line as furosemide. May administer eptifibatide injection in the same I.V. line with 0.9% NaCl or 0.9% NaCl/5% dextrose. With either vehicle, the infusion may also contain up to 60 mEq/L of potassium chloride. Withdraw the bolus dose(s) of eptifibatide injection from the 10 mL vial into a syringe. Administer the bolus dose(s) by I.V. push. Immediately following the bolus dose administration, initiate a continuous infusion of eptifibatide. When using an intravenous infusion pump, administer eptifibatide injection undiluted directly from the 100 mL vial. Spike the 100 mL vial with a vented infusion set. Center the spike within the circle on the stopper top. Discard any unused portion left in the vial. Administer eptifibatide injection by volume according to patient weight (see Table 1). Table 1: Eptifibatide Injection Dosing Charts by Weight Patient Weight 180 mcg/kg Bolus Volume 2 mcg/kg/min Infusion Volume (CrCl greater than or equal to 50 mL/min) 1 mcg/kg/min Infusion Volume (CrCl less than 50 mL/min) (kg) (lb) (from 2 mg/mL vial) (from 2 mg/mL 100 mL vial) (from 0.75 mg/mL 100 mL vial) (from 2 mg/mL 100 mL vial) (from 0.75 mg/mL 100 mL vial) 37 to 41 81 to 91 3.4 mL 2 mL/h 6 mL/h 1 mL/h 3 mL/h 42 to 46 92 to 102 4 mL 2.5 mL/h 7 mL/h 1.3 mL/h 3.5 mL/h 47 to 53 103 to 117 4.5 mL 3 mL/h 8 mL/h 1.5 mL/h 4 mL/h 54 to 59 118 to 130 5 mL 3.5 mL/h 9 mL/h 1.8 mL/h 4.5 mL/h 60 to 65 131 to 143 5.6 mL 3.8 mL/h 10 mL/h 1.9 mL/h 5 mL/h 66 to 71 144 to 157 6.2 mL 4 mL/h 11 mL/h 2 mL/h 5.5 mL/h 72 to 78 158 to 172 6.8 mL 4.5 mL/h 12 mL/h 2.3 mL/h 6 mL/h 79 to 84 173 to 185 7.3 mL 5 mL/h 13 mL/h 2.5 mL/h 6.5 mL/h 85 to 90 186 to 198 7.9 mL 5.3 mL/h 14 mL/h 2.7 mL/h 7 mL/h 91 to 96 199 to 212 8.5 mL 5.6 mL/h 15 mL/h 2.8 mL/h 7.5 mL/h 97 to 103 213 to 227 9 mL 6 mL/h 16 mL/h 3 mL/h 8 mL/h 104 to 109 228 to 240 9.5 mL 6.4 mL/h 17 mL/h 3.2 mL/h 8.5 mL/h 110 to 115 241 to 253 10.2 mL 6.8 mL/h 18 mL/h 3.4 mL/h 9 mL/h 116 to 121 254 to 267 10.7 mL 7 mL/h 19 mL/h 3.5 mL/h 9.5 mL/h >121 >267 11.3 mL 7.5 mL/h 20 mL/h 3.7 mL/h 10 mL/h"
    ],
    "dosage_and_administration_table": [
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"14%\"/><col width=\"39%\"/><col width=\"46%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Indication</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Normal Renal Function</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Creatinine Clearance less than 50 mL/min</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Patients with ACS </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"top\">180 mcg/kg intravenous (I.V.) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"top\">180 mcg/kg I.V. bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">  </td><td styleCode=\"Rrule\" colspan=\"2\" valign=\"top\"><list listType=\"unordered\" styleCode=\"disc\"><item>Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours</item><item>If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy</item><item>Aspirin, 160 to 325 mg, should be given daily</item></list></td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup><col width=\"13%\"/><col width=\"38%\"/><col width=\"48%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Indication</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Normal Renal Function</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Creatinine Clearance less than 50 mL/min</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Patients with PCI </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"top\">180 mcg/kg I.V. bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"top\">180 mcg/kg I.V. bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">  </td><td styleCode=\"Rrule\" colspan=\"2\" valign=\"top\"><list listType=\"unordered\" styleCode=\"disc\"><item>Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended.</item><item>In patients who undergo CABG surgery, eptifibatide infusion should be discontinued prior to surgery.</item><item>Aspirin, 160 to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter.</item></list></td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><caption>Table 1: Eptifibatide Injection Dosing Charts by Weight </caption><colgroup><col width=\"14.28%\"/><col width=\"14.28%\"/><col width=\"14.28%\"/><col width=\"14.28%\"/><col width=\"14.28%\"/><col width=\"14.28%\"/><col width=\"14.28%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"2\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Patient Weight</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">180 mcg/kg  Bolus Volume</content> </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">2 mcg/kg/min  Infusion Volume  (CrCl greater than or equal to 50 mL/min)</content> </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">1 mcg/kg/min  Infusion Volume  (CrCl less than 50 mL/min)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">(kg)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">(lb)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">(from 2 mg/mL  vial)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">(from 2 mg/mL  100 mL vial)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">(from 0.75 mg/mL  100 mL vial)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">(from 2 mg/mL  100 mL vial)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">(from 0.75 mg/mL  100 mL vial)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"> 37 to 41  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"> 81 to 91  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">3.4 mL </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">2 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">6 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">3 mL/h </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"> 42 to 46  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"> 92 to 102  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">4 mL </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">2.5 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">7 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1.3 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">3.5 mL/h </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"> 47 to 53  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"> 103 to 117  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">4.5 mL </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">3 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">8 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1.5 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">4 mL/h </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"> 54 to 59  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"> 118 to 130  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">5 mL </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">3.5 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">9 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1.8 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">4.5 mL/h </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"> 60 to 65  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"> 131 to 143  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">5.6 mL </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">3.8 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">10 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1.9 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">5 mL/h </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"> 66 to 71  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"> 144 to 157  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">6.2 mL </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">4 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">11 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">2 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">5.5 mL/h </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"> 72 to 78  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"> 158 to 172  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">6.8 mL </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">4.5 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">12 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">2.3 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">6 mL/h </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"> 79 to 84  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"> 173 to 185  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">7.3 mL </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">5 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">13 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">2.5 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">6.5 mL/h </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"> 85 to 90  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"> 186 to 198  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">7.9 mL </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">5.3 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">14 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">2.7 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">7 mL/h </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"> 91 to 96  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"> 199 to 212  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">8.5 mL </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">5.6 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">15 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">2.8 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">7.5 mL/h </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"> 97 to 103  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"> 213 to 227  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">9 mL </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">6 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">16 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">3 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">8 mL/h </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"> 104 to 109  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"> 228 to 240  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">9.5 mL </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">6.4 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">17 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">3.2 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">8.5 mL/h </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"> 110 to 115  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"> 241 to 253  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">10.2 mL </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">6.8 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">18 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">3.4 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">9 mL/h </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"> 116 to 121  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"> 254 to 267  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">10.7 mL </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">7 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">19 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">3.5 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">9.5 mL/h </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"> &gt;121  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"> &gt;267  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">11.3 mL </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">7.5 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">20 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">3.7 mL/h </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">10 mL/h </td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Injection: 20 mg of eptifibatide injection in 10 mL (2 mg/mL), for intravenous bolus. Injection: 75 mg of eptifibatide injection in 100 mL (0.75 mg/mL), for intravenous infusion. Injection: 200 mg of eptifibatide injection in 100 mL (2 mg/mL), for intravenous infusion. 20 mg/10 mL (2 mg/mL) in a single-dose vial for bolus injection (3) 75 mg/100 mL (0.75 mg/mL) in a single-dose vial for infusion (3) 200 mg/100 mL (2 mg/mL) in a single-dose vial for infusion (3)"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Treatment with eptifibatide injection is contraindicated in patients with: A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another parenteral GP IIb/IIIa inhibitor Dependency on renal dialysis Hypersensitivity to eptifibatide injection or any component of the product (hypersensitivity reactions that occurred included anaphylaxis and urticaria) Bleeding diathesis or bleeding within the previous 30 days (4) Severe uncontrolled hypertension (4) Major surgery within the preceding 6 weeks (4) Stroke within 30 days or any history of hemorrhagic stroke (4) Coadministration of another parenteral GP IIb/IIIa inhibitor (4) Dependency on renal dialysis (4) Known hypersensitivity to any component of the product (4)"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Eptifibatide can cause serious bleeding. If bleeding cannot be controlled, discontinue eptifibatide immediately. Minimize vascular and other traumas. If heparin is given concomitantly, monitor aPTT or ACT. (5.1) Thrombocytopenia: Discontinue eptifibatide and heparin. Monitor and treat condition appropriately. (5.2) 5.1 Bleeding Bleeding is the most common complication encountered during eptifibatide therapy. Administration of eptifibatide is associated with an increase in major and minor bleeding, as classified by the criteria of the Thrombolysis in Myocardial Infarction Study group (TIMI) [see Adverse Reactions (6.1) ] . Most major bleeding associated with eptifibatide has been at the arterial access site for cardiac catheterization or from the gastrointestinal or genitourinary tract. Minimize the use of arterial and venous punctures, intramuscular injections, and the use of urinary catheters, nasotracheal intubation, and nasogastric tubes. When obtaining intravenous access, avoid non-compressible sites (e.g., subclavian or jugular veins). Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Risk factors for bleeding include older age, a history of bleeding disorders, and concomitant use of drugs that increase the risk of bleeding (thrombolytics, oral anticoagulants, nonsteroidal anti-inflammatory drugs, and P2Y 12 inhibitors). Concomitant treatment with other inhibitors of platelet receptor glycoprotein (GP) IIb/IIIa should be avoided. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT [see Dosage and Administration (2) ] . Care of the Femoral Artery Access Site in Patients Undergoing Percutaneous Coronary Intervention (PCI) In patients undergoing PCI, treatment with eptifibatide is associated with an increase in major and minor bleeding at the site of arterial sheath placement. After PCI, eptifibatide infusion should be continued until hospital discharge or up to 18 to 24 hours, whichever comes first. Heparin use is discouraged after the PCI procedure. Early sheath removal is encouraged while eptifibatide is being infused. Prior to removing the sheath, it is recommended that heparin be discontinued for 3 to 4 hours and an aPTT of <45 seconds or ACT <150 seconds be achieved. In any case, both heparin and eptifibatide should be discontinued and sheath hemostasis should be achieved at least 2 to 4 hours before hospital discharge. If bleeding at access site cannot be controlled with pressure, infusion of eptifibatide and heparin should be discontinued immediately. 5.2 Thrombocytopenia There have been reports of acute, profound thrombocytopenia (immune-mediated and non-immune mediated) with eptifibatide. In the event of acute profound thrombocytopenia or a confirmed platelet decrease to <100,000/mm 3 , discontinue eptifibatide and heparin (unfractionated or low-molecular weight). Monitor serial platelet counts, assess the presence of drug-dependent antibodies, and treat as appropriate [see Adverse Reactions (6.1) ] . There has been no clinical experience with eptifibatide initiated in patients with a baseline platelet count <100,000/mm 3 . If a patient with low platelet counts is receiving eptifibatide, their platelet count should be monitored closely."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reaction is also discussed elsewhere in the labeling: Bleeding [see Contraindications (4) and Warnings and Precautions (5.1) ] Bleeding and hypotension are the most commonly reported adverse reactions. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Eugia US LLC at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. A total of 16,782 patients were treated in the Phase III clinical trials (PURSUIT, ESPRIT, and IMPACT II) [see Clinical Studies (14) ] . These 16,782 patients had a mean age of 62 years (range: 20 to 94 years). Eighty-nine percent of the patients were Caucasian, with the remainder being predominantly Black (5%) and Hispanic (5%). Sixty-eight percent were men. Because of the different regimens used in PURSUIT, IMPACT II, and ESPRIT, data from the 3 studies were not pooled. Bleeding and hypotension were the most commonly reported adverse reactions (incidence \u22655% and greater than placebo) in the eptifibatide controlled clinical trial database. Bleeding The incidence of bleeding and transfusions in the PURSUIT and ESPRIT studies are shown in Table 2. Bleeding was classified as major or minor by the criteria of the TIMI study group. Major bleeding consisted of intracranial hemorrhage and other bleeding that led to decreases in hemoglobin greater than 5 g/dL. Minor bleeding included spontaneous gross hematuria, spontaneous hematemesis, other observed blood loss with a hemoglobin decrease of more than 3 g/dL, and other hemoglobin decreases that were greater than 4 g/dL but less than 5 g/dL. In patients who received transfusions, the corresponding loss in hemoglobin was estimated through an adaptation of the method of Landefeld et al. Table 2: Bleeding and Transfusions in the PURSUIT and ESPRIT Studies Note: Denominator is based on patients for whom data are available. * For major and minor bleeding, patients are counted only once according to the most severe classification. \u2020 Includes transfusions of whole blood, packed red blood cells, fresh frozen plasma, cryoprecipitate, platelets, and autotransfusion during the initial hospitalization. PURSUIT (ACS) Placebo n (%) Eptifibatide 180/2 n (%) Patients 4696 4679 Major bleeding * 425 (9.3%) 498 (10.8%) Minor bleeding * 347 (7.6%) 604 (13.1%) Requiring transfusions \u2020 490 (10.4%) 601 (12.8%) ESPRIT (PCI) Placebo n (%) Eptifibatide 180/2/180 n (%) Patients 1024 1040 Major bleeding * 4 (0.4%) 13 (1.3%) Minor bleeding * 18 (2%) 29 (3%) Requiring transfusions \u2020 11 (1.1%) 16 (1.5%) The majority of major bleeding reactions in the ESPRIT study occurred at the vascular access site (1 and 8 patients, or 0.1% and 0.8% in the placebo and eptifibatide groups, respectively). Bleeding at \u201cother\u201d locations occurred in 0.2% and 0.4% of patients, respectively. In the PURSUIT study, the greatest increase in major bleeding in eptifibatide-treated patients compared to placebo-treated patients was also associated with bleeding at the femoral artery access site (2.8% versus 1.3%). Oropharyngeal (primarily gingival), genitourinary, gastrointestinal, and retroperitoneal bleeding were also seen more commonly in eptifibatide-treated patients compared to placebo-treated patients. Among patients experiencing a major bleed in the IMPACT II study, an increase in bleeding on eptifibatide versus placebo was observed only for the femoral artery access site (3.2% versus 2.8%). Table 3 displays the incidence of TIMI major bleeding according to the cardiac procedures carried out in the PURSUIT study. The most common bleeding complications were related to cardiac revascularization (CABG-related or femoral artery access site bleeding). A corresponding table for ESPRIT is not presented, as every patient underwent PCI in the ESPRIT study and only 11 patients underwent CABG. Table 3: Major Bleeding by Procedures in the PURSUIT Study Note: Denominators are based on the total number of patients whose TIMI classification was resolved. Placebo n (%) Eptifibatide 180/2 n (%) Patients 4577 4604 Overall incidence of major bleeding 425 (9.3%) 498 (10.8%) Breakdown by procedure: CABG 375 (8.2%) 377 (8.2%) Angioplasty without CABG 27 (0.6%) 64 (1.4%) Angiography without angioplasty or CABG 11 (0.2%) 29 (0.6%) Medical therapy only 12 (0.3%) 28 (0.6%) In the PURSUIT and ESPRIT studies, the risk of major bleeding with eptifibatide increased as patient weight decreased. This relationship was most apparent for patients weighing less than 70 kg. Bleeding resulting in discontinuation of the study drug was more frequent among patients receiving eptifibatide than placebo (4.6% versus 0.9% in ESPRIT, 8% versus 1% in PURSUIT, 3.5% versus 1.9% in IMPACT II). Intracranial Hemorrhage and Stroke Intracranial hemorrhage was rare in the PURSUIT, IMPACT II, and ESPRIT clinical studies. In the PURSUIT study, 3 patients in the placebo group, 1 patient in the group treated with eptifibatide 180/1.3, and 5 patients in the group treated with eptifibatide 180/2 experienced a hemorrhagic stroke. The overall incidence of stroke was 0.5% in patients receiving eptifibatide 180/1.3, 0.7% in patients receiving eptifibatide 180/2, and 0.8% in placebo patients. In the IMPACT II study, intracranial hemorrhage was experienced by 1 patient treated with eptifibatide 135/0.5, 2 patients treated with eptifibatide 135/0.75, and 2 patients in the placebo group. The overall incidence of stroke was 0.5% in patients receiving 135/0.5 eptifibatide, 0.7% in patients receiving eptifibatide 135/0.75, and 0.7% in the placebo group. In the ESPRIT study, there were 3 hemorrhagic strokes, 1 in the placebo group and 2 in the eptifibatide group. In addition there was 1 case of cerebral infarction in the eptifibatide group. Immunogenicity/Thrombocytopenia The potential for development of antibodies to eptifibatide has been studied in 433 subjects. Eptifibatide was nonantigenic in 412 patients receiving a single administration of eptifibatide (135 mcg/kg bolus followed by a continuous infusion of either 0.5 mcg/kg/min or 0.75 mcg/kg/min), and in 21 subjects to whom eptifibatide (135 mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min) was administered twice, 28 days apart. In both cases, plasma for antibody detection was collected approximately 30 days after each dose. The development of antibodies to eptifibatide at higher doses has not been evaluated. In patients with suspected eptifibatide-related immune-mediated thrombocytopenia, IgG antibodies that react with the GP IIb/IIIa complex were identified in the presence of eptifibatide and in eptifibatide-na\u00efve patients. These findings suggest acute thrombocytopenia after the administration of eptifibatide can develop as a result of naturally occurring drug-dependent antibodies or those induced by prior exposure to eptifibatide. Similar antibodies were identified with other GP IIb/IIIa ligand-mimetic agents. Immune-mediated thrombocytopenia with eptifibatide may be associated with hypotension and/or other signs of hypersensitivity. In the PURSUIT and IMPACT II studies, the incidence of thrombocytopenia (<100,000/mm 3 or \u226550% reduction from baseline) and the incidence of platelet transfusions were similar between patients treated with eptifibatide and placebo. In the ESPRIT study, the incidence was 0.6% in the placebo group and 1.2% in the eptifibatide group. Other Adverse Reactions In the PURSUIT and ESPRIT studies, the incidence of serious nonbleeding adverse reactions was similar in patients receiving placebo or eptifibatide (19% and 19%, respectively, in PURSUIT; 6% and 7%, respectively, in ESPRIT). In PURSUIT, the only serious nonbleeding adverse reaction that occurred at a rate of at least 1% and was more common with eptifibatide than placebo (7% versus 6%) was hypotension. Most of the serious nonbleeding adverse reactions consisted of cardiovascular reactions typical of a UA population. In the IMPACT II study, serious nonbleeding adverse reactions that occurred in greater than 1% of patients were uncommon and similar in incidence between placebo- and eptifibatide-treated patients. Discontinuation of study drug due to adverse reactions other than bleeding was uncommon in the PURSUIT, IMPACT II, and ESPRIT studies, with no single reaction occurring in >0.5% of the study population (except for \"other\" in the ESPRIT study). 6.2 Postmarketing Experience The following adverse reactions have been reported in post-approval use of eptifibatide in combination with heparin and aspirin. Because the reactions below are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure: cerebral, GI, and pulmonary hemorrhage. Fatal bleeding reactions have been reported. Acute profound thrombocytopenia, as well as immune-mediated thrombocytopenia, have been reported [see Adverse Reactions (6.1) ] ."
    ],
    "adverse_reactions_table": [
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><caption>Table 2: Bleeding and Transfusions in the PURSUIT and ESPRIT Studies </caption><colgroup><col width=\"33.34%\"/><col width=\"33.34%\"/><col width=\"33.34%\"/></colgroup><tfoot><tr><td colspan=\"3\">Note: Denominator is based on patients for whom data are available. <sup>*</sup> For major and minor bleeding, patients are counted only once according to the most severe classification. <sup>&#x2020;</sup> Includes transfusions of whole blood, packed red blood cells, fresh frozen plasma, cryoprecipitate, platelets, and autotransfusion during the initial hospitalization. </td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">PURSUIT (ACS)</content> <content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">n (%)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Eptifibatide</content><content styleCode=\"bold\"/> <content styleCode=\"bold\"> 180/2</content> <content styleCode=\"bold\">n (%)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Patients </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">4696 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">4679 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Major bleeding<sup>*</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">425 (9.3%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">498 (10.8%) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Minor bleeding<sup>*</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">347 (7.6%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">604 (13.1%) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Requiring transfusions<sup>&#x2020;</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">490 (10.4%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">601 (12.8%) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">ESPRIT (PCI)</content> <content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">n (%)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Eptifibatide</content><content styleCode=\"bold\"/> <content styleCode=\"bold\"> 180/2/180</content> <content styleCode=\"bold\">n (%)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Patients </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">1024 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">1040 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Major bleeding<sup>*</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">4 (0.4%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">13 (1.3%) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Minor bleeding<sup>*</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">18 (2%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">29 (3%) </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"> Requiring transfusions<sup>&#x2020;</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">11 (1.1%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">16 (1.5%) </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><caption>Table 3: Major Bleeding by Procedures in the PURSUIT Study </caption><colgroup><col width=\"58.9%\"/><col width=\"18.3%\"/><col width=\"22.8%\"/></colgroup><tfoot><tr><td colspan=\"3\">Note: Denominators are based on the total number of patients whose TIMI classification was resolved.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">n (%)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">180/2</content> <content styleCode=\"bold\">n (%)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Patients </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">4577 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">4604 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Overall incidence of major bleeding </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">425 (9.3%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">498 (10.8%) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Breakdown by procedure: </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">CABG </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">375 (8.2%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">377 (8.2%) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Angioplasty without CABG </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">27 (0.6%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">64 (1.4%) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Angiography without angioplasty or CABG </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">11 (0.2%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">29 (0.6%) </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"middle\">Medical therapy only </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">12 (0.3%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">28 (0.6%) </td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Avoid concomitant use with other glycoprotein (GP) IIb/IIIa inhibitors. (7.1) 7.1 Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Concomitant treatment with other inhibitors of platelet receptor GP IIb/IIIa should be avoided."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Geriatric Use: Risk of bleeding increases with age. (8.5) 8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus (see Clinical Considerations) . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide on the fetus Data Animal Data Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide. 8.2 Lactation Risk Summary There are no available data on the presence of eptifibatide in human milk, the effects on the breastfed infant, or the effects on milk production. As eptifibatide is a peptide, it is likely to be destroyed in the infant\u2019s gastrointestinal tract and not absorbed orally by the breastfed infant. 8.4 Pediatric Use Safety and effectiveness of eptifibatide in pediatric patients have not been studied. 8.5 Geriatric Use The PURSUIT and IMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUIT study; no such limitation was stipulated in the ESPRIT study [see Adverse Reactions (6.1) ] . 8.6 Renal Impairment Approximately 50% of eptifibatide is cleared by the kidney in patients with normal renal function. Total drug clearance is decreased by approximately 50% and steady-state plasma eptifibatide concentrations are doubled in patients with an estimated CrCl <50 mL/min (using the Cockcroft-Gault equation). Therefore, the infusion dose should be reduced to 1 mcg/kg/min in such patients [see Dosage and Administration (2) ] . The safety and efficacy of eptifibatide in patients dependent on dialysis has not been established."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus (see Clinical Considerations) . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide on the fetus Data Animal Data Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide."
    ],
    "labor_and_delivery": [
      "8.2 Lactation Risk Summary There are no available data on the presence of eptifibatide in human milk, the effects on the breastfed infant, or the effects on milk production. As eptifibatide is a peptide, it is likely to be destroyed in the infant\u2019s gastrointestinal tract and not absorbed orally by the breastfed infant."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety and effectiveness of eptifibatide in pediatric patients have not been studied."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use The PURSUIT and IMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUIT study; no such limitation was stipulated in the ESPRIT study [see Adverse Reactions (6.1) ] ."
    ],
    "overdosage": [
      "10 OVERDOSAGE There has been only limited experience with overdosage of eptifibatide. There were 8 patients in the IMPACT II study, 9 patients in the PURSUIT study, and no patients in the ESPRIT study who received bolus doses and/or infusion doses more than double those called for in the protocols. None of these patients experienced an intracranial bleed or other major bleeding. Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis). Symptoms of acute toxicity were loss of righting reflex, dyspnea, ptosis, and decreased muscle tone in rabbits and petechial hemorrhages in the femoral and abdominal areas of monkeys. From in vitro studies, eptifibatide is not extensively bound to plasma proteins and thus may be cleared from plasma by dialysis."
    ],
    "description": [
      "11 DESCRIPTION Eptifibatide is a cyclic heptapeptide containing 6 amino acids and 1 mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties. Chemically it is N 6 -(aminoiminomethyl)-N 2 -(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-\u03b1-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1\u21926)-disulfide. Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation. The eptifibatide peptide is produced by solution-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized. Eptifibatide is a white to off-white powder. The structural formula is: Eptifibatide injection is a clear, colorless, sterile, non-pyrogenic solution free from visible particles for intravenous (I.V.) use with a molecular formula of C 35 H 49 N 11 O 9 S 2 and a molecular weight of 831.96. Each 10 mL vial contains 2 mg/mL of eptifibatide and each 100 mL vial contains either 0.75 mg/mL of eptifibatide or 2 mg/mL of eptifibatide. Each vial of either size also contains 5.25 mg/mL citric acid and sodium hydroxide to adjust the pH to 5.35. Eptifibatide Chemical Structure"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet. 12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide was observed immediately after administration of a 180 mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide used in the IMPACT II and PURSUIT studies on ex vivo platelet aggregation induced by 20 \u00b5M ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRIT on platelet aggregation have not been studied. Table 4: Platelet Inhibition and Bleeding Time * 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. PURSUIT 180/2 * Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x The eptifibatide dosing regimen used in the ESPRIT study included two 180 mcg/kg bolus doses given 10 minutes apart combined with a continuous 2 mcg/kg/min infusion. When administered alone, eptifibatide has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed. 12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180 mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4 to 6 hours). This decline can be prevented by administering a second 180 mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20 to 94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations (8.6) and Dosage and Administration (2) ] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "clinical_pharmacology_table": [
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><caption>Table 4: Platelet Inhibition and Bleeding Time </caption><colgroup><col width=\"80.1%\"/><col width=\"19.9%\"/></colgroup><tfoot><tr><td colspan=\"2\"><sup>*</sup>180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">PURSUIT</content> <content styleCode=\"bold\">180/2<sup>*</sup></content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> Inhibition of platelet aggregation 15 min after bolus </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">84% </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> Inhibition of platelet aggregation at steady state </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">&gt;90% </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> Bleeding-time prolongation at steady state </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">&lt;5x </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> Inhibition of platelet aggregation 4h after infusion discontinuation </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">&lt;50% </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> Bleeding-time prolongation 6h after infusion discontinuation </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1.4x </td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide was observed immediately after administration of a 180 mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide used in the IMPACT II and PURSUIT studies on ex vivo platelet aggregation induced by 20 \u00b5M ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRIT on platelet aggregation have not been studied. Table 4: Platelet Inhibition and Bleeding Time * 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. PURSUIT 180/2 * Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x The eptifibatide dosing regimen used in the ESPRIT study included two 180 mcg/kg bolus doses given 10 minutes apart combined with a continuous 2 mcg/kg/min infusion. When administered alone, eptifibatide has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed."
    ],
    "pharmacodynamics_table": [
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><caption>Table 4: Platelet Inhibition and Bleeding Time </caption><colgroup><col width=\"80.1%\"/><col width=\"19.9%\"/></colgroup><tfoot><tr><td colspan=\"2\"><sup>*</sup>180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">PURSUIT</content> <content styleCode=\"bold\">180/2<sup>*</sup></content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> Inhibition of platelet aggregation 15 min after bolus </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">84% </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> Inhibition of platelet aggregation at steady state </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">&gt;90% </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> Bleeding-time prolongation at steady state </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">&lt;5x </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> Inhibition of platelet aggregation 4h after infusion discontinuation </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">&lt;50% </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\"> Bleeding-time prolongation 6h after infusion discontinuation </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1.4x </td></tr></tbody></table>"
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180 mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4 to 6 hours). This decline can be prevented by administering a second 180 mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20 to 94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations (8.6) and Dosage and Administration (2) ] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Eptifibatide was studied in 3 placebo-controlled, randomized studies. PURSUIT evaluated patients with acute coronary syndromes: UA or NSTEMI. Two other studies, ESPRIT and IMPACT II, evaluated patients about to undergo a PCI. Patients underwent primarily balloon angioplasty in IMPACT II and intracoronary stent placement, with or without angioplasty, in ESPRIT. 14.1 Non-ST-Segment Elevation Acute Coronary Syndrome Non-ST-segment elevation acute coronary syndrome is defined as prolonged (\u226510 minutes) symptoms of cardiac ischemia within the previous 24 hours associated with either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or positive CK-MB. This definition includes \"unstable angina\" and \"NSTEMI\" but excludes MI that is associated with Q waves or greater degrees of ST-segment elevation. PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Eptifibatide Therapy) PURSUIT was a 726-center, 27-country, double-blind, randomized, placebo-controlled study in 10,948 patients presenting with UA or NSTEMI. Patients could be enrolled only if they had experienced cardiac ischemia at rest (\u226510 minutes) within the previous 24 hours and had either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or increased CK-MB. Important exclusion criteria included a history of bleeding diathesis, evidence of abnormal bleeding within the previous 30 days, uncontrolled hypertension, major surgery within the previous 6 weeks, stroke within the previous 30 days, any history of hemorrhagic stroke, serum creatinine >2 mg/dL, dependency on renal dialysis, or platelet count <100,000/mm 3 . Patients were randomized to placebo, to eptifibatide 180 mcg/kg bolus followed by a 2 mcg/kg/min infusion (180/2), or to eptifibatide 180 mcg/kg bolus followed by a 1.3 mcg/kg/min infusion (180/1.3). The infusion was continued for 72 hours, until hospital discharge, or until the time of CABG, whichever occurred first, except that if PCI was performed, the eptifibatide infusion was continued for 24 hours after the procedure, allowing for a duration of infusion up to 96 hours. The lower-infusion-rate arm was stopped after the first interim analysis when the 2 active-treatment arms appeared to have the same incidence of bleeding. Patient age ranged from 20 to 94 (mean 63) years, and 65% were male. The patients were 89% Caucasian, 6% Hispanic, and 5% Black, recruited in the United States and Canada (40%), Western Europe (39%), Eastern Europe (16%), and Latin America (5%). This was a \"real world\" study; each patient was managed according to the usual standards of the investigational site; frequencies of angiography, PCI, and CABG therefore differed widely from site to site and from country to country. Of the patients in PURSUIT, 13% were managed with PCI during drug infusion, of whom 50% received intracoronary stents; 87% were managed medically (without PCI during drug infusion). The majority of patients received aspirin (75 to 325 mg once daily). Heparin was administered intravenously or subcutaneously, at the physician's discretion, most commonly as an intravenous bolus of 5,000 units followed by a continuous infusion of 1,000 units/h. For patients weighing less than 70 kg, the recommended heparin bolus dose was 60 units/kg followed by a continuous infusion of 12 units/kg/h. A target aPTT of 50 to 70 seconds was recommended. A total of 1250 patients underwent PCI within 72 hours after randomization, in which case they received intravenous heparin to maintain an ACT of 300 to 350 seconds. The primary endpoint of the study was the occurrence of death from any cause or new MI (evaluated by a blinded Clinical Endpoints Committee) within 30 days of randomization. Compared to placebo, eptifibatide administered as a 180 mcg/kg bolus followed by a 2 mcg/kg/min infusion significantly (p = 0.042) reduced the incidence of endpoint events (see Table 6). The reduction in the incidence of endpoint events in patients receiving eptifibatide was evident early during treatment, and this reduction was maintained through at least 30 days (see Figure 1). Table 5 also shows the incidence of the components of the primary endpoint, death (whether or not preceded by an MI) and new MI in surviving patients at 30 days. Table 5: Clinical Events in the PURSUIT Study Death or MI Placebo (n = 4739) n (%) Eptifibatide (180 mcg/kg bolus then 2 mcg/kg/min infusion) (n = 4722) n (%) p-value 3 days 359 (7.6%) 279 (5.9%) 0.001 7 days 552 (11.6%) 477 (10.1%) 0.016 30 days Death or MI (primary endpoint) 745 (15.7%) 672 (14.2%) 0.042 Death 177 (3.7%) 165 (3.5%) Nonfatal MI 568 (12%) 507 (10.7%) Figure 1: Kaplan-Meier Plot of Time to Death or Myocardial Infarction Within 30 Days of Randomization in the PURSUIT Study Treatment with eptifibatide prior to determination of patient management strategy reduced clinical events regardless of whether patients ultimately underwent diagnostic catheterization, revascularization (i.e., PCI or CABG surgery) or continued to receive medical management alone. Table 6 shows the incidence of death or MI within 72 hours. Table 6: Clinical Events (Death or MI) in the PURSUIT Study Within 72 Hours of Randomization Placebo Eptifibatide (180 mcg/kg bolus then 2 mcg/kg/min infusion) Overall patient population n = 4739 n = 4722 \u2013 At 72 hours 7.6% 5.9% Patients undergoing early PCI n = 631 n = 619 \u2013 Pre-procedure (nonfatal MI only) 5.5% 1.8% \u2013 At 72 hours 14.4% 9% Patients not undergoing early PCI n = 4108 n = 4103 \u2013 At 72 hours 6.5% 5.4% All of the effect of eptifibatide was established within 72 hours (during the period of drug infusion), regardless of management strategy. Moreover, for patients undergoing early PCI, a reduction in events was evident prior to the procedure. An analysis of the results by sex suggests that women who would not routinely be expected to undergo PCI receive less benefit from eptifibatide (95% confidence limits for relative risk of 0.94 to 1.28) than do men (0.72 to 0.9). This difference may be a true treatment difference, the effect of other differences in these subgroups, or a statistical anomaly. No differential outcomes were seen between male and female patients undergoing PCI (see results for ESPRIT) . Follow-up data were available through 165 days for 10,611 patients enrolled in the PURSUIT trial (96.9% of the initial enrollment). This follow-up included 4566 patients who received eptifibatide at the 180/2 dose. As reported by the investigators, the occurrence of death from any cause or new MI for patients followed for at least 165 days was reduced from 13.6% with placebo to 12.1% with eptifibatide 180/2. Figure 1: Kaplan-Meier Plot of Time to Death or Myocardial Infarction Within 30 Days of Randomization in the PURSUIT Study 14.2 Percutaneous Coronary Intervention (PCI) IMPACT II (Eptifibatide to Minimize Platelet Aggregation and Prevent Coronary Thrombosis II) IMPACT II was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States in 4010 patients undergoing PCI. Major exclusion criteria included a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm3, and pregnancy. Patient age ranged from 24 to 89 (mean 60) years, and 75% were male. The patients were 92% Caucasian, 5% Black, and 3% Hispanic. Forty-one percent of the patients underwent PCI for ongoing ACS. Patients were randomly assigned to 1 of 3 treatment regimens, each incorporating a bolus dose initiated immediately prior to PCI followed by a continuous infusion lasting 20 to 24 hours: 1) 135 mcg/kg bolus followed by a continuous infusion of 0.5 mcg/kg/min of eptifibatide (135/0.5); 2) 135 mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min of eptifibatide (135/0.75); or 3) a matching placebo bolus followed by a matching placebo continuous infusion. Each patient received aspirin and an intravenous heparin bolus of 100 units/kg, with additional bolus infusions of up to 2,000 additional units of heparin every 15 minutes to maintain an ACT of 300 to 350 seconds. The primary endpoint was the composite of death, MI, or urgent revascularization, analyzed at 30 days after randomization in all patients who received at least 1 dose of study drug. As shown in Table 7, each eptifibatide regimen reduced the rate of death, MI, or urgent intervention, although at 30 days, this finding was statistically significant only in the lower-dose eptifibatide group. As in the PURSUIT study, the effects of eptifibatide were seen early and persisted throughout the 30-day period. Table 7: Clinical Events in the IMPACT II Study *Kaplan-Meier estimate of event rate. Placebo n (%) Eptifibatide (135 mcg/kg bolus then 0.5 mcg/kg/min infusion) n (%) Eptifibatide (135 mcg/kg bolus then 0.75 mcg/kg/min infusion) n (%) Patients 1285 1300 1286 Abrupt Closure 65 (5.1%) 36 (2.8%) 43 (3.3%) p-value versus placebo 0.003 0.03 Death, MI, or Urgent Intervention 24 hours 123 (9.6%) 86 (6.6%) 89 (6.9%) p-value versus placebo 0.006 0.014 48 hours 131 (10.2%) 99 (7.6%) 102 (7.9%) p-value versus placebo 0.021 0.045 30 days (primary endpoint) 149 (11.6%) 118 (9.1%) 128 (10%) p-value versus placebo 0.035 0.179 Death or MI 30 days 110 (8.6%) 89 (6.8%) 95 (7.4%) p-value versus placebo 0.102 0.272 6 months 151 (11.9%) * 136 (10.6%) * 130 (10.3%) * p-value versus placebo 0.297 0.182 ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Eptifibatide Therapy) The ESPRIT study was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States and Canada that enrolled 2064 patients undergoing elective or urgent PCI with intended intracoronary stent placement. Exclusion criteria included MI within the previous 24 hours, ongoing chest pain, administration of any oral antiplatelet or oral anticoagulant other than aspirin within 30 days of PCI (although loading doses of thienopyridine on the day of PCI were encouraged), planned PCI of a saphenous vein graft or subsequent \"staged\" PCI, prior stent placement in the target lesion, PCI within the previous 90 days, a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 93 (mean 62) years, and 73% of patients were male. The study enrolled 90% Caucasian, 5% African American, 2% Hispanic, and 1% Asian patients. Patients received a wide variety of stents. Patients were randomized either to placebo or eptifibatide administered as an intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2 mcg/kg/min, and a second bolus of 180 mcg/kg administered 10 minutes later (180/2/180). Eptifibatide infusion was continued for 18 to 24 hours after PCI or until hospital discharge, whichever came first. Each patient received at least 1 dose of aspirin (162 to 325 mg) and 60 units/kg of heparin as a bolus (not to exceed 6,000 units) if not already receiving a heparin infusion. Additional boluses of heparin (10 to 40 units/kg) could be administered in order to reach a target ACT between 200 and 300 seconds. The primary endpoint of the ESPRIT study was the composite of death, MI, urgent target vessel revascularization (UTVR), and \"bailout\" to open-label eptifibatide due to a thrombotic complication of PCI (TBO) (e.g., visible thrombus, \"no reflow,\" or abrupt closure) at 48 hours. MI, UTVR, and TBO were evaluated by a blinded Clinical Events Committee. As shown in Table 8, the incidence of the primary endpoint and selected secondary endpoints was significantly reduced in patients who received eptifibatide. A treatment benefit in patients who received eptifibatide was seen by 48 hours and at the end of the 30-day observation period. Table 8: Clinical Events in the ESPRIT Study * Eptifibatide was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min. Placebo (n = 1024) Eptifibatide* (n = 1040) Relative Risk (95% CI) p-value Death, MI, UTVR, or Thrombotic \u201cBailout\u201d 48 hours (primary endpoint) 108 (10.5%) 69 (6.6%) 0.629 (0.471, 0.84) 0.0015 30 days 120 (11.7%) 78 (7.5%) 0.64 (0.488, 0.84) 0.0011 Death, MI, or UTVR 48 hours 95 (9.3%) 62 (6%) 0.643 (0.472, 0.875) 0.0045 30 days (key secondary endpoint) 107 (10.4%) 71 (6.8%) 0.653 (0.49, 0.871) 0.0034 Death or MI 48 hours 94 (9.2%) 57 (5.5%) 0.597 (0.435, 0.82) 0.0013 30 days 104 (10.2%) 66 (6.3%) 0.625 (0.465, 0.84) 0.0016 The need for thrombotic \"bailout\" was significantly reduced with eptifibatide at 48 hours (2.1% for placebo, 1% for eptifibatide; p = 0.029). Consistent with previous studies of GP IIb/IIIa inhibitors, most of the benefit achieved acutely with eptifibatide was in the reduction of MI. Eptifibatide reduced the occurrence of MI at 48 hours from 9% for placebo to 5.4% (p = 0.0015) and maintained that effect with significance at 30 days. There was no treatment difference with respect to sex in ESPRIT. Eptifibatide reduced the incidence of the primary endpoint in both men (95% confidence limits for relative risk: 0.54, 1.07) and women (0.24, 0.72) at 48 hours. Follow-up (12-month) mortality data were available for 2024 patients (1017 on eptifibatide) enrolled in the ESPRIT trial (98.1% of the initial enrollment). Twelve-month clinical event data were available for 1964 patients (988 on eptifibatide), representing 95.2% of the initial enrollment. As shown in Table 9, the treatment effect of eptifibatide seen at 48 hours and 30 days appeared preserved at 6 months and 1 year. Most of the benefit was in reduction of MI. Table 9: Clinical Events at 6 Months and 1 Year in the ESPRIT Study Percentages are Kaplan-Meier event rates. Placebo (n = 1024) Eptifibatide (n = 1040) Hazard Ratio (95% CI) Death, MI, or Target Vessel Revascularization 6 months 187 (18.5%) 146 (14.3%) 0.744 (0.599, 0.924) 1 year 222 (22.1%) 178 (17.5%) 0.762 (0.626, 0.929) Death, MI 6 months 117 (11.5%) 77 (7.4%) 0.631 (0.473, 0.841) 1 year 126 (12.4%) 83 (8%) 0.63 (0.478, 0.832)"
    ],
    "clinical_studies_table": [
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><caption>Table 5: Clinical Events in the PURSUIT Study </caption><colgroup><col width=\"41.1%\"/><col width=\"16.28%\"/><col width=\"31.16%\"/><col width=\"11.46%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Death or MI</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(n = 4739)</content> <content styleCode=\"bold\">n (%)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(180 mcg/kg bolus then  2 mcg/kg/min infusion)</content> <content styleCode=\"bold\">(n = 4722)</content> <content styleCode=\"bold\">n (%)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">p-value</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">3 days </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">359 (7.6%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">279 (5.9%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.001 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">7 days </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">552 (11.6%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">477 (10.1%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.016 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">30 days </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">Death or MI (primary endpoint) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">745 (15.7%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">672 (14.2%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.042 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">Death </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">177 (3.7%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">165 (3.5%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">Nonfatal MI </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">568 (12%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">507 (10.7%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><caption>Table 6: Clinical Events (Death or MI) in the PURSUIT Study Within 72 Hours of Randomization </caption><colgroup><col width=\"48.6%\"/><col width=\"19.26%\"/><col width=\"32.16%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Placebo</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(180 mcg/kg bolus then  2 mcg/kg/min infusion)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">Overall patient population </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">n = 4739 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">n = 4722 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">&#x2013; At 72 hours </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">7.6% </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">5.9% </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">Patients undergoing early PCI </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">n = 631 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">n = 619 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">&#x2013; Pre-procedure (nonfatal MI only) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">5.5% </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1.8% </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">&#x2013; At 72 hours </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">14.4% </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">9% </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">Patients not undergoing early PCI </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">n = 4108 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">n = 4103 </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">&#x2013; At 72 hours </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">6.5% </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">5.4% </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><caption>Table 7: Clinical Events in the IMPACT II Study</caption><colgroup><col width=\"36.38%\"/><col width=\"15.5%\"/><col width=\"24.16%\"/><col width=\"23.96%\"/></colgroup><tfoot><tr><td colspan=\"4\">*Kaplan-Meier estimate of event rate.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">n (%)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(135 mcg/kg bolus then</content> <content styleCode=\"bold\">0.5 mcg/kg/min infusion)</content> <content styleCode=\"bold\">n (%)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(135 mcg/kg bolus then</content> <content styleCode=\"bold\">0.75 mcg/kg/min </content><content styleCode=\"bold\">infusion)</content> <content styleCode=\"bold\">n (%)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Patients </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1285 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1300 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1286 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Abrupt Closure </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">65 (5.1%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">36 (2.8%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">43 (3.3%) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">p-value versus placebo </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.003 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.03 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Death, MI, or Urgent Intervention </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">24 hours </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">123 (9.6%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">86 (6.6%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">89 (6.9%) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">p-value versus placebo </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.006 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.014 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">48 hours </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">131 (10.2%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">99 (7.6%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">102 (7.9%) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">p-value versus placebo </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.021 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.045 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">30 days (primary endpoint) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">149 (11.6%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">118 (9.1%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">128 (10%) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">p-value versus placebo </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.035 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.179 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Death or MI </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">30 days </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">110 (8.6%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">89 (6.8%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">95 (7.4%) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">p-value versus placebo </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.102 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.272 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">6 months </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">151 (11.9%)<sup>*</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">136 (10.6%)<sup>*</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">130 (10.3%)<sup>*</sup> </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"middle\">p-value versus placebo </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.297 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.182 </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><caption>Table 8: Clinical Events in the ESPRIT Study </caption><colgroup><col width=\"31.24%\"/><col width=\"16.88%\"/><col width=\"17.84%\"/><col width=\"24%\"/><col width=\"10.04%\"/></colgroup><tfoot><tr><td colspan=\"5\">* Eptifibatide was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Placebo  (n = 1024)</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Eptifibatide*  (n = 1040)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Relative Risk  (95% CI)</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">p-value</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\" valign=\"middle\">Death, MI, UTVR, or Thrombotic &#x201C;Bailout&#x201D; </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">48 hours (primary endpoint) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">108 (10.5%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">69 (6.6%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.629 (0.471, 0.84) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.0015 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">30 days </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">120 (11.7%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">78 (7.5%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.64 (0.488, 0.84) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.0011 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\" valign=\"middle\">Death, MI, or UTVR </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">48 hours </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">95 (9.3%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">62 (6%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.643 (0.472, 0.875) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.0045 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">30 days (key secondary endpoint) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">107 (10.4%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">71 (6.8%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.653 (0.49, 0.871) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.0034 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"5\" valign=\"middle\">Death or MI </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">48 hours </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">94 (9.2%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">57 (5.5%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.597 (0.435, 0.82) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.0013 </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"middle\">30 days </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">104 (10.2%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">66 (6.3%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.625 (0.465, 0.84) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.0016 </td></tr></tbody></table>",
      "<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><caption>Table 9: Clinical Events at 6 Months and 1 Year in the ESPRIT Study </caption><colgroup><col width=\"29.32%\"/><col width=\"24.44%\"/><col width=\"21.24%\"/><col width=\"25%\"/></colgroup><tfoot><tr><td colspan=\"4\">Percentages are Kaplan-Meier event rates.</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Placebo  (n = 1024)</content>  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Eptifibatide  (n = 1040)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Hazard Ratio  (95% CI)</content>  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\" align=\"justify\" valign=\"top\">Death, MI, or Target Vessel Revascularization </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">6 months </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">187 (18.5%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">146 (14.3%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.744 (0.599, 0.924) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">1 year </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">222 (22.1%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">178 (17.5%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.762 (0.626, 0.929) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" colspan=\"4\" valign=\"middle\">Death, MI </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">6 months </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">117 (11.5%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">77 (7.4%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">0.631 (0.473, 0.841) </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\">1 year </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">126 (12.4%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">83 (8%) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.63 (0.478, 0.832) </td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Eptifibatide injection is a clear, colorless, sterile, non-pyrogenic solution free from visible particles and is supplied as follows: 75 mg per 100 mL (0.75 mg / mL) 100 mL Single-Dose Vials, packaged individually NDC 55150-218-99 20 mg per 10 mL (2 mg / mL) 10 mL Single-Dose Vials, packaged individually NDC 55150-219-10 200 mg per 100 mL (2 mg / mL) 100 mL Single-Dose Vials, packaged individually NDC 55150-220-99 16.2 Storage Vials should be stored refrigerated at 2\u00b0 to 8\u00b0C (36\u00b0 to 46\u00b0F). Vials may be transferred to room temperature storage* for a period not to exceed 2 months. Upon transfer, vial cartons must be marked by the dispensing pharmacist with a \"DISCARD BY\" date (2 months from the transfer date or the labeled expiration date, whichever comes first). * Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature]. Protect from light until administration. The vial stoppers are not made with natural rubber latex."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to inform the doctor or healthcare provider about any medical conditions, medications, and allergies. Distributed by: Eugia US LLC 279 Princeton-Hightstown Rd. E. Windsor, NJ 08520 Manufactured by: Eugia Pharma Specialities Limited Hyderabad - 500032 India"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 75 mg per 100 mL (0.75 mg / mL) - Container Label Rx only NDC 55150-218-99 Eptifibatide Injection 75 mg per 100 mL (0.75 mg/mL) For Intravenous Use Only for weight-adjusted infusion 100 mL Single-Dose Vial PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 75 mg per 100 mL (0.75 mg / mL) - Container Label",
      "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 75 mg per 100 mL (0.75 mg / mL) - Container-Carton (1 Vial) Rx only NDC 55150-218-99 Eptifibatide Injection 75 mg per 100 mL (0.75 mg/mL) For Intravenous Use Only 100 mL Single-Dose Vial for weight-adjusted infusion eugia PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 75 mg per 100 mL (0.75 mg / mL) - Container-Carton (1 Vial)",
      "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 20 mg per 10 mL (2 mg / mL) - Container Label Rx only NDC 55150-219-10 Eptifibatide Injection 20 mg per 10 mL (2 mg/mL) For Intravenous Use Only for weight-adjusted bolus dosing 10 mL Single-Dose Vial PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 20 mg per 10 mL (2 mg / mL) - Container Label",
      "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 20 mg per 10 mL (2 mg / mL) - Container-Carton (1 Vial) Rx only NDC 55150-219-10 Eptifibatide Injection 20 mg per 10 mL (2 mg/mL) For Intravenous Use Only 10 mL Single-Dose Vial for weight-adjusted bolus dosing eugia PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 20 mg per 10 mL (2 mg / mL) - Container-Carton (1 Vial)",
      "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 200 mg per 100 mL (2 mg / mL) - Container Label Rx only NDC 55150-220-99 Eptifibatide Injection 200 mg per 100 mL (2 mg/mL) For Intravenous Use Only for weight-adjusted infusion 100 mL Single-Dose Vial PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 200 mg per 100 mL (2 mg / mL) - Container Label",
      "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 200 mg per 100 mL (2 mg / mL) - Container-Carton (1 Vial) Rx only NDC 55150-220-99 Eptifibatide Injection 200 mg per 100 mL (2 mg/mL) For Intravenous Use Only 100 mL Single-Dose Vial for weight-adjusted infusion eugia PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 200 mg per 100 mL (2 mg / mL) - Container-Carton (1 Vial)"
    ],
    "set_id": "00ad7bbe-cadd-4647-b74b-adfc9f2b5e94",
    "id": "944b269c-d810-411d-9ed4-8edd9d0ac1b7",
    "effective_time": "20240104",
    "version": "7",
    "openfda": {
      "application_number": [
        "ANDA206127"
      ],
      "brand_name": [
        "Eptifibatide"
      ],
      "generic_name": [
        "EPTIFIBATIDE"
      ],
      "manufacturer_name": [
        "Eugia US LLC"
      ],
      "product_ndc": [
        "55150-218",
        "55150-219",
        "55150-220"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "INTRAVENOUS"
      ],
      "substance_name": [
        "EPTIFIBATIDE"
      ],
      "rxcui": [
        "200349",
        "1736470",
        "1736477"
      ],
      "spl_id": [
        "944b269c-d810-411d-9ed4-8edd9d0ac1b7"
      ],
      "spl_set_id": [
        "00ad7bbe-cadd-4647-b74b-adfc9f2b5e94"
      ],
      "package_ndc": [
        "55150-218-99",
        "55150-219-10",
        "55150-220-99"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0355150220991",
        "0355150219100"
      ],
      "nui": [
        "N0000008832",
        "N0000175578"
      ],
      "pharm_class_pe": [
        "Decreased Platelet Aggregation [PE]"
      ],
      "pharm_class_epc": [
        "Platelet Aggregation Inhibitor [EPC]"
      ],
      "unii": [
        "NA8320J834"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Eptifibatide eptifibatide CITRIC ACID MONOHYDRATE SODIUM HYDROXIDE EPTIFIBATIDE EPTIFIBATIDE Eptifibatide eptifibatide CITRIC ACID MONOHYDRATE SODIUM HYDROXIDE EPTIFIBATIDE EPTIFIBATIDE"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Eptifibatide injection is a platelet aggregation inhibitor indicated for: Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI). ( 1.1 ) Treatment of patients undergoing PCI (including intracoronary stenting) ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). 1.2 Percutaneous Coronary Intervention (PCI) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting [see Clinical Studies ( 14.1 , 14.2 )] ."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION Before infusion of eptifibatide injection, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured. The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT. ACS or PCI: 180 mcg/kg IV bolus as soon as possible after diagnosis followed by infusion at 2 mcg/kg/min. ( 2.1 , 2.2 ) PCI: Add a second 180 mcg/kg bolus at 10 minutes. ( 2.2 ) In patients with creatinine clearance less than 50 mL/min, reduce the infusion to 1 mcg/kg/min. ( 2.1 , 2.2 , 2.3 ) 2.1 Dosage in Acute Coronary Syndrome (ACS) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with ACS 180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min 180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours. If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy. Aspirin, 160 to 325 mg, should be given daily. Eptifibatide injection should be given concomitantly with heparin dosed to achieve the following parameters: During Medical Management : Target aPTT 50 to 70 seconds If weight greater than or equal to 70 kg, 5000-unit bolus followed by infusion of 1000 units/h. If weight less than 70 kg, 60-units/kg bolus followed by infusion of 12 units/kg/h. During PCI : Target ACT 200 to 300 seconds If heparin is initiated prior to PCI, additional boluses during PCI to maintain an ACT target of 200 to 300 seconds. Heparin infusion after the PCI is discouraged. 2.2 Dosage in Percutaneous Coronary Intervention (PCI) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with PCI 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. In patients who undergo CABG surgery, eptifibatide infusion should be discontinued prior to surgery. Aspirin, 160 to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter. Eptifibatide injection should be given concomitantly with heparin to achieve a target ACT of 200 to 300 seconds. Administer 60-units/kg bolus initially in patients not treated with heparin within 6 hours prior to PCI. Additional boluses during PCI to maintain ACT within target. Heparin infusion after the PCI is strongly discouraged. Patients requiring thrombolytic therapy should discontinue eptifibatide injection. 2.3 Important Administration Instructions Inspect eptifibatide injection for particulate matter and discoloration prior to administration, whenever solution and container permit. May administer eptifibatide injection in the same intravenous line as alteplase, atropine, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, or verapamil. Do not administer eptifibatide injection through the same intravenous line as furosemide. May administer eptifibatide injection in the same IV line with 0.9% NaCl or 0.9% NaCl/5% dextrose. With either vehicle, the infusion may also contain up to 60 mEq/L of potassium chloride. Withdraw the bolus dose(s) of eptifibatide injection from the 10 mL vial into a syringe. Administer the bolus dose(s) by IV push. Immediately following the bolus dose administration, initiate a continuous infusion of eptifibatide injection. When using an intravenous infusion pump, administer eptifibatide injection undiluted directly from the 100-mL vial. Spike the 100 mL vial with a vented infusion set. Center the spike within the circle on the stopper top. Discard any unused portion left in the vial. Administer eptifibatide injection by volume according to patient weight (see Table 1 ). Table 1. Eptifibatide Injection Dosing Charts by Weight Patient Weight 180 mcg/kg Bolus Volume 2 mcg/kg/min Infusion Volume (CrCl greater than or equal to 50 mL/min) 1 mcg/kg/min Infusion Volume (CrCl less than 50 mL/min) (kg) (lb) (from 2 mg/mL vial) (from 2 mg/mL 100 mL vial) (from 0.75 mg/mL 100 mL vial) (from 2 mg/mL 100 mL vial) (from 0.75 mg/mL 100 mL vial) 37-41 81-91 3.4 mL 2 mL/h 6 mL/h 1 mL/h 3 mL/h 42-46 92-102 4 mL 2.5 mL/h 7 mL/h 1.3 mL/h 3.5 mL/h 47-53 103-117 4.5 mL 3 mL/h 8 mL/h 1.5 mL/h 4 mL/h 54-59 118-130 5 mL 3.5 mL/h 9 mL/h 1.8 mL/h 4.5 mL/h 60-65 131-143 5.6 mL 3.8 mL/h 10 mL/h 1.9 mL/h 5 mL/h 66-71 144-157 6.2 mL 4 mL/h 11 mL/h 2 mL/h 5.5 mL/h 72-78 158-172 6.8 mL 4.5 mL/h 12 mL/h 2.3 mL/h 6 mL/h 79-84 173-185 7.3 mL 5 mL/h 13 mL/h 2.5 mL/h 6.5 mL/h 85-90 186-198 7.9 mL 5.3 mL/h 14 mL/h 2.7 mL/h 7 mL/h 91-96 199-212 8.5 mL 5.6 mL/h 15 mL/h 2.8 mL/h 7.5 mL/h 97-103 213-227 9 mL 6 mL/h 16 mL/h 3.0 mL/h 8 mL/h 104-109 228-240 9.5 mL 6.4 mL/h 17 mL/h 3.2 mL/h 8.5 mL/h 110-115 241-253 10.2 mL 6.8 mL/h 18 mL/h 3.4 mL/h 9 mL/h 116-121 254-267 10.7 mL 7 mL/h 19 mL/h 3.5 mL/h 9.5 mL/h >121 >267 11.3 mL 7.5 mL/h 20 mL/h 3.7 mL/h 10 mL/h"
    ],
    "dosage_and_administration_table": [
      "<table cellpadding=\"3.6pt\" width=\"100%\"><col width=\"23%\"/><col width=\"37%\"/><col width=\"40%\"/><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Indication</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Normal Renal Function</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Creatinine Clearance less than 50 mL/min</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>Patients with ACS</paragraph></td><td valign=\"top\"><paragraph>180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min</paragraph></td><td valign=\"top\"><paragraph>180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"/><td colspan=\"2\" styleCode=\"Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours.</item><item>If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy.</item><item>Aspirin, 160 to 325 mg, should be given daily.</item></list></td></tr></tbody></table>",
      "<table cellpadding=\"3.6pt\" width=\"100%\"><col width=\"23%\"/><col width=\"37%\"/><col width=\"40%\"/><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Indication</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Normal Renal Function</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Creatinine Clearance less than 50 mL/min</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>Patients with PCI</paragraph></td><td valign=\"top\"><paragraph>180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of</paragraph><paragraph>2 mcg/kg/min and a second bolus of</paragraph><paragraph>180 mcg/kg (given 10 minutes after the first bolus)</paragraph></td><td valign=\"top\"><paragraph>180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of</paragraph><paragraph>1 mcg/kg/min and a second bolus of</paragraph><paragraph>180 mcg/kg (given 10 minutes after the first bolus)</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"/><td colspan=\"2\" styleCode=\"Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended.</item><item>In patients who undergo CABG surgery, eptifibatide infusion should be discontinued prior to surgery.</item><item>Aspirin, 160 to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter.</item></list></td></tr></tbody></table>",
      "<table ID=\"_Ref468720797\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 1. Eptifibatide Injection Dosing Charts by Weight</caption><col width=\"14%\"/><col width=\"14%\"/><col width=\"16%\"/><col width=\"14%\"/><col width=\"14%\"/><col width=\"14%\"/><col width=\"14%\"/><tbody><tr><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Patient Weight</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">180 mcg/kg Bolus Volume</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">2 mcg/kg/min Infusion Volume (CrCl greater than or equal to 50 mL/min)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">1 mcg/kg/min Infusion Volume (CrCl less than 50 mL/min)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">(kg)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">(lb)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">(from 2 mg/mL vial)</content></paragraph></td><td align=\"center\" styleCode=\"Lrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">(from</content></paragraph><paragraph><content styleCode=\"bold\">2 mg/mL</content></paragraph><paragraph><content styleCode=\"bold\">100 mL vial)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">(from</content></paragraph><paragraph><content styleCode=\"bold\">0.75 mg/mL 100 mL vial)</content></paragraph></td><td align=\"center\" styleCode=\"Lrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">(from</content></paragraph><paragraph><content styleCode=\"bold\">2 mg/mL</content></paragraph><paragraph><content styleCode=\"bold\">100 mL vial)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">(from</content></paragraph><paragraph><content styleCode=\"bold\">0.75 mg/mL 100 mL vial)</content></paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>37-41</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>81-91</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>3.4 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>2 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>6 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>1 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>3 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>42-46</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>92-102</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>4 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>2.5 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>7 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>1.3 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>3.5 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>47-53</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>103-117</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>4.5 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>3 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>8 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>1.5 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>4 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>54-59</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>118-130</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>5 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>3.5 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>9 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>1.8 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>4.5 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>60-65</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>131-143</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>5.6 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>3.8 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>10 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>1.9 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>66-71</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>144-157</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>6.2 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>4 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>11 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>2 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5.5 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>72-78</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>158-172</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>6.8 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>4.5 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>12 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>2.3 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>6 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>79-84</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>173-185</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>7.3 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>5 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>13 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>2.5 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>6.5 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>85-90</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>186-198</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>7.9 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>5.3 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>14 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>2.7 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>7 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>91-96</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>199-212</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>8.5 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>5.6 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>15 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>2.8 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>7.5 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>97-103</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>213-227</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>9 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>6 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>16 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>3.0 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>8 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>104-109</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>228-240</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>9.5 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>6.4 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>17 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>3.2 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>8.5 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>110-115</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>241-253</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>10.2 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>6.8 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>18 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>3.4 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>9 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>116-121</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>254-267</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>10.7 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>7 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>19 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>3.5 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>9.5 mL/h</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Botrule \" valign=\"middle\"><paragraph>&gt;121</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>&gt;267</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>11.3 mL</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule \" valign=\"middle\"><paragraph>7.5 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>20 mL/h</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule \" valign=\"middle\"><paragraph>3.7 mL/h</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"middle\"><paragraph>10 mL/h</paragraph></td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Injection: 20 mg of eptifibatide injection in 10 mL (2 mg/mL), for intravenous bolus. Injection: 75 mg of eptifibatide injection in 100 mL (0.75 mg/mL), for intravenous infusion. 20 mg/10 mL (2 mg/mL) in a single-dose vial for bolus injection. ( 3 ) 75 mg/100 mL (0.75 mg/mL) in a single-dose vial for infusion. ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Treatment with eptifibatide injection is contraindicated in patients with: A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another parenteral GP IIb/IIIa inhibitor Dependency on renal dialysis Hypersensitivity to eptifibatide injection or any component of the product (hypersensitivity reactions that occurred included anaphylaxis and urticaria). Bleeding diathesis or bleeding within the previous 30 days. ( 4 ) Severe uncontrolled hypertension. ( 4 ) Major surgery within the preceding 6 weeks. ( 4 ) Stroke within 30 days or any history of hemorrhagic stroke. ( 4 ) Coadministration of another parenteral GP IIb/IIIa inhibitor. ( 4 ) Dependency on renal dialysis. ( 4 ) Known hypersensitivity to any component of the product. ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Eptifibatide injection can cause serious bleeding. If bleeding cannot be controlled, discontinue eptifibatide injection immediately. Minimize vascular and other traumas. If heparin is given concomitantly, monitor aPTT or ACT. ( 5.1 ) Thrombocytopenia: Discontinue eptifibatide injection and heparin. Monitor and treat condition appropriately. ( 5.2 ) 5.1 Bleeding Bleeding is the most common complication encountered during eptifibatide injection therapy. Administration of eptifibatide injection is associated with an increase in major and minor bleeding, as classified by the criteria of the Thrombolysis in Myocardial Infarction Study group (TIMI) [see Adverse Reactions ( 6.1 )] . Most major bleeding associated with eptifibatide injection has been at the arterial access site for cardiac catheterization or from the gastrointestinal or genitourinary tract. Minimize the use of arterial and venous punctures, intramuscular injections, and the use of urinary catheters, nasotracheal intubation, and nasogastric tubes. When obtaining intravenous access, avoid non-compressible sites (e.g., subclavian or jugular veins). Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Risk factors for bleeding include older age, a history of bleeding disorders, and concomitant use of drugs that increase the risk of bleeding (thrombolytics, oral anticoagulants, nonsteroidal anti-inflammatory drugs, and P2Y 12 inhibitors). Concomitant treatment with other inhibitors of platelet receptor glycoprotein (GP) IIb/IIIa should be avoided. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT [see Dosage and Administration ( 2 )] . Care of the Femoral Artery Access Site in Patients Undergoing Percutaneous Coronary Intervention (PCI) In patients undergoing PCI, treatment with eptifibatide injection is associated with an increase in major and minor bleeding at the site of arterial sheath placement. After PCI, eptifibatide infusion should be continued until hospital discharge or up to 18 to 24 hours, whichever comes first. Heparin use is discouraged after the PCI procedure. Early sheath removal is encouraged while eptifibatide injection is being infused. Prior to removing the sheath, it is recommended that heparin be discontinued for 3 to 4 hours and an aPTT of <45 seconds or ACT <150 seconds be achieved. In any case, both heparin and eptifibatide injection should be discontinued and sheath hemostasis should be achieved at least 2 to 4 hours before hospital discharge. If bleeding at access site cannot be controlled with pressure, infusion of eptifibatide injection and heparin should be discontinued immediately. 5.2 Thrombocytopenia There have been reports of acute, profound thrombocytopenia (immune-mediated and non-immune mediated) with eptifibatide injection. In the event of acute profound thrombocytopenia or a confirmed platelet decrease to <100,000/mm 3 , discontinue eptifibatide injection and heparin (unfractionated or low-molecular weight). Monitor serial platelet counts, assess the presence of drug-dependent antibodies, and treat as appropriate [see Adverse Reactions ( 6.1 )] . There has been no clinical experience with eptifibatide injection initiated in patients with a baseline platelet count <100,000/mm 3 . If a patient with low platelet counts is receiving eptifibatide injection, their platelet count should be monitored closely."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reaction is also discussed elsewhere in the labeling: Bleeding [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )] Bleeding and hypotension are the most commonly reported adverse reactions. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Slate Run Pharmaceuticals, LLC at 1-888-341-9214 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. A total of 16,782 patients were treated in the Phase III clinical trials (PURSUIT, ESPRIT, and IMPACT II) [see Clinical Studies ( 14 )] . These 16,782 patients had a mean age of 62 years (range: 20-94 years). Eighty-nine percent of the patients were Caucasian, with the remainder being predominantly Black (5%) and Hispanic (5%). Sixty-eight percent were men. Because of the different regimens used in PURSUIT, IMPACT II, and ESPRIT, data from the 3 studies were not pooled. Bleeding and hypotension were the most commonly reported adverse reactions (incidence \u22655% and greater than placebo) in the eptifibatide injection controlled clinical trial database. Bleeding The incidence of bleeding and transfusions in the PURSUIT and ESPRIT studies are shown in Table 2 . Bleeding was classified as major or minor by the criteria of the TIMI study group. Major bleeding consisted of intracranial hemorrhage and other bleeding that led to decreases in hemoglobin greater than 5 g/dL. Minor bleeding included spontaneous gross hematuria, spontaneous hematemesis, other observed blood loss with a hemoglobin decrease of more than 3 g/dL, and other hemoglobin decreases that were greater than 4 g/dL but less than 5 g/dL. In patients who received transfusions, the corresponding loss in hemoglobin was estimated through an adaptation of the method of Landefeld et al. Table 2. Bleeding and Transfusions in the PURSUIT and ESPRIT Studies Note: Denominator is based on patients for whom data are available. * For major and minor bleeding, patients are counted only once according to the most severe classification. \u2020 Includes transfusions of whole blood, packed red blood cells, fresh frozen plasma, cryoprecipitate, platelets, and autotransfusion during the initial hospitalization. PURSUIT (ACS) Placebo n (%) EptifibatideInjection 180/2 n (%) Patients 4696 4679 Major bleeding* 425 (9.3%) 498 (10.8%) Minor bleeding* 347 (7.6%) 604 (13.1%) Requiring transfusions\u2020 490 (10.4%) 601 (12.8%) ESPRIT (PCI) Placebo n (%) EptifibatideInjection 180/2/180 n (%) Patients 1024 1040 Major bleeding* 4 (0.4%) 13 (1.3%) Minor bleeding* 18 (2%) 29 (3%) Requiring transfusions\u2020 11 (1.1%) 16 (1.5%) The majority of major bleeding reactions in the ESPRIT study occurred at the vascular access site (1 and 8 patients, or 0.1% and 0.8% in the placebo and eptifibatide injection groups, respectively). Bleeding at \u201cother\u201d locations occurred in 0.2% and 0.4% of patients, respectively. In the PURSUIT study, the greatest increase in major bleeding in eptifibatide-treated patients compared to placebo-treated patients was also associated with bleeding at the femoral artery access site (2.8% versus 1.3%). Oropharyngeal (primarily gingival), genitourinary, gastrointestinal, and retroperitoneal bleeding were also seen more commonly in eptifibatide-treated patients compared to placebo-treated patients. Among patients experiencing a major bleed in the IMPACT II study, an increase in bleeding on eptifibatide injection versus placebo was observed only for the femoral artery access site (3.2% versus 2.8%). Table 3 displays the incidence of TIMI major bleeding according to the cardiac procedures carried out in the PURSUIT study. The most common bleeding complications were related to cardiac revascularization (CABG-related or femoral artery access site bleeding). A corresponding table for ESPRIT is not presented, as every patient underwent PCI in the ESPRIT study and only 11 patients underwent CABG. Table 3. Major Bleeding by Procedures in the PURSUIT Study Note: Denominators are based on the total number of patients whose TIMI classification was resolved. Placebo n (%) EptifibatideInjection 180/2 n (%) Patients 4577 4604 Overall incidence of major bleeding 425 (9.3%) 498 (10.8%) Breakdown by procedure: CABG 375 (8.2%) 377 (8.2%) Angioplasty without CABG 27 (0.6%) 64 (1.4%) Angiography without angioplasty or CABG 11 (0.2%) 29 (0.6%) Medical therapy only 12 (0.3%) 28 (0.6%) In the PURSUIT and ESPRIT studies, the risk of major bleeding with eptifibatide injection increased as patient weight decreased. This relationship was most apparent for patients weighing less than 70 kg. Bleeding resulting in discontinuation of the study drug was more frequent among patients receiving eptifibatide injection than placebo (4.6% versus 0.9% in ESPRIT, 8% versus 1% in PURSUIT, 3.5% versus 1.9% in IMPACT II). Intracranial Hemorrhage and Stroke Intracranial hemorrhage was rare in the PURSUIT, IMPACT II, and ESPRIT clinical studies. In the PURSUIT study, 3 patients in the placebo group, 1 patient in the group treated with eptifibatide injection 180/1.3, and 5 patients in the group treated with eptifibatide injection 180/2 experienced a hemorrhagic stroke. The overall incidence of stroke was 0.5% in patients receiving eptifibatide injection 180/1.3, 0.7% in patients receiving eptifibatide injection 180/2, and 0.8% in placebo patients. In the IMPACT II study, intracranial hemorrhage was experienced by 1 patient treated with eptifibatide injection 135/0.5, 2 patients treated with eptifibatide injection 135/0.75, and 2 patients in the placebo group. The overall incidence of stroke was 0.5% in patients receiving 135/0.5 eptifibatide injection, 0.7% in patients receiving eptifibatide injection 135/0.75, and 0.7% in the placebo group. In the ESPRIT study, there were 3 hemorrhagic strokes, 1 in the placebo group and 2 in the eptifibatide injection group. In addition there was 1 case of cerebral infarction in the eptifibatide injection group. Immunogenicity/Thrombocytopenia The potential for development of antibodies to eptifibatide has been studied in 433 subjects. Eptifibatide injection was nonantigenic in 412 patients receiving a single administration of eptifibatide injection (135 mcg/kg bolus followed by a continuous infusion of either 0.5 mcg/kg/min or 0.75 mcg/kg/min), and in 21 subjects to whom eptifibatide injection (135 mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min) was administered twice, 28 days apart. In both cases, plasma for antibody detection was collected approximately 30 days after each dose. The development of antibodies to eptifibatide at higher doses has not been evaluated. In patients with suspected eptifibatide-related immune-mediated thrombocytopenia, IgG antibodies that react with the GP IIb/IIIa complex were identified in the presence of eptifibatide and in eptifibatide-na\u00efve patients. These findings suggest acute thrombocytopenia after the administration of eptifibatide injection can develop as a result of naturally occurring drug-dependent antibodies or those induced by prior exposure to eptifibatide injection. Similar antibodies were identified with other GP IIb/IIIa ligand-mimetic agents. Immune-mediated thrombocytopenia with eptifibatide injection may be associated with hypotension and/or other signs of hypersensitivity. In the PURSUIT and IMPACT II studies, the incidence of thrombocytopenia (<100,000/mm 3 or \u226550% reduction from baseline) and the incidence of platelet transfusions were similar between patients treated with eptifibatide injection and placebo. In the ESPRIT study, the incidence was 0.6% in the placebo group and 1.2% in the eptifibatide injection group. Other Adverse Reactions In the PURSUIT and ESPRIT studies, the incidence of serious nonbleeding adverse reactions was similar in patients receiving placebo or eptifibatide injection (19% and 19%, respectively, in PURSUIT; 6% and 7%, respectively, in ESPRIT). In PURSUIT, the only serious nonbleeding adverse reaction that occurred at a rate of at least 1% and was more common with eptifibatide injection than placebo (7% versus 6%) was hypotension. Most of the serious nonbleeding adverse reactions consisted of cardiovascular reactions typical of a UA population. In the IMPACT II study, serious nonbleeding adverse reactions that occurred in greater than 1% of patients were uncommon and similar in incidence between placebo- and eptifibatide-treated patients. Discontinuation of study drug due to adverse reactions other than bleeding was uncommon in the PURSUIT, IMPACT II, and ESPRIT studies, with no single reaction occurring in >0.5% of the study population (except for \u201cother\u201d in the ESPRIT study). 6.2 Postmarketing Experience The following adverse reactions have been reported in post-approval use of eptifibatide injection in combination with heparin and aspirin. Because the reactions below are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure: cerebral, GI, and pulmonary hemorrhage. Fatal bleeding reactions have been reported. Acute profound thrombocytopenia, as well as immune-mediated thrombocytopenia, have been reported [see Adverse Reactions ( 6.1 )] ."
    ],
    "adverse_reactions_table": [
      "<table ID=\"_Ref468720999\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 2. Bleeding and Transfusions in the PURSUIT and ESPRIT Studies</caption><col width=\"34%\"/><col width=\"33%\"/><col width=\"33%\"/><tfoot><tr><td align=\"left\" colspan=\"3\" valign=\"top\">Note: Denominator is based on patients for whom data are available.   * For major and minor bleeding, patients are counted only once according to the most severe classification.   &#x2020; Includes transfusions of whole blood, packed red blood cells, fresh frozen plasma, cryoprecipitate, platelets, and autotransfusion during the initial hospitalization. </td></tr></tfoot><tbody><tr><td align=\"center\" colspan=\"3\" styleCode=\"Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">PURSUIT (ACS)</content></paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">EptifibatideInjection</content></paragraph><paragraph><content styleCode=\"bold\">180/2</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>Patients</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>4696</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>4679</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Major bleeding*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>425 (9.3%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>498 (10.8%)</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Minor bleeding*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>347 (7.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>604 (13.1%)</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph>Requiring transfusions&#x2020;</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>490 (10.4%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>601 (12.8%)</paragraph></td></tr><tr><td align=\"center\" colspan=\"3\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">ESPRIT (PCI)</content></paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">EptifibatideInjection</content></paragraph><paragraph><content styleCode=\"bold\">180/2/180</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>Patients</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1024</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1040</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Major bleeding*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>4 (0.4%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>13 (1.3%)</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Minor bleeding*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>18 (2%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>29 (3%)</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph>Requiring transfusions&#x2020;</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>11 (1.1%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>16 (1.5%)</paragraph></td></tr></tbody></table>",
      "<table ID=\"_Ref468721021\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 3. Major Bleeding by Procedures in the PURSUIT Study</caption><col width=\"39%\"/><col width=\"28%\"/><col width=\"33%\"/><tfoot><tr><td align=\"left\" colspan=\"3\" valign=\"top\">Note: Denominators are based on the total number of patients whose TIMI classification was resolved.</td></tr></tfoot><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">EptifibatideInjection</content></paragraph><paragraph><content styleCode=\"bold\">180/2</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>Patients</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>4577</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>4604</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Overall incidence of major bleeding</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>425 (9.3%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>498 (10.8%)</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Breakdown by procedure:</paragraph></td><td valign=\"top\"/><td valign=\"top\"/></tr><tr><td valign=\"top\"><paragraph> CABG</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>375 (8.2%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>377 (8.2%)</paragraph></td></tr><tr><td valign=\"top\"><paragraph> Angioplasty without CABG</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>27 (0.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>64 (1.4%)</paragraph></td></tr><tr><td valign=\"top\"><paragraph> Angiography without angioplasty or CABG</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>11 (0.2%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>29 (0.6%)</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph> Medical therapy only</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>12 (0.3%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>28 (0.6%)</paragraph></td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Avoid concomitant use with other glycoprotein (GP) IIb/IIIa inhibitors. ( 7.1 ) 7.1 Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Concomitant treatment with other inhibitors of platelet receptor GP IIb/IIIa should be avoided."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Geriatric Use: Risk of bleeding increases with age. ( 8.5 ) 8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus [see Clinical Considerations ] . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk: Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide injection on the fetus. Data Animal Data: Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide. 8.2 Lactation Risk Summary There are no available data on the presence of eptifibatide in human milk, the effects on the breastfed infant, or the effects on milk production. As eptifibatide is a peptide, it is likely to be destroyed in the infant\u2019s gastrointestinal tract and not absorbed orally by the breastfed infant. 8.4 Pediatric Use Safety and effectiveness of eptifibatide injection in pediatric patients have not been studied. 8.5 Geriatric Use The PURSUIT and IMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide injection. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide injection groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUIT study; no such limitation was stipulated in the ESPRIT study [see Adverse Reactions ( 6.1 )] . 8.6 Renal Impairment Approximately 50% of eptifibatide is cleared by the kidney in patients with normal renal function. Total drug clearance is decreased by approximately 50% and steady-state plasma eptifibatide injection concentrations are doubled in patients with an estimated CrCl <50 mL/min (using the Cockcroft-Gault equation). Therefore, the infusion dose should be reduced to 1 mcg/kg/min in such patients [see Dosage and Administration ( 2 )] . The safety and efficacy of eptifibatide injection in patients dependent on dialysis has not been established."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus [see Clinical Considerations ] . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk: Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide injection on the fetus. Data Animal Data: Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide."
    ],
    "risks": [
      "Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus [see Clinical Considerations ] . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.",
      "Risk Summary There are no available data on the presence of eptifibatide in human milk, the effects on the breastfed infant, or the effects on milk production. As eptifibatide is a peptide, it is likely to be destroyed in the infant\u2019s gastrointestinal tract and not absorbed orally by the breastfed infant."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety and effectiveness of eptifibatide injection in pediatric patients have not been studied."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use The PURSUIT and IMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide injection. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide injection groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUIT study; no such limitation was stipulated in the ESPRIT study [see Adverse Reactions ( 6.1 )] ."
    ],
    "overdosage": [
      "10 OVERDOSAGE There has been only limited experience with overdosage of eptifibatide injection. There were 8 patients in the IMPACT II study, 9 patients in the PURSUIT study, and no patients in the ESPRIT study who received bolus doses and/or infusion doses more than double those called for in the protocols. None of these patients experienced an intracranial bleed or other major bleeding. Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis). Symptoms of acute toxicity were loss of righting reflex, dyspnea, ptosis, and decreased muscle tone in rabbits and petechial hemorrhages in the femoral and abdominal areas of monkeys. From in vitro studies, eptifibatide is not extensively bound to plasma proteins and thus may be cleared from plasma by dialysis."
    ],
    "description": [
      "11 DESCRIPTION Eptifibatide is a cyclic heptapeptide containing 6 amino acids and 1 mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties. Chemically it is N 6 -(aminoiminomethyl)-N 2 -(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-\u03b1-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1\u21926)-disulfide. Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation. The eptifibatide peptide is produced by solution-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized. The structural formula is: Eptifibatide Injection is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use with an empirical formula of C 35 H 49 N 11 O 9 S 2 and a molecular weight of 831.96. Each 10 mL vial contains 2 mg/mL of eptifibatide injection and each 100 mL vial contains 0.75 mg/mL of eptifibatide injection. Each vial of either size also contains 5.25 mg/mL citric acid and sodium hydroxide to adjust the pH to 5.35. structural formula"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet. 12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide injection inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide injection was observed immediately after administration of a 180 mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide injection used in the IMPACT II and PURSUIT studies on ex vivo platelet aggregation induced by 20 \u00b5M ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRIT on platelet aggregation have not been studied. Table 4. Platelet Inhibition and Bleeding Time * 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. PURSUIT 180/2* Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x The eptifibatide injection dosing regimen used in the ESPRIT study included two 180 mcg/kg bolus doses given 10 minutes apart combined with a continuous 2 mcg/kg/min infusion. When administered alone, eptifibatide injection has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed. 12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180 mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4-6 hours). This decline can be prevented by administering a second 180 mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20-94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations ( 8.6 ) and Dosage and Administration ( 2 )] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "clinical_pharmacology_table": [
      "<table ID=\"_Ref468721121\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 4. Platelet Inhibition and Bleeding Time</caption><col width=\"73%\"/><col width=\"27%\"/><tfoot><tr><td align=\"left\" colspan=\"2\" valign=\"top\">* 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min.</td></tr></tfoot><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">PURSUIT</content></paragraph><paragraph><content styleCode=\"bold\">180/2*</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>Inhibition of platelet aggregation 15 min after bolus</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>84%</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Inhibition of platelet aggregation at steady state</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>&gt;90%</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Bleeding-time prolongation at steady state</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>&lt;5x</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Inhibition of platelet aggregation 4h after infusion discontinuation</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>&lt;50%</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph>Bleeding-time prolongation 6h after infusion discontinuation</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>1.4x</paragraph></td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide injection inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide injection was observed immediately after administration of a 180 mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide injection used in the IMPACT II and PURSUIT studies on ex vivo platelet aggregation induced by 20 \u00b5M ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRIT on platelet aggregation have not been studied. Table 4. Platelet Inhibition and Bleeding Time * 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. PURSUIT 180/2* Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x The eptifibatide injection dosing regimen used in the ESPRIT study included two 180 mcg/kg bolus doses given 10 minutes apart combined with a continuous 2 mcg/kg/min infusion. When administered alone, eptifibatide injection has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed."
    ],
    "pharmacodynamics_table": [
      "<table ID=\"_Ref468721121\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 4. Platelet Inhibition and Bleeding Time</caption><col width=\"73%\"/><col width=\"27%\"/><tfoot><tr><td align=\"left\" colspan=\"2\" valign=\"top\">* 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min.</td></tr></tfoot><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">PURSUIT</content></paragraph><paragraph><content styleCode=\"bold\">180/2*</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>Inhibition of platelet aggregation 15 min after bolus</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>84%</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Inhibition of platelet aggregation at steady state</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>&gt;90%</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Bleeding-time prolongation at steady state</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>&lt;5x</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Inhibition of platelet aggregation 4h after infusion discontinuation</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>&lt;50%</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph>Bleeding-time prolongation 6h after infusion discontinuation</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>1.4x</paragraph></td></tr></tbody></table>"
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180 mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4-6 hours). This decline can be prevented by administering a second 180 mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20-94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations ( 8.6 ) and Dosage and Administration ( 2 )] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Eptifibatide injection was studied in 3 placebo-controlled, randomized studies. PURSUIT evaluated patients with acute coronary syndromes: UA or NSTEMI. Two other studies, ESPRIT and IMPACT II, evaluated patients about to undergo a PCI. Patients underwent primarily balloon angioplasty in IMPACT II and intracoronary stent placement, with or without angioplasty, in ESPRIT. 14.1 Non-ST-Segment Elevation Acute Coronary Syndrome Non-ST-segment elevation acute coronary syndrome is defined as prolonged (\u226510 minutes) symptoms of cardiac ischemia within the previous 24 hours associated with either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or positive CK-MB. This definition includes \u201cunstable angina\u201d and \u201cNSTEMI\u201d but excludes MI that is associated with Q waves or greater degrees of ST-segment elevation. PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Eptifibatide Injection Therapy) PURSUIT was a 726-center, 27-country, double-blind, randomized, placebo-controlled study in 10,948 patients presenting with UA or NSTEMI. Patients could be enrolled only if they had experienced cardiac ischemia at rest (\u226510 minutes) within the previous 24 hours and had either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or increased CK-MB. Important exclusion criteria included a history of bleeding diathesis, evidence of abnormal bleeding within the previous 30 days, uncontrolled hypertension, major surgery within the previous 6 weeks, stroke within the previous 30 days, any history of hemorrhagic stroke, serum creatinine >2 mg/dL, dependency on renal dialysis, or platelet count <100,000/mm 3 . Patients were randomized to placebo, to eptifibatide injection 180 mcg/kg bolus followed by a 2 mcg/kg/min infusion (180/2), or to eptifibatide injection 180 mcg/kg bolus followed by a 1.3 mcg/kg/min infusion (180/1.3). The infusion was continued for 72 hours, until hospital discharge, or until the time of CABG, whichever occurred first, except that if PCI was performed, the eptifibatide infusion was continued for 24 hours after the procedure, allowing for a duration of infusion up to 96 hours. The lower-infusion-rate arm was stopped after the first interim analysis when the 2 active-treatment arms appeared to have the same incidence of bleeding. Patient age ranged from 20 to 94 (mean 63) years, and 65% were male. The patients were 89% Caucasian, 6% Hispanic, and 5% Black, recruited in the United States and Canada (40%), Western Europe (39%), Eastern Europe (16%), and Latin America (5%). This was a \u201creal world\u201d study; each patient was managed according to the usual standards of the investigational site; frequencies of angiography, PCI, and CABG therefore differed widely from site to site and from country to country. Of the patients in PURSUIT, 13% were managed with PCI during drug infusion, of whom 50% received intracoronary stents; 87% were managed medically (without PCI during drug infusion). The majority of patients received aspirin (75-325 mg once daily). Heparin was administered intravenously or subcutaneously, at the physician's discretion, most commonly as an intravenous bolus of 5000 units followed by a continuous infusion of 1000 units/h. For patients weighing less than 70 kg, the recommended heparin bolus dose was 60 units/kg followed by a continuous infusion of 12 units/kg/h. A target aPTT of 50 to 70 seconds was recommended. A total of 1250 patients underwent PCI within 72 hours after randomization, in which case they received intravenous heparin to maintain an ACT of 300 to 350 seconds. The primary endpoint of the study was the occurrence of death from any cause or new MI (evaluated by a blinded Clinical Endpoints Committee) within 30 days of randomization. Compared to placebo, eptifibatide injection administered as a 180 mcg/kg bolus followed by a 2 mcg/kg/min infusion significantly (p=0.042) reduced the incidence of endpoint events (see Table 6 ). The reduction in the incidence of endpoint events in patients receiving eptifibatide injection was evident early during treatment, and this reduction was maintained through at least 30 days (see Figure 1 ). Table 5 also shows the incidence of the components of the primary endpoint, death (whether or not preceded by an MI) and new MI in surviving patients at 30 days. Table 5. Clinical Events in the PURSUIT Study Death or MI Placebo (n=4739) n (%) EptifibatideInjection (180 mcg/kg bolus then 2 mcg/kg/min infusion) (n=4722) n (%) p-value 3 days 359 (7.6%) 279 (5.9%) 0.001 7 days 552 (11.6%) 477 (10.1%) 0.016 30 days Death or MI (primary endpoint) 745 (15.7%) 672 (14.2%) 0.042 Death 177 (3.7%) 165 (3.5%) Nonfatal MI 568 (12%) 507 (10.7%) Figure 1. Kaplan-Meier Plot of Time to Death or Myocardial Infarction Within 30 Days of Randomization in the PURSUIT Study Treatment with eptifibatide injection prior to determination of patient management strategy reduced clinical events regardless of whether patients ultimately underwent diagnostic catheterization, revascularization (i.e., PCI or CABG surgery) or continued to receive medical management alone. Table 6 shows the incidence of death or MI within 72 hours. Table 6. Clinical Events (Death or MI) in the PURSUIT Study Within 72 Hours of Randomization Placebo EptifibatideInjection (180 mcg/kg bolus then 2 mcg/kg/min infusion) Overall patient population n=4739 n=4722 \u2013 At 72 hours 7.6% 5.9% Patients undergoing early PCI n=631 n=619 \u2013 Pre-procedure (nonfatal MI only) 5.5% 1.8% \u2013 At 72 hours 14.4% 9% Patients not undergoing early PCI n=4108 n=4103 \u2013 At 72 hours 6.5% 5.4% All of the effect of eptifibatide injection was established within 72 hours (during the period of drug infusion), regardless of management strategy. Moreover, for patients undergoing early PCI, a reduction in events was evident prior to the procedure. An analysis of the results by sex suggests that women who would not routinely be expected to undergo PCI receive less benefit from eptifibatide injection (95% confidence limits for relative risk of 0.94 - 1.28) than do men (0.72 - 0.9). This difference may be a true treatment difference, the effect of other differences in these subgroups, or a statistical anomaly. No differential outcomes were seen between male and female patients undergoing PCI (see results for ESPRIT) . Follow-up data were available through 165 days for 10,611 patients enrolled in the PURSUIT trial (96.9% of the initial enrollment). This follow-up included 4566 patients who received eptifibatide injection at the 180/2 dose. As reported by the investigators, the occurrence of death from any cause or new MI for patients followed for at least 165 days was reduced from 13.6% with placebo to 12.1% with eptifibatide injection 180/2. figure 1 14.2 Percutaneous Coronary Intervention (PCI) IMPACT II (Eptifibatide Injection to Minimize Platelet Aggregation and Prevent Coronary Thrombosis II) IMPACT II was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States in 4010 patients undergoing PCI. Major exclusion criteria included a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 89 (mean 60) years, and 75% were male. The patients were 92% Caucasian, 5% Black, and 3% Hispanic. Forty-one percent of the patients underwent PCI for ongoing ACS. Patients were randomly assigned to 1 of 3 treatment regimens, each incorporating a bolus dose initiated immediately prior to PCI followed by a continuous infusion lasting 20 to 24 hours: 1) 135 mcg/kg bolus followed by a continuous infusion of 0.5 mcg/kg/min of eptifibatide injection (135/0.5); 2) 135 mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min of eptifibatide injection (135/0.75); or 3) a matching placebo bolus followed by a matching placebo continuous infusion. Each patient received aspirin and an intravenous heparin bolus of 100 units/kg, with additional bolus infusions of up to 2000 additional units of heparin every 15 minutes to maintain an ACT of 300 to 350 seconds. The primary endpoint was the composite of death, MI, or urgent revascularization, analyzed at 30 days after randomization in all patients who received at least 1 dose of study drug. As shown in Table 7 , each eptifibatide injection regimen reduced the rate of death, MI, or urgent intervention, although at 30 days, this finding was statistically significant only in the lower-dose eptifibatide injection group. As in the PURSUIT study, the effects of eptifibatide injection were seen early and persisted throughout the 30-day period. Table 7. Clinical Events in the IMPACT II Study Placebo n (%) Eptifibatide Injection (135 mcg/kg bolus then 0.5 mcg/kg/min infusion) n (%) Eptifibatide Injection (135 mcg/kg bolus then 0.75 mcg/kg/min infusion) n (%) * Kaplan-Meier estimate of event rate. Patients 1285 1300 1286 Abrupt Closure 65 (5.1%) 36 (2.8%) 43 (3.3%) p-value versus placebo 0.003 0.03 Death, MI, or Urgent Intervention 24 hours 123 (9.6%) 86 (6.6%) 89 (6.9%) p-value versus placebo 0.006 0.014 48 hours 131 (10.2%) 99 (7.6%) 102 (7.9%) p-value versus placebo 0.021 0.045 30 days (primary endpoint) 149 (11.6%) 118 (9.1%) 128 (10%) p-value versus placebo 0.035 0.179 Death or MI 30 days 110 (8.6%) 89 (6.8%) 95 (7.4%) p-value versus placebo 0.102 0.272 6 months 151 (11.9%)* 136 (10.6%)* 130 (10.3%)* p-value versus placebo 0.297 0.182 ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Eptifibatide Injection Therapy) The ESPRIT study was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States and Canada that enrolled 2064 patients undergoing elective or urgent PCI with intended intracoronary stent placement. Exclusion criteria included MI within the previous 24 hours, ongoing chest pain, administration of any oral antiplatelet or oral anticoagulant other than aspirin within 30 days of PCI (although loading doses of thienopyridine on the day of PCI were encouraged), planned PCI of a saphenous vein graft or subsequent \u201cstaged\u201d PCI, prior stent placement in the target lesion, PCI within the previous 90 days, a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 93 (mean 62) years, and 73% of patients were male. The study enrolled 90% Caucasian, 5% African American, 2% Hispanic, and 1% Asian patients. Patients received a wide variety of stents. Patients were randomized either to placebo or eptifibatide injection administered as an intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2 mcg/kg/min, and a second bolus of 180 mcg/kg administered 10 minutes later (180/2/180). Eptifibatide infusion was continued for 18 to 24 hours after PCI or until hospital discharge, whichever came first. Each patient received at least 1 dose of aspirin (162-325 mg) and 60 units/kg of heparin as a bolus (not to exceed 6000 units) if not already receiving a heparin infusion. Additional boluses of heparin (10-40 units/kg) could be administered in order to reach a target ACT between 200 and 300 seconds. The primary endpoint of the ESPRIT study was the composite of death, MI, urgent target vessel revascularization (UTVR), and \u201cbailout\u201d to open-label eptifibatide injection due to a thrombotic complication of PCI (TBO) (e.g., visible thrombus, \u201cno reflow,\u201d or abrupt closure) at 48 hours. MI, UTVR, and TBO were evaluated by a blinded Clinical Events Committee. As shown in Table 8 , the incidence of the primary endpoint and selected secondary endpoints was significantly reduced in patients who received eptifibatide injection. A treatment benefit in patients who received eptifibatide injection was seen by 48 hours and at the end of the 30-day observation period. Table 8. Clinical Events in the ESPRIT Study * Eptifibatide injection was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min. Placebo (n=1024) EptifibatideInjection* (n=1040) Relative Risk (95% CI) p-value Death, MI, UTVR, or Thrombotic \u201cBailout\u201d 48 hours (primary endpoint) 108 (10.5%) 69 (6.6%) 0.629 (0.471, 0.84) 0.0015 30 days 120 (11.7%) 78 (7.5%) 0.64 (0.488, 0.84) 0.0011 Death, MI, or UTVR 48 hours 95 (9.3%) 62 (6%) 0.643 (0.472, 0.875) 0.0045 30 days (key secondary endpoint) 107 (10.4%) 71 (6.8%) 0.653 (0.49, 0.871) 0.0034 Death or MI 48 hours 94 (9.2%) 57 (5.5%) 0.597 (0.435, 0.82) 0.0013 30 days 104 (10.2%) 66 (6.3%) 0.625 (0.465, 0.84) 0.0016 The need for thrombotic \u201cbailout\u201d was significantly reduced with eptifibatide injection at 48 hours (2.1% for placebo, 1% for eptifibatide injection; p=0.029). Consistent with previous studies of GP IIb/IIIa inhibitors, most of the benefit achieved acutely with eptifibatide injection was in the reduction of MI. Eptifibatide injection reduced the occurrence of MI at 48 hours from 9% for placebo to 5.4% (p=0.0015) and maintained that effect with significance at 30 days. There was no treatment difference with respect to sex in ESPRIT. Eptifibatide injection reduced the incidence of the primary endpoint in both men (95% confidence limits for relative risk: 0.54, 1.07) and women (0.24, 0.72) at 48 hours. Follow-up (12-month) mortality data were available for 2024 patients (1017 on eptifibatide injection) enrolled in the ESPRIT trial (98.1% of the initial enrollment). Twelve-month clinical event data were available for 1964 patients (988 on eptifibatide injection), representing 95.2% of the initial enrollment. As shown in Table 9 , the treatment effect of eptifibatide injection seen at 48 hours and 30 days appeared preserved at 6 months and 1 year. Most of the benefit was in reduction of MI. Table 9. Clinical Events at 6 Months and 1 Year in the ESPRIT Study Percentages are Kaplan-Meier event rates. Placebo (n=1024) EptifibatideInjection (n=1040) Hazard Ratio (95% CI) Death, MI, or Target Vessel Revascularization 6 months 187 (18.5%) 146 (14.3%) 0.744 (0.599, 0.924) 1 year 222 (22.1%) 178 (17.5%) 0.762 (0.626, 0.929) Death, MI 6 months 117 (11.5%) 77 (7.4%) 0.631 (0.473, 0.841) 1 year 126 (12.4%) 83 (8%) 0.63 (0.478, 0.832)"
    ],
    "clinical_studies_table": [
      "<table ID=\"_Ref468721221\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 5. Clinical Events in the PURSUIT Study</caption><col width=\"37%\"/><col width=\"15%\"/><col width=\"35%\"/><col width=\"12%\"/><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Death or MI</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(n=4739)</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">EptifibatideInjection (180 mcg/kg bolus then 2 mcg/kg/min infusion)</content></paragraph><paragraph><content styleCode=\"bold\">(n=4722) n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>3 days</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>359 (7.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>279 (5.9%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.001</paragraph></td></tr><tr><td valign=\"top\"><paragraph>7 days</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>552 (11.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>477 (10.1%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.016</paragraph></td></tr><tr><td valign=\"top\"><paragraph>30 days</paragraph></td><td valign=\"top\"/><td valign=\"top\"/><td valign=\"top\"/></tr><tr><td valign=\"top\"><paragraph> Death or MI (primary endpoint)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>745 (15.7%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>672 (14.2%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.042</paragraph></td></tr><tr><td valign=\"top\"><paragraph> Death</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>177 (3.7%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>165 (3.5%)</paragraph></td><td valign=\"top\"/></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph> Nonfatal MI</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>568 (12%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>507 (10.7%)</paragraph></td><td styleCode=\"Botrule \" valign=\"top\"/></tr></tbody></table>",
      "<table ID=\"_Ref468721193\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 6. Clinical Events (Death or MI) in the PURSUIT Study Within 72 Hours of Randomization</caption><col width=\"42%\"/><col width=\"29%\"/><col width=\"29%\"/><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">EptifibatideInjection</content></paragraph><paragraph><content styleCode=\"bold\">(180 mcg/kg bolus then 2 mcg/kg/min infusion)</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>Overall patient population</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>n=4739</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>n=4722</paragraph></td></tr><tr><td valign=\"top\"><paragraph> &#x2013; At 72 hours</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>7.6%</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5.9%</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Patients undergoing early PCI</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>n=631</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>n=619</paragraph></td></tr><tr><td valign=\"top\"><paragraph> &#x2013; Pre-procedure (nonfatal MI only)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5.5%</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.8%</paragraph></td></tr><tr><td valign=\"top\"><paragraph> &#x2013; At 72 hours</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>14.4%</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>9%</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Patients not undergoing early PCI</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>n=4108</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>n=4103</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph> &#x2013; At 72 hours</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>6.5%</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>5.4%</paragraph></td></tr></tbody></table>",
      "<table ID=\"_Ref468721254\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 7. Clinical Events in the IMPACT II Study</caption><col width=\"29%\"/><col width=\"15%\"/><col width=\"28%\"/><col width=\"28%\"/><thead><tr><th align=\"left\" styleCode=\"Botrule Toprule \" valign=\"bottom\"/><th align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">n (%)</content></th><th align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><content styleCode=\"bold\">Eptifibatide Injection</content> <content styleCode=\"bold\">(135 mcg/kg bolus then 0.5 mcg/kg/min infusion)</content> <content styleCode=\"bold\">n (%)</content></th><th align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><content styleCode=\"bold\">Eptifibatide Injection</content> <content styleCode=\"bold\">(135 mcg/kg bolus then 0.75 mcg/kg/min infusion)</content> <content styleCode=\"bold\">n (%)</content></th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"4\" valign=\"top\">* Kaplan-Meier estimate of event rate.</td></tr></tfoot><tbody><tr><td styleCode=\"Toprule \" valign=\"top\"><paragraph>Patients</paragraph></td><td align=\"center\" styleCode=\"Toprule \" valign=\"top\"><paragraph>1285</paragraph></td><td align=\"center\" styleCode=\"Toprule \" valign=\"top\"><paragraph>1300</paragraph></td><td align=\"center\" styleCode=\"Toprule \" valign=\"top\"><paragraph>1286</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Abrupt Closure</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>65 (5.1%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>36 (2.8%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>43 (3.3%)</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph> p-value versus placebo</paragraph></td><td styleCode=\"Botrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.003</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.03</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Death, MI, or Urgent Intervention</paragraph></td><td valign=\"top\"/><td valign=\"top\"/><td valign=\"top\"/></tr><tr><td valign=\"top\"><paragraph> 24 hours</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>123 (9.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>86 (6.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>89 (6.9%)</paragraph></td></tr><tr><td valign=\"top\"><paragraph> p-value versus placebo</paragraph></td><td valign=\"top\"/><td align=\"center\" valign=\"top\"><paragraph>0.006</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.014</paragraph></td></tr><tr><td valign=\"top\"><paragraph> 48 hours</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>131 (10.2%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>99 (7.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>102 (7.9%)</paragraph></td></tr><tr><td valign=\"top\"><paragraph> p-value versus placebo</paragraph></td><td valign=\"top\"/><td align=\"center\" valign=\"top\"><paragraph>0.021</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.045</paragraph></td></tr><tr><td valign=\"top\"><paragraph> 30 days (primary endpoint)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>149 (11.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>118 (9.1%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>128 (10%)</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph> p-value versus placebo</paragraph></td><td styleCode=\"Botrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.035</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.179</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Death or MI</paragraph></td><td valign=\"top\"/><td valign=\"top\"/><td valign=\"top\"/></tr><tr><td valign=\"top\"><paragraph> 30 days</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>110 (8.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>89 (6.8%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>95 (7.4%)</paragraph></td></tr><tr><td valign=\"top\"><paragraph> p-value versus placebo</paragraph></td><td valign=\"top\"/><td align=\"center\" valign=\"top\"><paragraph>0.102</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.272</paragraph></td></tr><tr><td valign=\"top\"><paragraph> 6 months</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>151 (11.9%)*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>136 (10.6%)*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>130 (10.3%)*</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph> p-value versus placebo</paragraph></td><td styleCode=\"Botrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.297</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.182</paragraph></td></tr></tbody></table>",
      "<table ID=\"_Ref468721274\" cellpadding=\"3.6pt\" width=\"97.88%\"><caption>Table 8. Clinical Events in the ESPRIT Study</caption><col width=\"26%\"/><col width=\"15%\"/><col width=\"23%\"/><col width=\"19%\"/><col width=\"18%\"/><tfoot><tr><td align=\"left\" colspan=\"5\" valign=\"top\">* Eptifibatide injection was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min.</td></tr></tfoot><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(n=1024)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">EptifibatideInjection*</content></paragraph><paragraph><content styleCode=\"bold\">(n=1040)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Relative Risk</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph></td></tr><tr><td colspan=\"5\" valign=\"top\"><paragraph>Death, MI, UTVR, or Thrombotic &#x201C;Bailout&#x201D;</paragraph></td></tr><tr><td valign=\"top\"><paragraph>48 hours (primary endpoint)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>108 (10.5%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>69 (6.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.629 (0.471, 0.84)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.0015</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph>30 days</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>120 (11.7%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>78 (7.5%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.64 (0.488, 0.84)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.0011</paragraph></td></tr><tr><td colspan=\"5\" valign=\"top\"><paragraph>Death, MI, or UTVR</paragraph></td></tr><tr><td valign=\"top\"><paragraph>48 hours</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>95 (9.3%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>62 (6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.643 (0.472, 0.875)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.0045</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph>30 days (key secondary endpoint)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>107 (10.4%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>71 (6.8%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.653 (0.49, 0.871)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.0034</paragraph></td></tr><tr><td colspan=\"5\" valign=\"top\"><paragraph>Death or MI</paragraph></td></tr><tr><td valign=\"top\"><paragraph>48 hours</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>94 (9.2%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>57 (5.5%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.597 (0.435, 0.82)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.0013</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph>30 days</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>104 (10.2%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>66 (6.3%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.625 (0.465, 0.84)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.0016</paragraph></td></tr></tbody></table>",
      "<table ID=\"_Ref468721295\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 9. Clinical Events at 6 Months and 1 Year in the ESPRIT Study</caption><col width=\"26%\"/><col width=\"25%\"/><col width=\"25%\"/><col width=\"25%\"/><tfoot><tr><td align=\"left\" colspan=\"4\" valign=\"top\">Percentages are Kaplan-Meier event rates.</td></tr></tfoot><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo (n=1024)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">EptifibatideInjection</content></paragraph><paragraph><content styleCode=\"bold\">(n=1040)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Hazard Ratio</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td colspan=\"4\" valign=\"top\"><paragraph>Death, MI, or Target Vessel Revascularization</paragraph></td></tr><tr><td valign=\"top\"><paragraph> 6 months</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>187 (18.5%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>146 (14.3%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.744 (0.599, 0.924)</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph> 1 year</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>222 (22.1%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>178 (17.5%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.762 (0.626, 0.929)</paragraph></td></tr><tr><td colspan=\"4\" valign=\"top\"><paragraph>Death, MI</paragraph></td></tr><tr><td valign=\"top\"><paragraph> 6 months</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>117 (11.5%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>77 (7.4%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.631 (0.473, 0.841)</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph> 1 year</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>126 (12.4%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>83 (8%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.63 (0.478, 0.832)</paragraph></td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Eptifibatide injection is supplied as a sterile solution in 10 mL vials containing 20 mg of eptifibatide (NDC 70436-162-80) and 100 mL vials containing 75 mg of eptifibatide (NDC 70436-163-80). 16.2 Storage Vials should be stored refrigerated at 2\u00b0 to 8\u00b0C (36\u00b0 to 46\u00b0F). Vials may be transferred to room temperature storage* for a period not to exceed 2 months. Upon transfer, vial cartons must be marked by the dispensing pharmacist with a \u201cDISCARD BY\u201d date (2 months from the transfer date or the labeled expiration date, whichever comes first). Protect from light until administration. *Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to inform the doctor or healthcare provider about any medical conditions, medications, and allergies. Rx only PREMIERProRx\u00ae is a registered trademark of Premier Healthcare Alliance, L.P., used under license. Manufactured by: Hainan Poly Pharm. Co., Ltd. Guilinyang Economic Development Area, Haikou, Hainan Province, China 571127 Distributed by: Slate Run Pharmaceuticals, LLC Columbus, Ohio 43215 10000233/02 Revised: 04/2021 premier-prorx-logo"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL - 20 mg CARTON LABEL NDC 70436-162-80 Eptifibatide Injection, 20 mg/10 mL (2 mg/mL) carton-2mgpermL",
      "PRINCIPAL DISPLAY PANEL - 75 mg CARTON LABEL NDC 70436-163-80 Eptifibatide Injection, 75 mg/100 mL (0.75 mg/mL) 70436-163-80"
    ],
    "set_id": "2ab98ecd-c578-4032-a3d5-ae14d58d86a7",
    "id": "4a614df8-4e1d-d610-e063-6294a90a7d7c",
    "effective_time": "20260209",
    "version": "6",
    "openfda": {
      "application_number": [
        "ANDA209864"
      ],
      "brand_name": [
        "Eptifibatide"
      ],
      "generic_name": [
        "EPTIFIBATIDE"
      ],
      "manufacturer_name": [
        "Slate Run Pharmaceuticals, LLC"
      ],
      "product_ndc": [
        "70436-162",
        "70436-163"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "INTRAVENOUS"
      ],
      "substance_name": [
        "EPTIFIBATIDE"
      ],
      "rxcui": [
        "200349",
        "1736470"
      ],
      "spl_id": [
        "4a614df8-4e1d-d610-e063-6294a90a7d7c"
      ],
      "spl_set_id": [
        "2ab98ecd-c578-4032-a3d5-ae14d58d86a7"
      ],
      "package_ndc": [
        "70436-162-80",
        "70436-163-80"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0370436163809"
      ],
      "nui": [
        "N0000008832",
        "N0000175578"
      ],
      "pharm_class_pe": [
        "Decreased Platelet Aggregation [PE]"
      ],
      "pharm_class_epc": [
        "Platelet Aggregation Inhibitor [EPC]"
      ],
      "unii": [
        "NA8320J834"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Eptifibatide Eptifibatide eptifibatide eptifibatide citric acid monohydrate sodium hydroxide water Eptifibatide Eptifibatide eptifibatide eptifibatide citric acid monohydrate sodium hydroxide water"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Eptifibatide Injection is a platelet aggregation inhibitor indicated for: Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI) ( 1.1 ) Treatment of patients undergoing PCI (including intracoronary stenting) ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Eptifibatide Injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). 1.2 Percutaneous Coronary Intervention (PCI) Eptifibatide Injection is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting [see Clinical Studies ( 14.1 , 14.2 )] ."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION Before infusion of eptifibatide injection, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured. The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT. ACS or PCI: 180 mcg/kg IV bolus as soon as possible after diagnosis followed by infusion at 2 mcg/kg/min. ( 2.1 , 2.2 ) PCI: Add a second 180 mcg/kg bolus at 10 minutes. ( 2.2 ) In patients with creatinine clearance less than 50 mL/min, reduce the infusion to 1 mcg/kg/min. ( 2.1 , 2.2 , 2.3 ) 2.1 Dosage in Acute Coronary Syndrome (ACS) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with ACS 180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min 180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy Aspirin, 160 to 325 mg, should be given daily Eptifibatide injection should be given concomitantly with heparin dosed to achieve the following parameters: During Medical Management : Target aPTT 50 to 70 seconds If weight greater than or equal to 70 kg, 5,000-unit bolus followed by infusion of 1,000 units/h. If weight less than 70 kg, 60-units/kg bolus followed by infusion of 12 units/kg/h. During PCI : Target ACT 200 to 300 seconds If heparin is initiated prior to PCI, additional boluses during PCI to maintain an ACT target of 200 to 300 seconds. Heparin infusion after the PCI is discouraged. 2.2 Dosage in Percutaneous Coronary Intervention (PCI) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with PCI 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. In patients who undergo CABG surgery, eptifibatide injection infusion should be discontinued prior to surgery. Aspirin, 160 to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter. Eptifibatide injection should be given concomitantly with heparin to achieve a target ACT of 200 to 300 seconds. Administer 60-units/kg bolus initially in patients not treated with heparin within 6 hours prior to PCI. Additional boluses during PCI to maintain ACT within target. Heparin infusion after the PCI is strongly discouraged. Patients requiring thrombolytic therapy should discontinue eptifibatide injection. 2.3 Important Administration Instructions Inspect eptifibatide injection for particulate matter and discoloration prior to administration, whenever solution and container permit. May administer eptifibatide injection in the same intravenous line as alteplase, atropine, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, or verapamil. Do not administer eptifibatide injection through the same intravenous line as furosemide. May administer eptifibatide injection in the same IV line with 0.9% NaCl or 0.9% NaCl/5% dextrose. With either vehicle, the infusion may also contain up to 60 mEq/L of potassium chloride. Withdraw the bolus dose(s) of eptifibatide injection from the 10 mL vial into a syringe. Administer the bolus dose(s) by IV push. Immediately following the bolus dose administration, initiate a continuous infusion of eptifibatide injection. When using an intravenous infusion pump, administer eptifibatide injection undiluted directly from the 100 mL vial. Spike the 100 mL vial with a vented infusion set. Center the spike within the circle on the stopper top. Discard any unused portion left in the vial. Administer eptifibatide injection by volume according to patient weight (see Table 1 ). Table 1: Eptifibatide Injection Dosing Charts by Weight Patient Weight 180 mcg/kg Bolus Volume 2 mcg/kg/min Infusion Volume (CrCl greater than or equal to 50 mL/min) 1 mcg/kg/min Infusion Volume (CrCl less than 50 mL/min) (kg) (lb) (from 2 mg per mL vial) (from 2 mg per mL 100 mL vial) (from 0.75 mg per mL 100 mL vial) (from 2 mg per mL 100 mL vial) (from 0.75 mg per mL 100 mL vial) 37-41 81-91 3.4 mL 2 mL/h 6 mL/h 1 mL/h 3 mL/h 42-46 92-102 4 mL 2.5 mL/h 7 mL/h 1.3 mL/h 3.5 mL/h 47-53 103-117 4.5 mL 3 mL/h 8 mL/h 1.5 mL/h 4 mL/h 54-59 118-130 5 mL 3.5 mL/h 9 mL/h 1.8 mL/h 4.5 mL/h 60-65 131-143 5.6 mL 3.8 mL/h. 10 mL/h 1.9 mL/h 5 mL/h 66-71 144-157 6.2 mL 4 mL/h 11 mL/h 2 mL/h 5.5 mL/h 72-78 158-172 6.8 mL 4.5 mL/h 12 mL/h 2.3 mL/h 6 mL/h 79-84 173-185 7.3 mL 5 mL/h 13 mL/h 2.5 mL/h 6.5 mL/h 85-90 186-198 7.9 mL 5.3 mL/h 14 mL/h 2.7 mL/h 7 mL/h 91-96 199-212 8.5 mL 5.6 mL/h 15 mL/h 2.8 mL/h 7.5 mL/h 97-103 213-227 9 mL 6 mL/h 16 mL/h 3.0 mL/h 8 mL/h 104-109 228-240 9.5 mL 6.4 mL/h 17 mL/h 3.2 mL/h 8.5 mL/h 110-115 241-253 10.2 mL 6.8 mL/h 18 mL/h 3.4 mL/h 9 mL/h 116-121 254-267 10.7 mL 7 mL/h 19 mL/h 3.5 mL/h 9.5 mL/h >121 >267 11.3 mL 7.5 mL/h 20 mL/h 3.7 mL/h 10 mL/h"
    ],
    "dosage_and_administration_table": [
      "<table width=\"100%\"><col width=\"19.200%\" align=\"left\"/><col width=\"32.733%\" align=\"left\"/><col width=\"48.067%\" align=\"left\"/><tbody><tr><td align=\"left\" valign=\"top\" styleCode=\"Toprule Botrule Lrule Rrule\"><content styleCode=\"bold\">Indication</content></td><td align=\"left\" valign=\"top\" styleCode=\"Toprule Botrule Rrule\"><content styleCode=\"bold\">Normal Renal Function</content></td><td align=\"left\" valign=\"top\" styleCode=\"Toprule Botrule Rrule\"><content styleCode=\"bold\">Creatinine Clearance less than 50 mL/min</content></td></tr><tr><td align=\"left\" valign=\"top\" styleCode=\"Botrule Lrule Rrule\">Patients with ACS </td><td align=\"left\" valign=\"top\" styleCode=\"Botrule Rrule\">180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min </td><td align=\"left\" valign=\"top\" styleCode=\"Botrule Rrule\">180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min </td></tr><tr><td align=\"left\" valign=\"top\" styleCode=\"Botrule Lrule Rrule\"/><td colspan=\"2\" align=\"left\" valign=\"top\" styleCode=\"Botrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours </item><item>If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy </item><item>Aspirin, 160 to 325 mg, should be given daily </item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"19.200%\" align=\"left\"/><col width=\"32.733%\" align=\"left\"/><col width=\"48.067%\" align=\"left\"/><tbody><tr><td align=\"left\" valign=\"top\" styleCode=\"Toprule Botrule Lrule Rrule\"><content styleCode=\"bold\">Indication</content></td><td align=\"left\" valign=\"top\" styleCode=\"Toprule Botrule Rrule\"><content styleCode=\"bold\">Normal Renal Function</content></td><td align=\"left\" valign=\"top\" styleCode=\"Toprule Botrule Rrule\"><content styleCode=\"bold\">Creatinine Clearance less than 50 mL/min</content></td></tr><tr><td align=\"left\" valign=\"top\" styleCode=\"Botrule Lrule Rrule\">Patients with PCI </td><td align=\"left\" valign=\"top\" styleCode=\"Botrule Rrule\">180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) </td><td align=\"left\" valign=\"top\" styleCode=\"Botrule Rrule\">180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) </td></tr><tr><td align=\"left\" valign=\"top\" styleCode=\"Botrule Lrule Rrule\"/><td colspan=\"2\" align=\"left\" valign=\"top\" styleCode=\"Botrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. </item><item>In patients who undergo CABG surgery, eptifibatide injection infusion should be discontinued prior to surgery. </item><item>Aspirin, 160 to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter. </item></list></td></tr></tbody></table>",
      "<table ID=\"t1\" width=\"100%\"><caption>Table 1: Eptifibatide Injection Dosing Charts by Weight </caption><col width=\"9.613%\" align=\"left\"/><col width=\"9.656%\" align=\"left\"/><col width=\"15.384%\" align=\"left\"/><col width=\"15.384%\" align=\"left\"/><col width=\"17.298%\" align=\"left\"/><col width=\"16.326%\" align=\"left\"/><col width=\"16.341%\" align=\"left\"/><tbody><tr><td colspan=\"2\" align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule Lrule\"><content styleCode=\"bold\">Patient Weight</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">180 mcg/kg</content> <content styleCode=\"bold\">Bolus Volume</content></td><td colspan=\"2\" align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">2 mcg/kg/min</content> <content styleCode=\"bold\">Infusion Volume</content> <content styleCode=\"bold\">(CrCl greater than or equal to 50 mL/min)</content></td><td colspan=\"2\" align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule Rrule\"><content styleCode=\"bold\">1 mcg/kg/min</content> <content styleCode=\"bold\">Infusion Volume</content> <content styleCode=\"bold\">(CrCl less than 50 mL/min)</content></td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Botrule Lrule\"><content styleCode=\"bold\">(kg)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"><content styleCode=\"bold\">(lb)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"><content styleCode=\"bold\">(from 2 mg  per mL vial)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"><content styleCode=\"bold\">(from 2 mg  per mL</content> <content styleCode=\"bold\">100 mL vial)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"><content styleCode=\"bold\">(from 0.75 mg  per mL</content> <content styleCode=\"bold\">100 mL vial)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"><content styleCode=\"bold\">(from 2 mg  per mL</content> <content styleCode=\"bold\">100 mL vial)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule Rrule\"><content styleCode=\"bold\">(from 0.75 mg  per mL</content> <content styleCode=\"bold\">100 mL vial)</content></td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">37-41 </td><td align=\"center\" valign=\"top\">81-91 </td><td align=\"center\" valign=\"top\">3.4 mL </td><td align=\"center\" valign=\"top\">2 mL/h </td><td align=\"center\" valign=\"top\">6 mL/h </td><td align=\"center\" valign=\"top\">1 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">3 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">42-46 </td><td align=\"center\" valign=\"top\">92-102 </td><td align=\"center\" valign=\"top\">4 mL </td><td align=\"center\" valign=\"top\">2.5 mL/h </td><td align=\"center\" valign=\"top\">7 mL/h </td><td align=\"center\" valign=\"top\">1.3 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">3.5 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">47-53 </td><td align=\"center\" valign=\"top\">103-117 </td><td align=\"center\" valign=\"top\">4.5 mL </td><td align=\"center\" valign=\"top\">3 mL/h </td><td align=\"center\" valign=\"top\">8 mL/h </td><td align=\"center\" valign=\"top\">1.5 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">4 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">54-59 </td><td align=\"center\" valign=\"top\">118-130 </td><td align=\"center\" valign=\"top\">5 mL </td><td align=\"center\" valign=\"top\">3.5 mL/h </td><td align=\"center\" valign=\"top\">9 mL/h </td><td align=\"center\" valign=\"top\">1.8 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">4.5 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">60-65 </td><td align=\"center\" valign=\"top\">131-143 </td><td align=\"center\" valign=\"top\">5.6 mL </td><td align=\"center\" valign=\"top\">3.8 mL/h. </td><td align=\"center\" valign=\"top\">10 mL/h </td><td align=\"center\" valign=\"top\">1.9 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">5 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">66-71 </td><td align=\"center\" valign=\"top\">144-157 </td><td align=\"center\" valign=\"top\">6.2 mL </td><td align=\"center\" valign=\"top\">4 mL/h </td><td align=\"center\" valign=\"top\">11 mL/h </td><td align=\"center\" valign=\"top\">2 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">5.5 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">72-78 </td><td align=\"center\" valign=\"top\">158-172 </td><td align=\"center\" valign=\"top\">6.8 mL </td><td align=\"center\" valign=\"top\">4.5 mL/h </td><td align=\"center\" valign=\"top\">12 mL/h </td><td align=\"center\" valign=\"top\">2.3 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">6 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">79-84 </td><td align=\"center\" valign=\"top\">173-185 </td><td align=\"center\" valign=\"top\">7.3 mL </td><td align=\"center\" valign=\"top\">5 mL/h </td><td align=\"center\" valign=\"top\">13 mL/h </td><td align=\"center\" valign=\"top\">2.5 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">6.5 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">85-90 </td><td align=\"center\" valign=\"top\">186-198 </td><td align=\"center\" valign=\"top\">7.9 mL </td><td align=\"center\" valign=\"top\">5.3 mL/h </td><td align=\"center\" valign=\"top\">14 mL/h </td><td align=\"center\" valign=\"top\">2.7 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">7 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">91-96 </td><td align=\"center\" valign=\"top\">199-212 </td><td align=\"center\" valign=\"top\">8.5 mL </td><td align=\"center\" valign=\"top\">5.6 mL/h </td><td align=\"center\" valign=\"top\">15 mL/h </td><td align=\"center\" valign=\"top\">2.8 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">7.5 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">97-103 </td><td align=\"center\" valign=\"top\">213-227 </td><td align=\"center\" valign=\"top\">9 mL </td><td align=\"center\" valign=\"top\">6 mL/h </td><td align=\"center\" valign=\"top\">16 mL/h </td><td align=\"center\" valign=\"top\">3.0 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">8 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">104-109 </td><td align=\"center\" valign=\"top\">228-240 </td><td align=\"center\" valign=\"top\">9.5 mL </td><td align=\"center\" valign=\"top\">6.4 mL/h </td><td align=\"center\" valign=\"top\">17 mL/h </td><td align=\"center\" valign=\"top\">3.2 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">8.5 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">110-115 </td><td align=\"center\" valign=\"top\">241-253 </td><td align=\"center\" valign=\"top\">10.2 mL </td><td align=\"center\" valign=\"top\">6.8 mL/h </td><td align=\"center\" valign=\"top\">18 mL/h </td><td align=\"center\" valign=\"top\">3.4 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">9 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">116-121 </td><td align=\"center\" valign=\"top\">254-267 </td><td align=\"center\" valign=\"top\">10.7 mL </td><td align=\"center\" valign=\"top\">7 mL/h </td><td align=\"center\" valign=\"top\">19 mL/h </td><td align=\"center\" valign=\"top\">3.5 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">9.5 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Botrule Lrule\">&gt;121 </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">&gt;267 </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">11.3 mL </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">7.5 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">20 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">3.7 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule Rrule\">10 mL/h </td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Injection: 20 mg of Eptifibatide Injection in 10 mL (2 mg per mL), for intravenous bolus Injection: 75 mg of Eptifibatide Injection in 100 mL (0.75 mg per mL), for intravenous infusion 20 mg per 10 mL (2 mg per mL) in a single-dose vial for bolus injection ( 3 ) 75 mg per 100 mL (0.75 mg per mL) in a single-dose vial for infusion ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Treatment with eptifibatide is contraindicated in patients with: A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another parenteral GP IIb/IIIa inhibitor Dependency on renal dialysis Hypersensitivity to eptifibatide or any component of the product (hypersensitivity reactions that occurred included anaphylaxis and urticaria) Bleeding diathesis or bleeding within the previous 30 days ( 4 ) Severe uncontrolled hypertension ( 4 ) Major surgery within the preceding 6 weeks ( 4 ) Stroke within 30 days or any history of hemorrhagic stroke ( 4 ) Coadministration of another parenteral GP IIb/IIIa inhibitor ( 4 ) Dependency on renal dialysis ( 4 ) Known hypersensitivity to any component of the product ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Eptifibatide injection can cause serious bleeding. If bleeding cannot be controlled, discontinue eptifibatide injection immediately. Minimize vascular and other traumas. If heparin is given concomitantly, monitor aPTT or ACT. ( 5.1 ) Thrombocytopenia: Discontinue eptifibatide injection and heparin. Monitor and treat condition appropriately. ( 5.2 ) 5.1 Bleeding Bleeding is the most common complication encountered during eptifibatide therapy. Administration of eptifibatide is associated with an increase in major and minor bleeding, as classified by the criteria of the Thrombolysis in Myocardial Infarction Study group (TIMI) [see Adverse Reactions ( 6.1 )] . Most major bleeding associated with eptifibatide has been at the arterial access site for cardiac catheterization or from the gastrointestinal or genitourinary tract. Minimize the use of arterial and venous punctures, intramuscular injections, and the use of urinary catheters, nasotracheal intubation, and nasogastric tubes. When obtaining intravenous access, avoid non-compressible sites (e.g., subclavian or jugular veins). Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Risk factors for bleeding include older age, a history of bleeding disorders, and concomitant use of drugs that increase the risk of bleeding (thrombolytics, oral anticoagulants, nonsteroidal anti-inflammatory drugs, and P2Y 12 inhibitors). Concomitant treatment with other inhibitors of platelet receptor glycoprotein (GP) IIb/IIIa should be avoided. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT [see Dosage and Administration ( 2 )] . Care of the Femoral Artery Access Site in Patients Undergoing Percutaneous Coronary Intervention (PCI) In patients undergoing PCI, treatment with eptifibatide is associated with an increase in major and minor bleeding at the site of arterial sheath placement. After PCI, eptifibatide infusion should be continued until hospital discharge or up to 18 to 24 hours, whichever comes first. Heparin use is discouraged after the PCI procedure. Early sheath removal is encouraged while eptifibatide is being infused. Prior to removing the sheath, it is recommended that heparin be discontinued for 3 to 4 hours and an aPTT of <45 seconds or ACT <150 seconds be achieved. In any case, both heparin and eptifibatide should be discontinued and sheath hemostasis should be achieved at least 2 to 4 hours before hospital discharge. If bleeding at access site cannot be controlled with pressure, infusion of eptifibatide and heparin should be discontinued immediately. 5.2 Thrombocytopenia There have been reports of acute, profound thrombocytopenia (immune-mediated and non-immune mediated) with eptifibatide. In the event of acute profound thrombocytopenia or a confirmed platelet decrease to <100,000/mm 3 , discontinue eptifibatide and heparin (unfractionated or low-molecular weight). Monitor serial platelet counts, assess the presence of drug-dependent antibodies, and treat as appropriate [see Adverse Reactions ( 6.1 )] . There has been no clinical experience with eptifibatide initiated in patients with a baseline platelet count <100,000/mm 3 . If a patient with low platelet counts is receiving eptifibatide, their platelet count should be monitored closely."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reaction is also discussed elsewhere in the labeling: Bleeding [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )] Bleeding and hypotension are the most commonly reported adverse reactions. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals, Inc. at 1-844-824-8426 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. A total of 16,782 patients were treated in the Phase III clinical trials (PURSUIT, ESPRIT, and IMPACT II) [see Clinical Studies ( 14 )] . These 16,782 patients had a mean age of 62 years (range: 20-94 years). Eighty-nine percent of the patients were Caucasian, with the remainder being predominantly Black (5%) and Hispanic (5%). Sixty-eight percent were men. Because of the different regimens used in PURSUIT, IMPACT II, and ESPRIT, data from the 3 studies were not pooled. Bleeding and hypotension were the most commonly reported adverse reactions (incidence \u22655% and greater than placebo) in the eptifibatide controlled clinical trial database. Bleeding The incidence of bleeding and transfusions in the PURSUIT and ESPRIT studies are shown in Table 2 . Bleeding was classified as major or minor by the criteria of the TIMI study group. Major bleeding consisted of intracranial hemorrhage and other bleeding that led to decreases in hemoglobin greater than 5 g/dL. Minor bleeding included spontaneous gross hematuria, spontaneous hematemesis, other observed blood loss with a hemoglobin decrease of more than 3 g/dL, and other hemoglobin decreases that were greater than 4 g/dL but less than 5 g/dL. In patients who received transfusions, the corresponding loss in hemoglobin was estimated through an adaptation of the method of Landefeld et al. Table 2: Bleeding and Transfusions in the PURSUIT and ESPRIT Studies Note: Denominator is based on patients for whom data are available. * For major and minor bleeding, patients are counted only once according to the most severe classification. \u2020 Includes transfusions of whole blood, packed red blood cells, fresh frozen plasma, cryoprecipitate, platelets, and autotransfusion during the initial hospitalization. PURSUIT (ACS) Placebo n (%) Eptifibatide 180/2 n (%) Patients 4696 4679 Major bleeding* 425 (9.3%) 498 (10.8%) Minor bleeding* 347 (7.6%) 604 (13.1%) Requiring transfusions \u2020 490 (10.4%) 601 (12.8%) ESPRIT (PCI) Placebo n (%) Eptifibatide 180/2/180 n (%) Patients 1024 1040 Major bleeding* 4 (0.4%) 13 (1.3%) Minor bleeding* 18 (2%) 29 (3%) Requiring transfusions \u2020 11 (1.1%) 16 (1.5%) The majority of major bleeding reactions in the ESPRIT study occurred at the vascular access site (1 and 8 patients, or 0.1% and 0.8% in the placebo and eptifibatide groups, respectively). Bleeding at \"other\" locations occurred in 0.2% and 0.4% of patients, respectively. In the PURSUIT study, the greatest increase in major bleeding in eptifibatide-treated patients compared to placebo-treated patients was also associated with bleeding at the femoral artery access site (2.8% versus 1.3%). Oropharyngeal (primarily gingival), genitourinary, gastrointestinal, and retroperitoneal bleeding were also seen more commonly in eptifibatide-treated patients compared to placebo-treated patients. Among patients experiencing a major bleed in the IMPACT II study, an increase in bleeding on eptifibatide versus placebo was observed only for the femoral artery access site (3.2% versus 2.8%). Table 3 displays the incidence of TIMI major bleeding according to the cardiac procedures carried out in the PURSUIT study. The most common bleeding complications were related to cardiac revascularization (CABG-related or femoral artery access site bleeding). A corresponding table for ESPRIT is not presented, as every patient underwent PCI in the ESPRIT study and only 11 patients underwent CABG. Table 3: Major Bleeding by Procedures in the PURSUIT Study Note: Denominators are based on the total number of patients whose TIMI classification was resolved. Placebo n (%) Eptifibatide 180/2 n (%) Patients 4577 4604 Overall incidence of major bleeding 425 (9.3%) 498 (10.8%) Breakdown by procedure: CABG 375 (8.2%) 377 (8.2%) Angioplasty without CABG 27 (0.6%) 64 (1.4%) Angiography without angioplasty or CABG 11 (0.2%) 29 (0.6%) Medical therapy only 12 (0.3%) 28 (0.6%) In the PURSUIT and ESPRIT studies, the risk of major bleeding with eptifibatide increased as patient weight decreased. This relationship was most apparent for patients weighing less than 70 kg. Bleeding resulting in discontinuation of the study drug was more frequent among patients receiving eptifibatide than placebo (4.6% versus 0.9% in ESPRIT, 8% versus 1% in PURSUIT, 3.5% versus 1.9% in IMPACT II). Intracranial Hemorrhage and Stroke Intracranial hemorrhage was rare in the PURSUIT, IMPACT II, and ESPRIT clinical studies. In the PURSUIT study, 3 patients in the placebo group, 1 patient in the group treated with eptifibatide 180/1.3, and 5 patients in the group treated with eptifibatide 180/2 experienced a hemorrhagic stroke. The overall incidence of stroke was 0.5% in patients receiving eptifibatide 180/1.3, 0.7% in patients receiving eptifibatide 180/2, and 0.8% in placebo patients. In the IMPACT II study, intracranial hemorrhage was experienced by 1 patient treated with eptifibatide 135/0.5, 2 patients treated with eptifibatide 135/0.75, and 2 patients in the placebo group. The overall incidence of stroke was 0.5% in patients receiving 135/0.5 eptifibatide, 0.7% in patients receiving eptifibatide 135/0.75, and 0.7% in the placebo group. In the ESPRIT study, there were 3 hemorrhagic strokes, 1 in the placebo group and 2 in the eptifibatide group. In addition there was 1 case of cerebral infarction in the eptifibatide group. Immunogenicity/Thrombocytopenia The potential for development of antibodies to eptifibatide has been studied in 433 subjects. eptifibatide was nonantigenic in 412 patients receiving a single administration of eptifibatide (135-mcg/kg bolus followed by a continuous infusion of either 0.5 mcg/kg/min or 0.75 mcg/kg/min), and in 21 subjects to whom eptifibatide (135 mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min) was administered twice, 28 days apart. In both cases, plasma for antibody detection was collected approximately 30 days after each dose. The development of antibodies to eptifibatide at higher doses has not been evaluated. In patients with suspected eptifibatide-related immune-mediated thrombocytopenia, IgG antibodies that react with the GP IIb/IIIa complex were identified in the presence of eptifibatide and in eptifibatide-na\u00efve patients. These findings suggest acute thrombocytopenia after the administration of eptifibatide can develop as a result of naturally occurring drug-dependent antibodies or those induced by prior exposure to eptifibatide. Similar antibodies were identified with other GP IIb/IIIa ligand-mimetic agents. Immune-mediated thrombocytopenia with eptifibatide may be associated with hypotension and/or other signs of hypersensitivity. In the PURSUIT and IMPACT II studies, the incidence of thrombocytopenia (<100,000/mm 3 or \u226550% reduction from baseline) and the incidence of platelet transfusions were similar between patients treated with eptifibatide and placebo. In the ESPRIT study, the incidence was 0.6% in the placebo group and 1.2% in the eptifibatide group. Other Adverse Reactions In the PURSUIT and ESPRIT studies, the incidence of serious nonbleeding adverse reactions was similar in patients receiving placebo or eptifibatide (19% and 19%, respectively, in PURSUIT; 6% and 7%, respectively, in ESPRIT). In PURSUIT, the only serious nonbleeding adverse reaction that occurred at a rate of at least 1% and was more common with eptifibatide than placebo (7% versus 6%) was hypotension. Most of the serious nonbleeding adverse reactions consisted of cardiovascular reactions typical of a UA population. In the IMPACT II study, serious nonbleeding adverse reactions that occurred in greater than 1% of patients were uncommon and similar in incidence between placebo- and eptifibatide-treated patients. Discontinuation of study drug due to adverse reactions other than bleeding was uncommon in the PURSUIT, IMPACT II, and ESPRIT studies, with no single reaction occurring in >0.5% of the study population (except for \"other\" in the ESPRIT study). 6.2 Postmarketing Experience The following adverse reactions have been reported in post-approval use of eptifibatide in combination with heparin and aspirin. Because the reactions below are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure: cerebral, GI, and pulmonary hemorrhage. Fatal bleeding reactions have been reported. Acute profound thrombocytopenia, as well as immune-mediated thrombocytopenia, have been reported [see Adverse Reactions ( 6.1 )] ."
    ],
    "adverse_reactions_table": [
      "<table ID=\"t2\" width=\"100%\"><caption>Table 2: Bleeding and Transfusions in the PURSUIT and ESPRIT Studies </caption><colgroup><col width=\"33.333%\" align=\"left\"/><col width=\"33.333%\" align=\"left\"/><col width=\"33.333%\" align=\"left\"/></colgroup><tfoot><tr><td colspan=\"3\" align=\"left\" valign=\"top\"><paragraph styleCode=\"First Footnote\">Note: Denominator is based on patients for whom data are available.</paragraph></td></tr><tr><td colspan=\"3\" align=\"left\" valign=\"top\"><paragraph styleCode=\"First Footnote\">* For major and minor bleeding, patients are counted only once according to the most severe classification.</paragraph></td></tr><tr><td colspan=\"3\" align=\"left\" valign=\"top\"><paragraph styleCode=\"First Footnote\"><sup>&#x2020;</sup> Includes transfusions of whole blood, packed red blood cells, fresh frozen plasma, cryoprecipitate, platelets, and autotransfusion during the initial hospitalization.</paragraph></td></tr></tfoot><tbody><tr><td styleCode=\"Toprule\" colspan=\"3\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">PURSUIT (ACS)</content></td></tr><tr><td styleCode=\"Botrule\" align=\"left\" valign=\"top\"/><td styleCode=\"Botrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Placebo</content>  <content styleCode=\"bold\">n (%)</content></td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">180/2</content> <content styleCode=\"bold\">n (%)</content></td></tr><tr><td align=\"left\" valign=\"top\">Patients</td><td align=\"center\" valign=\"top\">4696</td><td align=\"center\" valign=\"top\">4679</td></tr><tr><td align=\"left\" valign=\"top\">Major bleeding*</td><td align=\"center\" valign=\"top\">425 (9.3%)</td><td align=\"center\" valign=\"top\">498 (10.8%)</td></tr><tr><td align=\"left\" valign=\"top\">Minor bleeding*</td><td align=\"center\" valign=\"top\">347 (7.6%)</td><td align=\"center\" valign=\"top\">604 (13.1%)</td></tr><tr><td styleCode=\"Botrule\" align=\"left\" valign=\"top\">Requiring transfusions<sup>&#x2020;</sup></td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">490 (10.4%)</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">601 (12.8%)</td></tr><tr><td colspan=\"3\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">ESPRIT (PCI)</content></td></tr><tr><td styleCode=\"Botrule\" align=\"left\" valign=\"top\"/><td styleCode=\"Botrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Placebo</content>  <content styleCode=\"bold\">n (%)</content></td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">180/2/180</content> <content styleCode=\"bold\">n (%)</content></td></tr><tr><td align=\"left\" valign=\"top\">Patients</td><td align=\"center\" valign=\"top\">1024</td><td align=\"center\" valign=\"top\">1040</td></tr><tr><td align=\"left\" valign=\"top\">Major bleeding*</td><td align=\"center\" valign=\"top\">4 (0.4%)</td><td align=\"center\" valign=\"top\">13 (1.3%)</td></tr><tr><td align=\"left\" valign=\"top\">Minor bleeding*</td><td align=\"center\" valign=\"top\">18 (2%)</td><td align=\"center\" valign=\"top\">29 (3%)</td></tr><tr><td styleCode=\"Botrule\" align=\"left\" valign=\"top\">Requiring transfusions<sup>&#x2020;</sup></td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">11 (1.1%)</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">16 (1.5%)</td></tr></tbody></table>",
      "<table ID=\"t3\" width=\"100%\"><caption>Table 3: Major Bleeding by Procedures in the PURSUIT Study </caption><colgroup><col width=\"55.785%\" align=\"left\"/><col width=\"22.107%\" align=\"left\"/><col width=\"22.107%\" align=\"left\"/></colgroup><tfoot><tr styleCode=\"First Last\"><td colspan=\"3\" align=\"left\" valign=\"top\"><paragraph styleCode=\"First Footnote\">Note: Denominators are based on the total number of patients whose TIMI classification was resolved.</paragraph></td></tr></tfoot><tbody><tr><td styleCode=\"Botrule Toprule\" align=\"left\" valign=\"top\"/><td styleCode=\"Botrule Toprule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Placebo</content>  <content styleCode=\"bold\">n (%)</content></td><td styleCode=\"Botrule Toprule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">180/2</content> <content styleCode=\"bold\">n (%)</content></td></tr><tr><td align=\"left\" valign=\"top\">Patients</td><td align=\"center\" valign=\"top\">4577</td><td align=\"center\" valign=\"top\">4604</td></tr><tr><td align=\"left\" valign=\"top\">Overall incidence of major bleeding</td><td align=\"center\" valign=\"top\">425 (9.3%)</td><td align=\"center\" valign=\"top\">498 (10.8%)</td></tr><tr><td align=\"left\" valign=\"top\">Breakdown by procedure:</td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/></tr><tr><td align=\"left\" valign=\"top\"> CABG</td><td align=\"center\" valign=\"top\">375 (8.2%)</td><td align=\"center\" valign=\"top\">377 (8.2%)</td></tr><tr><td align=\"left\" valign=\"top\"> Angioplasty without CABG</td><td align=\"center\" valign=\"top\">27 (0.6%)</td><td align=\"center\" valign=\"top\">64 (1.4%)</td></tr><tr><td align=\"left\" valign=\"top\"> Angiography without angioplasty or CABG</td><td align=\"center\" valign=\"top\">11 (0.2%)</td><td align=\"center\" valign=\"top\">29 (0.6%)</td></tr><tr><td styleCode=\"Botrule\" align=\"left\" valign=\"top\"> Medical therapy only</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">12 (0.3%)</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">28 (0.6%)</td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Avoid concomitant use with other glycoprotein (GP) IIb/IIIa inhibitors. ( 7.1 ) 7.1 Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Concomitant treatment with other inhibitors of platelet receptor GP IIb/IIIa should be avoided."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Geriatric Use: Risk of bleeding increases with age. ( 8.5 ) 8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus (see Clinical Considerations ) . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide on the fetus. Data Animal Data Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide. 8.2 Lactation Risk Summary There are no available data on the presence of eptifibatide in human milk, the effects on the breastfed infant, or the effects on milk production. As eptifibatide is a peptide, it is likely to be destroyed in the infant\u2019s gastrointestinal tract and not absorbed orally by the breastfed infant. 8.4 Pediatric Use Safety and effectiveness of eptifibatide in pediatric patients have not been studied. 8.5 Geriatric Use The PURSUIT and IMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUIT study; no such limitation was stipulated in the ESPRIT study [see Adverse Reactions ( 6.1 )] . 8.6 Renal Impairment Approximately 50% of eptifibatide is cleared by the kidney in patients with normal renal function. Total drug clearance is decreased by approximately 50% and steady-state plasma eptifibatide concentrations are doubled in patients with an estimated CrCl <50 mL/min (using the Cockcroft-Gault equation). Therefore, the infusion dose should be reduced to 1 mcg/kg/min in such patients [see Dosage and Administration ( 2 )] . The safety and efficacy of eptifibatide in patients dependent on dialysis has not been established."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus (see Clinical Considerations ) . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide on the fetus. Data Animal Data Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety and effectiveness of eptifibatide in pediatric patients have not been studied."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use The PURSUIT and IMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUIT study; no such limitation was stipulated in the ESPRIT study [see Adverse Reactions ( 6.1 )] ."
    ],
    "overdosage": [
      "10 OVERDOSAGE There has been only limited experience with overdosage of eptifibatide. There were 8 patients in the IMPACT II study, 9 patients in the PURSUIT study, and no patients in the ESPRIT study who received bolus doses and/or infusion doses more than double those called for in the protocols. None of these patients experienced an intracranial bleed or other major bleeding. Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis). Symptoms of acute toxicity were loss of righting reflex, dyspnea, ptosis, and decreased muscle tone in rabbits and petechial hemorrhages in the femoral and abdominal areas of monkeys. From in vitro studies, eptifibatide is not extensively bound to plasma proteins and thus may be cleared from plasma by dialysis."
    ],
    "description": [
      "11 DESCRIPTION Eptifibatide is a cyclic heptapeptide containing 6 amino acids and 1 mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties. Chemically it is N 6 -(aminoiminomethyl)-N 2 -(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-\u03b1-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1\u21926)-disulfide. Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation. The eptifibatide peptide is produced by solid-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized. The structural formula is: Eptifibatide Injection is a clear, colorless, sterile, nonpyrogenic solution for intravenous (IV) use with an empirical formula of C 35 H 49 N 11 O 9 S 2 and a molecular weight of 831.96. Each 10 mL single-dose vial contains 2 mg per mL of Eptifibatide Injection and each 100 mL single-dose vial contains 0.75 mg per mL of Eptifibatide Injection. Each vial of either size also contains 5.25 mg per mL citric acid monohydrate and sodium hydroxide to adjust the pH to 5.35. structural formula"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet. 12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide was observed immediately after administration of a 180 mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide used in the IMPACT II and PURSUIT studies on ex vivo platelet aggregation induced by 20 \u03bcM ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRIT on platelet aggregation have not been studied. Table 4: Platelet Inhibition and Bleeding Time * 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. PURSUIT 180/2* Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x The eptifibatide dosing regimen used in the ESPRIT study included two 180 mcg/kg bolus doses given 10 minutes apart combined with a continuous 2 mcg/kg/min infusion. When administered alone, eptifibatide has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed. 12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180 mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4-6 hours). This decline can be prevented by administering a second 180 mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20-94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations ( 8.6 ) and Dosage and Administration ( 2 )] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "clinical_pharmacology_table": [
      "<table ID=\"t4\" width=\"100%\"><caption>Table 4: Platelet Inhibition and Bleeding Time </caption><col width=\"80.100%\" align=\"left\"/><col width=\"19.900%\" align=\"left\"/><tfoot><tr><td colspan=\"2\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\">* 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. </paragraph></td></tr></tfoot><tbody><tr><td align=\"left\" valign=\"top\" styleCode=\"Toprule Botrule\"/><td align=\"left\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">PURSUIT</content> <content styleCode=\"bold\">180/2*</content></td></tr><tr><td align=\"left\" valign=\"top\">Inhibition of platelet aggregation 15 min after bolus </td><td align=\"left\" valign=\"top\">84% </td></tr><tr><td align=\"left\" valign=\"top\">Inhibition of platelet aggregation at steady state </td><td align=\"left\" valign=\"top\">&gt;90% </td></tr><tr><td align=\"left\" valign=\"top\">Bleeding-time prolongation at steady state </td><td align=\"left\" valign=\"top\">&lt;5x </td></tr><tr><td align=\"left\" valign=\"top\">Inhibition of platelet aggregation 4h after infusion discontinuation </td><td align=\"left\" valign=\"top\">&lt;50% </td></tr><tr><td align=\"left\" valign=\"top\" styleCode=\"Botrule\">Bleeding-time prolongation 6h after infusion discontinuation </td><td align=\"left\" valign=\"top\" styleCode=\"Botrule\">1.4x </td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide was observed immediately after administration of a 180 mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide used in the IMPACT II and PURSUIT studies on ex vivo platelet aggregation induced by 20 \u03bcM ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRIT on platelet aggregation have not been studied. Table 4: Platelet Inhibition and Bleeding Time * 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. PURSUIT 180/2* Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x The eptifibatide dosing regimen used in the ESPRIT study included two 180 mcg/kg bolus doses given 10 minutes apart combined with a continuous 2 mcg/kg/min infusion. When administered alone, eptifibatide has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed."
    ],
    "pharmacodynamics_table": [
      "<table ID=\"t4\" width=\"100%\"><caption>Table 4: Platelet Inhibition and Bleeding Time </caption><col width=\"80.100%\" align=\"left\"/><col width=\"19.900%\" align=\"left\"/><tfoot><tr><td colspan=\"2\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\">* 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. </paragraph></td></tr></tfoot><tbody><tr><td align=\"left\" valign=\"top\" styleCode=\"Toprule Botrule\"/><td align=\"left\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">PURSUIT</content> <content styleCode=\"bold\">180/2*</content></td></tr><tr><td align=\"left\" valign=\"top\">Inhibition of platelet aggregation 15 min after bolus </td><td align=\"left\" valign=\"top\">84% </td></tr><tr><td align=\"left\" valign=\"top\">Inhibition of platelet aggregation at steady state </td><td align=\"left\" valign=\"top\">&gt;90% </td></tr><tr><td align=\"left\" valign=\"top\">Bleeding-time prolongation at steady state </td><td align=\"left\" valign=\"top\">&lt;5x </td></tr><tr><td align=\"left\" valign=\"top\">Inhibition of platelet aggregation 4h after infusion discontinuation </td><td align=\"left\" valign=\"top\">&lt;50% </td></tr><tr><td align=\"left\" valign=\"top\" styleCode=\"Botrule\">Bleeding-time prolongation 6h after infusion discontinuation </td><td align=\"left\" valign=\"top\" styleCode=\"Botrule\">1.4x </td></tr></tbody></table>"
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180 mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4-6 hours). This decline can be prevented by administering a second 180 mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20-94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations ( 8.6 ) and Dosage and Administration ( 2 )] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Eptifibatide was studied in 3 placebo-controlled, randomized studies. PURSUIT evaluated patients with acute coronary syndromes: UA or NSTEMI. Two other studies, ESPRIT and IMPACT II, evaluated patients about to undergo a PCI. Patients underwent primarily balloon angioplasty in IMPACT II and intracoronary stent placement, with or without angioplasty, in ESPRIT. 14.1 Non-ST-Segment Elevation Acute Coronary Syndrome Non-ST-segment elevation acute coronary syndrome is defined as prolonged (\u226510 minutes) symptoms of cardiac ischemia within the previous 24 hours associated with either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or positive CK-MB. This definition includes \"unstable angina\" and \"NSTEMI\" but excludes MI that is associated with Q waves or greater degrees of ST-segment elevation. PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Eptifibatide Therapy) PURSUIT was a 726-center, 27-country, double-blind, randomized, placebo-controlled study in 10,948 patients presenting with UA or NSTEMI. Patients could be enrolled only if they had experienced cardiac ischemia at rest (\u226510 minutes) within the previous 24 hours and had either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or increased CK-MB. Important exclusion criteria included a history of bleeding diathesis, evidence of abnormal bleeding within the previous 30 days, uncontrolled hypertension, major surgery within the previous 6 weeks, stroke within the previous 30 days, any history of hemorrhagic stroke, serum creatinine >2 mg/dL, dependency on renal dialysis, or platelet count <100,000/mm 3 . Patients were randomized to placebo, to eptifibatide 180 mcg/kg bolus followed by a 2 mcg/kg/min infusion (180/2), or to eptifibatide 180 mcg/kg bolus followed by a 1.3 mcg/kg/min infusion (180/1.3). The infusion was continued for 72 hours, until hospital discharge, or until the time of CABG, whichever occurred first, except that if PCI was performed, the eptifibatide infusion was continued for 24 hours after the procedure, allowing for a duration of infusion up to 96 hours. The lower-infusion-rate arm was stopped after the first interim analysis when the 2 active-treatment arms appeared to have the same incidence of bleeding. Patient age ranged from 20 to 94 (mean 63) years, and 65% were male. The patients were 89% Caucasian, 6% Hispanic, and 5% Black, recruited in the United States and Canada (40%), Western Europe (39%), Eastern Europe (16%), and Latin America (5%). This was a \"real world\" study; each patient was managed according to the usual standards of the investigational site; frequencies of angiography, PCI, and CABG therefore differed widely from site to site and from country to country. Of the patients in PURSUIT, 13% were managed with PCI during drug infusion, of whom 50% received intracoronary stents; 87% were managed medically (without PCI during drug infusion). The majority of patients received aspirin (75-325 mg once daily). Heparin was administered intravenously or subcutaneously, at the physician's discretion, most commonly as an intravenous bolus of 5,000 units followed by a continuous infusion of 1000 units/h. For patients weighing less than 70 kg, the recommended heparin bolus dose was 60 units/kg followed by a continuous infusion of 12 units/kg/h. A target aPTT of 50 to 70 seconds was recommended. A total of 1250 patients underwent PCI within 72 hours after randomization, in which case they received intravenous heparin to maintain an ACT of 300 to 350 seconds. The primary endpoint of the study was the occurrence of death from any cause or new MI (evaluated by a blinded Clinical Endpoints Committee) within 30 days of randomization. Compared to placebo, eptifibatide administered as a 180 mcg/kg bolus followed by a 2 mcg/kg/min infusion significantly (p=0.042) reduced the incidence of endpoint events (see Table 6 ). The reduction in the incidence of endpoint events in patients receiving eptifibatide was evident early during treatment, and this reduction was maintained through at least 30 days (see Figure 1 ). Table 5 also shows the incidence of the components of the primary endpoint, death (whether or not preceded by an MI) and new MI in surviving patients at 30 days. Table 5: Clinical Events in the PURSUIT Study Death or MI Placebo (n=4739) n (%) Eptifibatide (180 mcg/kg bolus then 2 mcg/kg/min infusion) (n=4722) n (%) p-value 3 days 359 (7.6%) 279 (5.9%) 0.001 7 days 552 (11.6%) 477 (10.1%) 0.016 30 days Death or MI (primary endpoint) 745 (15.7%) 672 (14.2%) 0.042 Death 177 (3.7%) 165 (3.5%) Nonfatal MI 568 (12%) 507 (10.7%) Figure 1: Kaplan-Meier Plot of Time to Death or Myocardial Infarction Within 30 Days of Randomization in the PURSUIT Study Treatment with eptifibatide prior to determination of patient management strategy reduced clinical events regardless of whether patients ultimately underwent diagnostic catheterization, revascularization (i.e., PCI or CABG surgery) or continued to receive medical management alone. Table 6 shows the incidence of death or MI within 72 hours. Table 6: Clinical Events (Death or MI) in the PURSUIT Study Within 72 Hours of Randomization Placebo Eptifibatide (180 mcg/kg bolus then 2 mcg/kg/min infusion) Overall patient population n=4739 n=4722 \u2013 At 72 hours 7.6% 5.9% Patients undergoing early PCI n=631 n=619 \u2013 Pre-procedure (nonfatal MI only) 5.5% 1.8% \u2013 At 72 hours 14.4% 9% Patients not undergoing early PCI n=4108 n=4103 \u2013 At 72 hours 6.5% 5.4% All of the effect of eptifibatide was established within 72 hours (during the period of drug infusion), regardless of management strategy. Moreover, for patients undergoing early PCI, a reduction in events was evident prior to the procedure. An analysis of the results by sex suggests that women who would not routinely be expected to undergo PCI receive less benefit from eptifibatide (95% confidence limits for relative risk of 0.94 - 1.28) than do men (0.72 - 0.9). This difference may be a true treatment difference, the effect of other differences in these subgroups, or a statistical anomaly. No differential outcomes were seen between male and female patients undergoing PCI (see results for ESPRIT) . Follow-up data were available through 165 days for 10,611 patients enrolled in the PURSUIT trial (96.9% of the initial enrollment). This follow-up included 4566 patients who received eptifibatide at the 180/2 dose. As reported by the investigators, the occurrence of death from any cause or new MI for patients followed for at least 165 days was reduced from 13.6% with placebo to 12.1% with eptifibatide 180/2. Figure 1 14.2 Percutaneous Coronary Intervention (PCI) IMPACT II (Eptifibatide to Minimize Platelet Aggregation and Prevent Coronary Thrombosis II) IMPACT II was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States in 4010 patients undergoing PCI. Major exclusion criteria included a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 89 (mean 60) years, and 75% were male. The patients were 92% Caucasian, 5% Black, and 3% Hispanic. Forty-one percent of the patients underwent PCI for ongoing ACS. Patients were randomly assigned to 1 of 3 treatment regimens, each incorporating a bolus dose initiated immediately prior to PCI followed by a continuous infusion lasting 20 to 24 hours: 1) 135 mcg/kg bolus followed by a continuous infusion of 0.5 mcg/kg/min of eptifibatide (135/0.5); 2) 135 mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min of eptifibatide (135/0.75); or 3) a matching placebo bolus followed by a matching placebo continuous infusion. Each patient received aspirin and an intravenous heparin bolus of 100 units/kg, with additional bolus infusions of up to 2,000 additional units of heparin every 15 minutes to maintain an ACT of 300 to 350 seconds. The primary endpoint was the composite of death, MI, or urgent revascularization, analyzed at 30 days after randomization in all patients who received at least 1 dose of study drug. As shown in Table 7 , each eptifibatide regimen reduced the rate of death, MI, or urgent intervention, although at 30 days, this finding was statistically significant only in the lower-dose eptifibatide group. As in the PURSUIT study, the effects of eptifibatide were seen early and persisted throughout the 30-day period. Table 7: Clinical Events in the IMPACT II Study * Kaplan-Meier estimate of event rate. Placebo n (%) Eptifibatide (135 mcg/kg bolus then 0.5 mcg/kg/min infusion) n (%) Eptifibatide (135 mcg/kg bolus then 0.75 mcg/kg/min infusion) n (%) Patients 1285 1300 1286 Abrupt Closure 65 (5.1%) 36 (2.8%) 43 (3.3%) p-value versus placebo 0.003 0.03 Death, MI, or Urgent Intervention 24 hours 123 (9.6%) 86 (6.6%) 89 (6.9%) p-value versus placebo 0.006 0.014 48 hours 131 (10.2%) 99 (7.6%) 102 (7.9%) p-value versus placebo 0.021 0.045 30 days (primary endpoint) 149 (11.6%) 118 (9.1%) 128 (10%) p-value versus placebo 0.035 0.179 Death or MI 30 days 110 (8.6%) 89 (6.8%) 95 (7.4%) p-value versus placebo 0.102 0.272 6 months 151 (11.9%)* 136 (10.6%)* 130 (10.3%)* p-value versus placebo 0.297 0.182 ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with INTEGRILIN (eptifibatide) Therapy) The ESPRIT study was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States and Canada that enrolled 2064 patients undergoing elective or urgent PCI with intended intracoronary stent placement. Exclusion criteria included MI within the previous 24 hours, ongoing chest pain, administration of any oral antiplatelet or oral anticoagulant other than aspirin within 30 days of PCI (although loading doses of thienopyridine on the day of PCI were encouraged), planned PCI of a saphenous vein graft or subsequent \u201cstaged\u201d PCI, prior stent placement in the target lesion, PCI within the previous 90 days, a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 93 (mean 62) years, and 73% of patients were male. The study enrolled 90% Caucasian, 5% African American, 2% Hispanic, and 1% Asian patients. Patients received a wide variety of stents. Patients were randomized either to placebo or eptifibatide administered as an intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2 mcg/kg/min, and a second bolus of 180 mcg/kg administered 10 minutes later (180/2/180). Eptifibatide infusion was continued for 18 to 24 hours after PCI or until hospital discharge, whichever came first. Each patient received at least 1 dose of aspirin (162-325 mg) and 60 units/kg of heparin as a bolus (not to exceed 6,000 units) if not already receiving a heparin infusion. Additional boluses of heparin (10-40 units/kg) could be administered in order to reach a target ACT between 200 and 300 seconds. The primary endpoint of the ESPRIT study was the composite of death, MI, urgent target vessel revascularization (UTVR), and \u201cbailout\u201d to open-label eptifibatide due to a thrombotic complication of PCI (TBO) (e.g., visible thrombus, \u201cno reflow,\u201d or abrupt closure) at 48 hours. MI, UTVR, and TBO were evaluated by a blinded Clinical Events Committee. As shown in Table 8 , the incidence of the primary endpoint and selected secondary endpoints was significantly reduced in patients who received eptifibatide. A treatment benefit in patients who received eptifibatide was seen by 48 hours and at the end of the 30-day observation period. Table 8: Clinical Events in the ESPRIT Study *Eptifibatide was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min. Placebo (n=1024) Eptifibatide* (n=1040) Relative Risk (95% CI) p-value Death, MI, UTVR, or Thrombotic \u201cBailout\u201d 48 hours (primary endpoint) 108 (10.5%) 69 (6.6%) 0.629 (0.471, 0.84) 0.0015 30 days 120 (11.7%) 78 (7.5%) 0.64 (0.488, 0.84) 0.0011 Death, MI, or UTVR 48 hours 95 (9.3%) 62 (6%) 0.643 (0.472, 0.875) 0.0045 30 days (key secondary endpoint) 107 (10.4%) 71 (6.8%) 0.653 (0.49, 0.871) 0.0034 Death or MI 48 hours 94 (9.2%) 57 (5.5%) 0.597 (0.435, 0.82) 0.0013 30 days 104 (10.2%) 66 (6.3%) 0.625 (0.465, 0.84) 0.0016 The need for thrombotic \u201cbailout\u201d was significantly reduced with eptifibatide at 48 hours (2.1% for placebo, 1% for eptifibatide; p=0.029). Consistent with previous studies of GP IIb/IIIa inhibitors, most of the benefit achieved acutely with eptifibatide was in the reduction of MI. Eptifibatide reduced the occurrence of MI at 48 hours from 9% for placebo to 5.4% (p=0.0015) and maintained that effect with significance at 30 days. There was no treatment difference with respect to sex in ESPRIT. Eptifibatide reduced the incidence of the primary endpoint in both men (95% confidence limits for relative risk: 0.54, 1.07) and women (0.24, 0.72) at 48 hours. Follow-up (12-month) mortality data were available for 2024 patients (1017 on eptifibatide) enrolled in the ESPRIT trial (98.1% of the initial enrollment). Twelve-month clinical event data were available for 1964 patients (988 on eptifibatide), representing 95.2% of the initial enrollment. As shown in Table 9 , the treatment effect of eptifibatide seen at 48 hours and 30 days appeared preserved at 6 months and 1 year. Most of the benefit was in reduction of MI. Table 9: Clinical Events at 6 Months and 1 Year in the ESPRIT Study Percentages are Kaplan-Meier event rates. Placebo (n=1024) Eptifibatide (n=1040) Hazard Ratio (95% CI) Death, MI, or Target Vessel Revascularization 6 months 187 (18.5%) 146 (14.3%) 0.744 (0.599, 0.924) 1 year 222 (22.1%) 178 (17.5%) 0.762 (0.626, 0.929) Death, MI 6 months 117 (11.5%) 77 (7.4%) 0.631 (0.473, 0.841) 1 year 126 (12.4%) 83 (8%) 0.63 (0.478, 0.832)"
    ],
    "clinical_studies_table": [
      "<table ID=\"t5\" width=\"100%\"><caption>Table 5: Clinical Events in the PURSUIT Study </caption><colgroup><col width=\"36.541%\" align=\"left\"/><col width=\"24.519%\" align=\"left\"/><col width=\"24.519%\" align=\"left\"/><col width=\"14.421%\" align=\"left\"/></colgroup><tbody><tr><td styleCode=\"Botrule Toprule\" align=\"left\" valign=\"middle\"><content styleCode=\"bold\">Death or MI</content></td><td styleCode=\"Botrule Toprule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Placebo</content>  <content styleCode=\"bold\">(n=4739)</content> <content styleCode=\"bold\">n (%)</content></td><td styleCode=\"Botrule Toprule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(180 mcg/kg bolus then 2 mcg/kg/min infusion)  (n=4722)</content> <content styleCode=\"bold\">n (%)</content></td><td styleCode=\"Botrule Toprule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">p-value</content></td></tr><tr><td align=\"left\" valign=\"top\">3 days</td><td align=\"center\" valign=\"top\">359 (7.6%)</td><td align=\"center\" valign=\"top\">279 (5.9%)</td><td align=\"center\" valign=\"top\">0.001</td></tr><tr><td align=\"left\" valign=\"top\">7 days</td><td align=\"center\" valign=\"top\">552 (11.6%)</td><td align=\"center\" valign=\"top\">477 (10.1%)</td><td align=\"center\" valign=\"top\">0.016</td></tr><tr><td align=\"left\" valign=\"top\">30 days</td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/></tr><tr><td align=\"left\" valign=\"top\"> Death or MI (primary endpoint)</td><td align=\"center\" valign=\"top\">745 (15.7%)</td><td align=\"center\" valign=\"top\">672 (14.2%)</td><td align=\"center\" valign=\"top\">0.042</td></tr><tr><td align=\"left\" valign=\"top\"> Death</td><td align=\"center\" valign=\"top\">177 (3.7%)</td><td align=\"center\" valign=\"top\">165 (3.5%)</td><td align=\"center\" valign=\"top\"/></tr><tr><td styleCode=\"Botrule\" align=\"left\" valign=\"top\"> Nonfatal MI</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">568 (12%)</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">507 (10.7%)</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\"/></tr></tbody></table>",
      "<table ID=\"t6\" width=\"100%\"><caption>Table 6: Clinical Events (Death or MI) in the PURSUIT Study Within 72 Hours of Randomization </caption><colgroup><col width=\"46.040%\" align=\"left\"/><col width=\"26.760%\" align=\"left\"/><col width=\"26.760%\" align=\"left\"/></colgroup><tbody><tr><td styleCode=\"Toprule\" align=\"left\" valign=\"top\"/><td styleCode=\"Toprule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Placebo</content></td><td styleCode=\"Toprule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(180 mcg/kg bolus</content> <content styleCode=\"bold\">then 2 mcg/kg/min infusion)</content></td></tr><tr><td align=\"left\" valign=\"top\">Overall patient population</td><td align=\"center\" valign=\"top\">n=4739</td><td align=\"center\" valign=\"top\">n=4722</td></tr><tr><td align=\"left\" valign=\"top\"> &#x2013; At 72 hours</td><td align=\"center\" valign=\"top\">7.6%</td><td align=\"center\" valign=\"top\">5.9%</td></tr><tr><td align=\"left\" valign=\"top\">Patients undergoing early PCI</td><td align=\"center\" valign=\"top\">n=631</td><td align=\"center\" valign=\"top\">n=619</td></tr><tr><td align=\"left\" valign=\"top\"> &#x2013; Pre-procedure (nonfatal MI only)</td><td align=\"center\" valign=\"top\">5.5%</td><td align=\"center\" valign=\"top\">1.8%</td></tr><tr><td align=\"left\" valign=\"top\"> &#x2013; At 72 hours</td><td align=\"center\" valign=\"top\">14.4%</td><td align=\"center\" valign=\"top\">9%</td></tr><tr><td align=\"left\" valign=\"top\">Patients not undergoing early PCI</td><td align=\"center\" valign=\"top\">n=4108</td><td align=\"center\" valign=\"top\">n=4103</td></tr><tr><td styleCode=\"Botrule\" align=\"left\" valign=\"top\"> &#x2013; At 72 hours</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">6.5%</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">5.4%</td></tr></tbody></table>",
      "<table ID=\"t7\" width=\"100%\"><caption>Table 7: Clinical Events in the IMPACT II Study </caption><colgroup><col width=\"38.100%\" align=\"left\"/><col width=\"20.325%\" align=\"left\"/><col width=\"20.325%\" align=\"left\"/><col width=\"21.250%\" align=\"left\"/></colgroup><tfoot><tr styleCode=\"First Last\"><td colspan=\"4\" align=\"left\" valign=\"top\"><paragraph styleCode=\"First Footnote\">* Kaplan-Meier estimate of event rate.</paragraph></td></tr></tfoot><tbody><tr><td styleCode=\"Botrule Toprule\" align=\"left\" valign=\"top\"/><td styleCode=\"Botrule Toprule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Placebo</content>  <content styleCode=\"bold\">n (%)</content></td><td styleCode=\"Botrule Toprule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(135 mcg/kg bolus then</content> <content styleCode=\"bold\">0.5 mcg/kg/min infusion)</content> <content styleCode=\"bold\">n (%)</content></td><td styleCode=\"Botrule Toprule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(135 mcg/kg bolus then</content> <content styleCode=\"bold\">0.75 mcg/kg/min infusion)</content> <content styleCode=\"bold\">n (%)</content></td></tr><tr><td align=\"left\" valign=\"top\">Patients</td><td align=\"center\" valign=\"top\">1285</td><td align=\"center\" valign=\"top\">1300</td><td align=\"center\" valign=\"top\">1286</td></tr><tr><td align=\"left\" valign=\"top\">Abrupt Closure</td><td align=\"center\" valign=\"top\">65 (5.1%)</td><td align=\"center\" valign=\"top\">36 (2.8%)</td><td align=\"center\" valign=\"top\">43 (3.3%)</td></tr><tr><td align=\"left\" valign=\"top\"> p-value versus placebo</td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\">0.003</td><td align=\"center\" valign=\"top\">0.03</td></tr><tr><td align=\"left\" valign=\"top\">Death, MI, or Urgent Intervention</td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/></tr><tr><td align=\"left\" valign=\"top\"> 24 hours</td><td align=\"center\" valign=\"top\">123 (9.6%)</td><td align=\"center\" valign=\"top\">86 (6.6%)</td><td align=\"center\" valign=\"top\">89 (6.9%)</td></tr><tr><td align=\"left\" valign=\"top\"> p-value versus placebo</td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\">0.006</td><td align=\"center\" valign=\"top\">0.014</td></tr><tr><td align=\"left\" valign=\"top\"> 48 hours</td><td align=\"center\" valign=\"top\">131 (10.2%)</td><td align=\"center\" valign=\"top\">99 (7.6%)</td><td align=\"center\" valign=\"top\">102 (7.9%)</td></tr><tr><td align=\"left\" valign=\"top\"> p-value versus placebo</td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\">0.021</td><td align=\"center\" valign=\"top\">0.045</td></tr><tr><td align=\"left\" valign=\"top\"> 30 days (primary endpoint)</td><td align=\"center\" valign=\"top\">149 (11.6%)</td><td align=\"center\" valign=\"top\">118 (9.1%)</td><td align=\"center\" valign=\"top\">128 (10%)</td></tr><tr><td align=\"left\" valign=\"top\"> p-value versus placebo</td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\">0.035</td><td align=\"center\" valign=\"top\">0.179</td></tr><tr><td align=\"left\" valign=\"top\">Death or MI</td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/></tr><tr><td align=\"left\" valign=\"top\"> 30 days</td><td align=\"center\" valign=\"top\">110 (8.6%)</td><td align=\"center\" valign=\"top\">89 (6.8%)</td><td align=\"center\" valign=\"top\">95 (7.4%)</td></tr><tr><td align=\"left\" valign=\"top\"> p-value versus placebo</td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\">0.102</td><td align=\"center\" valign=\"top\">0.272</td></tr><tr><td align=\"left\" valign=\"top\"> 6 months</td><td align=\"center\" valign=\"top\">151 (11.9%)*</td><td align=\"center\" valign=\"top\">136 (10.6%)*</td><td align=\"center\" valign=\"top\">130 (10.3%)*</td></tr><tr><td styleCode=\"Botrule\" align=\"left\" valign=\"top\"> p-value versus placebo</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\"/><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">0.297</td><td styleCode=\"Botrule\" align=\"center\" valign=\"top\">0.182</td></tr></tbody></table>",
      "<table ID=\"t8\" width=\"100%\"><caption>Table 8: Clinical Events in the ESPRIT Study </caption><col width=\"34.620%\" align=\"left\"/><col width=\"15.860%\" align=\"left\"/><col width=\"15.880%\" align=\"left\"/><col width=\"23.080%\" align=\"left\"/><col width=\"10.560%\" align=\"left\"/><tfoot><tr><td colspan=\"5\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\">*Eptifibatide was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min. </paragraph></td></tr></tfoot><tbody><tr><td align=\"left\" valign=\"top\" styleCode=\"Toprule Botrule\"/><td align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Placebo</content>  <content styleCode=\"bold\">(n=1024)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Eptifibatide*</content>  <content styleCode=\"bold\">(n=1040)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Relative Risk  (95% CI)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule\"> <content styleCode=\"bold\">p-value</content></td></tr><tr><td colspan=\"5\" align=\"left\" valign=\"top\">Death, MI, UTVR, or Thrombotic &#x201C;Bailout&#x201D; </td></tr><tr><td align=\"left\" valign=\"top\">48 hours (primary endpoint) </td><td align=\"center\" valign=\"top\">108 (10.5%) </td><td align=\"center\" valign=\"top\">69 (6.6%) </td><td align=\"center\" valign=\"top\">0.629 (0.471, 0.84) </td><td align=\"center\" valign=\"top\">0.0015 </td></tr><tr><td align=\"left\" valign=\"top\">30 days </td><td align=\"center\" valign=\"top\">120 (11.7%) </td><td align=\"center\" valign=\"top\">78 (7.5%) </td><td align=\"center\" valign=\"top\">0.64 (0.488, 0.84) </td><td align=\"center\" valign=\"top\">0.0011 </td></tr><tr><td colspan=\"5\" align=\"left\" valign=\"top\"> Death, MI, or UTVR </td></tr><tr><td align=\"left\" valign=\"top\">48 hours </td><td align=\"center\" valign=\"top\">95 (9.3%) </td><td align=\"center\" valign=\"top\">62 (6%) </td><td align=\"center\" valign=\"top\">0.643 (0.472, 0.875) </td><td align=\"center\" valign=\"top\">0.0045 </td></tr><tr><td align=\"left\" valign=\"top\">30 days (key secondary endpoint) </td><td align=\"center\" valign=\"top\">107 (10.4%) </td><td align=\"center\" valign=\"top\">71 (6.8%) </td><td align=\"center\" valign=\"top\">0.653 (0.49, 0.871) </td><td align=\"center\" valign=\"top\">0.0034 </td></tr><tr><td colspan=\"5\" align=\"left\" valign=\"top\"> Death or MI </td></tr><tr><td align=\"left\" valign=\"top\">48 hours </td><td align=\"center\" valign=\"top\">94 (9.2%) </td><td align=\"center\" valign=\"top\">57 (5.5%) </td><td align=\"center\" valign=\"top\">0.597 (0.435, 0.82) </td><td align=\"center\" valign=\"top\">0.0013 </td></tr><tr><td align=\"left\" valign=\"top\" styleCode=\"Botrule\">30 days </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">104 (10.2%) </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">66 (6.3%) </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">0.625 (0.465, 0.84) </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">0.0016 </td></tr></tbody></table>",
      "<table ID=\"t9\" width=\"100%\"><caption>Table 9: Clinical Events at 6 Months and 1 Year in the ESPRIT Study </caption><col width=\"23.069%\" align=\"left\"/><col width=\"25.644%\" align=\"left\"/><col width=\"25.644%\" align=\"left\"/><col width=\"25.644%\" align=\"left\"/><tfoot><tr><td colspan=\"4\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\">Percentages are Kaplan-Meier event rates. </paragraph></td></tr></tfoot><tbody><tr><td align=\"left\" valign=\"top\" styleCode=\"Toprule Botrule\"/><td align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(n=1024)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(n=1040)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Hazard Ratio</content> <content styleCode=\"bold\">(95% CI)</content></td></tr><tr><td colspan=\"4\" align=\"left\" valign=\"top\">Death, MI, or Target Vessel Revascularization </td></tr><tr><td align=\"left\" valign=\"top\"> 6 months </td><td align=\"center\" valign=\"top\">187 (18.5%) </td><td align=\"center\" valign=\"top\">146 (14.3%) </td><td align=\"center\" valign=\"top\">0.744 (0.599, 0.924) </td></tr><tr><td align=\"left\" valign=\"top\"> 1 year </td><td align=\"center\" valign=\"top\">222 (22.1%) </td><td align=\"center\" valign=\"top\">178 (17.5%) </td><td align=\"center\" valign=\"top\">0.762 (0.626, 0.929) </td></tr><tr><td colspan=\"4\" align=\"left\" valign=\"top\">Death, MI </td></tr><tr><td align=\"left\" valign=\"top\"> 6 months </td><td align=\"center\" valign=\"top\">117 (11.5%) </td><td align=\"center\" valign=\"top\">77 (7.4%) </td><td align=\"center\" valign=\"top\">0.631 (0.473, 0.841) </td></tr><tr><td align=\"left\" valign=\"top\" styleCode=\"Botrule\"> 1 year </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">126 (12.4%) </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">83 (8%) </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">0.63 (0.478, 0.832) </td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Eptifibatide Injection is a sterile solution and is supplied as follows: NDC Eptifibatide Injection (2 mg per mL) Package Factor 71288- 412 -10 20 mg per 10 mL Single-Dose Vial 1 vial per carton NDC Eptifibatide Injection (0.75 mg per mL) Package Factor 71288- 413 -51 75 mg per 100 mL Single-Dose Vial 1 vial per carton 16.2 Storage Vials should be stored refrigerated between 2\u00b0 and 8\u00b0C (36\u00b0 and 46\u00b0F). Vials may be transferred to room temperature storage* for a period not to exceed 2 months. Upon transfer, vial cartons must be marked by the dispensing pharmacist with a \"DISCARD BY\" date (2 months from the transfer date or the labeled expiration date, whichever comes first). Protect from light until administration. * Store at 25\u00b0C (77\u00b0F); excursions permitted between 15\u00b0 and 30\u00b0C (59\u00b0 and 86\u00b0F). [See USP Controlled Room Temperature.] Discard unused portion. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex.",
      "16.1 How Supplied Eptifibatide Injection is a sterile solution and is supplied as follows: NDC Eptifibatide Injection (2 mg per mL) Package Factor 71288- 412 -10 20 mg per 10 mL Single-Dose Vial 1 vial per carton NDC Eptifibatide Injection (0.75 mg per mL) Package Factor 71288- 413 -51 75 mg per 100 mL Single-Dose Vial 1 vial per carton"
    ],
    "how_supplied_table": [
      "<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"24.067%\" align=\"left\"/><col width=\"49.000%\" align=\"left\"/><col width=\"26.933%\" align=\"left\"/><tbody><tr><td align=\"left\" valign=\"top\"><content styleCode=\"bold\">NDC</content></td><td align=\"left\" valign=\"top\"><content styleCode=\"bold\">Eptifibatide Injection (2 mg per mL)</content></td><td align=\"left\" valign=\"top\"><content styleCode=\"bold\">Package Factor</content></td></tr><tr><td align=\"left\" valign=\"top\">71288-<content styleCode=\"bold\">412</content>-10 </td><td align=\"left\" valign=\"top\">20 mg per 10 mL Single-Dose Vial </td><td align=\"left\" valign=\"top\">1 vial per carton </td></tr><tr><td align=\"left\" valign=\"top\"><content styleCode=\"bold\">NDC</content></td><td align=\"left\" valign=\"top\"><content styleCode=\"bold\">Eptifibatide Injection (0.75 mg per mL)</content></td><td align=\"left\" valign=\"top\"><content styleCode=\"bold\">Package Factor</content></td></tr><tr><td align=\"left\" valign=\"top\">71288-<content styleCode=\"bold\">413</content>-51 </td><td align=\"left\" valign=\"top\">75 mg per 100 mL Single-Dose Vial </td><td align=\"left\" valign=\"top\">1 vial per carton </td></tr></tbody></table>",
      "<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"24.067%\" align=\"left\"/><col width=\"49.000%\" align=\"left\"/><col width=\"26.933%\" align=\"left\"/><tbody><tr><td align=\"left\" valign=\"top\"><content styleCode=\"bold\">NDC</content></td><td align=\"left\" valign=\"top\"><content styleCode=\"bold\">Eptifibatide Injection (2 mg per mL)</content></td><td align=\"left\" valign=\"top\"><content styleCode=\"bold\">Package Factor</content></td></tr><tr><td align=\"left\" valign=\"top\">71288-<content styleCode=\"bold\">412</content>-10 </td><td align=\"left\" valign=\"top\">20 mg per 10 mL Single-Dose Vial </td><td align=\"left\" valign=\"top\">1 vial per carton </td></tr><tr><td align=\"left\" valign=\"top\"><content styleCode=\"bold\">NDC</content></td><td align=\"left\" valign=\"top\"><content styleCode=\"bold\">Eptifibatide Injection (0.75 mg per mL)</content></td><td align=\"left\" valign=\"top\"><content styleCode=\"bold\">Package Factor</content></td></tr><tr><td align=\"left\" valign=\"top\">71288-<content styleCode=\"bold\">413</content>-51 </td><td align=\"left\" valign=\"top\">75 mg per 100 mL Single-Dose Vial </td><td align=\"left\" valign=\"top\">1 vial per carton </td></tr></tbody></table>"
    ],
    "storage_and_handling": [
      "16.2 Storage Vials should be stored refrigerated between 2\u00b0 and 8\u00b0C (36\u00b0 and 46\u00b0F). Vials may be transferred to room temperature storage* for a period not to exceed 2 months. Upon transfer, vial cartons must be marked by the dispensing pharmacist with a \"DISCARD BY\" date (2 months from the transfer date or the labeled expiration date, whichever comes first). Protect from light until administration. * Store at 25\u00b0C (77\u00b0F); excursions permitted between 15\u00b0 and 30\u00b0C (59\u00b0 and 86\u00b0F). [See USP Controlled Room Temperature.] Discard unused portion. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to inform the doctor or healthcare provider about any medical conditions, medications, and allergies. Brands listed are the trademarks of their respective owners. meitheal \u00ae Mfd. for Meitheal Pharmaceuticals Chicago, IL 60631 (USA) \u00a92021 Meitheal Pharmaceuticals Inc. Mfd. by Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Nanjing, China 210061 May 2021 810042-00"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL \u2013 Eptifibatide Injection, 20 mg per 10 mL Container Label NDC 71288- 412 -10 Rx Only Eptifibatide Injection 20 mg per 10 mL (2 mg per mL) For Intravenous Use Only 10 mL Single-Dose Vial PRINCIPAL DISPLAY PANEL \u2013 Eptifibatide Injection, 20 mg per 10 mL Container Label",
      "PRINCIPAL DISPLAY PANEL \u2013 Eptifibatide Injection, 20 mg per 10 mL Carton NDC 71288- 412 -10 Rx Only Eptifibatide Injection 20 mg per 10 mL (2 mg per mL) For Intravenous Use Only 1 x 10 mL Single-Dose Vial for weight-adjusted bolus dosing PRINCIPAL DISPLAY PANEL \u2013 Eptifibatide Injection, 20 mg per 10 mL Carton",
      "PRINCIPAL DISPLAY PANEL \u2013 Eptifibatide Injection, 75 mg per 100 mL Container Label NDC 71288- 413 -51 Rx Only Eptifibatide Injection 75 mg per 100 mL (0.75 mg per mL) For Intravenous Use Only 100 mL Single-Dose Vial PRINCIPAL DISPLAY PANEL \u2013 Eptifibatide Injection, 75 mg per 100 mL Container Label",
      "PRINCIPAL DISPLAY PANEL \u2013 Eptifibatide Injection, 75 mg per 100 mL Carton NDC 71288- 413 -51 Rx Only Eptifibatide Injection 75 mg per 100 mL (0.75 mg per mL) For Intravenous Use Only 1 x 100 mL Single-Dose Vial for weight-adjusted infusion PRINCIPAL DISPLAY PANEL \u2013 Eptifibatide Injection, 75 mg per 100 mL Carton"
    ],
    "set_id": "3e7e7cd3-8efa-4d91-a5ab-7fd78b0cc65e",
    "id": "a15dafa6-7923-4999-8938-28e580304e57",
    "effective_time": "20240514",
    "version": "8",
    "openfda": {
      "application_number": [
        "ANDA213599"
      ],
      "brand_name": [
        "Eptifibatide"
      ],
      "generic_name": [
        "EPTIFIBATIDE"
      ],
      "manufacturer_name": [
        "Meitheal Pharmaceuticals Inc."
      ],
      "product_ndc": [
        "71288-412",
        "71288-413"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "INTRAVENOUS"
      ],
      "substance_name": [
        "EPTIFIBATIDE"
      ],
      "rxcui": [
        "200349",
        "1736470"
      ],
      "spl_id": [
        "a15dafa6-7923-4999-8938-28e580304e57"
      ],
      "spl_set_id": [
        "3e7e7cd3-8efa-4d91-a5ab-7fd78b0cc65e"
      ],
      "package_ndc": [
        "71288-412-10",
        "71288-413-51"
      ],
      "is_original_packager": [
        true
      ],
      "nui": [
        "N0000008832",
        "N0000175578"
      ],
      "pharm_class_pe": [
        "Decreased Platelet Aggregation [PE]"
      ],
      "pharm_class_epc": [
        "Platelet Aggregation Inhibitor [EPC]"
      ],
      "unii": [
        "NA8320J834"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Eptifibatide Eptifibatide EPTIFIBATIDE EPTIFIBATIDE CITRIC ACID MONOHYDRATE SODIUM HYDROXIDE WATER"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Eptifibatide injection is a platelet aggregation inhibitor indicated for: \u2022 Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI) (1.1) \u2022 Treatment of patients undergoing PCI (including intracoronary stenting) (1.2) 1.1 Acute Coronary Syndrome (ACS) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). 1.2 Percutaneous Coronary Intervention (PCI) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting [see Clinical Studies (14.1, 14.2) ] ."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION Eptifibatide injection in Galaxy container is for intravenous infusion only, not for intravenous bolus use. Before infusion of eptifibatide injection, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured. The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT. Eptifibatide injection in Galaxy container is for intravenous infusion only, not for intravenous bolus use. ACS or PCI: 180 mcg/kg IV bolus as soon as possible after diagnosis followed by infusion at 2 mcg/kg/min. (2.1 , 2.2) PCI: Add a second 180 mcg/kg bolus at 10 minutes. ( 2.2 ) In patients with creatinine clearance less than 50 mL/min, reduce the infusion to 1 mcg/kg/min. (2.1, 2.2 , 2.3 ) 2.1 Dosage in Acute Coronary Syndrome (ACS) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with ACS 180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min 180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min \u2022 Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours \u2022 If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy \u2022 Aspirin, 160 to 325 mg, should be given daily Eptifibatide injection should be given concomitantly with heparin dosed to achieve the following parameters: During Medical Management : Target aPTT 50 to 70 seconds \u2022 If weight greater than or equal to 70 kg, 5000-unit bolus followed by infusion of 1000 units/h. \u2022 If weight less than 70 kg, 60-units/kg bolus followed by infusion of 12 units/kg/h. During PCI : Target ACT 200 to 300 seconds \u2022 If heparin is initiated prior to PCI, additional boluses during PCI to maintain an ACT target of 200 to 300 seconds. \u2022 Heparin infusion after the PCI is discouraged. 2.2 Dosage in Percutaneous Coronary Intervention (PCI) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with PCI 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) \u2022 Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. \u2022 In patients who undergo CABG surgery, eptifibatide injection infusion should be discontinued prior to surgery. \u2022 Aspirin, 160 to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter. \u2022 Eptifibatide injection should be given concomitantly with heparin to achieve a target ACT of 200 to 300 seconds. Administer 60-units/kg bolus initially in patients not treated with heparin within 6 hours prior to PCI. \u2022 Additional boluses during PCI to maintain ACT within target. \u2022 Heparin infusion after the PCI is strongly discouraged. Patients requiring thrombolytic therapy should discontinue eptifibatide injection. 2.3 Important Administration Instructions 1. Inspect eptifibatide injection for particulate matter and discoloration prior to administration. Use only if solution is clear and container and seals are intact. Check for minute leaks prior to use by squeezing bag firmly. If leaks are found, discard solution as sterility may be impaired. If the administration port protector is damaged, detached or not present, discard the container as the solution path sterility may be compromised. 2. Do not use Galaxy containers in series connections. Such use would result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is complete. If administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result. 3. This premixed solution is for intravenous infusion only, no further dilution is required. Not For Intravenous Bolus Use. 4. Do not introduce supplemental medication or additives into the Galaxy container. 5. May administer eptifibatide injection in the same intravenous line as alteplase, atropine, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, or verapamil. Do not administer eptifibatide injection through the same intravenous line as furosemide. 6. May administer eptifibatide injection in the same IV line with 0.9% NaCl or 0.9% NaCl/5% dextrose. With either vehicle, the infusion may also contain up to 60 mEq/L of potassium chloride. 7. Withdraw the bolus dose(s) of eptifibatide injection from the 10-mL vial into a syringe. Administer the bolus dose(s) by IV push. 8. Immediately following the bolus dose administration, initiate a continuous infusion of eptifibatide injection. When using an intravenous infusion pump, administer eptifibatide injection undiluted directly from the 100-mL Galaxy container. 9. The premixed Galaxy container is for single-dose only, discard any unused portion. Administer eptifibatide injection by volume according to patient weight (see Table 1). Table 1: Eptifibatide Injection Dosing Charts by Weight Patient Weight 180-mcg/kg Bolus Volume 2-mcg/kg/min Infusion Volume (CrCl greater than or equal to 50 mL/min) 1-mcg/kg/min Infusion Volume (CrCl less than 50 mL/min) (kg) (lb) (from 2 mg/mL vial) (from 0.75-mg/mL 100-mL Galaxy container) (from 0.75-mg/mL 100-mL Galaxy container) 37-41 81-91 3.4 mL 6 mL/h 3 mL/h 42-46 92-102 4 mL 7 mL/h 3.5 mL/h 47-53 103-117 4.5 mL 8 mL/h 4 mL/h 54-59 118-130 5 mL 9 mL/h 4.5 mL/h 60-65 131-143 5.6 mL 10 mL/h 5 mL/h 66-71 144-157 6.2 mL 11 mL/h 5.5 mL/h 72-78 158-172 6.8 mL 12 mL/h 6 mL/h 79-84 173-185 7.3 mL 13 mL/h 6.5 mL/h 85-90 186-198 7.9 mL 14 mL/h 7 mL/h 91-96 199-212 8.5 mL 15 mL/h 7.5 mL/h 97-103 213-227 9 mL 16 mL/h 8 mL/h 104-109 228-240 9.5 mL 17 mL/h 8.5 mL/h 110-115 241-253 10.2 mL 18 mL/h 9 mL/h 116-121 254-267 10.7 mL 19 mL/h 9.5 mL/h >121 >267 11.3 mL 20 mL/h 10 mL/h"
    ],
    "dosage_and_administration_table": [
      "<table cellpadding=\"0pt\" cellspacing=\"0pt\" width=\"100%\"><col width=\"14%\"/><col width=\"39%\"/><col width=\"46%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\"> Indication</content> </paragraph></td><td styleCode=\"Rrule Botrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\"> Normal Renal Function</content> </paragraph></td><td styleCode=\"Rrule Botrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\"> Creatinine Clearance less than 50 mL/min</content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Patients with  ACS </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>  </paragraph></td><td colspan=\"2\" styleCode=\"Rrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours</item><item><caption>&#x2022;</caption>If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy</item><item><caption>&#x2022;</caption>Aspirin, 160 to 325 mg, should be given daily</item></list></td></tr></tbody></table>",
      "<table cellpadding=\"0pt\" cellspacing=\"0pt\" width=\"100%\"><col width=\"14%\"/><col width=\"40%\"/><col width=\"45%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\"> Indication </content> </paragraph></td><td styleCode=\"Rrule Botrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\"> Normal Renal Function </content> </paragraph></td><td styleCode=\"Rrule Botrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\"> Creatinine Clearance less than 50 mL/min </content> </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>Patients with PCI  </item></list></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) </paragraph></td><td styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>  </paragraph></td><td colspan=\"2\" styleCode=\"Rrule Botrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended.</item><item><caption>&#x2022;</caption>In patients who undergo CABG surgery, eptifibatide injection infusion should be discontinued prior to surgery.</item><item><caption>&#x2022;</caption>Aspirin, 160 to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter. </item></list></td></tr></tbody></table>",
      "<table cellpadding=\"0pt\" cellspacing=\"0pt\" width=\"100%\"><caption>Table 1: Eptifibatide Injection Dosing Charts by Weight</caption><col width=\"14%\"/><col width=\"14%\"/><col width=\"14%\"/><col width=\"28%\"/><col width=\"29%\"/><tbody><tr><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Patient Weight</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">180-mcg/kg Bolus Volume</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">2-mcg/kg/min  Infusion Volume (CrCl greater than or equal to 50 mL/min)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">1-mcg/kg/min Infusion Volume (CrCl less than 50 mL/min)</content> </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">(kg)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">(lb)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">(from 2  mg/mL vial)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">(from 0.75-mg/mL 100-mL Galaxy container)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">(from 0.75-mg/mL 100-mL Galaxy container)</content> </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 37-41  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 81-91  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>3.4 mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>6 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>3 mL/h </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 42-46  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 92-102  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>4 mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>7 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>3.5 mL/h </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 47-53  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 103-117  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>4.5 mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>8 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>4 mL/h </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 54-59  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 118-130  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>5 mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>9 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>4.5 mL/h </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 60-65  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 131-143  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>5.6 mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>10 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>5 mL/h </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 66-71  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph> 144-157  </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>6.2 mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>11 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>5.5 mL/h </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> 72-78  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph> 158-172  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>6.8 mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"middle\"><paragraph>12 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>6 mL/h </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> 79-84  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph> 173-185  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>7.3 mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"middle\"><paragraph>13 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>6.5 mL/h </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> 85-90  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph> 186-198  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>7.9 mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"middle\"><paragraph>14 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>7 mL/h </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> 91-96  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph> 199-212  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>8.5 mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"middle\"><paragraph>15 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>7.5 mL/h </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> 97-103  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph> 213-227  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>9 mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"middle\"><paragraph>16 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>8 mL/h </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> 104-109  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph> 228-240  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>9.5 mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"middle\"><paragraph>17 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>8.5 mL/h </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> 110-115  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph> 241-253  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>10.2 mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"middle\"><paragraph>18 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>9 mL/h </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph> 116-121  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph> 254-267  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>10.7 mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"middle\"><paragraph>19 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>9.5 mL/h </paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph> &gt;121  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph> &gt;267  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>11.3 mL </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"middle\"><paragraph>20 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>10 mL/h </paragraph></td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS \u2022 Injection: 75 mg of eptifibatide per 100 mL (0.75 mg/mL) in a single-dose Galaxy container, for intravenous infusion only, not for intravenous bolus use \u2022 Injection: 75 mg of eptifibatide per 100 mL in a single-dose Galaxy container. (3)"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Treatment with eptifibatide is contraindicated in patients with: \u2022 A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days \u2022 Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy \u2022 Major surgery within the preceding 6 weeks \u2022 History of stroke within 30 days or any history of hemorrhagic stroke \u2022 Current or planned administration of another parenteral GP IIb/IIIa inhibitor \u2022 Dependency on renal dialysis \u2022 Hypersensitivity to eptifibatide or any component of the product (hypersensitivity reactions that occurred included anaphylaxis and urticaria) \u2022 Bleeding diathesis or bleeding within the previous 30 days (4) \u2022 Severe uncontrolled hypertension (4) \u2022 Major surgery within the preceding 6 weeks (4) \u2022 Stroke within 30 days or any history of hemorrhagic stroke (4) \u2022 Coadministration of another parenteral GP IIb/IIIa inhibitor (4) \u2022 Dependency on renal dialysis (4) \u2022 Known hypersensitivity to any component of the product (4)"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS \u2022 Eptifibatide can cause serious bleeding. If bleeding cannot be controlled, discontinue eptifibatide immediately. Minimize vascular and other traumas. If heparin is given concomitantly, monitor aPTT or ACT. (5.1) \u2022 Thrombocytopenia: Discontinue eptifibatide and heparin. Monitor and treat condition appropriately. (5.2) 5.1 Bleeding Bleeding is the most common complication encountered during eptifibatide therapy. Administration of eptifibatide is associated with an increase in major and minor bleeding, as classified by the criteria of the Thrombolysis in Myocardial Infarction Study group (TIMI) [see Adverse Reactions (6.1) ] . Most major bleeding associated with eptifibatide has been at the arterial access site for cardiac catheterization or from the gastrointestinal or genitourinary tract. Minimize the use of arterial and venous punctures, intramuscular injections, and the use of urinary catheters, nasotracheal intubation, and nasogastric tubes. When obtaining intravenous access, avoid non-compressible sites (e.g., subclavian or jugular veins). Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Risk factors for bleeding include older age, a history of bleeding disorders, and concomitant use of drugs that increase the risk of bleeding (thrombolytics, oral anticoagulants, nonsteroidal anti-inflammatory drugs, and P2Y 12 inhibitors). Concomitant treatment with other inhibitors of platelet receptor glycoprotein (GP) IIb/IIIa should be avoided. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT [see Dosage and Administration (2) ] . Care of the Femoral Artery Access Site in Patients Undergoing Percutaneous Coronary Intervention (PCI) In patients undergoing PCI, treatment with eptifibatide is associated with an increase in major and minor bleeding at the site of arterial sheath placement. After PCI, eptifibatide infusion should be continued until hospital discharge or up to 18 to 24 hours, whichever comes first. Heparin use is discouraged after the PCI procedure. Early sheath removal is encouraged while eptifibatide is being infused. Prior to removing the sheath, it is recommended that heparin be discontinued for 3 to 4 hours and an aPTT of <45 seconds or ACT <150 seconds be achieved. In any case, both heparin and eptifibatide should be discontinued and sheath hemostasis should be achieved at least 2 to 4 hours before hospital discharge. If bleeding at access site cannot be controlled with pressure, infusion of eptifibatide and heparin should be discontinued immediately. 5.2 Thrombocytopenia There have been reports of acute, profound thrombocytopenia (immune-mediated and non-immune mediated) with eptifibatide. In the event of acute profound thrombocytopenia or a confirmed platelet decrease to <100,000/mm 3 , discontinue eptifibatide and heparin (unfractionated or low-molecular weight). Monitor serial platelet counts, assess the presence of drug-dependent antibodies, and treat as appropriate [see Adverse Reactions (6.1) ] . There has been no clinical experience with eptifibatide initiated in patients with a baseline platelet count <100,000/mm 3 . If a patient with low platelet counts is receiving eptifibatide, their platelet count should be monitored closely."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reaction is also discussed elsewhere in the labeling: \u2022 Bleeding [see Contraindications (4) and Warnings and Precautions (5.1) ] Bleeding and hypotension are the most commonly reported adverse reactions. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare at 1-866-888-2472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. A total of 16,782 patients were treated in the Phase III clinical trials (PURSUIT, ESPRIT, and IMPACT II) [see Clinical Studies (14) ] . These 16,782 patients had a mean age of 62 years (range: 20-94 years). Eighty-nine percent of the patients were Caucasian, with the remainder being predominantly Black (5%) and Hispanic (5%). Sixty-eight percent were men. Because of the different regimens used in PURSUIT, IMPACT II, and ESPRIT, data from the 3 studies were not pooled. Bleeding and hypotension were the most commonly reported adverse reactions (incidence \u22655% and greater than placebo) in the eptifibatide controlled clinical trial database. Bleeding The incidence of bleeding and transfusions in the PURSUIT and ESPRIT studies are shown in Table 2. Bleeding was classified as major or minor by the criteria of the TIMI study group. Major bleeding consisted of intracranial hemorrhage and other bleeding that led to decreases in hemoglobin greater than 5 g/dL. Minor bleeding included spontaneous gross hematuria, spontaneous hematemesis, other observed blood loss with a hemoglobin decrease of more than 3 g/dL, and other hemoglobin decreases that were greater than 4 g/dL but less than 5 g/dL. In patients who received transfusions, the corresponding loss in hemoglobin was estimated through an adaptation of the method of Landefeld et al. Table 2: Bleeding and Transfusions in the PURSUIT and ESPRIT Studies Note: Denominator is based on patients for whom data are available. PURSUIT (ACS) Placebo n (%) Eptifibatide 180/2 n (%) Patients Major bleeding For major and minor bleeding, patients are counted only once according to the most severe classification. Minor bleeding Requiring transfusions Includes transfusions of whole blood, packed red blood cells, fresh frozen plasma, cryoprecipitate, platelets, and autotransfusion during the initial hospitalization. 4696 425 (9.3%) 347 (7.6%) 490 (10.4%) 4679 498 (10.8%) 604 (13.1%) 601 (12.8%) ESPRIT (PCI) Placebo n (%) Eptifibatide 180/2/180 n (%) Patients Major bleeding Minor bleeding Requiring transfusions 1024 4 (0.4%) 18 (2%) 11 (1.1%) 1040 13 (1.3%) 29 (3%) 16 (1.5%) The majority of major bleeding reactions in the ESPRIT study occurred at the vascular access site (1 and 8 patients, or 0.1% and 0.8% in the placebo and eptifibatide groups, respectively). Bleeding at \u201cother\u201d locations occurred in 0.2% and 0.4% of patients, respectively. In the PURSUIT study, the greatest increase in major bleeding in eptifibatide-treated patients compared to placebo-treated patients was also associated with bleeding at the femoral artery access site (2.8% versus 1.3%). Oropharyngeal (primarily gingival), genitourinary, gastrointestinal, and retroperitoneal bleeding were also seen more commonly in eptifibatide-treated patients compared to placebo-treated patients. Among patients experiencing a major bleed in the IMPACT II study, an increase in bleeding on eptifibatide versus placebo was observed only for the femoral artery access site (3.2% versus 2.8%). Table 3 displays the incidence of TIMI major bleeding according to the cardiac procedures carried out in the PURSUIT study. The most common bleeding complications were related to cardiac revascularization (CABG-related or femoral artery access site bleeding). A corresponding table for ESPRIT is not presented, as every patient underwent PCI in the ESPRIT study and only 11 patients underwent CABG. Table 3: Major Bleeding by Procedures in the PURSUIT Study Placebo n (%) Eptifibatide 180/2 n (%) Patients Overall incidence of major bleeding Breakdown by procedure: CABG Angioplasty without CABG Angiography without angioplasty or CABG Medical therapy only 4577 425 (9.3%) 375 (8.2%) 27 (0.6%) 11 (0.2%) 12 (0.3%) 4604 498 (10.8%) 377 (8.2%) 64 (1.4%) 29 (0.6%) 28 (0.6%) Note: Denominators are based on the total number of patients whose TIMI classification was resolved. In the PURSUIT and ESPRIT studies, the risk of major bleeding with eptifibatide increased as patient weight decreased. This relationship was most apparent for patients weighing less than 70 kg. Bleeding resulting in discontinuation of the study drug was more frequent among patients receiving eptifibatide than placebo (4.6% versus 0.9% in ESPRIT, 8% versus 1% in PURSUIT, 3.5% versus 1.9% in IMPACT II). Intracranial Hemorrhage and Stroke Intracranial hemorrhage was rare in the PURSUIT, IMPACT II, and ESPRIT clinical studies. In the PURSUIT study, 3 patients in the placebo group, 1 patient in the group treated with eptifibatide 180/1.3, and 5 patients in the group treated with eptifibatide 180/2 experienced a hemorrhagic stroke. The overall incidence of stroke was 0.5% in patients receiving eptifibatide 180/1.3, 0.7% in patients receiving eptifibatide 180/2, and 0.8% in placebo patients. In the IMPACT II study, intracranial hemorrhage was experienced by 1 patient treated with eptifibatide 135/0.5, 2 patients treated with eptifibatide 135/0.75, and 2 patients in the placebo group. The overall incidence of stroke was 0.5% in patients receiving 135/0.5 eptifibatide, 0.7% in patients receiving eptifibatide 135/0.75, and 0.7% in the placebo group. In the ESPRIT study, there were 3 hemorrhagic strokes, 1 in the placebo group and 2 in the eptifibatide group. In addition there was 1 case of cerebral infarction in the eptifibatide group. Immunogenicity/Thrombocytopenia The potential for development of antibodies to eptifibatide has been studied in 433 subjects. Eptifibatide was nonantigenic in 412 patients receiving a single administration of eptifibatide (135-mcg/kg bolus followed by a continuous infusion of either 0.5 mcg/kg/min or 0.75 mcg/kg/min), and in 21 subjects to whom eptifibatide (135-mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min) was administered twice, 28 days apart. In both cases, plasma for antibody detection was collected approximately 30 days after each dose. The development of antibodies to eptifibatide at higher doses has not been evaluated. In patients with suspected eptifibatide-related immune-mediated thrombocytopenia, IgG antibodies that react with the GP IIb/IIIa complex were identified in the presence of eptifibatide and in eptifibatide-na\u00efve patients. These findings suggest acute thrombocytopenia after the administration of eptifibatide can develop as a result of naturally occurring drug-dependent antibodies or those induced by prior exposure to eptifibatide. Similar antibodies were identified with other GP IIb/IIIa ligand-mimetic agents. Immune-mediated thrombocytopenia with eptifibatide may be associated with hypotension and/or other signs of hypersensitivity. In the PURSUIT and IMPACT II studies, the incidence of thrombocytopenia (<100,000/mm 3 or \u226550% reduction from baseline) and the incidence of platelet transfusions were similar between patients treated with eptifibatide and placebo. In the ESPRIT study, the incidence was 0.6% in the placebo group and 1.2% in the eptifibatide group. Other Adverse Reactions In the PURSUIT and ESPRIT studies, the incidence of serious nonbleeding adverse reactions was similar in patients receiving placebo or eptifibatide (19% and 19%, respectively, in PURSUIT; 6% and 7%, respectively, in ESPRIT). In PURSUIT, the only serious nonbleeding adverse reaction that occurred at a rate of at least 1% and was more common with eptifibatide than placebo (7% versus 6%) was hypotension. Most of the serious nonbleeding adverse reactions consisted of cardiovascular reactions typical of a UA population. In the IMPACT II study, serious nonbleeding adverse reactions that occurred in greater than 1% of patients were uncommon and similar in incidence between placebo and eptifibatide-treated patients. Discontinuation of study drug due to adverse reactions other than bleeding was uncommon in the PURSUIT, IMPACT II, and ESPRIT studies, with no single reaction occurring in >0.5% of the study population (except for \u201cother\u201d in the ESPRIT study). 6.2 Postmarketing Experience The following adverse reactions have been reported in post-approval use of eptifibatide in combination with heparin and aspirin. Because the reactions below are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure: cerebral, GI, and pulmonary hemorrhage. Fatal bleeding reactions have been reported. Acute profound thrombocytopenia, as well as immune-mediated thrombocytopenia, have been reported [see Adverse Reactions (6.1) ] ."
    ],
    "adverse_reactions_table": [
      "<table cellpadding=\"0pt\" cellspacing=\"0pt\" width=\"100%\"><caption>Table 2: Bleeding and Transfusions in the PURSUIT and ESPRIT Studies</caption><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><tfoot><tr><td align=\"left\" colspan=\"3\" valign=\"top\">Note: Denominator is based on patients for whom data are available.</td></tr></tfoot><tbody><tr styleCode=\"Toprule\"><td styleCode=\"Botrule Lrule Toprule \" valign=\"top\"><paragraph>  </paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">PURSUIT (ACS)</content> <content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">n (%)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">180/2</content> <content styleCode=\"bold\">n (%)</content> </paragraph></td></tr><tr><td styleCode=\"Lrule Toprule Botrule \" valign=\"top\"><paragraph> Patients  Major bleeding<footnote ID=\"_Ref534615054\">For major and minor bleeding, patients are counted only once according to the most severe classification.</footnote>  Minor bleeding<footnoteRef IDREF=\"_Ref534615054\"/>  Requiring transfusions<footnote ID=\"_Ref534615166\">Includes transfusions of whole blood, packed red blood cells, fresh frozen plasma, cryoprecipitate, platelets, and autotransfusion during the initial hospitalization.</footnote> </paragraph></td><td align=\"center\" styleCode=\"Toprule Botrule \" valign=\"top\"><paragraph>4696 425 (9.3%) 347 (7.6%) 490 (10.4%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"top\"><paragraph>4679 498 (10.8%) 604 (13.1%) 601 (12.8%)</paragraph></td></tr><tr><td styleCode=\"Lrule Toprule Botrule \" valign=\"top\"><paragraph>  </paragraph></td><td align=\"center\" styleCode=\"Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">ESPRIT (PCI) Placebo n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">180/2/180</content> <content styleCode=\"bold\">n (%)</content></paragraph></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Botrule Lrule \" valign=\"top\"><paragraph> Patients   Major bleeding<footnoteRef IDREF=\"_Ref534615054\"/><sup/> Minor bleeding<footnoteRef IDREF=\"_Ref534615054\"/><sup/>  Requiring transfusions<footnoteRef IDREF=\"_Ref534615166\"/> </paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>1024 4 (0.4%) 18 (2%) 11 (1.1%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>1040 13 (1.3%) 29 (3%) 16 (1.5%) </paragraph></td></tr></tbody></table>",
      "<table cellpadding=\"0pt\" cellspacing=\"0pt\" width=\"100%\"><caption>Table 3: Major Bleeding by Procedures in the PURSUIT Study</caption><col width=\"59%\"/><col width=\"18%\"/><col width=\"23%\"/><tbody><tr><td styleCode=\"Botrule Lrule Toprule \" valign=\"top\"><paragraph>  </paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo  n (%)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">180/2</content> <content styleCode=\"bold\">n (%)</content> </paragraph></td></tr><tr><td styleCode=\"Lrule Toprule Botrule \" valign=\"top\"><paragraph>Patients Overall incidence of major bleeding</paragraph><paragraph> Breakdown by procedure: CABG Angioplasty without CABG Angiography without angioplasty or CABG Medical therapy only</paragraph></td><td align=\"center\" styleCode=\"Toprule Botrule \" valign=\"top\"><paragraph>4577 425 (9.3%)</paragraph><paragraph> 375 (8.2%) 27 (0.6%) 11 (0.2%) 12 (0.3%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule Botrule \" valign=\"top\"><paragraph>4604 498 (10.8%)</paragraph><paragraph> 377 (8.2%) 64 (1.4%) 29 (0.6%) 28 (0.6%)</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Botrule Toprule \" valign=\"middle\"><paragraph>Note: Denominators are based on the total number of patients whose TIMI classification was resolved.</paragraph></td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS \u2022 Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Avoid concomitant use with other glycoprotein (GP) IIb/IIIa inhibitors. (7.1) 7.1 Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Concomitant treatment with other inhibitors of platelet receptor GP IIb/IIIa should be avoided."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS \u2022 Geriatric Use: Risk of bleeding increases with age. (8.5) 8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus (see Clinical Considerations ). In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide on the fetus. Data Animal Data Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide. 8.2 Lactation Risk Summary There are no available data on the presence of eptifibatide in human milk, the effects on the breastfed infant, or the effects on milk production. As eptifibatide is a peptide, it is likely to be destroyed in the infant\u2019s gastrointestinal tract and not absorbed orally by the breastfed infant. 8.4 Pediatric Use Safety and effectiveness of eptifibatide in pediatric patients have not been studied. 8.5 Geriatric Use The PURSUIT and IMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUIT study; no such limitation was stipulated in the ESPRIT study [see Adverse Reactions (6.1) ] . 8.6 Renal Impairment Approximately 50% of eptifibatide is cleared by the kidney in patients with normal renal function. Total drug clearance is decreased by approximately 50% and steady-state plasma eptifibatide concentrations are doubled in patients with an estimated CrCl <50 mL/min (using the Cockcroft-Gault equation). Therefore, the infusion dose should be reduced to 1 mcg/kg/min in such patients [see Dosage and Administration (2) ] . The safety and efficacy of eptifibatide in patients dependent on dialysis has not been established."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus (see Clinical Considerations ). In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide on the fetus. Data Animal Data Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety and effectiveness of eptifibatide in pediatric patients have not been studied."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use The PURSUIT and IMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUIT study; no such limitation was stipulated in the ESPRIT study [see Adverse Reactions (6.1) ] ."
    ],
    "overdosage": [
      "10 OVERDOSAGE There has been only limited experience with overdosage of eptifibatide. There were 8 patients in the IMPACT II study, 9 patients in the PURSUIT study, and no patients in the ESPRIT study who received bolus doses and/or infusion doses more than double those called for in the protocols. None of these patients experienced an intracranial bleed or other major bleeding. Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis). Symptoms of acute toxicity were loss of righting reflex, dyspnea, ptosis, and decreased muscle tone in rabbits and petechial hemorrhages in the femoral and abdominal areas of monkeys. From in vitro studies, eptifibatide is not extensively bound to plasma proteins and thus may be cleared from plasma by dialysis."
    ],
    "description": [
      "11 DESCRIPTION Eptifibatide is a cyclic heptapeptide containing 6 amino acids and 1 mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties. Chemically it is N 6 -(aminoiminomethyl)-N 2 -(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-\u03b1-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1\u21926)-disulfide. Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation. The eptifibatide peptide is produced by solution-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized. The structural formula is: Eptifibatide Injection is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use with an empirical formula of C 35 H 49 N 11 O 9 S 2 and a molecular weight of 831.96. Eptifibatide injection is a refrigerated, premixed, sterile, non-pyrogenic single-dose solution packaged in the Galaxy container. The 100 mL container consists of 0.75 mg/mL of eptifibatide. The container also contains 5.25 mg/mL citric acid and sodium hydroxide to adjust the pH to 5.35. The Galaxy container is fabricated from a specially designed multilayered plastic. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period. The suitability of the plastic has been confirmed in tests in animals according to the USP biological tests for plastic containers, as well as by tissue culture toxicity studies. Eptifibatide Chemical Structure"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet. 12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide was observed immediately after administration of a 180-mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide used in the IMPACT II and PURSUIT studies on ex vivo platelet aggregation induced by 20 \u00b5M ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRIT on platelet aggregation have not been studied. Table 4: Platelet Inhibition and Bleeding Time PURSUIT 180/2 180-mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. Inhibition of platelet aggregation 15 min after bolus Inhibition of platelet aggregation at steady state Bleeding-time prolongation at steady state Inhibition of platelet aggregation 4h after infusion discontinuation Bleeding-time prolongation 6h after infusion discontinuation 84% >90% <5x <50% 1.4x The eptifibatide dosing regimen used in the ESPRIT study included two 180-mcg/kg bolus doses given 10 minutes apart combined with a continuous 2-mcg/kg/min infusion. When administered alone, eptifibatide has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed. 12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180-mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4-6 hours). This decline can be prevented by administering a second 180-mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20-94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations (8.6) and Dosage and Administration (2) ] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "clinical_pharmacology_table": [
      "<table cellpadding=\"0pt\" cellspacing=\"0pt\" width=\"100%\"><caption>Table 4: Platelet Inhibition and Bleeding Time</caption><col width=\"80%\"/><col width=\"20%\"/><tbody><tr><td styleCode=\"Botrule Lrule Toprule \" valign=\"top\"><paragraph>  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">PURSUIT</content> <content styleCode=\"bold\">180/2</content><footnote ID=\"_Ref534617387\">180-mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min.</footnote> </paragraph></td></tr><tr><td styleCode=\"Botrule Lrule \" valign=\"middle\"><paragraph>Inhibition of platelet aggregation 15 min after bolus Inhibition of platelet aggregation at steady state Bleeding-time prolongation at steady state Inhibition of platelet aggregation 4h after infusion discontinuation Bleeding-time prolongation 6h after infusion discontinuation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>84% &gt;90% &lt;5x &lt;50% 1.4x </paragraph></td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide was observed immediately after administration of a 180-mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide used in the IMPACT II and PURSUIT studies on ex vivo platelet aggregation induced by 20 \u00b5M ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRIT on platelet aggregation have not been studied. Table 4: Platelet Inhibition and Bleeding Time PURSUIT 180/2 180-mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. Inhibition of platelet aggregation 15 min after bolus Inhibition of platelet aggregation at steady state Bleeding-time prolongation at steady state Inhibition of platelet aggregation 4h after infusion discontinuation Bleeding-time prolongation 6h after infusion discontinuation 84% >90% <5x <50% 1.4x The eptifibatide dosing regimen used in the ESPRIT study included two 180-mcg/kg bolus doses given 10 minutes apart combined with a continuous 2-mcg/kg/min infusion. When administered alone, eptifibatide has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed."
    ],
    "pharmacodynamics_table": [
      "<table cellpadding=\"0pt\" cellspacing=\"0pt\" width=\"100%\"><caption>Table 4: Platelet Inhibition and Bleeding Time</caption><col width=\"80%\"/><col width=\"20%\"/><tbody><tr><td styleCode=\"Botrule Lrule Toprule \" valign=\"top\"><paragraph>  </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">PURSUIT</content> <content styleCode=\"bold\">180/2</content><footnote ID=\"_Ref534617387\">180-mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min.</footnote> </paragraph></td></tr><tr><td styleCode=\"Botrule Lrule \" valign=\"middle\"><paragraph>Inhibition of platelet aggregation 15 min after bolus Inhibition of platelet aggregation at steady state Bleeding-time prolongation at steady state Inhibition of platelet aggregation 4h after infusion discontinuation Bleeding-time prolongation 6h after infusion discontinuation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>84% &gt;90% &lt;5x &lt;50% 1.4x </paragraph></td></tr></tbody></table>"
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180-mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4-6 hours). This decline can be prevented by administering a second 180-mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20-94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations (8.6) and Dosage and Administration (2) ] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Eptifibatide was studied in 3 placebo-controlled, randomized studies. PURSUIT evaluated patients with acute coronary syndromes: UA or NSTEMI. Two other studies, ESPRIT and IMPACT II, evaluated patients about to undergo a PCI. Patients underwent primarily balloon angioplasty in IMPACT II and intracoronary stent placement, with or without angioplasty, in ESPRIT. 14.1 Non-ST-Segment Elevation Acute Coronary Syndrome Non-ST-segment elevation acute coronary syndrome is defined as prolonged (\u226510 minutes) symptoms of cardiac ischemia within the previous 24 hours associated with either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or positive CK-MB. This definition includes \"unstable angina\" and \"NSTEMI\" but excludes MI that is associated with Q waves or greater degrees of ST-segment elevation. PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Eptifibatide Therapy) PURSUIT was a 726-center, 27-country, double-blind, randomized, placebo-controlled study in 10,948 patients presenting with UA or NSTEMI. Patients could be enrolled only if they had experienced cardiac ischemia at rest (\u226510 minutes) within the previous 24 hours and had either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or increased CK-MB. Important exclusion criteria included a history of bleeding diathesis, evidence of abnormal bleeding within the previous 30 days, uncontrolled hypertension, major surgery within the previous 6 weeks, stroke within the previous 30 days, any history of hemorrhagic stroke, serum creatinine >2 mg/dL, dependency on renal dialysis, or platelet count <100,000/mm 3 . Patients were randomized to placebo, to eptifibatide 180-mcg/kg bolus followed by a 2-mcg/kg/min infusion (180/2), or to eptifibatide 180-mcg/kg bolus followed by a 1.3-mcg/kg/min infusion (180/1.3). The infusion was continued for 72 hours, until hospital discharge, or until the time of CABG, whichever occurred first, except that if PCI was performed, the eptifibatide infusion was continued for 24 hours after the procedure, allowing for a duration of infusion up to 96 hours. The lower-infusion-rate arm was stopped after the first interim analysis when the 2 active-treatment arms appeared to have the same incidence of bleeding. Patient age ranged from 20 to 94 (mean 63) years, and 65% were male. The patients were 89% Caucasian, 6% Hispanic, and 5% Black, recruited in the United States and Canada (40%), Western Europe (39%), Eastern Europe (16%), and Latin America (5%). This was a \u201creal world\u201d study; each patient was managed according to the usual standards of the investigational site; frequencies of angiography, PCI, and CABG therefore differed widely from site to site and from country to country. Of the patients in PURSUIT, 13% were managed with PCI during drug infusion, of whom 50% received intracoronary stents; 87% were managed medically (without PCI during drug infusion). The majority of patients received aspirin (75-325 mg once daily). Heparin was administered intravenously or subcutaneously, at the physician's discretion, most commonly as an intravenous bolus of 5000 units followed by a continuous infusion of 1000 units/h. For patients weighing less than 70 kg, the recommended heparin bolus dose was 60 units/kg followed by a continuous infusion of 12 units/kg/h. A target aPTT of 50 to 70 seconds was recommended. A total of 1250 patients underwent PCI within 72 hours after randomization, in which case they received intravenous heparin to maintain an ACT of 300 to 350 seconds. The primary endpoint of the study was the occurrence of death from any cause or new MI (evaluated by a blinded Clinical Endpoints Committee) within 30 days of randomization. Compared to placebo, eptifibatide administered as a 180-mcg/kg bolus followed by a 2-mcg/kg/min infusion significantly (p=0.042) reduced the incidence of endpoint events (see Table 6). The reduction in the incidence of endpoint events in patients receiving eptifibatide was evident early during treatment, and this reduction was maintained through at least 30 days (see Figure 1). Table 5 also shows the incidence of the components of the primary endpoint, death (whether or not preceded by an MI) and new MI in surviving patients at 30 days. Table 5: Clinical Events in the PURSUIT Study Death or MI Placebo (n=4739) n (%) Eptifibatide (180 mcg/kg bolus then 2 mcg/kg/min infusion) (n=4722) n (%) p-value 3 days 7 days 30 days Death or MI (primary endpoint) Death Nonfatal MI 359 (7.6%) 552 (11.6%) 745 (15.7%) 177 (3.7%) 568 (12%) 279 (5.9%) 477 (10.1%) 672 (14.2%) 165 (3.5%) 507 (10.7%) 0.001 0.016 0.042 Figure 1: Kaplan-Meier Plot of Time to Death or Myocardial Infarction Within 30 Days of Randomization in the PURSUIT Study Treatment with eptifibatide prior to determination of patient management strategy reduced clinical events regardless of whether patients ultimately underwent diagnostic catheterization, revascularization (i.e., PCI or CABG surgery) or continued to receive medical management alone. Table 6 shows the incidence of death or MI within 72 hours. Table 6: Clinical Events (Death or MI) in the PURSUIT Study Within 72 Hours of Randomization Placebo Eptifibatide (180 mcg/kg bolus then then 2 mcg/kg/min infusion) Overall patient population \u2013 At 72 hours Patients undergoing early PCI \u2013 Pre-procedure (nonfatal MI only) \u2013 At 72 hours Patients not undergoing early PCI \u2013 At 72 hours n=4739 7.6% n=631 5.5% 14.4% n=4108 6.5% n=4722 5.9% n=619 1.8% 9% n=4103 5.4% All of the effect of eptifibatide was established within 72 hours (during the period of drug infusion), regardless of management strategy. Moreover, for patients undergoing early PCI, a reduction in events was evident prior to the procedure. An analysis of the results by sex suggests that women who would not routinely be expected to undergo PCI receive less benefit from eptifibatide (95% confidence limits for relative risk of 0.94 - 1.28) than do men (0.72 - 0.9). This difference may be a true treatment difference, the effect of other differences in these subgroups, or a statistical anomaly. No differential outcomes were seen between male and female patients undergoing PCI (see results for ESPRIT) . Follow-up data were available through 165 days for 10,611 patients enrolled in the PURSUIT trial (96.9% of the initial enrollment). This follow-up included 4566 patients who received eptifibatide at the 180/2 dose. As reported by the investigators, the occurrence of death from any cause or new MI for patients followed for at least 165 days was reduced from 13.6% with placebo to 12.1% with eptifibatide 180/2. Figure 1: Kaplan-Meier Plot of Time to Death or Myocardial Infarction Within 30 Days of Randomization in the PURSUIT Study 14.2 Percutaneous Coronary Intervention (PCI) IMPACT II (Eptifibatide to Minimize Platelet Aggregation and Prevent Coronary Thrombosis II) IMPACT II was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States in 4010 patients undergoing PCI. Major exclusion criteria included a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 89 (mean 60) years, and 75% were male. The patients were 92% Caucasian, 5% Black, and 3% Hispanic. Forty-one percent of the patients underwent PCI for ongoing ACS. Patients were randomly assigned to 1 of 3 treatment regimens, each incorporating a bolus dose initiated immediately prior to PCI followed by a continuous infusion lasting 20 to 24 hours: 1) 135-mcg/kg bolus followed by a continuous infusion of 0.5 mcg/kg/min of eptifibatide (135/0.5); 2) 135-mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min of eptifibatide (135/0.75); or 3) a matching placebo bolus followed by a matching placebo continuous infusion. Each patient received aspirin and an intravenous heparin bolus of 100 units/kg, with additional bolus infusions of up to 2000 additional units of heparin every 15 minutes to maintain an ACT of 300 to 350 seconds. The primary endpoint was the composite of death, MI, or urgent revascularization, analyzed at 30 days after randomization in all patients who received at least 1 dose of study drug. As shown in Table 7, each eptifibatide regimen reduced the rate of death, MI, or urgent intervention, although at 30 days, this finding was statistically significant only in the lower-dose eptifibatide group. As in the PURSUIT study, the effects of eptifibatide were seen early and persisted throughout the 30-day period. Table 7: Clinical Events in the IMPACT II Study Placebo n (%) Eptifibatide (135 mcg/kg bolus then 0.5 mcg/kg/min infusion) n (%) Eptifibatide (135 mcg/kg bolus then 0.75 mcg/kg/min infusion) n (%) Patients 1285 1300 1286 Abrupt Closure 65 (5.1%) 36 (2.8%) 43 (3.3%) p-value versus placebo 0.003 0.03 Death, MI, or Urgent Intervention 24 hours p-value versus placebo 48 hours p-value versus placebo 30 days (primary endpoint) p-value versus placebo Death or MI 30 days p-value versus placebo 6 months p-value versus placebo 123 (9.6%) 131 (10.2%) 149 (11.6%) 110 (8.6%) 151 (11.9%) Kaplan-Meier estimate of event rate. 86 (6.6%) 0.006 99 (7.6%) 0.021 118 (9.1%) 0.035 89 (6.8%) 0.102 136 (10.6%) 0.297 89 (6.9%) 0.014 102 (7.9%) 0.045 128 (10%) 0.179 95 (7.4%) 0.272 130 (10.3%) 0.182 ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Eptifibatide Therapy) The ESPRIT study was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States and Canada that enrolled 2064 patients undergoing elective or urgent PCI with intended intracoronary stent placement. Exclusion criteria included MI within the previous 24 hours, ongoing chest pain, administration of any oral antiplatelet or oral anticoagulant other than aspirin within 30 days of PCI (although loading doses of thienopyridine on the day of PCI were encouraged), planned PCI of a saphenous vein graft or subsequent \u201cstaged\u201d PCI, prior stent placement in the target lesion, PCI within the previous 90 days, a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 93 (mean 62) years, and 73% of patients were male. The study enrolled 90% Caucasian, 5% African American, 2% Hispanic, and 1% Asian patients. Patients received a wide variety of stents. Patients were randomized either to placebo or eptifibatide administered as an intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2 mcg/kg/min, and a second bolus of 180 mcg/kg administered 10 minutes later (180/2/180). Eptifibatide infusion was continued for 18 to 24 hours after PCI or until hospital discharge, whichever came first. Each patient received at least 1 dose of aspirin (162-325 mg) and 60 units/kg of heparin as a bolus (not to exceed 6000 units) if not already receiving a heparin infusion. Additional boluses of heparin (10-40 units/kg) could be administered in order to reach a target ACT between 200 and 300 seconds. The primary endpoint of the ESPRIT study was the composite of death, MI, urgent target vessel revascularization (UTVR), and \u201cbailout\u201d to open-label eptifibatide due to a thrombotic complication of PCI (TBO) (e.g., visible thrombus, \u201cno reflow,\u201d or abrupt closure) at 48 hours. MI, UTVR, and TBO were evaluated by a blinded Clinical Events Committee. As shown in Table 8, the incidence of the primary endpoint and selected secondary endpoints was significantly reduced in patients who received eptifibatide. A treatment benefit in patients who received eptifibatide was seen by 48 hours and at the end of the 30-day observation period. Table 8: Clinical Events in the ESPRIT Study * Eptifibatide was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min. Placebo (n=1024) Eptifibatide * (n=1040) Relative Risk (95% CI) p-value Death, MI, UTVR, or Thrombotic \u201cBailout\u201d 48 hours (primary endpoint) 30 days Death, MI, or UTVR 48 hours 30 days (key secondary endpoint) Death or MI 48 hours 30 DAYS 108 (10.5%) 120 (11.7%) 95 (9.3%) 107 (10.4%) 94 (9.2%) 104 (10.2%) 69 (6.6%) 78 (7.5%) 62 (6%) 71 (6.8%) 57 (5.5%) 66 (6.3%) 0.629 (0.471, 0.84) 0.64 (0.488, 0.84) 0.643 (0.472, 0.875) 0.653 (0.49, 0.871) 0.597 (0.435, 0.82) 0.625 (0.465, 0.84) 0.0015 0.0011 0.0045 0.0034 0.0013 0.0016 The need for thrombotic \u201cbailout\u201d was significantly reduced with eptifibatide at 48 hours (2.1% for placebo, 1% for eptifibatide; p=0.029). Consistent with previous studies of GP IIb/IIIa inhibitors, most of the benefit achieved acutely with eptifibatide was in the reduction of MI. Eptifibatide reduced the occurrence of MI at 48 hours from 9% for placebo to 5.4% (p=0.0015) and maintained that effect with significance at 30 days. There was no treatment difference with respect to sex in ESPRIT. Eptifibatide reduced the incidence of the primary endpoint in both men (95% confidence limits for relative risk: 0.54, 1.07) and women (0.24, 0.72) at 48 hours. Follow-up (12-month) mortality data were available for 2024 patients (1017 on eptifibatide) enrolled in the ESPRIT trial (98.1% of the initial enrollment). Twelve-month clinical event data were available for 1964 patients (988 on eptifibatide), representing 95.2% of the initial enrollment. As shown in Table 9, the treatment effect of eptifibatide seen at 48 hours and 30 days appeared preserved at 6 months and 1 year. Most of the benefit was in reduction of MI. Table 9: Clinical Events at 6 Months and 1 Year in the ESPRIT Study Placebo (n=1024) Eptifibatide (n=1040) Hazard Ratio (95% CI) Death, MI, or Target Vessel Revascularization 6 months 187 (18.5%) 146 (14.3%) 0.744 (0.599, 0.924) 1 year 222 (22.1%) 178 (17.5%) 0.762 (0.626, 0.929) Death, MI 6 months 117 (11.5%) 77 (7.4%) 0.631 (0.473, 0.841) 1 year 126 (12.4%) 83 (8%) 0.63 (0.478, 0.832) Percentages are Kaplan-Meier event rates."
    ],
    "clinical_studies_table": [
      "<table cellpadding=\"0pt\" cellspacing=\"0pt\" width=\"100%\"><caption>Table 5: Clinical Events in the PURSUIT Study</caption><col width=\"41%\"/><col width=\"16%\"/><col width=\"31%\"/><col width=\"11%\"/><tbody><tr styleCode=\"Toprule\"><td styleCode=\"Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\"> Death or MI </content>   </paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content>  <content styleCode=\"bold\">(n=4739) </content> <content styleCode=\"bold\">n (%)</content> </paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(180 mcg/kg bolus then</content> <content styleCode=\"bold\"> 2 mcg/kg/min infusion) </content> <content styleCode=\"bold\">(n=4722)</content> <content styleCode=\"bold\">n (%) </content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">p-value </content>   </paragraph></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Botrule Lrule \" valign=\"top\"><paragraph>3 days 7 days 30 days  Death or MI (primary endpoint)</paragraph><paragraph> Death  Nonfatal MI </paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>359 (7.6%)</paragraph><paragraph>552 (11.6%)  745 (15.7%) 177 (3.7%) 568 (12%) </paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>279 (5.9%) 477 (10.1%)  672 (14.2%) 165 (3.5%) 507 (10.7%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>0.001 0.016  0.042</paragraph></td></tr></tbody></table>",
      "<table cellpadding=\"0pt\" cellspacing=\"0pt\" width=\"100%\"><caption>Table 6: Clinical Events (Death or MI) in the PURSUIT Study Within 72 Hours of Randomization</caption><col width=\"49%\"/><col width=\"19%\"/><col width=\"32%\"/><tbody><tr><td styleCode=\"Botrule Lrule Toprule \" valign=\"top\"><paragraph>  </paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\"> Placebo </content>   </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(180 mcg/kg bolus then then</content> <content styleCode=\"bold\"> 2 mcg/kg/min infusion) </content> </paragraph></td></tr><tr><td styleCode=\"Botrule Lrule Toprule \" valign=\"middle\"><paragraph> Overall patient population   &#x2013; At 72 hours  Patients undergoing early PCI  &#x2013; Pre-procedure (nonfatal MI only)  &#x2013; At 72 hours  Patients not undergoing early PCI  &#x2013; At 72 hours</paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"middle\"><paragraph>n=4739  7.6% n=631 5.5% 14.4% n=4108 6.5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph>n=4722  5.9% n=619 1.8% 9% n=4103 5.4% </paragraph></td></tr></tbody></table>",
      "<table cellpadding=\"0pt\" cellspacing=\"0pt\" width=\"100%\"><caption>Table 7: Clinical Events in the IMPACT II Study</caption><col width=\"33%\"/><col width=\"17%\"/><col width=\"27%\"/><col width=\"24%\"/><tbody><tr styleCode=\"Toprule\"><td styleCode=\"Lrule Toprule \" valign=\"top\"><paragraph>  </paragraph></td><td align=\"center\" styleCode=\"Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content>   <content styleCode=\"bold\">n (%)</content> </paragraph></td><td align=\"center\" styleCode=\"Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(135 mcg/kg bolus then</content> <content styleCode=\"bold\"> 0.5 mcg/kg/min infusion)</content> <content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(135 mcg/kg bolus then</content> <content styleCode=\"bold\"> 0.75 mcg/kg/min infusion)</content> <content styleCode=\"bold\">n (%)</content></paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph>Patients</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1285</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1300</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"top\"><paragraph>1286</paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph>Abrupt Closure</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>65 (5.1%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>36 (2.8%)</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"top\"><paragraph>43 (3.3%)</paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph> p-value versus placebo</paragraph></td><td valign=\"top\"/><td align=\"center\" valign=\"top\"><paragraph>0.003</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"top\"><paragraph>0.03</paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph>Death, MI, or Urgent Intervention</paragraph></td><td valign=\"top\"/><td valign=\"top\"/><td styleCode=\"Rrule \" valign=\"top\"/></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph> 24 hours  p-value versus placebo  48 hours  p-value versus placebo  30 days (primary endpoint)  p-value versus placebo Death or MI  30 days  p-value versus placebo   6 months   p-value versus placebo </paragraph></td><td align=\"center\" valign=\"top\"><paragraph>123 (9.6%)  131 (10.2%)  149 (11.6%)   110 (8.6%)   151 (11.9%)<footnote ID=\"_Ref535221924\">Kaplan-Meier estimate of event rate.</footnote>  </paragraph></td><td align=\"center\" valign=\"top\"><paragraph>86 (6.6%) 0.006 99 (7.6%) 0.021 118 (9.1%) 0.035  89 (6.8%)  0.102  136 (10.6%)<footnoteRef IDREF=\"_Ref535221924\"/> 0.297 </paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"top\"><paragraph>89 (6.9%) 0.014 102 (7.9%) 0.045 128 (10%) 0.179  95 (7.4%)  0.272  130 (10.3%)<footnoteRef IDREF=\"_Ref535221924\"/> 0.182  </paragraph></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Botrule Lrule \" valign=\"top\"/><td styleCode=\"Botrule \" valign=\"top\"/><td styleCode=\"Botrule \" valign=\"top\"/><td styleCode=\"Rrule Botrule \" valign=\"top\"/></tr></tbody></table>",
      "<table ID=\"_RefID0EBHAI\" cellpadding=\"0pt\" cellspacing=\"0pt\" width=\"100%\"><caption>Table 8: Clinical Events in the ESPRIT Study </caption><col width=\"33%\"/><col width=\"17%\"/><col width=\"19%\"/><col width=\"19%\"/><col width=\"12%\"/><tfoot><tr><td align=\"left\" colspan=\"5\" valign=\"top\">* Eptifibatide was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min.</td></tr></tfoot><tbody><tr styleCode=\"Toprule\"><td align=\"center\" styleCode=\"Botrule Lrule Toprule \" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\"> (n=1024)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide<sup>*</sup></content> <content styleCode=\"bold\"> (n=1040)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Relative Risk</content> <content styleCode=\"bold\">(95% CI)</content> </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\"> p-value</content> </paragraph></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Botrule Lrule Toprule \" valign=\"top\"><paragraph>Death, MI, UTVR, or Thrombotic &#x201C;Bailout&#x201D;   48 hours (primary endpoint)  30 days Death, MI, or UTVR  48 hours  30 days (key secondary  endpoint) Death or MI  48 hours  30 DAYS</paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph>  108 (10.5%) 120 (11.7%)  95 (9.3%) 107 (10.4%)  94 (9.2%) 104 (10.2%) </paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph>  69 (6.6%) 78 (7.5%)  62 (6%) 71 (6.8%)  57 (5.5%) 66 (6.3%) </paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph>  0.629 (0.471, 0.84) 0.64 (0.488, 0.84)  0.643 (0.472, 0.875) 0.653 (0.49, 0.871)  0.597 (0.435, 0.82) 0.625 (0.465, 0.84) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph>  0.0015 0.0011  0.0045 0.0034  0.0013 0.0016 </paragraph></td></tr></tbody></table>",
      "<table cellpadding=\"0pt\" cellspacing=\"0pt\" width=\"100%\"><caption>Table 9: Clinical Events at 6 Months and 1 Year in the ESPRIT Study</caption><col width=\"43%\"/><col width=\"18%\"/><col width=\"17%\"/><col width=\"22%\"/><tbody><tr><td styleCode=\"Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">  </content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(n=1024)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(n=1040)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hazard Ratio</content> <content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td colspan=\"4\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Death, MI, or Target Vessel Revascularization </paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\"> </content>6 months</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>187 (18.5%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>146 (14.3%)</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"top\"><paragraph>0.744 (0.599, 0.924)</paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><paragraph> 1 year </paragraph></td><td align=\"center\" valign=\"top\"><paragraph>222 (22.1%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>178 (17.5%)</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"top\"><paragraph>0.762 (0.626, 0.929)</paragraph></td></tr><tr><td colspan=\"4\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>Death, MI</paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"middle\"><paragraph> 6 months </paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>117 (11.5%)</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>77 (7.4%)</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>0.631 (0.473, 0.841)</paragraph></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Botrule Lrule \" valign=\"top\"><paragraph> 1 year </paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>126 (12.4%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>83 (8%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"top\"><paragraph>0.63 (0.478, 0.832)</paragraph></td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Eptifibatide injection is supplied as a refrigerated, premixed, sterile, non-pyrogenic solution in single-dose Galaxy containers packed in individual cartons. The single-dose Galaxy plastic containers are available as follows: Code NDC No. Container Strength Number of Cartons 2G3476 0338-9558-10 Galaxy single-dose 75 mg per 100 mL (0.75 mg per mL) 12 Cartons 16.2 Storage Galaxy containers should be stored refrigerated at 2-8\u00b0C (36-46\u00b0F). Galaxy containers may be transferred to room temperature storage1 for a period not to exceed 2 months. Upon transfer, Eptifibatide injection cartons must be marked by the dispensing pharmacist with a \u201cDISCARD BY\u201d date (2 months from the transfer date or the labeled expiration date, whichever comes first). Protect from light. Retain in carton until time of use. Discard unused portion. 1 Store at 25\u00b0C (77\u00b0F); excursions permitted to 15-30\u00b0C (59-86\u00b0F) [see USP Controlled Room Temperature]."
    ],
    "how_supplied_table": [
      "<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"17%\"/><col width=\"21%\"/><col width=\"21%\"/><col width=\"20%\"/><col width=\"20%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Code</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>NDC No.</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Container</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Strength</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Number of Cartons</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>2G3476</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>0338-9558-10</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Galaxy</content> single-dose</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>75 mg per 100 mL (0.75 mg per mL)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>12 Cartons</paragraph></td></tr></tbody></table>"
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Instruct patients to inform the doctor or healthcare provider about any medical conditions, medications, and allergies."
    ],
    "spl_unclassified_section": [
      "Baxter and Galaxy are trademarks of Baxter International Inc. or its subsidiaries. Baxter Logo Baxter Healthcare Corporation Deerfield, IL 60015 USA 07-19-07-571 Made in USA."
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL-PRINCIPAL DISPLAY PANEL Container Label NDC 0338-9558-10 Eptifibatide Injection 75 mg per 100 mL (0.75 mg / mL) For Intravenous Infusion Only. Not for Intravenous Bolus Use. GALAXY Single Dose Container Discard unused portion Code 2G3476 Sterile Nonpyrogenic Each mL contains 0.75 mg Eptifibatide; 5.25 mg citric acid, USP; and Water for Injection, USP. pH adjusted with sodium hydroxide to 5.35. Dosage: See prescribing information. Caution: Do not add supplemental medication or additives. Rx only Use carton to protect contents from light until administration. Store refrigerated at 2-8\u00b0C (36-46\u00b0F). May be transferred to 25\u00b0C (77\u00b0F; USP Controlled Room Temperature) for up to 2 months. Must be discarded if not used within 2 months of transfer. ____________________________________________________________ Baxter Logo Baxter and Galaxy are registered trademarks of Baxter International Inc. Baxter Healthcare Corporation , Deerfield, IL 60015 USA Made in USA 07-34-00-2284 Bar Code Position Only 303389558101 NDC 0338-9558-10 Eptifibatide Injection 75 mg per 100 mL (0.75 mg/mL) For Intravenous Infusion Only. Not for Intravenous Bolus Use. Rx Only USE CARTON TO PROTECT CONTENTS FROM LIGHT UNTIL ADMINISTRATION 1 GALAXY Single Dose Container Discard unused portion Baxter Logo Deerfield, IL 60015 USA For Intravenous Infusion Only. Not for Intravenous Bolus Use. Eptifibatide Injection 75 mg per 100 mL (0.75 mg/mL) NDC 0338-9558-10 Eptifibatide Injection 75 mg per 100 mL (0.75 mg/mL) For Intravenous Infusion Only. Not For Intravenous Bolus Use. UNVARNISHED AREA FOR ON-LINE PRINTING OF LOT & EXP *UPC-A Bar Code Placement 303389558101 Each mL contains 0.75 mg Eptifibatide; 5.25 mg citric acid, USP; and Water for Injection, USP. pH adjusted with sodium hydroxide to 5.35. Dosage: See prescribing information. Caution: Do not add supplemental medication or additives. Rx only Use carton to protect contents from light until administration. Store refrigerated at 2-8\u00b0C (36-46\u00b0F). May be transferred to 25\u00b0C (77\u00b0F; USP Controlled Room Temperature) for up to 2 months. Must be discarded if not used within 2 months of transfer. Discard if not used within 2 months of transfer to 25\u00b0C (77\u00b0F) Discard Use (Month) (Day) (Year) (to be completed by dispensing pharmacist) Baxter and Galaxy are registered trademarks of Baxter International Inc. Baxter Healthcare Corporation , Deerfield, IL 60015 USA 07-01-75-957 For Intravenous Infusion Only. Not For Intravenous Bolus Use. Eptifibatide Injection 75 mg per 100 mL (0.75 mg/ mL) For Intravenous Infusion Only. Not For Intravenous Bolus Use. Eptifibatide Injection 75 mg per 100 mL (0.75 mg/ mL) For Intravenous Infusion Only. Not For Intravenous Bolus Use. Eptifibatide Injection 75 mg per 100 mL (0.75 mg/ mL) Representative Container Label NDC 0338-9558-10 1 of 2 Representative Container Label NDC 0338-9558-10 2 of 2 Representative Carton Label 0338-9558-10"
    ],
    "package_label_principal_display_panel_table": [
      "<table width=\"100%\"><col width=\"22%\"/><col width=\"24%\"/><col width=\"20%\"/><col width=\"2%\"/><tbody><tr><td align=\"center\" colspan=\"4\" styleCode=\"Rrule Lrule Toprule \" valign=\"top\"><paragraph>Discard if not used within 2 months of transfer to 25&#xB0;C (77&#xB0;F)</paragraph></td></tr><tr><td align=\"center\" colspan=\"4\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Discard Use</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Botrule \" valign=\"top\"/></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>(Month)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule \" valign=\"top\"><paragraph>(Day)</paragraph></td><td align=\"center\" styleCode=\"Lrule Toprule \" valign=\"top\"><paragraph>(Year)</paragraph></td><td styleCode=\"Rrule Toprule \" valign=\"top\"/></tr><tr><td align=\"center\" colspan=\"4\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><paragraph>(to be completed by dispensing pharmacist)</paragraph></td></tr></tbody></table>"
    ],
    "set_id": "5f46b76b-5c83-49b9-ada8-4ad5cf81a38c",
    "id": "ef735fed-22fb-4b20-9b28-828f4610e367",
    "effective_time": "20240529",
    "version": "12",
    "openfda": {
      "application_number": [
        "ANDA208554"
      ],
      "brand_name": [
        "Eptifibatide"
      ],
      "generic_name": [
        "EPTIFIBATIDE"
      ],
      "manufacturer_name": [
        "Baxter Healthcare Company"
      ],
      "product_ndc": [
        "0338-9558"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "INTRAVENOUS"
      ],
      "substance_name": [
        "EPTIFIBATIDE"
      ],
      "rxcui": [
        "200349"
      ],
      "spl_id": [
        "ef735fed-22fb-4b20-9b28-828f4610e367"
      ],
      "spl_set_id": [
        "5f46b76b-5c83-49b9-ada8-4ad5cf81a38c"
      ],
      "package_ndc": [
        "0338-9558-10"
      ],
      "is_original_packager": [
        true
      ],
      "nui": [
        "N0000008832",
        "N0000175578"
      ],
      "pharm_class_pe": [
        "Decreased Platelet Aggregation [PE]"
      ],
      "pharm_class_epc": [
        "Platelet Aggregation Inhibitor [EPC]"
      ],
      "unii": [
        "NA8320J834"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Eptifibatide eptifibatide EPTIFIBATIDE EPTIFIBATIDE CITRIC ACID MONOHYDRATE SODIUM HYDROXIDE Eptifibatide eptifibatide EPTIFIBATIDE EPTIFIBATIDE CITRIC ACID MONOHYDRATE SODIUM HYDROXIDE Eptifibatide eptifibatide EPTIFIBATIDE EPTIFIBATIDE CITRIC ACID MONOHYDRATE SODIUM HYDROXIDE"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Eptifibatide injection is a platelet aggregation inhibitor indicated for: \u2022 Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI) ( 1.1 ) \u2022 Treatment of patients undergoing PCI (including intracoronary stenting) ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS (unstable angina [UA]/non-ST- elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). 1.2 Percutaneous Coronary Intervention (PCI) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting [see Clinical Studies (14.1 , 14.2) ] ."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION Before infusion of eptifibatide injection, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured. The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT. ACS or PCI: 180 mcg/kg IV bolus as soon as possible after diagnosis followed by infusion at 2 mcg/kg/min. ( 2.1 , 2.2 ) PCI: Add a second 180 mcg/kg bolus at 10 minutes. ( 2.2 ) In patients with creatinine clearance less than 50 mL/min, reduce the infusion to 1 mcg/kg/min. ( 2.1 , 2.2 , 2.3 ) 2.1 Dosage in Acute Coronary Syndrome (ACS) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with ACS 180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min 180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min \u2022 Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours \u2022 If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy \u2022 Aspirin, 160 mg to 325 mg, should be given daily Eptifibatide injection should be given concomitantly with heparin dosed to achieve the following parameters: During Medical Management : Target aPTT 50 to 70 seconds \u2022 If weight greater than or equal to 70 kg, 5000-unit bolus followed by infusion of 1000 units/h. \u2022 If weight less than 70 kg, 60-units/kg bolus followed by infusion of 12 units/kg/h. During PCI : Target ACT 200 to 300 seconds \u2022 If heparin is initiated prior to PCI, additional boluses during PCI to maintain an ACT target of 200 to 300 seconds. \u2022 Heparin infusion after the PCI is discouraged. 2.2 Dosage in Percutaneous Coronary Intervention (PCI) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with PCI 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) \u2022 Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. \u2022 In patients who undergo CABG surgery, eptifibatide infusion should be discontinued prior to surgery. \u2022 Aspirin, 160 mg to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter. \u2022 Eptifibatide injection should be given concomitantly with heparin to achieve a target ACT of 200 to 300 seconds. Administer 60-units/kg bolus initially in patients not treated with heparin within 6 hours prior to PCI. \u2022 Additional boluses during PCI to maintain ACT within target. \u2022 Heparin infusion after the PCI is strongly discouraged. Patients requiring thrombolytic therapy should discontinue eptifibatide injection. 2.3 Important Administration Instructions 1. Inspect eptifibatide injection for particulate matter and discoloration prior to administration, whenever solution and container permit. 2. May administer eptifibatide injection in the same intravenous line as alteplase, atropine, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, or verapamil. Do not administer eptifibatide injection through the same intravenous line as furosemide. 3. May administer eptifibatide injection in the same IV line with 0.9% NaCl or 0.9% NaCl/5% dextrose. With either vehicle, the infusion may also contain up to 60 mEq/L of potassium chloride. 4. Withdraw the bolus dose(s) of eptifibatide injection from the 10 mL vial into a syringe. Administer the bolus dose(s) by IV push. 5. Immediately following the bolus dose administration, initiate a continuous infusion of eptifibatide injection. When using an intravenous infusion pump, administer eptifibatide injection undiluted directly from the 100 mL vial. Spike the 100 mL vial with a vented infusion set. Center the spike within the circle on the stopper top. 6. Discard any unused portion left in the vial. Administer eptifibatide injection by volume according to patient weight (see Table 1). Table 1: Eptifibatide Injection Dosing Charts by Weight Patient Weight 180 mcg/kg Bolus Volume 2 mcg/kg/min Infusion Volume (CrCl greater than or equal to 50 mL/min) 1 mcg/kg/min Infusion Volume (CrCl less than 50 mL/min) (kg) (lb) (from 2 mg/mL vial) (from 2 mg/mL 100 mL vial) (from 0.75 mg/mL 100 mL vial) (from 2 mg/mL 100 mL vial) (from 0.75 mg/mL 100 mL vial) 37 to 41 81 to 91 3.4 mL 2 mL/h 6 mL/h 1 mL/h 3 mL/h 42 to 46 92 to 102 4 mL 2.5 mL/h 7 mL/h 1.3 mL/h 3.5 mL/h 47 to 53 103 to 117 4.5 mL 3 mL/h 8 mL/h 1.5 mL/h 4 mL/h 54 to 59 118 to 130 5 mL 3.5 mL/h 9 mL/h 1.8 mL/h 4.5 mL/h 60 to 65 131 to 143 5.6 mL 3.8 mL/h 10 mL/h 1.9 mL/h 5 mL/h 66 to 71 144 to 157 6.2 mL 4 mL/h 11 mL/h 2 mL/h 5.5 mL/h 72 to 78 158 to 172 6.8 mL 4.5 mL/h 12 mL/h 2.3 mL/h 6 mL/h 79 to 84 173 to 185 7.3 mL 5 mL/h 13 mL/h 2.5 mL/h 6.5 mL/h 85 to 90 186 to 198 7.9 mL 5.3 mL/h 14 mL/h 2.7 mL/h 7 mL/h 91 to 96 199 to 212 8.5 mL 5.6 mL/h 15 mL/h 2.8 mL/h 7.5 mL/h 97 to 103 213 to 227 9 mL 6 mL/h 16 mL/h 3.0 mL/h 8 mL/h 104 to 109 228 to 240 9.5 mL 6.4 mL/h 17 mL/h 3.2 mL/h 8.5 mL/h 110 to 115 241 to 253 10.2 mL 6.8 mL/h 18 mL/h 3.4 mL/h 9 mL/h 116 to 121 254 to 267 10.7 mL 7 mL/h 19 mL/h 3.5 mL/h 9.5 mL/h >121 >267 11.3 mL 7.5 mL/h 20 mL/h 3.7 mL/h 10 mL/h"
    ],
    "dosage_and_administration_table": [
      "<table width=\"100%\"><col width=\"17%\"/><col width=\"37%\"/><col width=\"45%\"/><tbody><tr styleCode=\"Toprule\"><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Indication </content></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Normal Renal Function </content></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Creatinine Clearance less than 50 mL/min </content></paragraph></td></tr><tr styleCode=\"Toprule\"><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Patients with ACS </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min </paragraph></td></tr><tr styleCode=\"Toprule\"><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours </item><item><caption>&#x2022;</caption>If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy </item><item><caption>&#x2022;</caption>Aspirin, 160 mg to 325 mg, should be given daily</item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"19%\"/><col width=\"39%\"/><col width=\"42%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Indication</content></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Normal Renal Function</content></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Creatinine Clearance less than 50 mL/min</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Patients with</paragraph><paragraph>PCI</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) </paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"/><td colspan=\"2\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. </item><item><caption>&#x2022;</caption>In patients who undergo CABG surgery, eptifibatide infusion should be discontinued prior to surgery. </item><item><caption>&#x2022;</caption>Aspirin, 160 mg to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter.</item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"10%\"/><col width=\"10%\"/><col width=\"15%\"/><col width=\"19%\"/><col width=\"19%\"/><col width=\"14%\"/><col width=\"13%\"/><tbody><tr><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Patient Weight </content></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">180 mcg/kg Bolus Volume </content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">2 mcg/kg/min Infusion Volume (CrCl greater than or equal to 50 mL/min) </content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">1 mcg/kg/min Infusion Volume (CrCl less than 50 mL/min) </content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">(kg) </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">(lb)</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">(from 2 mg/mL vial) </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">(from 2 mg/mL 100 mL vial) </content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">(from 0.75 mg/mL 100 mL vial)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">(from 2 mg/mL 100 mL vial) </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">(from 0.75 mg/mL </content></paragraph><paragraph><content styleCode=\"bold\">100 mL vial)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>37 to 41 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>81 to 91 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.4 mL</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2 mL/h </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1 mL/h </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3 mL/h</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>42 to 46</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>92 to 102 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4 mL</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.5 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.3 mL/h </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.5 mL/h</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>47 to 53 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>103 to 117 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4.5 mL</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>8 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.5 mL/h </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4 mL/h</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>54 to 59 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>118 to 130 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5 mL</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.5 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>9 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.8 mL/h </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4.5 mL/h</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>60 to 65 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>131 to 143 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5.6 mL</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.8 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.9 mL/h </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5 mL/h</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>66 to 71 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>144 to 157 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6.2 mL</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>11 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2 mL/h </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5.5 mL/h</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>72 to 78 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>158 to 172 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6.8 mL</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4.5 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>12 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.3 mL/h </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6 mL/h</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>79 to 84 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>173 to 185 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7.3 mL</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.5 mL/h </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6.5 mL/h</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>85 to 90 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>186 to 198 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7.9 mL</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5.3 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.7 mL/h </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7 mL/h</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>91 to 96 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>199 to 212 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>8.5 mL</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5.6 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>15 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.8 mL/h </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7.5 mL/h</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>97 to 103 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>213 to 227 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>9 mL</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>16 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.0 mL/h </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>8 mL/h</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>104 to 109</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>228 to 240</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>9.5 mL</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6.4 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.2 mL/h </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>8.5 mL/h</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>110 to 115</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>241 to 253</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10.2 mL</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6.8 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>18 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.4 mL/h </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>9 mL/h</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>116 to 121</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>254 to 267</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10.7 mL</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.5 mL/h </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>9.5 mL/h</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>&gt;121</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>&gt;267</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>11.3 mL</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>7.5 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>20 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>3.7 mL/h </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>10 mL/h</paragraph></td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS \u2022 Injection: 20 mg of eptifibatide in 10 mL (2 mg/mL), for intravenous bolus. \u2022 Injection: 75 mg of eptifibatide in 100 mL (0.75 mg/mL), for intravenous infusion. \u2022 Injection: 200 mg of eptifibatide in 100 mL (2 mg/mL), for intravenous infusion. \u2022 20 mg/10 mL (2 mg/mL) in a single-dose vial for bolus injection ( 3 ) \u2022 75 mg/100 mL (0.75 mg/mL) in a single-dose vial for infusion ( 3 ) \u2022 200 mg/100 mL (2 mg/mL) in a single-dose vial for infusion ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Treatment with eptifibatide is contraindicated in patients with: \u2022 A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days \u2022 Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy \u2022 Major surgery within the preceding 6 weeks \u2022 History of stroke within 30 days or any history of hemorrhagic stroke \u2022 Current or planned administration of another parenteral GP IIb/IIIa inhibitor \u2022 Dependency on renal dialysis \u2022 Hypersensitivity to eptifibatide or any component of the product (hypersensitivity reactions that occurred included anaphylaxis and urticaria) \u2022 Bleeding diathesis or bleeding within the previous 30 days ( 4 ) \u2022 Severe uncontrolled hypertension ( 4 ) \u2022 Major surgery within the preceding 6 weeks ( 4 ) \u2022 Stroke within 30 days or any history of hemorrhagic stroke ( 4 ) \u2022 Coadministration of another parenteral GP IIb/IIIa inhibitor ( 4 ) \u2022 Dependency on renal dialysis ( 4 ) \u2022 Known hypersensitivity to any component of the product ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS \u2022 Eptifibatide can cause serious bleeding. If bleeding cannot be controlled, discontinue eptifibatide immediately. Minimize vascular and other traumas. If heparin is given concomitantly, monitor aPTT or ACT. ( 5.1 ) \u2022 Thrombocytopenia: Discontinue eptifibatide and heparin. Monitor and treat condition appropriately. ( 5.2 ) 5.1 Bleeding Bleeding is the most common complication encountered during eptifibatide therapy. Administration of eptifibatide is associated with an increase in major and minor bleeding, as classified by the criteria of the Thrombolysis in Myocardial Infarction Study group (TIMI) [see Adverse Reactions (6.1) ] . Most major bleeding associated with eptifibatide has been at the arterial access site for cardiac catheterization or from the gastrointestinal or genitourinary tract. Minimize the use of arterial and venous punctures, intramuscular injections, and the use of urinary catheters, nasotracheal intubation, and nasogastric tubes. When obtaining intravenous access, avoid non-compressible sites (e.g., subclavian or jugular veins). Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Risk factors for bleeding include older age, a history of bleeding disorders, and concomitant use of drugs that increase the risk of bleeding (thrombolytics, oral anticoagulants, nonsteroidal anti-inflammatory drugs, and P2Y 12 inhibitors). Concomitant treatment with other inhibitors of platelet receptor glycoprotein (GP) IIb/IIIa should be avoided. In patient treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT [see Dosage and Administration (2) ] . Care of the Femoral Artery Access Site in Patients Undergoing Percutaneous Coronary Intervention (PCI) In patients undergoing PCI, treatment with eptifibatide is associated with an increase in major and minor bleeding at the site of arterial sheath placement. After PCI, eptifibatide infusion should be continued until hospital discharge or up to 18 to 24 hours, whichever comes first. Heparin use is discouraged after the PCI procedure. Early sheath removal is encouraged while eptifibatide is being infused. Prior to removing the sheath, it is recommended that heparin be discontinued for 3 to 4 hours and an aPTT of <45 seconds or ACT <150 seconds be achieved. In any case, both heparin and eptifibatide should be discontinued and sheath hemostasis should be achieved at least 2 to 4 hours before hospital discharge. If bleeding at access site cannot be controlled with pressure, infusion of eptifibatide and heparin should be discontinued immediately. 5.2 Thrombocytopenia There have been reports of acute, profound thrombocytopenia (immune-mediated and non-immune mediated) with eptifibatide. In the event of acute profound thrombocytopenia or a confirmed platelet decrease to <100,000/mm 3 , discontinue eptifibatide and heparin (unfractionated or low-molecular weight). Monitor serial platelet counts, assess the presence of drug-dependent antibodies, and treat as appropriate [see Adverse Reactions (6.1) ] . There has been no clinical experience with eptifibatide initiated in patients with a baseline platelet count <100,000/mm 3 . If a patient with low platelet counts is receiving eptifibatide, their platelet count should be monitored closely."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reaction is also discussed elsewhere in the labeling: \u2022 Bleeding [see Contraindications (4) and Warnings and Precautions (5.1) ] Bleeding and hypotension are the most commonly reported adverse reactions. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. A total of 16,782 patients were treated in the Phase III clinical trials (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Eptifibatide Therapy (PURSUET), Enhanced Suppression of the Platelet IIb/IIIa Receptor with Eptifibatide Therapy (ESPRET), and Eptifibatide to Minimize Platelet Aggregation and Prevent Coronary Thrombosis II (EMPACT II)) [see Clinical Studies (14)] . These 16,782 patients had a mean age of 62 years (range: 20 to 94 years). Eighty-nine percent of the patients were Caucasian, with the remainder being predominantly Black (5%) and Hispanic (5%). Sixty-eight percent were men. Because of the different regimens used in PURSUET, EMPACT II, and ESPRET, data from the 3 studies were not pooled. Bleeding and hypotension were the most commonly reported adverse reactions (incidence \u22655% and greater than placebo) in the eptifibatide controlled clinical trial database. Bleeding The incidence of bleeding and transfusions in the PURSUET and ESPRET studies are shown in Table 2. Bleeding was classified as major or minor by the criteria of the TIMI study group. Major bleeding consisted of intracranial hemorrhage and other bleeding that led to decreases in hemoglobin greater than 5 g/dL. Minor bleeding included spontaneous gross hematuria, spontaneous hematemesis, other observed blood loss with a hemoglobin decrease of more than 3 g/dL, and other hemoglobin decreases that were greater than 4 g/dL but less than 5 g/dL. In patients who received transfusions, the corresponding loss in hemoglobin was estimated through an adaptation of the method of Landefeld et al. Table 2: Bleeding and Transfusions in the PURSUET and ESPRET Studies PURSUET (ACS) Placebo n (%) Eptifibatide Injection 180/2 n (%) Patients 4696 4679 Major bleeding* Minor bleeding* Requiring transfusions \u2020 425 (9.3%) 347 (7.6%) 490 (10.4%) 498 (10.8%) 604 (13.1%) 601 (12.8%) ESPRET (PCI) Placebo n (%) Eptifibatide Injection 180/2/180 n (%) Patients 1024 1040 Major bleeding* Minor bleeding* Requiring transfusions \u2020 4 (0.4%) 18 (2%) 11 (1.1%) 13 (1.3%) 29 (3%) 16 (1.5%) Note: Denominator is based on patients for whom data are available. * For major and minor bleeding, patients are counted only once according to the most severe classification. \u2020 Includes transfusions of whole blood, packed red blood cells, fresh frozen plasma, cryoprecipitate, platelets, and autotransfusion during the initial hospitalization. The majority of major bleeding reactions in the ESPRET study occurred at the vascular access site (1 and 8 patients, or 0.1% and 0.8% in the placebo and eptifibatide groups, respectively). Bleeding at \u201cother\u201d locations occurred in 0.2% and 0.4% of patients, respectively. In the PURSUET study, the greatest increase in major bleeding in eptifibatide-treated patients compared to placebo-treated patients was also associated with bleeding at the femoral artery access site (2.8% versus 1.3%). Oropharyngeal (primarily gingival), genitourinary, gastrointestinal, and retroperitoneal bleeding were also seen more commonly in eptifibatide-treated patients compared to placebo-treated patients. Among patients experiencing a major bleed in the EMPACT II study, an increase in bleeding on eptifibatide versus placebo was observed only for the femoral artery access site (3.2% versus 2.8%). Table 3 displays the incidence of TIMI major bleeding according to the cardiac procedures carried out in the PURSUET study. The most common bleeding complications were related to cardiac revascularization (CABG-related or femoral artery access site bleeding). A corresponding table for ESPRET is not presented, as every patient underwent PCI in the ESPRET study and only 11 patients underwent CABG. Table 3: Major Bleeding by Procedures in the PURSUET Study Placebo n (%) Eptifibatide 180/2 n (%) Patients 4577 4604 Overall incidence of major bleeding 425 (9.3%) 498 (10.8%) Breakdown by procedure: CABG 375 (8.2%) 377 (8.2%) Angioplasty without CABG 27 (0.6%) 64 (1.4%) Angiography without angioplasty or CABG 11 (0.2%) 29 (0.6%) Medical therapy only 12 (0.3%) 28 (0.6%) Note: Denominators are based on the total number of patients whose TIMI classification was resolved. In the PURSUET and ESPRET studies, the risk of major bleeding with eptifibatide increased as patient weight decreased. This relationship was most apparent for patients weighing less than 70 kg. Bleeding resulting in discontinuation of the study drug was more frequent among patients receiving eptifibatide than placebo (4.6% versus 0.9% in ESPRET, 8% versus 1% in PURSUET, 3.5% versus 1.9% in EMPACT II). Intracranial Hemorrhage and Stroke Intracranial hemorrhage was rare in the PURSUET, EMPACT II, and ESPRET clinical studies. In the PURSUET study, 3 patients in the placebo group, 1 patient in the group treated with eptifibatide 180/1.3, and 5 patients in the group treated with eptifibatide 180/2 experienced a hemorrhagic stroke. The overall incidence of stroke was 0.5% in patients receiving eptifibatide 180/1.3, 0.7% in patients receiving eptifibatide 180/2, and 0.8% in placebo patients. In the EMPACT II study, intracranial hemorrhage was experienced by 1 patient treated with eptifibatide 135/0.5, 2 patients treated with eptifibatide 135/0.75, and 2 patients in the placebo group. The overall incidence of stroke was 0.5% in patients receiving 135/0.5 eptifibatide, 0.7% in patients receiving eptifibatide 135/0.75, and 0.7% in the placebo group. In the ESPRET study, there were 3 hemorrhagic strokes, 1 in the placebo group and 2 in the eptifibatide group. In addition there was 1 case of cerebral infarction in the eptifibatide group. Immunogenicity/Thrombocytopenia The potential for development of antibodies to eptifibatide has been studied in 433 subjects. Eptifibatide was nonantigenic in 412 patients receiving a single administration of eptifibatide (135 mcg/kg bolus followed by a continuous infusion of either 0.5 mcg/kg/min or 0.75 mcg/kg/min), and in 21 subjects to whom eptifibatide (135 mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min) was administered twice, 28 days apart. In both cases, plasma for antibody detection was collected approximately 30 days after each dose. The development of antibodies to eptifibatide at higher doses has not been evaluated. In patients with suspected eptifibatide-related immune-mediated thrombocytopenia, IgG antibodies that react with the GP IIb/IIIa complex were identified in the presence of eptifibatide and in eptifibatide injection-na\u00efve patients. These findings suggest acute thrombocytopenia after the administration of eptifibatide can develop as a result of naturally occurring drug-dependent antibodies or those induced by prior exposure to eptifibatide. Similar antibodies were identified with other GP IIb/IIIa ligand-mimetic agents. Immune-mediated thrombocytopenia with eptifibatide may be associated with hypotension and/or other signs of hypersensitivity. In the PURSUET and EMPACT II studies, the incidence of thrombocytopenia (<100,000/mm 3 or \u226550% reduction from baseline) and the incidence of platelet transfusions were similar between patients treated with eptifibatide and placebo. In the ESPRET study, the incidence was 0.6% in the placebo group and 1.2% in the eptifibatide group. Other Adverse Reactions In the PURSUET and ESPRET studies, the incidence of serious nonbleeding adverse reactions was similar in patients receiving placebo or eptifibatide (19% and 19%, respectively, in PURSUET; 6% and 7%, respectively, in ESPRET). In PURSUET, the only serious nonbleeding adverse reaction that occurred at a rate of at least 1% and was more common with eptifibatide than placebo (7% versus 6%) was hypotension. Most of the serious nonbleeding adverse reactions consisted of cardiovascular reactions typical of a UA population. In the EMPACT II study, serious nonbleeding adverse reactions that occurred in greater than 1% of patients were uncommon and similar in incidence between placebo- and eptifibatide-treated patients. Discontinuation of study drug due to adverse reactions other than bleeding was uncommon in the PURSUET, EMPACT II, and ESPRIT studies, with no single reaction occurring in >0.5% of the study population (except for \u201cother\u201d in the ESPRET study). 6.2 Postmarketing Experience The following adverse reactions have been reported in post-approval use of eptifibatide in combination with heparin and aspirin. Because the reactions below are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure: cerebral, GI, and pulmonary hemorrhage. Fatal bleeding reactions have been reported. Acute profound thrombocytopenia, as well as immune-mediated thrombocytopenia, have been reported [see Adverse Reactions (6.1) ] ."
    ],
    "adverse_reactions_table": [
      "<table width=\"100%\"><col width=\"35%\"/><col width=\"35%\"/><col width=\"30%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"/><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">PURSUET (ACS)</content></paragraph><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Eptifibatide Injection </content></paragraph><paragraph><content styleCode=\"bold\">180/2</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>Patients</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4696</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>4679</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Major bleeding*</paragraph><paragraph>Minor bleeding*</paragraph><paragraph>Requiring transfusions<sup>&#x2020;</sup></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>425 (9.3%)</paragraph><paragraph>347 (7.6%)</paragraph><paragraph>490 (10.4%)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>498 (10.8%)</paragraph><paragraph> 604 (13.1%) </paragraph><paragraph>601 (12.8%)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">ESPRET (PCI) </content></paragraph><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\"> n (%)</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Eptifibatide Injection </content></paragraph><paragraph><content styleCode=\"bold\">180/2/180</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>Patients</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>1024</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>1040</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph>Major bleeding*</paragraph><paragraph>Minor bleeding*</paragraph><paragraph>Requiring transfusions<sup>&#x2020;</sup></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>4 (0.4%)</paragraph><paragraph>18 (2%)</paragraph><paragraph>11 (1.1%)</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>13 (1.3%)</paragraph><paragraph>29 (3%)</paragraph><paragraph>16 (1.5%)</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"57%\"/><col width=\"25%\"/><col width=\"17%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide </content></paragraph><paragraph><content styleCode=\"bold\">180/2</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Patients </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>4577</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>4604</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Overall incidence of major bleeding </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>425 (9.3%)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>498 (10.8%)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Breakdown by procedure:</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>CABG </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>375 (8.2%)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>377 (8.2%)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>Angioplasty without CABG </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>27 (0.6%)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>64 (1.4%)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>Angiography without angioplasty or CABG </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>11 (0.2%)</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>29 (0.6%)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><list listType=\"ordered\"><item><caption> </caption>Medical therapy only </item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph>12 (0.3%)</paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph>28 (0.6%)</paragraph></td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS \u2022 Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Avoid concomitant use with other glycoprotein (GP) IIb/IIIa inhibitors. ( 7.1 ) 7.1 Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Concomitant treatment with other inhibitors of platelet receptor GP IIb/IIIa should be avoided."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS \u2022 Geriatric Use: Risk of bleeding increases with age. ( 8.5 ) 8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus (see Clinical Considerations) . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide on the fetus. Data Animal Data Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide. 8.2 Lactation Risk Summary There are no available data on the presence of eptifibatide in human milk, the effects on the breastfed infant, or the effects on milk production. As eptifibatide is a peptide, it is likely to be destroyed in the infant\u2019s gastrointestinal tract and not absorbed orally by the breastfed infant. 8.4 Pediatric Use Safety and effectiveness of eptifibatide in pediatric patients have not been studied. 8.5 Geriatric Use The PURSUET and EMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUET study; no such limitation was stipulated in the ESPRET study [see Adverse Reactions (6.1) ]. 8.6 Renal Impairment Approximately 50% of eptifibatide is cleared by the kidney in patients with normal renal function. Total drug clearance is decreased by approximately 50% and steady-state plasma eptifibatide concentrations are doubled in patients with an estimated CrCl <50 mL/min (using the Cockcroft-Gault equation). Therefore, the infusion dose should be reduced to 1 mcg/kg/min in such patients [see Dosage and Administration (2) ] . The safety and efficacy of eptifibatide in patients dependent on dialysis has not been established."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus (see Clinical Considerations) . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide on the fetus. Data Animal Data Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety and effectiveness of eptifibatide in pediatric patients have not been studied."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use The PURSUET and EMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUET study; no such limitation was stipulated in the ESPRET study [see Adverse Reactions (6.1) ]."
    ],
    "overdosage": [
      "10 OVERDOSAGE There has been only limited experience with overdosage of eptifibatide. There were 8 patients in the EMPACT II study, 9 patients in the PURSUET study, and no patients in the ESPRET study who received bolus doses and/or infusion doses more than double those called for in the protocols. None of these patients experienced an intracranial bleed or other major bleeding. Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis). Symptoms of acute toxicity were loss of righting reflex, dyspnea, ptosis, and decreased muscle tone in rabbits and petechial hemorrhages in the femoral and abdominal areas of monkeys. From in vitro studies, eptifibatide is not extensively bound to plasma proteins and thus may be cleared from plasma by dialysis."
    ],
    "description": [
      "11 DESCRIPTION Eptifibatide is a cyclic heptapeptide containing 6 amino acids and 1 mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties. Chemically it is N 6 -(aminoiminomethyl)-N 2 -(3-mercapto-1-oxopropyl)-L\u2011lysylglycyl-L-\u03b1-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1\u21926)-disulfide. Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation. The eptifibatide peptide is produced by solution-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized. The structural formula is: Eptifibatide Injection is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use with an empirical formula of C 35 H 49 N 11 O 9 S 2 a molecular weight of 832. Each 10 mL vial contains 2 mg/mL of eptifibatide injection and each 100 mL vial contains either 0.75 mg/mL of eptifibatide injection or 2 mg/mL of eptifibatide injection. Each vial of either size also contains 5.25 mg/mL citric acid and sodium hydroxide to adjust the pH to 5.35. Figure 1"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet. 12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide was observed immediately after administration of a 180 mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide used in the EMPACT II and PURSUET studies on ex vivo platelet aggregation induced by 20 micromolar ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRET on platelet aggregation have not been studied. Table 4: Platelet Inhibition and Bleeding Time PURSUET 180/2* Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x *180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. The eptifibatide dosing regimen used in the ESPRET study included two 180 mcg/kg bolus doses given 10 minutes apart combined with a continuous 2 mcg/kg/min infusion. When administered alone, eptifibatide has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed. 12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180 mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4 to 6 hours). This decline can be prevented by administering a second 180 mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20 to 94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations (8.6) and Dosage and Administration (2) ] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "clinical_pharmacology_table": [
      "<table width=\"100%\"><col width=\"73%\"/><col width=\"27%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">PURSUET </content></paragraph><paragraph><content styleCode=\"bold\">180/2*</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Inhibition of platelet aggregation 15 min after bolus </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>84%</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Inhibition of platelet aggregation at steady state</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&gt;90%</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Bleeding-time prolongation at steady state</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&lt;5x</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Inhibition of platelet aggregation 4h after infusion discontinuation</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&lt;50%</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Bleeding-time prolongation 6h after infusion discontinuation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>1.4x</paragraph></td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide was observed immediately after administration of a 180 mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide used in the EMPACT II and PURSUET studies on ex vivo platelet aggregation induced by 20 micromolar ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRET on platelet aggregation have not been studied. Table 4: Platelet Inhibition and Bleeding Time PURSUET 180/2* Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x *180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. The eptifibatide dosing regimen used in the ESPRET study included two 180 mcg/kg bolus doses given 10 minutes apart combined with a continuous 2 mcg/kg/min infusion. When administered alone, eptifibatide has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed."
    ],
    "pharmacodynamics_table": [
      "<table width=\"100%\"><col width=\"73%\"/><col width=\"27%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">PURSUET </content></paragraph><paragraph><content styleCode=\"bold\">180/2*</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Inhibition of platelet aggregation 15 min after bolus </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>84%</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Inhibition of platelet aggregation at steady state</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&gt;90%</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Bleeding-time prolongation at steady state</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&lt;5x</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Inhibition of platelet aggregation 4h after infusion discontinuation</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&lt;50%</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Bleeding-time prolongation 6h after infusion discontinuation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>1.4x</paragraph></td></tr></tbody></table>"
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180 mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4 to 6 hours). This decline can be prevented by administering a second 180 mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20 to 94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations (8.6) and Dosage and Administration (2) ] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Eptifibatide was studied in 3 placebo-controlled, randomized studies. PURSUET evaluated patients with acute coronary syndromes: UA or NSTEMI. Two other studies, ESPRET and EMPACT II, evaluated patients about to undergo a PCI. Patients underwent primarily balloon angioplasty in EMPACT II and intracoronary stent placement, with or without angioplasty, in ESPRET. 14.1 Non-ST-Segment Elevation Acute Coronary Syndrome Non-ST-segment elevation acute coronary syndrome is defined as prolonged (\u226510 minutes) symptoms of cardiac ischemia within the previous 24 hours associated with either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or positive CK-MB. This definition includes \"unstable angina\" and \"NSTEMI\" but excludes MI that is associated with Q waves or greater degrees of ST-segment elevation. PURSUET (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Eptifibatide Therapy) PURSUET was a 726-center, 27-country, double-blind, randomized, placebo-controlled study in 10,948 patients presenting with UA or NSTEMI. Patients could be enrolled only if they had experienced cardiac ischemia at rest (\u226510 minutes) within the previous 24 hours and had either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or increased CK-MB. Important exclusion criteria included a history of bleeding diathesis, evidence of abnormal bleeding within the previous 30 days, uncontrolled hypertension, major surgery within the previous 6 weeks, stroke within the previous 30 days, any history of hemorrhagic stroke, serum creatinine >2 mg/dL, dependency on renal dialysis, or platelet count <100,000/mm 3 . Patients were randomized to placebo, to eptifibatide 180 mcg/kg bolus followed by a 2 mcg/kg/min infusion (180/2), or to eptifibatide 180 mcg/kg bolus followed by a 1.3 mcg/kg/min infusion (180/1.3). The infusion was continued for 72 hours, until hospital discharge, or until the time of CABG, whichever occurred first, except that if PCI was performed, the eptifibatide infusion was continued for 24 hours after the procedure, allowing for a duration of infusion up to 96 hours. The lower-infusion-rate arm was stopped after the first interim analysis when the 2 active-treatment arms appeared to have the same incidence of bleeding. Patient age ranged from 20 to 94 (mean 63) years, and 65% were male. The patients were 89% Caucasian, 6% Hispanic, and 5% Black, recruited in the United States and Canada (40%), Western Europe (39%), Eastern Europe (16%), and Latin America (5%). This was a \"real world\" study; each patient was managed according to the usual standards of the investigational site; frequencies of angiography, PCI, and CABG therefore differed widely from site to site and from country to country. Of the patients in PURSUET, 13% were managed with PCI during drug infusion, of whom 50% received intracoronary stents; 87% were managed medically (without PCI during drug infusion). The majority of patients received aspirin (75 to 325 mg once daily). Heparin was administered intravenously or subcutaneously, at the physician's discretion, most commonly as an intravenous bolus of 5000 units followed by a continuous infusion of 1000 units/h. For patients weighing less than 70 kg, the recommended heparin bolus dose was 60 units/kg followed by a continuous infusion of 12 units/kg/h. A target aPTT of 50 to 70 seconds was recommended. A total of 1250 patients underwent PCI within 72 hours after randomization, in which case they received intravenous heparin to maintain an ACT of 300 to 350 seconds. The primary endpoint of the study was the occurrence of death from any cause or new MI (evaluated by a blinded Clinical Endpoints Committee) within 30 days of randomization. Compared to placebo, eptifibatide administered as a 180 mcg/kg bolus followed by a 2 mcg/kg/min infusion significantly (p=0.042) reduced the incidence of endpoint events (see Table 6). The reduction in the incidence of endpoint events in patients receiving eptifibatide was evident early during treatment, and this reduction was maintained through at least 30 days (see Figure 1). Table 5 also shows the incidence of the components of the primary endpoint, death (whether or not preceded by an MI) and new MI in surviving patients at 30 days. Table 5: Clinical Events in the PURSUET Study Death or MI Placebo (n=4739) n (%) Eptifibatide (180 mcg/kg bolus then 2 mcg/kg/min infusion) (n=4722) n (%) p-value 3 days 359 (7.6%) 279 (5.9%) 0.001 7 days 552 (11.6%) 477 (10.1%) 0.016 30 days Death or MI (primary endpoint) 745 (15.7%) 672 (14.2%) 0.042 Death 177 (3.7%) 165 (3.5%) Nonfatal MI 568 (12%) 507 (10.7%) Figure 1: Kaplan-Meier Plot of Time to Death or Myocardial Infarction Within 30 Days of Randomization in the PURSUET Study Treatment with eptifibatide prior to determination of patient management strategy reduced clinical events regardless of whether patients ultimately underwent diagnostic catheterization, revascularization (i.e., PCI or CABG surgery) or continued to receive medical management alone. Table 6 shows the incidence of death or MI within 72 hours. Table 6: Clinical Events (Death or MI) in the PURSUET Study Within 72 Hours of Randomization Placebo Eptifibatide (180 mcg/kg bolus then 2 mcg/kg/min infusion) Overall patient population n=4739 n=4722 \u2013 At 72 hours 7.6% 5.9% Patients undergoing early PCI n=631 n=619 \u2013 Pre-procedure (nonfatal MI only) 5.5% 1.8% \u2013 At 72 hours 14.4% 9% Patients not undergoing early PCI n=4108 n=4103 \u2013 At 72 hours 6.5% 5.4% All of the effect of eptifibatide was established within 72 hours (during the period of drug infusion), regardless of management strategy. Moreover, for patients undergoing early PCI, a reduction in events was evident prior to the procedure. An analysis of the results by sex suggests that women who would not routinely be expected to undergo PCI receive less benefit from eptifibatide (95% confidence limits for relative risk of 0.94 to 1.28) than do men (0.72 to 0.9). This difference may be a true treatment difference, the effect of other differences in these subgroups, or a statistical anomaly. No differential outcomes were seen between male and female patients undergoing PCI (see results for ESPRET) . Follow-up data were available through 165 days for 10,611 patients enrolled in the PURSUET trial (96.9% of the initial enrollment). This follow-up included 4566 patients who received eptifibatide at the 180/2 dose. As reported by the investigators, the occurrence of death from any cause or new MI for patients followed for at least 165 days was reduced from 13.6% with placebo to 12.1% with eptifibatide 180/2. Graph 1 14.2 Percutaneous Coronary Intervention (PCI) EMPACT II (Eptifibatide to Minimize Platelet Aggregation and Prevent Coronary Thrombosis II) EMPACT II was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States in 4010 patients undergoing PCI. Major exclusion criteria included a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 89 (mean 60) years, and 75% were male. The patients were 92% Caucasian, 5% Black, and 3% Hispanic. Forty-one percent of the patients underwent PCI for ongoing ACS. Patients were randomly assigned to 1 of 3 treatment regimens, each incorporating a bolus dose initiated immediately prior to PCI followed by a continuous infusion lasting 20 to 24 hours: 1) 135 mcg/kg bolus followed by a continuous infusion of 0.5 mcg/kg/min of eptifibatide (135/0.5); 2) 135 mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min of eptifibatide (135/0.75); or 3) a matching placebo bolus followed by a matching placebo continuous infusion. Each patient received aspirin and an intravenous heparin bolus of 100 units/kg, with additional bolus infusions of up to 2000 additional units of heparin every 15 minutes to maintain an ACT of 300 to 350 seconds. The primary endpoint was the composite of death, MI, or urgent revascularization, analyzed at 30 days after randomization in all patients who received at least 1 dose of study drug. As shown in Table 7, each eptifibatide regimen reduced the rate of death, MI, or urgent intervention, although at 30 days, this finding was statistically significant only in the lower-dose eptifibatide group. As in the PURSUET study, the effects of eptifibatide were seen early and persisted throughout the 30-day period. Table 7: Clinical Events in the EMPACT II Study Placebo n (%) Eptifibatide (135 mcg/kg bolus then 0.5 mcg/kg/min infusion) n (%) Eptifibatide (135 mcg/kg bolus then 0.75 mcg/kg/min infusion) n (%) Patients 1285 1300 1286 Abrupt Closure 65 (5.1%) 36 (2.8%) 43 (3.3%) p-value versus placebo 0.003 0.03 Death, MI, or Urgent Intervention 24 hours 123 (9.6%) 86 (6.6%) 89 (6.9%) p-value versus placebo 0.006 0.014 48 hours 131 (10.2%) 99 (7.6%) 102 (7.9%) p-value versus placebo 0.021 0.045 30 days (primary endpoint) 149 (11.6%) 118 (9.1%) 128 (10%) p-value versus placebo 0.035 0.179 Death or MI 30 days 110 (8.6%) 89 (6.8%) 95 (7.4%) p-value versus placebo 0.102 0.272 6 months 151 (11.9%)* 136 (10.6%)* 130 (10.3%)* p-value versus placebo 0.297 0.182 * Kaplan-Meier estimate of event rate. ESPRET (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Eptifibatide Therapy) The ESPRET study was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States and Canada that enrolled 2064 patients undergoing elective or urgent PCI with intended intracoronary stent placement. Exclusion criteria included MI within the previous 24 hours, ongoing chest pain, administration of any oral antiplatelet or oral anticoagulant other than aspirin within 30 days of PCI (although loading doses of thienopyridine on the day of PCI were encouraged), planned PCI of a saphenous vein graft or subsequent \u201cstaged\u201d PCI, prior stent placement in the target lesion, PCI within the previous 90 days, a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 93 (mean 62) years, and 73% of patients were male. The study enrolled 90% Caucasian, 5% African American, 2% Hispanic, and 1% Asian patients. Patients received a wide variety of stents. Patients were randomized either to placebo or eptifibatide administered as an intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2 mcg/kg/min, and a second bolus of 180 mcg/kg administered 10 minutes later (180/2/180). Eptifibatide infusion was continued for 18 to 24 hours after PCI or until hospital discharge, whichever came first. Each patient received at least 1 dose of aspirin (162 to 325 mg) and 60 units/kg of heparin as a bolus (not to exceed 6000 units) if not already receiving a heparin infusion. Additional boluses of heparin (10 to 40 units/kg) could be administered in order to reach a target ACT between 200 and 300 seconds. The primary endpoint of the ESPRET study was the composite of death, MI, urgent target vessel revascularization (UTVR), and \u201cbailout\u201d to open-label eptifibatide due to a thrombotic complication of PCI (TBO) (e.g., visible thrombus, \u201cno reflow,\u201d or abrupt closure) at 48 hours. MI, UTVR, and TBO were evaluated by a blinded Clinical Events Committee. As shown in Table 8, the incidence of the primary endpoint and selected secondary endpoints was significantly reduced in patients who received eptifibatide. A treatment benefit in patients who received eptifibatide was seen by 48 hours and at the end of the 30-day observation period. Table 8: Clinical Events in the ESPRET Study Placebo (n=1024) Eptifibatide* (n=1040) Relative Risk (95% CI) p-value Death, MI, UTVR, or Thrombotic \u201cBailout\u201d 48 hours (primary endpoint) 108 (10.5%) 69 (6.6%) 0.629 (0.471, 0.84) 0.0015 30 days 120 (11.7%) 78 (7.5%) 0.64 (0.488, 0.84) 0.0011 Death, MI, or UTVR 48 hours 95 (9.3%) 62 (6%) 0.643 (0.472, 0.875) 0.0045 30 days (key secondary endpoint) 107 (10.4%) 71 (6.8%) 0.653 (0.49, 0.871) 0.0034 Death or MI 48 hours 94 (9.2%) 57 (5.5%) 0.597 (0.435, 0.82) 0.0013 30 days 104 (10.2%) 66 (6.3%) 0.625 (0.465, 0.84) 0.0016 * Eptifibatide was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min. The need for thrombotic \u201cbailout\u201d was significantly reduced with eptifibatide at 48 hours (2.1% for placebo, 1% for eptifibatide; p=0.029). Consistent with previous studies of GP IIb/IIIa inhibitors, most of the benefit achieved acutely with eptifibatide was in the reduction of MI. Eptifibatide reduced the occurrence of MI at 48 hours from 9% for placebo to 5.4% (p=0.0015) and maintained that effect with significance at 30 days. There was no treatment difference with respect to sex in ESPRET. Eptifibatide reduced the incidence of the primary endpoint in both men (95% confidence limits for relative risk: 0.54, 1.07) and women (0.24, 0.72) at 48 hours. Follow-up (12-month) mortality data were available for 2024 patients (1017 on eptifibatide) enrolled in the ESPRET trial (98.1% of the initial enrollment). Twelve-month clinical event data were available for 1964 patients (988 on eptifibatide), representing 95.2% of the initial enrollment. As shown in Table 9, the treatment effect of eptifibatide seen at 48 hours and 30 days appeared preserved at 6 months and 1 year. Most of the benefit was in reduction of MI. Table 9: Clinical Events at 6 Months and 1 Year in the ESPRET Study Placebo (n=1024) Eptifibatide (n=1040) Hazard Ratio (95% CI) Death, MI, or Target Vessel Revascularization 6 months 187 (18.5%) 146 (14.3%) 0.744 (0.599, 0.924) 1 year 222 (22.1%) 178 (17.5%) 0.762 (0.626, 0.929) Death, MI 6 months 117 (11.5%) 77 (7.4%) 0.631 (0.473, 0.841) 1 year 126 (12.4%) 83 (8%) 0.63 (0.478, 0.832) Percentages are Kaplan-Meier event rates."
    ],
    "clinical_studies_table": [
      "<table width=\"100%\"><col width=\"37%\"/><col width=\"20%\"/><col width=\"30%\"/><col width=\"13%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Death or MI </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo (n=4739) </content></paragraph><paragraph><content styleCode=\"bold\">n (%) </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide</content></paragraph><paragraph><content styleCode=\"bold\">(180 mcg/kg bolus then 2 mcg/kg/min infusion) </content></paragraph><paragraph><content styleCode=\"bold\">(n=4722) </content></paragraph><paragraph><content styleCode=\"bold\">n (%) </content></paragraph></td><td align=\"right\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">p-value </content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>3 days </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>359 (7.6%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>279 (5.9%) </paragraph></td><td align=\"right\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.001 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>7 days </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>552 (11.6%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>477 (10.1%) </paragraph></td><td align=\"right\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.016 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>30 days</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>Death or MI (primary endpoint) </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>745 (15.7%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>672 (14.2%) </paragraph></td><td align=\"right\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.042 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>Death </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>177 (3.7%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>165 (3.5%) </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>Nonfatal MI </item></list></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>568 (12%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>507 (10.7%) </paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"/></tr></tbody></table>",
      "<table width=\"97.36%\"><col width=\"37%\"/><col width=\"30%\"/><col width=\"33%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide </content></paragraph><paragraph><content styleCode=\"bold\">(180 mcg/kg bolus then 2</content> <content styleCode=\"bold\">mcg/kg/min infusion)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Overall patient population </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>n=4739 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>n=4722 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>&#x2013; At 72 hours </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>7.6% </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>5.9% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Patients undergoing early PCI </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>n=631 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>n=619 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>&#x2013; Pre-procedure (nonfatal MI only) </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>5.5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>1.8% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>&#x2013; At 72 hours </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>14.4% </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>9% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Patients not undergoing early PCI </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>n=4108 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>n=4103 </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><list listType=\"ordered\"><item><caption> </caption>&#x2013; At 72 hours </item></list></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>6.5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>5.4% </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"38%\"/><col width=\"17%\"/><col width=\"22%\"/><col width=\"23%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide (135 mcg/kg bolus then 0.5 mcg/kg/min infusion)</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide </content></paragraph><paragraph><content styleCode=\"bold\">(135 mcg/kg bolus then 0.75 mcg/kg/min infusion) </content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Patients </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>1285</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>1300 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>1286 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Abrupt Closure </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>65 (5.1%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>36 (2.8%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>43 (3.3%) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>p-value versus placebo</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.003 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.03 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Death, MI, or Urgent Intervention</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>24 hours </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>123 (9.6%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>86 (6.6%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>89 (6.9%) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>p-value versus placebo </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.006 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.014 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>48 hours </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>131 (10.2%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>99 (7.6%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>102 (7.9%) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>p-value versus placebo </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.021 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.045 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>30 days (primary endpoint) </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>149 (11.6%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>118 (9.1%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>128 (10%) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>p-value versus placebo </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.035 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.179 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Death or MI </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>30 days </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>110 (8.6%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>89 (6.8%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>95 (7.4%) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>p-value versus placebo </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.102 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.272 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>6 months </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>151 (11.9%)*</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>136 (10.6%)* </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>130 (10.3%)* </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>p-value versus placebo </item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>0.297 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>0.182 </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"34%\"/><col width=\"16%\"/><col width=\"21%\"/><col width=\"16%\"/><col width=\"12%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"/><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">Placebo </content></item><item><caption> </caption><content styleCode=\"bold\">(n=1024) </content></item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">Eptifibatide* </content></item><item><caption> </caption><content styleCode=\"bold\">(n=1040) </content></item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">Relative Risk </content></item><item><caption> </caption><content styleCode=\"bold\">(95% CI) </content></item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">p-value</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>Death, MI, UTVR, or Thrombotic &#x201C;Bailout&#x201D; </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>48 hours (primary endpoint) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>108 (10.5%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>69 (6.6%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>0.629 (0.471, 0.84) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>0.0015 </item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>30 days </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>120 (11.7%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>78 (7.5%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>0.64 (0.488, 0.84) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>0.0011 </item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>Death, MI, or UTVR</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>48 hours </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>95 (9.3%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>62 (6%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>0.643 (0.472, 0.875) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>0.0045 </item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>30 days (key secondary endpoint) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>107 (10.4%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>71 (6.8%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>0.653 (0.49, 0.871) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>0.0034 </item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>Death or MI</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>48 hours </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>94 (9.2%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>57 (5.5%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>0.597 (0.435, 0.82) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>0.0013 </item></list></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>30 days </item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>104 (10.2%) </item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>66 (6.3%) </item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>0.625 (0.465, 0.84) </item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>0.0016 </item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"39%\"/><col width=\"18%\"/><col width=\"21%\"/><col width=\"22%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo </content></paragraph><paragraph><content styleCode=\"bold\">(n=1024) </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide </content></paragraph><paragraph><content styleCode=\"bold\">(n=1040) </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hazard Ratio</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Death, MI, or Target Vessel Revascularization</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>6 months </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>187 (18.5%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>146 (14.3%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.744 (0.599, 0.924)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>1 year </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>222 (22.1%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>178 (17.5%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.762 (0.626, 0.929)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Death, MI</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>6 months </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>117 (11.5%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>77 (7.4%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.631 (0.473, 0.841)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>1 year </item></list></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>126 (12.4%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>83 (8%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0.63 (0.478, 0.832)</paragraph></td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Eptifibatide injection is supplied as a sterile solution as follows: NDC Eptifibatide Injection Package Factor 67457-629-10 20 mg/10 mL vial 1\u2019s 67457-630-10 200 mg/100 mL vial 1\u2019s 67457-631-10 75 mg/100 mL vial 1\u2019s 16.2 Storage Vials should be stored refrigerated at 2\u00b0 to 8\u00b0C (36\u00b0 to 46\u00b0F). Vials may be transferred to room temperature storage* for a period not to exceed 2 months. Upon transfer, vial cartons must be marked by the dispensing pharmacist with a \u201cDISCARD BY\u201d date (2 months from the transfer date or the labeled expiration date, whichever comes first). Protect from light until administration. * Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]."
    ],
    "how_supplied_table": [
      "<table width=\"100%\"><col width=\"46%\"/><col width=\"26%\"/><col width=\"28%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>NDC</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>Eptifibatide Injection</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>Package Factor</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>67457-629-10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>20 mg/10 mL vial</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1&#x2019;s</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>67457-630-10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>200 mg/100 mL vial</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1&#x2019;s</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>67457-631-10</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>75 mg/100 mL vial</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1&#x2019;s</paragraph></td></tr></tbody></table>"
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to inform the doctor or healthcare provider about any medical conditions, medications, and allergies. Manufactured for: Mylan Institutional LLC Morgantown, WV 26505 U.S.A Manufactured by: Mylan Laboratories Limited Bangalore, India MAY 2021"
    ],
    "package_label_principal_display_panel": [
      "Package/Label Display Panel NDC 67457-629-10 Eptibatide Injection 20 mg/10 mL (2 mg/mL) (20 mg/10 mL vial for weight-adjusted bolus dosing) FOR INTRAVENOUS USE ONLY Sterile Mylan Rx only Single-Dose Vial Carton-20",
      "Package/Label Display Panel NDC 67457-631-10 Eptibatide Injection 75 mg/100 mL (0.75 mg/mL) (75 mg/100 mL for weight-adjusted infusion) FOR INTRAVENOUS USE ONLY Sterile Mylan Rx only Single-Dose Vial Carton-75",
      "Package/Label Display Panel NDC 67457-630-10 Eptibatide Injection 200 mg/100 mL (2 mg/mL) (200 mg/100 mL for weight-adjusted infusion) Sterile Mylan Rx only Single-Dose Vial Carton-200"
    ],
    "set_id": "88a37f9c-496b-4a6b-9665-4550abba04f1",
    "id": "e966c894-560e-4805-bdd5-16e153bb4687",
    "effective_time": "20210528",
    "version": "5",
    "openfda": {
      "application_number": [
        "ANDA203258"
      ],
      "brand_name": [
        "Eptifibatide"
      ],
      "generic_name": [
        "EPTIFIBATIDE"
      ],
      "manufacturer_name": [
        "Mylan Institutional LLC"
      ],
      "product_ndc": [
        "67457-629",
        "67457-631",
        "67457-630"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "INTRAVENOUS"
      ],
      "substance_name": [
        "EPTIFIBATIDE"
      ],
      "rxcui": [
        "200349",
        "1736470",
        "1736477"
      ],
      "spl_id": [
        "e966c894-560e-4805-bdd5-16e153bb4687"
      ],
      "spl_set_id": [
        "88a37f9c-496b-4a6b-9665-4550abba04f1"
      ],
      "package_ndc": [
        "67457-629-10",
        "67457-631-10",
        "67457-630-10"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0367457631103",
        "0367457630106",
        "0367457629100"
      ],
      "nui": [
        "N0000008832",
        "N0000175578"
      ],
      "pharm_class_pe": [
        "Decreased Platelet Aggregation [PE]"
      ],
      "pharm_class_epc": [
        "Platelet Aggregation Inhibitor [EPC]"
      ],
      "unii": [
        "NA8320J834"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "eptifibatide eptifibatide eptifibatide eptifibatide citric acid monohydrate sodium hydroxide eptifibatide eptifibatide eptifibatide eptifibatide citric acid monohydrate sodium hydroxide"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Eptifibatide Injection is a platelet aggregation inhibitor indicated for: Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI) ( 1.1 ) Treatment of patients undergoing PCI (including intracoronary stenting) ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Eptifibatide Injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). 1.2 Percutaneous Coronary Intervention (PCI) Eptifibatide Injection is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting [see Clinical Studies ( 14.1 , 14.2 )] ."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION Before infusion of eptifibatide injection, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured. The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT. ACS or PCI: 180 mcg/kg IV bolus as soon as possible after diagnosis followed by infusion at 2 mcg/kg/min. ( 2.1 , 2.2 ) PCI: Add a second 180 mcg/kg bolus at 10 minutes. ( 2.2 ) In patients with creatinine clearance less than 50 mL/min, reduce the infusion to 1 mcg/kg/min. ( 2.1 , 2.2 , 2.3 ) 2.1 Dosage in Acute Coronary Syndrome (ACS) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with ACS 180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min 180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy Aspirin, 160 to 325 mg, should be given daily Eptifibatide injection should be given concomitantly with heparin dosed to achieve the following parameters: During Medical Management : Target aPTT 50 to 70 seconds If weight greater than or equal to 70 kg, 5,000 unit bolus followed by infusion of 1,000 units/h. If weight less than 70 kg, 60 units/kg bolus followed by infusion of 12 units/kg/h. During PCI : Target ACT 200 to 300 seconds If heparin is initiated prior to PCI, additional boluses during PCI to maintain an ACT target of 200 to 300 seconds. Heparin infusion after the PCI is discouraged. 2.2 Dosage in Percutaneous Coronary Intervention (PCI) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with PCI 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. In patients who undergo CABG surgery, eptifibatide injection infusion should be discontinued prior to surgery. Aspirin, 160 to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter. Eptifibatide injection should be given concomitantly with heparin to achieve a target ACT of 200 to 300 seconds. Administer 60 units/kg bolus initially in patients not treated with heparin within 6 hours prior to PCI. Additional boluses during PCI to maintain ACT within target. Heparin infusion after the PCI is strongly discouraged. Patients requiring thrombolytic therapy should discontinue eptifibatide injection. 2.3 Important Administration Instructions Inspect eptifibatide injection for particulate matter and discoloration prior to administration, whenever solution and container permit. May administer eptifibatide injection in the same intravenous line as alteplase, atropine, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, or verapamil. Do not administer eptifibatide injection through the same intravenous line as furosemide. May administer eptifibatide injection in the same IV line with 0.9% NaCl or 0.9% NaCl/5% dextrose. With either vehicle, the infusion may also contain up to 60 mEq/L of potassium chloride. Withdraw the bolus dose(s) of eptifibatide injection from the 10 mL vial into a syringe. Administer the bolus dose(s) by IV push. Immediately following the bolus dose administration, initiate a continuous infusion of eptifibatide injection. When using an intravenous infusion pump, administer eptifibatide injection undiluted directly from the 100 mL vial. Spike the 100 mL vial with a vented infusion set. Center the spike within the circle on the stopper top. Discard any unused portion left in the vial. Administer eptifibatide injection by volume according to patient weight (see Table 1 ). Table 1: Eptifibatide Injection Dosing Charts by Weight Patient Weight 180 mcg/kg Bolus Volume 2 mcg/kg/min Infusion Volume (CrCl greater than or equal to 50 mL/min) 1 mcg/kg/min Infusion Volume (CrCl less than 50 mL/min) (kg) (lb) (from 2 mg per mL vial) (from 2 mg per mL 100 mL vial) (from 0.75 mg per mL 100 mL vial) (from 2 mg per mL 100 mL vial) (from 0.75 mg per mL 100 mL vial) 37 to 41 81 to 91 3.4 mL 2 mL/h 6 mL/h 1 mL/h 3 mL/h 42 to 46 92 to 102 4 mL 2.5 mL/h 7 mL/h 1.3 mL/h 3.5 mL/h 47 to 53 103 to 117 4.5 mL 3 mL/h 8 mL/h 1.5 mL/h 4 mL/h 54 to 59 118 to 130 5 mL 3.5 mL/h 9 mL/h 1.8 mL/h 4.5 mL/h 60 to 65 131 to 143 5.6 mL 3.8 mL/h 10 mL/h 1.9 mL/h 5 mL/h 66 to 71 144 to 157 6.2 mL 4 mL/h 11 mL/h 2 mL/h 5.5 mL/h 72 to 78 158 to 172 6.8 mL 4.5 mL/h 12 mL/h 2.3 mL/h 6 mL/h 79 to 84 173 to 185 7.3 mL 5 mL/h 13 mL/h 2.5 mL/h 6.5 mL/h 85 to 90 186 to 198 7.9 mL 5.3 mL/h 14 mL/h 2.7 mL/h 7 mL/h 91 to 96 199 to 212 8.5 mL 5.6 mL/h 15 mL/h 2.8 mL/h 7.5 mL/h 97 to 103 213 to 227 9 mL 6 mL/h 16 mL/h 3.0 mL/h 8 mL/h 104 to 109 228 to 240 9.5 mL 6.4 mL/h 17 mL/h 3.2 mL/h 8.5 mL/h 110 to 115 241 to 253 10.2 mL 6.8 mL/h 18 mL/h 3.4 mL/h 9 mL/h 116 to 121 254 to 267 10.7 mL 7 mL/h 19 mL/h 3.5 mL/h 9.5 mL/h >121 >267 11.3 mL 7.5 mL/h 20 mL/h 3.7 mL/h 10 mL/h"
    ],
    "dosage_and_administration_table": [
      "<table width=\"100%\"><col width=\"14.200%\" align=\"left\"/><col width=\"30.467%\" align=\"left\"/><col width=\"55.333%\" align=\"left\"/><tbody><tr><td align=\"justify\" valign=\"middle\" styleCode=\"Toprule Botrule Lrule Rrule\"><content styleCode=\"bold\">Indication</content></td><td align=\"justify\" valign=\"middle\" styleCode=\"Toprule Botrule Rrule\"><content styleCode=\"bold\">Normal Renal Function</content></td><td align=\"justify\" valign=\"middle\" styleCode=\"Toprule Botrule Rrule\"><content styleCode=\"bold\">Creatinine Clearance less than 50 mL/min</content></td></tr><tr><td align=\"left\" valign=\"top\" styleCode=\"Botrule Lrule Rrule\">Patients with ACS </td><td align=\"left\" valign=\"top\" styleCode=\"Botrule Rrule\">180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min </td><td align=\"left\" valign=\"top\" styleCode=\"Botrule Rrule\">180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min </td></tr><tr><td align=\"left\" valign=\"top\" styleCode=\"Botrule Lrule Rrule\"/><td colspan=\"2\" align=\"left\" valign=\"top\" styleCode=\"Botrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours </item><item>If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy </item><item>Aspirin, 160 to 325 mg, should be given daily </item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"13.367%\" align=\"left\"/><col width=\"42.067%\" align=\"left\"/><col width=\"44.567%\" align=\"left\"/><tbody><tr><td align=\"justify\" valign=\"middle\" styleCode=\"Toprule Botrule Lrule Rrule\"><content styleCode=\"bold\">Indication</content></td><td align=\"justify\" valign=\"middle\" styleCode=\"Toprule Botrule Rrule\"><content styleCode=\"bold\">Normal Renal Function</content></td><td align=\"justify\" valign=\"middle\" styleCode=\"Toprule Botrule Rrule\"><content styleCode=\"bold\">Creatinine Clearance less than 50 mL/min</content></td></tr><tr><td align=\"left\" valign=\"top\" styleCode=\"Botrule Lrule Rrule\">Patients with PCI </td><td align=\"left\" valign=\"top\" styleCode=\"Botrule Rrule\">180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) </td><td align=\"left\" valign=\"top\" styleCode=\"Botrule Rrule\">180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) </td></tr><tr><td align=\"left\" valign=\"top\" styleCode=\"Botrule Lrule Rrule\"/><td colspan=\"2\" align=\"left\" valign=\"top\" styleCode=\"Botrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. </item><item>In patients who undergo CABG surgery, eptifibatide injection infusion should be discontinued prior to surgery. </item><item>Aspirin, 160 to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter. </item></list></td></tr></tbody></table>",
      "<table ID=\"t1\" width=\"100%\"><caption>Table 1: Eptifibatide Injection Dosing Charts by Weight </caption><col width=\"10.800%\" align=\"left\"/><col width=\"9.814%\" align=\"left\"/><col width=\"14.729%\" align=\"left\"/><col width=\"16.371%\" align=\"left\"/><col width=\"15.543%\" align=\"left\"/><col width=\"16.371%\" align=\"left\"/><col width=\"16.371%\" align=\"left\"/><tbody><tr><td colspan=\"2\" align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule Lrule\"><content styleCode=\"bold\">Patient Weight</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">180 mcg/kg</content> <content styleCode=\"bold\">Bolus Volume</content></td><td colspan=\"2\" align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">2 mcg/kg/min</content> <content styleCode=\"bold\">Infusion Volume</content> <content styleCode=\"bold\">(CrCl greater than or equal to 50 mL/min)</content></td><td colspan=\"2\" align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule Rrule\"><content styleCode=\"bold\">1 mcg/kg/min</content> <content styleCode=\"bold\">Infusion Volume</content> <content styleCode=\"bold\">(CrCl less than 50 mL/min)</content></td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Botrule Lrule\"><content styleCode=\"bold\">(kg)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"><content styleCode=\"bold\">(lb)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"><content styleCode=\"bold\">(from</content> <content styleCode=\"bold\">2 mg per mL vial)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"><content styleCode=\"bold\">(from</content> <content styleCode=\"bold\">2 mg per mL</content> <content styleCode=\"bold\">100 mL vial)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"><content styleCode=\"bold\">(from</content> <content styleCode=\"bold\">0.75 mg per mL</content> <content styleCode=\"bold\">100 mL vial)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"><content styleCode=\"bold\">(from</content> <content styleCode=\"bold\">2 mg per mL</content> <content styleCode=\"bold\">100 mL vial)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule Rrule\"><content styleCode=\"bold\">(from</content> <content styleCode=\"bold\">0.75 mg per mL</content> <content styleCode=\"bold\">100 mL vial)</content></td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">37 to 41 </td><td align=\"center\" valign=\"top\">81 to 91 </td><td align=\"center\" valign=\"top\">3.4 mL </td><td align=\"center\" valign=\"top\">2 mL/h </td><td align=\"center\" valign=\"top\">6 mL/h </td><td align=\"center\" valign=\"top\">1 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">3 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">42 to 46 </td><td align=\"center\" valign=\"top\">92 to 102 </td><td align=\"center\" valign=\"top\">4 mL </td><td align=\"center\" valign=\"top\">2.5 mL/h </td><td align=\"center\" valign=\"top\">7 mL/h </td><td align=\"center\" valign=\"top\">1.3 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">3.5 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">47 to 53 </td><td align=\"center\" valign=\"top\">103 to 117 </td><td align=\"center\" valign=\"top\">4.5 mL </td><td align=\"center\" valign=\"top\">3 mL/h </td><td align=\"center\" valign=\"top\">8 mL/h </td><td align=\"center\" valign=\"top\">1.5 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">4 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">54 to 59 </td><td align=\"center\" valign=\"top\">118 to 130 </td><td align=\"center\" valign=\"top\">5 mL </td><td align=\"center\" valign=\"top\">3.5 mL/h </td><td align=\"center\" valign=\"top\">9 mL/h </td><td align=\"center\" valign=\"top\">1.8 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">4.5 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">60 to 65 </td><td align=\"center\" valign=\"top\">131 to 143 </td><td align=\"center\" valign=\"top\">5.6 mL </td><td align=\"center\" valign=\"top\">3.8 mL/h </td><td align=\"center\" valign=\"top\">10 mL/h </td><td align=\"center\" valign=\"top\">1.9 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">5 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">66 to 71 </td><td align=\"center\" valign=\"top\">144 to 157 </td><td align=\"center\" valign=\"top\">6.2 mL </td><td align=\"center\" valign=\"top\">4 mL/h </td><td align=\"center\" valign=\"top\">11 mL/h </td><td align=\"center\" valign=\"top\">2 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">5.5 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">72 to 78 </td><td align=\"center\" valign=\"top\">158 to 172 </td><td align=\"center\" valign=\"top\">6.8 mL </td><td align=\"center\" valign=\"top\">4.5 mL/h </td><td align=\"center\" valign=\"top\">12 mL/h </td><td align=\"center\" valign=\"top\">2.3 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">6 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule\">79 to 84 </td><td align=\"center\" valign=\"middle\">173 to 185 </td><td align=\"center\" valign=\"middle\">7.3 mL </td><td align=\"center\" valign=\"middle\">5 mL/h </td><td align=\"center\" valign=\"middle\">13 mL/h </td><td align=\"center\" valign=\"middle\">2.5 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">6.5 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule\">85 to 90 </td><td align=\"center\" valign=\"middle\">186 to 198 </td><td align=\"center\" valign=\"middle\">7.9 mL </td><td align=\"center\" valign=\"middle\">5.3 mL/h </td><td align=\"center\" valign=\"middle\">14 mL/h </td><td align=\"center\" valign=\"middle\">2.7 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">7 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">91 to 96 </td><td align=\"center\" valign=\"top\">199 to 212 </td><td align=\"center\" valign=\"top\">8.5 mL </td><td align=\"center\" valign=\"top\">5.6 mL/h </td><td align=\"center\" valign=\"top\">15 mL/h </td><td align=\"center\" valign=\"top\">2.8 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">7.5 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule\">97 to 103 </td><td align=\"center\" valign=\"middle\">213 to 227 </td><td align=\"center\" valign=\"middle\">9 mL </td><td align=\"center\" valign=\"middle\">6 mL/h </td><td align=\"center\" valign=\"middle\">16 mL/h </td><td align=\"center\" valign=\"middle\">3.0 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">8 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule\">104 to 109 </td><td align=\"center\" valign=\"middle\">228 to 240 </td><td align=\"center\" valign=\"middle\">9.5 mL </td><td align=\"center\" valign=\"middle\">6.4 mL/h </td><td align=\"center\" valign=\"middle\">17 mL/h </td><td align=\"center\" valign=\"middle\">3.2 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">8.5 mL/h </td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Lrule\">110 to 115 </td><td align=\"center\" valign=\"top\">241 to 253 </td><td align=\"center\" valign=\"top\">10.2 mL </td><td align=\"center\" valign=\"top\">6.8 mL/h </td><td align=\"center\" valign=\"top\">18 mL/h </td><td align=\"center\" valign=\"top\">3.4 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">9 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule\">116 to 121 </td><td align=\"center\" valign=\"middle\">254 to 267 </td><td align=\"center\" valign=\"middle\">10.7 mL </td><td align=\"center\" valign=\"middle\">7 mL/h </td><td align=\"center\" valign=\"middle\">19 mL/h </td><td align=\"center\" valign=\"middle\">3.5 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">9.5 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Botrule Lrule\">&gt;121 </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">&gt;267 </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">11.3 mL </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">7.5 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">20 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">3.7 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule Rrule\">10 mL/h </td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS 20 mg of Eptifibatide Injection in 10 mL (2 mg per mL), for intravenous bolus. 75 mg of Eptifibatide Injection in 100 mL (0.75 mg per mL), for intravenous infusion. 200 mg of Eptifibatide Injection in 100 mL (2 mg per mL), for intravenous infusion. 20 mg per 10 mL (2 mg per mL) in a single-dose vial for bolus injection ( 3 ) 75 mg per 100 mL (0.75 mg per mL) in a single-dose vial for infusion ( 3 ) 200 mg per 100 mL (2 mg per mL) in a single-dose vial for infusion ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Treatment with eptifibatide is contraindicated in patients with: A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another parenteral GP IIb/IIIa inhibitor Dependency on renal dialysis Hypersensitivity to eptifibatide or any component of the product (hypersensitivity reactions that occurred included anaphylaxis and urticaria). Bleeding diathesis or bleeding within the previous 30 days ( 4 ) Severe uncontrolled hypertension ( 4 ) Major surgery within the preceding 6 weeks ( 4 ) Stroke within 30 days or any history of hemorrhagic stroke ( 4 ) Coadministration of another parenteral GP IIb/IIIa inhibitor ( 4 ) Dependency on renal dialysis ( 4 ) Known hypersensitivity to any component of the product ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Eptifibatide can cause serious bleeding. If bleeding cannot be controlled, discontinue eptifibatide immediately. Minimize vascular and other traumas. If heparin is given concomitantly, monitor aPTT or ACT. ( 5.1 ) Thrombocytopenia: Discontinue eptifibatide and heparin. Monitor and treat condition appropriately. ( 5.2 ) 5.1 Bleeding Bleeding is the most common complication encountered during eptifibatide therapy. Administration of eptifibatide is associated with an increase in major and minor bleeding, as classified by the criteria of the Thrombolysis in Myocardial Infarction Study group (TIMI) [see Adverse Reactions ( 6.1 )] . Most major bleeding associated with eptifibatide has been at the arterial access site for cardiac catheterization or from the gastrointestinal or genitourinary tract. Minimize the use of arterial and venous punctures, intramuscular injections, and the use of urinary catheters, nasotracheal intubation, and nasogastric tubes. When obtaining intravenous access, avoid non-compressible sites (e.g., subclavian or jugular veins). Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Risk factors for bleeding include older age, a history of bleeding disorders, and concomitant use of drugs that increase the risk of bleeding (thrombolytics, oral anticoagulants, nonsteroidal anti-inflammatory drugs, and P2Y 12 inhibitors). Concomitant treatment with other inhibitors of platelet receptor glycoprotein (GP) IIb/IIIa should be avoided. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT [see Dosage and Administration ( 2 )] . Care of the Femoral Artery Access Site in Patients Undergoing Percutaneous Coronary Intervention (PCI) In patients undergoing PCI, treatment with eptifibatide is associated with an increase in major and minor bleeding at the site of arterial sheath placement. After PCI, eptifibatide infusion should be continued until hospital discharge or up to 18 to 24 hours, whichever comes first. Heparin use is discouraged after the PCI procedure. Early sheath removal is encouraged while eptifibatide is being infused. Prior to removing the sheath, it is recommended that heparin be discontinued for 3 to 4 hours and an aPTT of <45 seconds or ACT <150 seconds be achieved. In any case, both heparin and eptifibatide should be discontinued and sheath hemostasis should be achieved at least 2 to 4 hours before hospital discharge. If bleeding at access site cannot be controlled with pressure, infusion of eptifibatide and heparin should be discontinued immediately. 5.2 Thrombocytopenia There have been reports of acute, profound thrombocytopenia (immune-mediated and non-immune mediated) with eptifibatide. In the event of acute profound thrombocytopenia or a confirmed platelet decrease to <100,000/mm 3 , discontinue eptifibatide and heparin (unfractionated or low-molecular weight). Monitor serial platelet counts, assess the presence of drug-dependent antibodies, and treat as appropriate [see Adverse Reactions ( 6.1 )] . There has been no clinical experience with eptifibatide initiated in patients with a baseline platelet count <100,000/mm 3 . If a patient with low platelet counts is receiving eptifibatide, their platelet count should be monitored closely."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reaction is also discussed elsewhere in the labeling: Bleeding [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )] Bleeding and hypotension are the most commonly reported adverse reactions. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals, Inc. at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. A total of 16,782 patients were treated in the Phase III clinical trials (PURSUIT, ESPRIT, and IMPACT II) [see Clinical Studies ( 14 )] . These 16,782 patients had a mean age of 62 years (range: 20 to 94 years). Eighty-nine percent of the patients were Caucasian, with the remainder being predominantly Black (5%) and Hispanic (5%). Sixty-eight percent were men. Because of the different regimens used in PURSUIT, IMPACT II, and ESPRIT, data from the 3 studies were not pooled. Bleeding and hypotension were the most commonly reported adverse reactions (incidence \u22655% and greater than placebo) in the eptifibatide controlled clinical trial database. Bleeding The incidence of bleeding and transfusions in the PURSUIT and ESPRIT studies are shown in Table 2 . Bleeding was classified as major or minor by the criteria of the TIMI study group. Major bleeding consisted of intracranial hemorrhage and other bleeding that led to decreases in hemoglobin greater than 5 g/dL. Minor bleeding included spontaneous gross hematuria, spontaneous hematemesis, other observed blood loss with a hemoglobin decrease of more than 3 g/dL, and other hemoglobin decreases that were greater than 4 g/dL but less than 5 g/dL. In patients who received transfusions, the corresponding loss in hemoglobin was estimated through an adaptation of the method of Landefeld et al. Table 2: Bleeding and Transfusions in the PURSUIT and ESPRIT Studies Note: Denominator is based on patients for whom data are available. * For major and minor bleeding, patients are counted only once according to the most severe classification. \u2020 Includes transfusions of whole blood, packed red blood cells, fresh frozen plasma, cryoprecipitate, platelets, and autotransfusion during the initial hospitalization. PURSUIT (ACS) Eptifibatide Placebo 180/2 n (%) n (%) Patients 4696 4679 Major bleeding* 425 (9.3%) 498 (10.8%) Minor bleeding* 347 (7.6%) 604 (13.1%) Requiring transfusions \u2020 490 (10.4%) 601 (12.8%) ESPRIT (PCI) Placebo n (%) Eptifibatide 180/2/180 n (%) Patients 1024 1040 Major bleeding* 4 (0.4%) 13 (1.3%) Minor bleeding* 18 (2%) 29 (3%) Requiring transfusions \u2020 11 (1.1%) 16 (1.5%) The majority of major bleeding reactions in the ESPRIT study occurred at the vascular access site (1 and 8 patients, or 0.1% and 0.8% in the placebo and eptifibatide groups, respectively). Bleeding at \u201cother\u201d locations occurred in 0.2% and 0.4% of patients, respectively. In the PURSUIT study, the greatest increase in major bleeding in eptifibatide-treated patients compared to placebo-treated patients was also associated with bleeding at the femoral artery access site (2.8% versus 1.3%). Oropharyngeal (primarily gingival), genitourinary, gastrointestinal, and retroperitoneal bleeding were also seen more commonly in eptifibatide-treated patients compared to placebo-treated patients. Among patients experiencing a major bleed in the IMPACT II study, an increase in bleeding on eptifibatide versus placebo was observed only for the femoral artery access site (3.2% versus 2.8%). Table 3 displays the incidence of TIMI major bleeding according to the cardiac procedures carried out in the PURSUIT study. The most common bleeding complications were related to cardiac revascularization (CABG-related or femoral artery access site bleeding). A corresponding table for ESPRIT is not presented, as every patient underwent PCI in the ESPRIT study and only 11 patients underwent CABG. Table 3: Major Bleeding by Procedures in the PURSUIT Study Note: Denominators are based on the total number of patients whose TIMI classification was resolved. Placebo n (%) Eptifibatide 180/2 n (%) Patients 4577 4604 Overall incidence of major bleeding 425 (9.3%) 498 (10.8%) Breakdown by procedure: CABG 375 (8.2%) 377 (8.2%) Angioplasty without CABG 27 (0.6%) 64 (1.4%) Angiography without angioplasty or CABG 11 (0.2%) 29 (0.6%) Medical therapy only 12 (0.3%) 28 (0.6%) In the PURSUIT and ESPRIT studies, the risk of major bleeding with eptifibatide increased as patient weight decreased. This relationship was most apparent for patients weighing less than 70 kg. Bleeding resulting in discontinuation of the study drug was more frequent among patients receiving eptifibatide than placebo (4.6% versus 0.9% in ESPRIT, 8% versus 1% in PURSUIT, 3.5% versus 1.9% in IMPACT II). Intracranial Hemorrhage and Stroke Intracranial hemorrhage was rare in the PURSUIT, IMPACT II, and ESPRIT clinical studies. In the PURSUIT study, 3 patients in the placebo group, 1 patient in the group treated with eptifibatide 180/1.3, and 5 patients in the group treated with eptifibatide 180/2 experienced a hemorrhagic stroke. The overall incidence of stroke was 0.5% in patients receiving eptifibatide 180/1.3, 0.7% in patients receiving eptifibatide 180/2, and 0.8% in placebo patients. In the IMPACT II study, intracranial hemorrhage was experienced by 1 patient treated with eptifibatide 135/0.5, 2 patients treated with eptifibatide 135/0.75, and 2 patients in the placebo group. The overall incidence of stroke was 0.5% in patients receiving 135/0.5 eptifibatide, 0.7% in patients receiving eptifibatide 135/0.75, and 0.7% in the placebo group. In the ESPRIT study, there were 3 hemorrhagic strokes, 1 in the placebo group and 2 in the eptifibatide group. In addition there was 1 case of cerebral infarction in the eptifibatide group. Immunogenicity/Thrombocytopenia The potential for development of antibodies to eptifibatide has been studied in 433 subjects. Eptifibatide was nonantigenic in 412 patients receiving a single administration of eptifibatide (135 mcg/kg bolus followed by a continuous infusion of either 0.5 mcg/kg/min or 0.75 mcg/kg/min), and in 21 subjects to whom eptifibatide (135 mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min) was administered twice, 28 days apart. In both cases, plasma for antibody detection was collected approximately 30 days after each dose. The development of antibodies to eptifibatide at higher doses has not been evaluated. In patients with suspected eptifibatide-related immune-mediated thrombocytopenia, IgG antibodies that react with the GP IIb/IIIa complex were identified in the presence of eptifibatide and in eptifibatide-na\u00efve patients. These findings suggest acute thrombocytopenia after the administration of eptifibatide can develop as a result of naturally occurring drug-dependent antibodies or those induced by prior exposure to eptifibatide. Similar antibodies were identified with other GP IIb/IIIa ligand-mimetic agents. Immune-mediated thrombocytopenia with eptifibatide may be associated with hypotension and/or other signs of hypersensitivity. In the PURSUIT and IMPACT II studies, the incidence of thrombocytopenia (<100,000/mm 3 or \u226550% reduction from baseline) and the incidence of platelet transfusions were similar between patients treated with eptifibatide and placebo. In the ESPRIT study, the incidence was 0.6% in the placebo group and 1.2% in the eptifibatide group. Other Adverse Reactions In the PURSUIT and ESPRIT studies, the incidence of serious nonbleeding adverse reactions was similar in patients receiving placebo or eptifibatide (19% and 19%, respectively, in PURSUIT; 6% and 7%, respectively, in ESPRIT). In PURSUIT, the only serious nonbleeding adverse reaction that occurred at a rate of at least 1% and was more common with eptifibatide than placebo (7% versus 6%) was hypotension. Most of the serious nonbleeding adverse reactions consisted of cardiovascular reactions typical of a UA population. In the IMPACT II study, serious nonbleeding adverse reactions that occurred in greater than 1% of patients were uncommon and similar in incidence between placebo- and eptifibatide-treated patients. Discontinuation of study drug due to adverse reactions other than bleeding was uncommon in the PURSUIT, IMPACT II, and ESPRIT studies, with no single reaction occurring in >0.5% of the study population (except for \u201cother\u201d in the ESPRIT study). 6.2 Postmarketing Experience The following adverse reactions have been reported in post-approval use of eptifibatide in combination with heparin and aspirin. Because the reactions below are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure: cerebral, GI, and pulmonary hemorrhage. Fatal bleeding reactions have been reported. Acute profound thrombocytopenia, as well as immune-mediated thrombocytopenia, have been reported [see Adverse Reactions ( 6.1 )] ."
    ],
    "adverse_reactions_table": [
      "<table ID=\"t2\" width=\"100%\"><caption>Table 2: Bleeding and Transfusions in the PURSUIT and ESPRIT Studies </caption><col width=\"47.200%\" align=\"left\"/><col width=\"25.575%\" align=\"left\"/><col width=\"10%\" align=\"left\"/><col width=\"26.400%\" align=\"left\"/><tfoot><tr><td colspan=\"4\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\">Note: Denominator is based on patients for whom data are available. </paragraph></td></tr><tr><td colspan=\"4\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\">* For major and minor bleeding, patients are counted only once according to the most severe classification. </paragraph></td></tr><tr><td colspan=\"4\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\"><sup>&#x2020;</sup> Includes transfusions of whole blood, packed red blood cells, fresh frozen plasma, cryoprecipitate, platelets, and autotransfusion during the initial hospitalization. </paragraph></td></tr></tfoot><tbody><tr><td colspan=\"4\" align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">PURSUIT (ACS)</content></td></tr><tr><td rowspan=\"3\" align=\"justify\" valign=\"top\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"top\"/><td colspan=\"2\" align=\"center\" valign=\"bottom\"><content styleCode=\"bold\">Eptifibatide</content></td></tr><tr><td align=\"center\" valign=\"bottom\"><content styleCode=\"bold\">Placebo</content></td><td colspan=\"2\" align=\"center\" valign=\"bottom\"><content styleCode=\"bold\">180/2</content></td></tr><tr><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"><content styleCode=\"bold\">n (%)</content></td><td colspan=\"2\" align=\"center\" valign=\"bottom\" styleCode=\"Botrule\"><content styleCode=\"bold\">n (%)</content></td></tr><tr><td align=\"justify\" valign=\"bottom\">Patients </td><td align=\"center\" valign=\"bottom\">4696 </td><td colspan=\"2\" align=\"center\" valign=\"top\">4679 </td></tr><tr><td align=\"justify\" valign=\"top\">Major bleeding* </td><td align=\"center\" valign=\"top\">425 (9.3%) </td><td colspan=\"2\" align=\"center\" valign=\"top\">498 (10.8%) </td></tr><tr><td align=\"justify\" valign=\"top\">Minor bleeding* </td><td align=\"center\" valign=\"top\">347 (7.6%) </td><td colspan=\"2\" align=\"center\" valign=\"top\">604 (13.1%) </td></tr><tr><td align=\"justify\" valign=\"top\" styleCode=\"Botrule\">Requiring transfusions<sup>&#x2020;</sup></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">490 (10.4%) </td><td colspan=\"2\" align=\"center\" valign=\"top\" styleCode=\"Botrule\">601 (12.8%) </td></tr><tr><td colspan=\"4\" align=\"center\" valign=\"bottom\"><content styleCode=\"bold\">ESPRIT (PCI)</content></td></tr><tr><td align=\"center\" valign=\"bottom\"/><td colspan=\"2\" rowspan=\"3\" align=\"center\" valign=\"bottom\" styleCode=\"Botrule\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">n (%)</content></td><td align=\"center\" valign=\"bottom\"><content styleCode=\"bold\">Eptifibatide</content></td></tr><tr><td align=\"center\" valign=\"bottom\"/><td align=\"center\" valign=\"bottom\"><content styleCode=\"bold\">180/2/180</content></td></tr><tr><td align=\"justify\" valign=\"bottom\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"bottom\" styleCode=\"Botrule\"><content styleCode=\"bold\">n (%)</content></td></tr><tr><td align=\"justify\" valign=\"bottom\">Patients </td><td colspan=\"2\" align=\"center\" valign=\"bottom\">1024 </td><td align=\"center\" valign=\"bottom\">1040 </td></tr><tr><td align=\"justify\" valign=\"bottom\">Major bleeding* </td><td colspan=\"2\" align=\"center\" valign=\"bottom\">4 (0.4%) </td><td align=\"center\" valign=\"bottom\">13 (1.3%) </td></tr><tr><td align=\"justify\" valign=\"bottom\">Minor bleeding* </td><td colspan=\"2\" align=\"center\" valign=\"bottom\">18 (2%) </td><td align=\"center\" valign=\"bottom\">29 (3%) </td></tr><tr><td align=\"justify\" valign=\"bottom\" styleCode=\"Botrule\">Requiring transfusions<sup>&#x2020;</sup></td><td colspan=\"2\" align=\"center\" valign=\"bottom\" styleCode=\"Botrule\">11 (1.1%) </td><td align=\"center\" valign=\"bottom\" styleCode=\"Botrule\">16 (1.5%) </td></tr></tbody></table>",
      "<table ID=\"t3\" width=\"100%\"><caption>Table 3: Major Bleeding by Procedures in the PURSUIT Study </caption><col width=\"45.533%\" align=\"left\"/><col width=\"28.067%\" align=\"left\"/><col width=\"26.400%\" align=\"left\"/><tfoot><tr><td colspan=\"3\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\">Note: Denominators are based on the total number of patients whose TIMI classification was resolved. </paragraph></td></tr></tfoot><tbody><tr><td align=\"justify\" valign=\"top\" styleCode=\"Toprule\"/><td rowspan=\"3\" align=\"center\" valign=\"bottom\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">n (%)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">Eptifibatide</content></td></tr><tr><td align=\"justify\" valign=\"top\"/><td align=\"center\" valign=\"top\"><content styleCode=\"bold\">180/2</content></td></tr><tr><td align=\"justify\" valign=\"middle\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"><content styleCode=\"bold\">n (%)</content></td></tr><tr><td align=\"justify\" valign=\"middle\">Patients </td><td align=\"center\" valign=\"middle\">4577 </td><td align=\"center\" valign=\"middle\">4604 </td></tr><tr><td align=\"justify\" valign=\"middle\">Overall incidence of major bleeding </td><td align=\"center\" valign=\"middle\">425 (9.3%) </td><td align=\"center\" valign=\"middle\">498 (10.8%) </td></tr><tr><td align=\"left\" valign=\"middle\">Breakdown by procedure: </td><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\"/></tr><tr><td align=\"justify\" valign=\"middle\"> CABG </td><td align=\"center\" valign=\"middle\">375 (8.2%) </td><td align=\"center\" valign=\"middle\">377 (8.2%) </td></tr><tr><td align=\"justify\" valign=\"middle\"> Angioplasty without CABG </td><td align=\"center\" valign=\"middle\">27 (0.6%) </td><td align=\"center\" valign=\"middle\">64 (1.4%) </td></tr><tr><td align=\"justify\" valign=\"middle\"> Angiography without angioplasty or CABG </td><td align=\"center\" valign=\"middle\">11 (0.2%) </td><td align=\"center\" valign=\"middle\">29 (0.6%) </td></tr><tr><td align=\"justify\" valign=\"middle\" styleCode=\"Botrule\"> Medical therapy only </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">12 (0.3%) </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">28 (0.6%) </td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Avoid concomitant use with other glycoprotein (GP) IIb/IIIa inhibitors. ( 7.1 ) 7.1 Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Concomitant treatment with other inhibitors of platelet receptor GP IIb/IIIa should be avoided."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Geriatric Use: Risk of bleeding increases with age. ( 8.5 ) 8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus (see Clinical Considerations ) . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide on the fetus. Data Animal Data Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide. 8.2 Lactation Risk Summary There are no available data on the presence of eptifibatide in human milk, the effects on the breastfed infant, or the effects on milk production. As eptifibatide is a peptide, it is likely to be destroyed in the infant's gastrointestinal tract and not absorbed orally by the breastfed infant. 8.4 Pediatric Use Safety and effectiveness of eptifibatide in pediatric patients have not been studied. 8.5 Geriatric Use The PURSUIT and IMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUIT study; no such limitation was stipulated in the ESPRIT study [see Adverse Reactions ( 6.1 )] . 8.6 Renal Impairment Approximately 50% of eptifibatide is cleared by the kidney in patients with normal renal function. Total drug clearance is decreased by approximately 50% and steady-state plasma eptifibatide concentrations are doubled in patients with an estimated CrCl <50 mL/min (using the Cockcroft-Gault equation). Therefore, the infusion dose should be reduced to 1 mcg/kg/min in such patients [see Dosage and Administration ( 2 )] . The safety and efficacy of eptifibatide in patients dependent on dialysis has not been established."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus (see Clinical Considerations ) . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide on the fetus. Data Animal Data Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety and effectiveness of eptifibatide in pediatric patients have not been studied."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use The PURSUIT and IMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUIT study; no such limitation was stipulated in the ESPRIT study [see Adverse Reactions ( 6.1 )] ."
    ],
    "overdosage": [
      "10 OVERDOSAGE There has been only limited experience with overdosage of eptifibatide. There were 8 patients in the IMPACT II study, 9 patients in the PURSUIT study, and no patients in the ESPRIT study who received bolus doses and/or infusion doses more than double those called for in the protocols. None of these patients experienced an intracranial bleed or other major bleeding. Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis). Symptoms of acute toxicity were loss of righting reflex, dyspnea, ptosis, and decreased muscle tone in rabbits and petechial hemorrhages in the femoral and abdominal areas of monkeys. From in vitro studies, eptifibatide is not extensively bound to plasma proteins and thus may be cleared from plasma by dialysis."
    ],
    "description": [
      "11 DESCRIPTION Eptifibatide is a cyclic heptapeptide containing 6 amino acids and 1 mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties. Chemically it is N 6 -(aminoiminomethyl)-N 2 -(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-\u03b1-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1\u21926)-disulfide. Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation. The eptifibatide peptide is produced by solution-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized. The structural formula is: Eptifibatide Injection is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use with an empirical formula of C 35 H 49 N 11 O 9 S 2 and a molecular weight of 831.96. Each 10 mL vial contains 2 mg per mL of eptifibatide and each 100 mL vial contains either 0.75 mg per mL of eptifibatide or 2 mg per mL of eptifibatide. Each vial of either size also contains 5.25 mg per mL citric acid and sodium hydroxide to adjust the pH to 5.35. Structural Formula"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet. 12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide was observed immediately after administration of a 180 mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide used in the IMPACT II and PURSUIT studies on ex vivo platelet aggregation induced by 20 \u03bcM ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRIT on platelet aggregation have not been studied. Table 4: Platelet Inhibition and Bleeding Time * 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. PURSUIT 180/2 * Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x The eptifibatide dosing regimen used in the ESPRIT study included two 180 mcg/kg bolus doses given 10 minutes apart combined with a continuous 2 mcg/kg/min infusion. When administered alone, eptifibatide has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed. 12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180 mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4 to 6 hours). This decline can be prevented by administering a second 180 mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20 to 94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations ( 8.6 ) and Dosage and Administration ( 2 )] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "clinical_pharmacology_table": [
      "<table ID=\"t4\" width=\"100%\"><caption>Table 4: Platelet Inhibition and Bleeding Time </caption><col width=\"68.550%\" align=\"left\"/><col width=\"31.450%\" align=\"left\"/><tfoot><tr><td colspan=\"2\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\">* 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. </paragraph></td></tr></tfoot><tbody><tr><td align=\"justify\" valign=\"top\" styleCode=\"Toprule Botrule\"/><td align=\"justify\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">PURSUIT</content> <content styleCode=\"bold\">180/2</content>* </td></tr><tr><td align=\"justify\" valign=\"top\">Inhibition of platelet aggregation 15 min after bolus </td><td align=\"justify\" valign=\"top\">84% </td></tr><tr><td align=\"justify\" valign=\"top\">Inhibition of platelet aggregation at steady state </td><td align=\"justify\" valign=\"top\">&gt;90% </td></tr><tr><td align=\"justify\" valign=\"top\">Bleeding-time prolongation at steady state </td><td align=\"justify\" valign=\"top\">&lt;5x </td></tr><tr><td align=\"justify\" valign=\"top\">Inhibition of platelet aggregation 4h after infusion discontinuation </td><td align=\"justify\" valign=\"top\">&lt;50% </td></tr><tr><td align=\"justify\" valign=\"top\" styleCode=\"Botrule\">Bleeding-time prolongation 6h after infusion discontinuation </td><td align=\"justify\" valign=\"top\" styleCode=\"Botrule\">1.4x </td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide was observed immediately after administration of a 180 mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide used in the IMPACT II and PURSUIT studies on ex vivo platelet aggregation induced by 20 \u03bcM ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRIT on platelet aggregation have not been studied. Table 4: Platelet Inhibition and Bleeding Time * 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. PURSUIT 180/2 * Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x The eptifibatide dosing regimen used in the ESPRIT study included two 180 mcg/kg bolus doses given 10 minutes apart combined with a continuous 2 mcg/kg/min infusion. When administered alone, eptifibatide has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed."
    ],
    "pharmacodynamics_table": [
      "<table ID=\"t4\" width=\"100%\"><caption>Table 4: Platelet Inhibition and Bleeding Time </caption><col width=\"68.550%\" align=\"left\"/><col width=\"31.450%\" align=\"left\"/><tfoot><tr><td colspan=\"2\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\">* 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. </paragraph></td></tr></tfoot><tbody><tr><td align=\"justify\" valign=\"top\" styleCode=\"Toprule Botrule\"/><td align=\"justify\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">PURSUIT</content> <content styleCode=\"bold\">180/2</content>* </td></tr><tr><td align=\"justify\" valign=\"top\">Inhibition of platelet aggregation 15 min after bolus </td><td align=\"justify\" valign=\"top\">84% </td></tr><tr><td align=\"justify\" valign=\"top\">Inhibition of platelet aggregation at steady state </td><td align=\"justify\" valign=\"top\">&gt;90% </td></tr><tr><td align=\"justify\" valign=\"top\">Bleeding-time prolongation at steady state </td><td align=\"justify\" valign=\"top\">&lt;5x </td></tr><tr><td align=\"justify\" valign=\"top\">Inhibition of platelet aggregation 4h after infusion discontinuation </td><td align=\"justify\" valign=\"top\">&lt;50% </td></tr><tr><td align=\"justify\" valign=\"top\" styleCode=\"Botrule\">Bleeding-time prolongation 6h after infusion discontinuation </td><td align=\"justify\" valign=\"top\" styleCode=\"Botrule\">1.4x </td></tr></tbody></table>"
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180 mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4 to 6 hours). This decline can be prevented by administering a second 180 mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20 to 94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations ( 8.6 ) and Dosage and Administration ( 2 )] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Eptifibatide was studied in 3 placebo-controlled, randomized studies. PURSUIT evaluated patients with acute coronary syndromes: UA or NSTEMI. Two other studies, ESPRIT and IMPACT II, evaluated patients about to undergo a PCI. Patients underwent primarily balloon angioplasty in IMPACT II and intracoronary stent placement, with or without angioplasty, in ESPRIT. 14.1 Non-ST-Segment Elevation Acute Coronary Syndrome Non-ST-segment elevation acute coronary syndrome is defined as prolonged (\u226510 minutes) symptoms of cardiac ischemia within the previous 24 hours associated with either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or positive CK-MB. This definition includes \u201cunstable angina\u201d and \u201cNSTEMI\u201d but excludes MI that is associated with Q waves or greater degrees of ST-segment elevation. PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using INTEGRILIN (eptifibatide) Therapy) PURSUIT was a 726-center, 27-country, double-blind, randomized, placebo-controlled study in 10,948 patients presenting with UA or NSTEMI. Patients could be enrolled only if they had experienced cardiac ischemia at rest (\u226510 minutes) within the previous 24 hours and had either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or increased CK-MB. Important exclusion criteria included a history of bleeding diathesis, evidence of abnormal bleeding within the previous 30 days, uncontrolled hypertension, major surgery within the previous 6 weeks, stroke within the previous 30 days, any history of hemorrhagic stroke, serum creatinine >2 mg/dL, dependency on renal dialysis, or platelet count <100,000/mm 3 . Patients were randomized to placebo, to eptifibatide 180 mcg/kg bolus followed by a 2 mcg/kg/min infusion (180/2), or to eptifibatide 180 mcg/kg bolus followed by a 1.3 mcg/kg/min infusion (180/1.3). The infusion was continued for 72 hours, until hospital discharge, or until the time of CABG, whichever occurred first, except that if PCI was performed, the eptifibatide infusion was continued for 24 hours after the procedure, allowing for a duration of infusion up to 96 hours. The lower-infusion-rate arm was stopped after the first interim analysis when the 2 active-treatment arms appeared to have the same incidence of bleeding. Patient age ranged from 20 to 94 (mean 63) years, and 65% were male. The patients were 89% Caucasian, 6% Hispanic, and 5% Black, recruited in the United States and Canada (40%), Western Europe (39%), Eastern Europe (16%), and Latin America (5%). This was a \u201creal world\u201d study; each patient was managed according to the usual standards of the investigational site; frequencies of angiography, PCI, and CABG therefore differed widely from site to site and from country to country. Of the patients in PURSUIT, 13% were managed with PCI during drug infusion, of whom 50% received intracoronary stents; 87% were managed medically (without PCI during drug infusion). The majority of patients received aspirin (75 to 325 mg once daily). Heparin was administered intravenously or subcutaneously, at the physician's discretion, most commonly as an intravenous bolus of 5,000 units followed by a continuous infusion of 1,000 units/h. For patients weighing less than 70 kg, the recommended heparin bolus dose was 60 units/kg followed by a continuous infusion of 12 units/kg/h. A target aPTT of 50 to 70 seconds was recommended. A total of 1250 patients underwent PCI within 72 hours after randomization, in which case they received intravenous heparin to maintain an ACT of 300 to 350 seconds. The primary endpoint of the study was the occurrence of death from any cause or new MI (evaluated by a blinded Clinical Endpoints Committee) within 30 days of randomization. Compared to placebo, eptifibatide administered as a 180 mcg/kg bolus followed by a 2 mcg/kg/min infusion significantly (p=0.042) reduced the incidence of endpoint events (see Table 6 ). The reduction in the incidence of endpoint events in patients receiving eptifibatide was evident early during treatment, and this reduction was maintained through at least 30 days (see Figure 1 ). Table 5 also shows the incidence of the components of the primary endpoint, death (whether or not preceded by an MI) and new MI in surviving patients at 30 days. Table 5: Clinical Events in the PURSUIT Study Death or MI Placebo (n=4739) n (%) Eptifibatide (180 mcg/kg bolus then 2 mcg/kg/min infusion) (n=4722) n (%) p-value 3 days 359 (7.6%) 279 (5.9%) 0.001 7 days 552 (11.6%) 477 (10.1%) 0.016 30 days Death or MI (primary endpoint) 745 (15.7%) 672 (14.2%) 0.042 Death 177 (3.7%) 165 (3.5%) Nonfatal MI 568 (12%) 507 (10.7%) Figure 1: Kaplan-Meier Plot of Time to Death or Myocardial Infarction Within 30 Days of Randomization in the PURSUIT Study Treatment with eptifibatide prior to determination of patient management strategy reduced clinical events regardless of whether patients ultimately underwent diagnostic catheterization, revascularization (i.e., PCI or CABG surgery) or continued to receive medical management alone. Table 6 shows the incidence of death or MI within 72 hours. Table 6: Clinical Events (Death or MI) in the PURSUIT Study Within 72 Hours of Randomization Placebo Eptifibatide (180 mcg/kg bolus then 2 mcg/kg/min infusion) Overall patient population n=4739 n=4722 \u2013 At 72 hours 7.6% 5.9% Patients undergoing early PCI n=631 n=619 \u2013 Pre-procedure (nonfatal MI only) 5.5% 1.8% \u2013 At 72 hours 14.4% 9% Patients not undergoing early PCI n=4108 n=4103 \u2013 At 72 hours 6.5% 5.4% All of the effect of eptifibatide was established within 72 hours (during the period of drug infusion), regardless of management strategy. Moreover, for patients undergoing early PCI, a reduction in events was evident prior to the procedure. An analysis of the results by sex suggests that women who would not routinely be expected to undergo PCI receive less benefit from eptifibatide (95% confidence limits for relative risk of 0.94 to 1.28) than do men (0.72 to 0.9). This difference may be a true treatment difference, the effect of other differences in these subgroups, or a statistical anomaly. No differential outcomes were seen between male and female patients undergoing PCI (see results for ESPRIT) . Follow-up data were available through 165 days for 10,611 patients enrolled in the PURSUIT trial (96.9% of the initial enrollment). This follow-up included 4566 patients who received eptifibatide at the 180/2 dose. As reported by the investigators, the occurrence of death from any cause or new MI for patients followed for at least 165 days was reduced from 13.6% with placebo to 12.1% with eptifibatide 180/2. Figure 1 14.2 Percutaneous Coronary Intervention (PCI) IMPACT II (INTEGRILIN (eptifibatide) to Minimize Platelet Aggregation and Prevent Coronary Thrombosis II) IMPACT II was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States in 4010 patients undergoing PCI. Major exclusion criteria included a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 89 (mean 60) years, and 75% were male. The patients were 92% Caucasian, 5% Black, and 3% Hispanic. Forty-one percent of the patients underwent PCI for ongoing ACS. Patients were randomly assigned to 1 of 3 treatment regimens, each incorporating a bolus dose initiated immediately prior to PCI followed by a continuous infusion lasting 20 to 24 hours: 135 mcg/kg bolus followed by a continuous infusion of 0.5 mcg/kg/min of eptifibatide (135/0.5); 135 mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min of eptifibatide (135/0.75); or a matching placebo bolus followed by a matching placebo continuous infusion. Each patient received aspirin and an intravenous heparin bolus of 100 units/kg, with additional bolus infusions of up to 2,000 additional units of heparin every 15 minutes to maintain an ACT of 300 to 350 seconds. The primary endpoint was the composite of death, MI, or urgent revascularization, analyzed at 30 days after randomization in all patients who received at least 1 dose of study drug. As shown in Table 7 , each eptifibatide regimen reduced the rate of death, MI, or urgent intervention, although at 30 days, this finding was statistically significant only in the lower-dose eptifibatide group. As in the PURSUIT study, the effects of eptifibatide were seen early and persisted throughout the 30-day period. Table 7: Clinical Events in the IMPACT II Study * Kaplan-Meier estimate of event rate. Placebo n (%) Eptifibatide (135 mcg/kg bolus then 0.5 mcg/kg/min infusion) n (%) Eptifibatide (135 mcg/kg bolus then 0.75 mcg/kg/min infusion) n (%) Patients 1285 1300 1286 Abrupt Closure 65 (5.1%) 36 (2.8%) 43 (3.3%) p-value versus placebo 0.003 0.03 Death, MI, or Urgent Intervention 24 hours 123 (9.6%) 86 (6.6%) 89 (6.9%) p-value versus placebo 0.006 0.014 48 hours 131 (10.2%) 99 (7.6%) 102 (7.9%) p-value versus placebo 0.021 0.045 30 days (primary endpoint) 149 (11.6%) 118 (9.1%) 128 (10%) p-value versus placebo 0.035 0.179 Death or MI 30 days 110 (8.6%) 89 (6.8%) 95 (7.4%) p-value versus placebo 0.102 0.272 6 months 151 (11.9%)* 136 (10.6%)* 130 (10.3%)* p-value versus placebo 0.297 0.182 ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with INTEGRILIN (eptifibatide) Therapy) The ESPRIT study was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States and Canada that enrolled 2064 patients undergoing elective or urgent PCI with intended intracoronary stent placement. Exclusion criteria included MI within the previous 24 hours, ongoing chest pain, administration of any oral antiplatelet or oral anticoagulant other than aspirin within 30 days of PCI (although loading doses of thienopyridine on the day of PCI were encouraged), planned PCI of a saphenous vein graft or subsequent \u201cstaged\u201d PCI, prior stent placement in the target lesion, PCI within the previous 90 days, a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 93 (mean 62) years, and 73% of patients were male. The study enrolled 90% Caucasian, 5% African American, 2% Hispanic, and 1% Asian patients. Patients received a wide variety of stents. Patients were randomized either to placebo or eptifibatide administered as an intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2 mcg/kg/min, and a second bolus of 180 mcg/kg administered 10 minutes later (180/2/180). Eptifibatide infusion was continued for 18 to 24 hours after PCI or until hospital discharge, whichever came first. Each patient received at least 1 dose of aspirin (162 to 325 mg) and 60 units/kg of heparin as a bolus (not to exceed 6,000 units) if not already receiving a heparin infusion. Additional boluses of heparin (10 to 40 units/kg) could be administered in order to reach a target ACT between 200 and 300 seconds. The primary endpoint of the ESPRIT study was the composite of death, MI, urgent target vessel revascularization (UTVR), and \u201cbailout\u201d to open-label eptifibatide due to a thrombotic complication of PCI (TBO) (e.g., visible thrombus, \u201cno reflow,\u201d or abrupt closure) at 48 hours. MI, UTVR, and TBO were evaluated by a blinded Clinical Events Committee. As shown in Table 8 , the incidence of the primary endpoint and selected secondary endpoints was significantly reduced in patients who received eptifibatide. A treatment benefit in patients who received eptifibatide was seen by 48 hours and at the end of the 30-day observation period. Table 8: Clinical Events in the ESPRIT Study * Eptifibatide was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min. Placebo Eptifibatide* Relative Risk p-value (n=1024) (n=1040) (95% CI) Death, MI, UTVR, or Thrombotic \u201cBailout\u201d 48 hours (primary endpoint) 108 (10.5%) 69 (6.6%) 0.629 (0.471, 0.84) 0.0015 30 days 120 (11.7%) 78 (7.5%) 0.64 (0.488, 0.84) 0.0011 Death, MI, or UTVR 48 hours 95 (9.3%) 62 (6%) 0.643 (0.472, 0.875) 0.0045 30 days (key secondary endpoint) 107 (10.4%) 71 (6.8%) 0.653 (0.49, 0.871) 0.0034 Death or MI 48 hours 94 (9.2%) 57 (5.5%) 0.597 (0.435, 0.82) 0.0013 30 days 104 (10.2%) 66 (6.3%) 0.625 (0.465, 0.84) 0.0016 The need for thrombotic \u201cbailout\u201d was significantly reduced with eptifibatide at 48 hours (2.1% for placebo, 1% for eptifibatide; p=0.029). Consistent with previous studies of GP IIb/IIIa inhibitors, most of the benefit achieved acutely with eptifibatide was in the reduction of MI. Eptifibatide reduced the occurrence of MI at 48 hours from 9% for placebo to 5.4% (p=0.0015) and maintained that effect with significance at 30 days. There was no treatment difference with respect to sex in ESPRIT. Eptifibatide reduced the incidence of the primary endpoint in both men (95% confidence limits for relative risk: 0.54, 1.07) and women (0.24, 0.72) at 48 hours. Follow-up (12-month) mortality data were available for 2024 patients (1017 on eptifibatide) enrolled in the ESPRIT trial (98.1% of the initial enrollment). Twelve-month clinical event data were available for 1964 patients (988 on eptifibatide), representing 95.2% of the initial enrollment. As shown in Table 9 , the treatment effect of eptifibatide seen at 48 hours and 30 days appeared preserved at 6 months and 1 year. Most of the benefit was in reduction of MI. Table 9: Clinical Events at 6 Months and 1 Year in the ESPRIT Study Percentages are Kaplan-Meier event rates. Placebo Eptifibatide Hazard Ratio (n=1024) (n=1040) (95% CI) Death, MI, or Target Vessel Revascularization 6 months 187 (18.5%) 146 (14.3%) 0.744 (0.599, 0.924) 1 year 222 (22.1%) 178 (17.5%) 0.762 (0.626, 0.929) Death, MI 6 months 117 (11.5%) 77 (7.4%) 0.631 (0.473, 0.841) 1 year 126 (12.4%) 83 (8%) 0.63 (0.478, 0.832)"
    ],
    "clinical_studies_table": [
      "<table ID=\"t5\" width=\"100%\"><caption>Table 5: Clinical Events in the PURSUIT Study </caption><col width=\"29.050%\" align=\"left\"/><col width=\"24.750%\" align=\"left\"/><col width=\"24.750%\" align=\"left\"/><col width=\"21.450%\" align=\"left\"/><tbody><tr><td align=\"center\" valign=\"bottom\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Death or MI</content></td><td align=\"center\" valign=\"bottom\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(n=4739)</content> <content styleCode=\"bold\">n (%)</content></td><td align=\"center\" valign=\"bottom\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(180 mcg/kg bolus then</content> <content styleCode=\"bold\">2 mcg/kg/min infusion) (n=4722)</content> <content styleCode=\"bold\">n (%)</content></td><td align=\"center\" valign=\"bottom\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">p-value</content></td></tr><tr><td align=\"justify\" valign=\"top\">3 days </td><td align=\"center\" valign=\"top\">359 (7.6%) </td><td align=\"center\" valign=\"top\">279 (5.9%) </td><td align=\"center\" valign=\"top\">0.001 </td></tr><tr><td align=\"justify\" valign=\"middle\">7 days </td><td align=\"center\" valign=\"middle\">552 (11.6%) </td><td align=\"center\" valign=\"middle\">477 (10.1%) </td><td align=\"center\" valign=\"middle\">0.016 </td></tr><tr><td align=\"justify\" valign=\"top\">30 days </td><td align=\"justify\" valign=\"top\"/><td align=\"justify\" valign=\"top\"/><td align=\"justify\" valign=\"middle\"/></tr><tr><td align=\"justify\" valign=\"middle\"> Death or MI (primary endpoint) </td><td align=\"center\" valign=\"middle\">745 (15.7%) </td><td align=\"center\" valign=\"middle\">672 (14.2%) </td><td align=\"center\" valign=\"middle\">0.042 </td></tr><tr><td align=\"justify\" valign=\"middle\"> Death </td><td align=\"center\" valign=\"middle\">177 (3.7%) </td><td align=\"center\" valign=\"middle\">165 (3.5%) </td><td align=\"center\" valign=\"top\"/></tr><tr><td align=\"justify\" valign=\"middle\" styleCode=\"Botrule\"> Nonfatal MI </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">568 (12%) </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">507 (10.7%) </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"/></tr></tbody></table>",
      "<table ID=\"t6\" width=\"100%\"><caption>Table 6: Clinical Events (Death or MI) in the PURSUIT Study Within 72 Hours of Randomization </caption><col width=\"33.333%\" align=\"left\"/><col width=\"15.633%\" align=\"left\"/><col width=\"51.033%\" align=\"left\"/><tbody><tr><td align=\"justify\" valign=\"bottom\" styleCode=\"Toprule Botrule\"/><td align=\"center\" valign=\"bottom\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Placebo</content></td><td align=\"center\" valign=\"bottom\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(180 mcg/kg bolus</content> <content styleCode=\"bold\">then 2 mcg/kg/min</content> <content styleCode=\"bold\">infusion)</content></td></tr><tr><td align=\"justify\" valign=\"middle\">Overall patient population </td><td align=\"center\" valign=\"middle\">n=4739 </td><td align=\"center\" valign=\"middle\">n=4722 </td></tr><tr><td align=\"left\" valign=\"middle\"> &#x2013; At 72 hours </td><td align=\"center\" valign=\"middle\">7.6% </td><td align=\"center\" valign=\"middle\">5.9% </td></tr><tr><td align=\"left\" valign=\"middle\">Patients undergoing early PCI </td><td align=\"center\" valign=\"middle\">n=631 </td><td align=\"center\" valign=\"middle\">n=619 </td></tr><tr><td align=\"left\" valign=\"bottom\"> &#x2013; Pre-procedure (nonfatal MI only) </td><td align=\"center\" valign=\"bottom\">5.5% </td><td align=\"center\" valign=\"bottom\">1.8% </td></tr><tr><td align=\"left\" valign=\"bottom\"> &#x2013; At 72 hours </td><td align=\"center\" valign=\"bottom\">14.4% </td><td align=\"center\" valign=\"bottom\">9% </td></tr><tr><td align=\"left\" valign=\"bottom\">Patients not undergoing early PCI </td><td align=\"center\" valign=\"bottom\">n=4108 </td><td align=\"center\" valign=\"bottom\">n=4103 </td></tr><tr><td align=\"left\" valign=\"bottom\" styleCode=\"Botrule\"> &#x2013; At 72 hours </td><td align=\"center\" valign=\"bottom\" styleCode=\"Botrule\">6.5% </td><td align=\"center\" valign=\"bottom\" styleCode=\"Botrule\">5.4% </td></tr></tbody></table>",
      "<table ID=\"t7\" width=\"100%\"><caption>Table 7: Clinical Events in the IMPACT II Study </caption><col width=\"29.725%\" align=\"left\"/><col width=\"23.975%\" align=\"left\"/><col width=\"23.975%\" align=\"left\"/><col width=\"22.325%\" align=\"left\"/><tfoot><tr><td colspan=\"4\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\">* Kaplan-Meier estimate of event rate. </paragraph></td></tr></tfoot><tbody><tr><td align=\"justify\" valign=\"top\" styleCode=\"Toprule Botrule\"/><td align=\"center\" valign=\"bottom\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">n (%)</content></td><td align=\"center\" valign=\"bottom\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(135 mcg/kg</content> <content styleCode=\"bold\">bolus then</content> <content styleCode=\"bold\">0.5 mcg/kg/min</content> <content styleCode=\"bold\">infusion)</content> <content styleCode=\"bold\">n (%)</content></td><td align=\"center\" valign=\"bottom\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(135 mcg/kg</content> <content styleCode=\"bold\">bolus then</content> <content styleCode=\"bold\">0.75 mcg/kg/min</content> <content styleCode=\"bold\">infusion)</content> <content styleCode=\"bold\">n (%)</content></td></tr><tr><td align=\"justify\" valign=\"middle\">Patients </td><td align=\"center\" valign=\"middle\">1285 </td><td align=\"center\" valign=\"middle\">1300 </td><td align=\"center\" valign=\"middle\">1286 </td></tr><tr><td align=\"justify\" valign=\"middle\">Abrupt Closure </td><td align=\"center\" valign=\"middle\">65 (5.1%) </td><td align=\"center\" valign=\"middle\">36 (2.8%) </td><td align=\"center\" valign=\"middle\">43 (3.3%) </td></tr><tr><td align=\"justify\" valign=\"top\"> p-value versus placebo </td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\">0.003 </td><td align=\"center\" valign=\"top\">0.03 </td></tr><tr><td align=\"justify\" valign=\"middle\">Death, MI, or Urgent Intervention </td><td colspan=\"3\" align=\"center\" valign=\"top\"/></tr><tr><td align=\"justify\" valign=\"middle\"> 24 hours </td><td align=\"center\" valign=\"middle\">123 (9.6%) </td><td align=\"center\" valign=\"middle\">86 (6.6%) </td><td align=\"center\" valign=\"middle\">89 (6.9%) </td></tr><tr><td align=\"justify\" valign=\"middle\"> p-value versus placebo </td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"middle\">0.006 </td><td align=\"center\" valign=\"middle\">0.014 </td></tr><tr><td align=\"justify\" valign=\"middle\"> 48 hours </td><td align=\"center\" valign=\"middle\">131 (10.2%) </td><td align=\"center\" valign=\"middle\">99 (7.6%) </td><td align=\"center\" valign=\"middle\">102 (7.9%) </td></tr><tr><td align=\"justify\" valign=\"middle\"> p-value versus placebo </td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"middle\">0.021 </td><td align=\"center\" valign=\"middle\">0.045 </td></tr><tr><td align=\"justify\" valign=\"middle\"> 30 days (primary endpoint) </td><td align=\"center\" valign=\"middle\">149 (11.6%) </td><td align=\"center\" valign=\"middle\">118 (9.1%) </td><td align=\"center\" valign=\"middle\">128 (10%) </td></tr><tr><td align=\"justify\" valign=\"middle\"> p-value versus placebo </td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"middle\">0.035 </td><td align=\"center\" valign=\"middle\">0.179 </td></tr><tr><td align=\"justify\" valign=\"middle\">Death or MI </td><td colspan=\"2\" align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/></tr><tr><td align=\"justify\" valign=\"middle\"> 30 days </td><td align=\"center\" valign=\"middle\">110 (8.6%) </td><td align=\"center\" valign=\"middle\">89 (6.8%) </td><td align=\"center\" valign=\"middle\">95 (7.4%) </td></tr><tr><td align=\"justify\" valign=\"middle\"> p-value versus placebo </td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"middle\">0.102 </td><td align=\"center\" valign=\"middle\">0.272 </td></tr><tr><td align=\"justify\" valign=\"middle\"> 6 months </td><td align=\"center\" valign=\"middle\">151 (11.9%)* </td><td align=\"center\" valign=\"middle\">136 (10.6%)* </td><td align=\"center\" valign=\"middle\">130 (10.3%)* </td></tr><tr><td align=\"justify\" valign=\"middle\" styleCode=\"Botrule\"> p-value versus placebo </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">0.297 </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">0.182 </td></tr></tbody></table>",
      "<table ID=\"t8\" width=\"100%\"><caption>Table 8: Clinical Events in the ESPRIT Study </caption><col width=\"35.613%\" align=\"left\"/><col width=\"16.497%\" align=\"left\"/><col width=\"16.497%\" align=\"left\"/><col width=\"18.136%\" align=\"left\"/><col width=\"13.257%\" align=\"left\"/><tfoot><tr><td colspan=\"5\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\"><content styleCode=\"bold\">*</content> Eptifibatide was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min. </paragraph></td></tr></tfoot><tbody><tr><td align=\"justify\" valign=\"top\" styleCode=\"Toprule\"/><td align=\"center\" valign=\"bottom\" styleCode=\"Toprule\"><content styleCode=\"bold\">Placebo</content></td><td align=\"center\" valign=\"bottom\" styleCode=\"Toprule\"><content styleCode=\"bold\">Eptifibatide*</content></td><td align=\"center\" valign=\"bottom\" styleCode=\"Toprule\"><content styleCode=\"bold\">Relative Risk</content></td><td rowspan=\"2\" align=\"center\" valign=\"bottom\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">p-value</content></td></tr><tr><td align=\"justify\" valign=\"bottom\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"bottom\" styleCode=\"Botrule\"><content styleCode=\"bold\">(n=1024)</content></td><td align=\"center\" valign=\"bottom\" styleCode=\"Botrule\"><content styleCode=\"bold\">(n=1040)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\"><content styleCode=\"bold\">(95% CI)</content></td></tr><tr><td align=\"justify\" valign=\"middle\">Death, MI, UTVR, or Thrombotic &#x201C;Bailout&#x201D; </td><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\"/></tr><tr><td align=\"justify\" valign=\"middle\">48 hours (primary endpoint) </td><td align=\"center\" valign=\"middle\">108 (10.5%) </td><td align=\"center\" valign=\"middle\">69 (6.6%) </td><td align=\"center\" valign=\"middle\">0.629 (0.471, 0.84) </td><td align=\"center\" valign=\"middle\">0.0015 </td></tr><tr><td align=\"justify\" valign=\"top\">30 days </td><td align=\"center\" valign=\"top\">120 (11.7%) </td><td align=\"center\" valign=\"top\">78 (7.5%) </td><td align=\"center\" valign=\"top\">0.64 (0.488, 0.84) </td><td align=\"center\" valign=\"top\">0.0011 </td></tr><tr><td align=\"justify\" valign=\"top\">Death, MI, or UTVR </td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/></tr><tr><td align=\"justify\" valign=\"top\">48 hours </td><td align=\"center\" valign=\"top\">95 (9.3%) </td><td align=\"center\" valign=\"top\">62 (6%) </td><td align=\"center\" valign=\"top\">0.643 (0.472, 0.875) </td><td align=\"center\" valign=\"top\">0.0045 </td></tr><tr><td align=\"justify\" valign=\"top\">30 days (key secondary endpoint) </td><td align=\"center\" valign=\"top\">107 (10.4%) </td><td align=\"center\" valign=\"top\">71 (6.8%) </td><td align=\"center\" valign=\"top\">0.653 (0.49, 0.871) </td><td align=\"center\" valign=\"top\">0.0034 </td></tr><tr><td align=\"justify\" valign=\"middle\">Death or MI </td><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\"/></tr><tr><td align=\"justify\" valign=\"middle\">48 hours </td><td align=\"center\" valign=\"middle\">94 (9.2%) </td><td align=\"center\" valign=\"middle\">57 (5.5%) </td><td align=\"center\" valign=\"middle\">0.597 (0.435, 0.82) </td><td align=\"center\" valign=\"middle\">0.0013 </td></tr><tr><td align=\"justify\" valign=\"top\" styleCode=\"Botrule\">30 days </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">104 (10.2%) </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">66 (6.3%) </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">0.625 (0.465, 0.84) </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">0.0016 </td></tr></tbody></table>",
      "<table ID=\"t9\" width=\"100%\"><caption>Table 9: Clinical Events at 6 Months and 1 Year in the ESPRIT Study </caption><col width=\"37.300%\" align=\"left\"/><col width=\"19.800%\" align=\"left\"/><col width=\"21.450%\" align=\"left\"/><col width=\"21.450%\" align=\"left\"/><tfoot><tr><td colspan=\"4\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\">Percentages are Kaplan-Meier event rates. </paragraph></td></tr></tfoot><tbody><tr><td align=\"justify\" valign=\"top\" styleCode=\"Toprule\"/><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">Placebo</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">Eptifibatide</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule\"><content styleCode=\"bold\">Hazard Ratio</content></td></tr><tr><td align=\"justify\" valign=\"middle\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\"><content styleCode=\"bold\">(n=1024)</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\"><content styleCode=\"bold\">(n=1040)</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\"><content styleCode=\"bold\">(95% CI)</content></td></tr><tr><td align=\"left\" valign=\"top\">Death, MI, or Target Vessel Revascularization </td><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/><td align=\"center\" valign=\"top\"/></tr><tr><td align=\"justify\" valign=\"top\"> 6 months </td><td align=\"center\" valign=\"top\">187 (18.5%) </td><td align=\"center\" valign=\"top\">146 (14.3%) </td><td align=\"center\" valign=\"top\">0.744 (0.599, 0.924) </td></tr><tr><td align=\"justify\" valign=\"top\"> 1 year </td><td align=\"center\" valign=\"top\">222 (22.1%) </td><td align=\"center\" valign=\"top\">178 (17.5%) </td><td align=\"center\" valign=\"top\">0.762 (0.626, 0.929) </td></tr><tr><td align=\"left\" valign=\"middle\">Death, MI </td><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\"/></tr><tr><td align=\"justify\" valign=\"middle\"> 6 months </td><td align=\"center\" valign=\"middle\">117 (11.5%) </td><td align=\"center\" valign=\"middle\">77 (7.4%) </td><td align=\"center\" valign=\"middle\">0.631 (0.473, 0.841) </td></tr><tr><td align=\"justify\" valign=\"top\" styleCode=\"Botrule\"> 1 year </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">126 (12.4%) </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">83 (8%) </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule\">0.63 (0.478, 0.832) </td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Eptifibatide Injection is supplied as follows: NDC Eptifibatide Injection (0.75 mg per mL) Package Factor 25021-408-51 75 mg per 100 mL Single-Dose Vial 1 vial per carton NDC Eptifibatide Injection (2 mg per mL) Package Factor 25021-409-10 20 mg per 10 mL Single-Dose Vial 1 vial per carton 25021-409-51 200 mg per 100 mL Single-Dose Vial 1 vial per carton 16.2 Storage Store refrigerated between 2\u00b0 and 8\u00b0C (36\u00b0 and 46\u00b0F). May be transferred to room temperature storage* for a period not to exceed 2 months. Upon transfer, vial cartons must be marked by the dispensing pharmacist with a \"DISCARD BY\" date (2 months from the transfer date or the labeled expiration date, whichever comes first). *Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0 and 30\u00b0C (59\u00b0 and 86\u00b0F) [see USP Controlled Room Temperature.] Protect from light. Retain in carton until time of use. Discard unused portion. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex."
    ],
    "how_supplied_table": [
      "<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"24.667%\" align=\"left\"/><col width=\"42.000%\" align=\"left\"/><col width=\"33.333%\" align=\"left\"/><tbody><tr><td align=\"justify\" valign=\"top\"><content styleCode=\"bold\">NDC</content></td><td align=\"justify\" valign=\"top\"><content styleCode=\"bold\">Eptifibatide Injection (0.75 mg per mL)</content></td><td align=\"justify\" valign=\"top\"><content styleCode=\"bold\">Package Factor</content></td></tr><tr><td align=\"justify\" valign=\"top\">25021-408-51 </td><td align=\"justify\" valign=\"top\">75 mg per 100 mL Single-Dose Vial </td><td align=\"justify\" valign=\"top\">1 vial per carton </td></tr><tr><td align=\"justify\" valign=\"top\"> </td><td align=\"justify\" valign=\"top\"/><td align=\"justify\" valign=\"top\"/></tr><tr><td align=\"justify\" valign=\"top\"><content styleCode=\"bold\">NDC</content></td><td align=\"justify\" valign=\"top\"><content styleCode=\"bold\">Eptifibatide Injection (2 mg per mL)</content></td><td align=\"justify\" valign=\"top\"><content styleCode=\"bold\">Package Factor</content></td></tr><tr><td align=\"justify\" valign=\"top\">25021-409-10 </td><td align=\"justify\" valign=\"top\">20 mg per 10 mL Single-Dose Vial </td><td align=\"justify\" valign=\"top\">1 vial per carton </td></tr><tr><td align=\"justify\" valign=\"top\">25021-409-51 </td><td align=\"justify\" valign=\"top\">200 mg per 100 mL Single-Dose Vial </td><td align=\"justify\" valign=\"top\">1 vial per carton </td></tr></tbody></table>"
    ],
    "storage_and_handling": [
      "16.2 Storage Store refrigerated between 2\u00b0 and 8\u00b0C (36\u00b0 and 46\u00b0F). May be transferred to room temperature storage* for a period not to exceed 2 months. Upon transfer, vial cartons must be marked by the dispensing pharmacist with a \"DISCARD BY\" date (2 months from the transfer date or the labeled expiration date, whichever comes first). *Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0 and 30\u00b0C (59\u00b0 and 86\u00b0F) [see USP Controlled Room Temperature.] Protect from light. Retain in carton until time of use. Discard unused portion. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to inform the doctor or healthcare provider about any medical conditions, medications, and allergies. INTEGRILIN is a registered trademark of Millennium Pharmaceuticals, Inc. SAGENT \u00ae Mfd. for SAGENT Pharmaceuticals Schaumburg, IL 60195 (USA) Made in India \u00a92021 Sagent Pharmaceuticals, Inc. Revised: March 2021 SAGENT Pharmaceuticals \u00ae"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL \u2013 PRINCIPAL DISPLAY PANEL \u2013 Vial Label NDC 25021-408-51 Rx only EPTIFIBATIDE INJECTION 75 mg per 100 mL (0.75 mg per mL) For Intravenous Use Only 100 mL Single-Dose Vial PACKAGE LABEL \u2013 PRINCIPAL DISPLAY PANEL \u2013 Vial Label",
      "PACKAGE LABEL \u2013 PRINCIPAL DISPLAY PANEL \u2013 Vial Label NDC 25021-409-10 Rx only EPTIFIBATIDE INJECTION 20 mg per 10 mL (2 mg per mL) For Intravenous Use Only 10 mL Single-Use Vial PACKAGE LABEL \u2013 PRINCIPAL DISPLAY PANEL \u2013 Vial Label"
    ],
    "set_id": "a0d18778-0194-461a-a4ea-b2fca5df57c3",
    "id": "7e4a3720-9c2e-4fb7-b703-f896f7fd0686",
    "effective_time": "20240815",
    "version": "6",
    "openfda": {
      "application_number": [
        "ANDA204693"
      ],
      "brand_name": [
        "eptifibatide"
      ],
      "generic_name": [
        "EPTIFIBATIDE"
      ],
      "manufacturer_name": [
        "Sagent Pharmaceuticals"
      ],
      "product_ndc": [
        "25021-408",
        "25021-409"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "INTRAVENOUS"
      ],
      "substance_name": [
        "EPTIFIBATIDE"
      ],
      "rxcui": [
        "200349",
        "1736470"
      ],
      "spl_id": [
        "7e4a3720-9c2e-4fb7-b703-f896f7fd0686"
      ],
      "spl_set_id": [
        "a0d18778-0194-461a-a4ea-b2fca5df57c3"
      ],
      "package_ndc": [
        "25021-408-51",
        "25021-409-10"
      ],
      "is_original_packager": [
        true
      ],
      "nui": [
        "N0000008832",
        "N0000175578"
      ],
      "pharm_class_pe": [
        "Decreased Platelet Aggregation [PE]"
      ],
      "pharm_class_epc": [
        "Platelet Aggregation Inhibitor [EPC]"
      ],
      "unii": [
        "NA8320J834"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Eptifibatide eptifibatide EPTIFIBATIDE EPTIFIBATIDE CITRIC ACID MONOHYDRATE SODIUM HYDROXIDE Eptifibatide eptifibatide EPTIFIBATIDE EPTIFIBATIDE CITRIC ACID MONOHYDRATE SODIUM HYDROXIDE Eptifibatide eptifibatide EPTIFIBATIDE EPTIFIBATIDE CITRIC ACID MONOHYDRATE SODIUM HYDROXIDE"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Eptifibatide injection is a platelet aggregation inhibitor indicated for: \u2022 Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI) ( 1.1 ) \u2022 Treatment of patients undergoing PCI (including intracoronary stenting) ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS (unstable angina [UA]/non-ST- elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). 1.2 Percutaneous Coronary Intervention (PCI) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting [see Clinical Studies (14.1 , 14.2) ] ."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION Before infusion of eptifibatide injection, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured. The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT. ACS or PCI: 180 mcg/kg IV bolus as soon as possible after diagnosis followed by infusion at 2 mcg/kg/min. ( 2.1 , 2.2 ) PCI: Add a second 180 mcg/kg bolus at 10 minutes. ( 2.2 ) In patients with creatinine clearance less than 50 mL/min, reduce the infusion to 1 mcg/kg/min. ( 2.1 , 2.2 , 2.3 ) 2.1 Dosage in Acute Coronary Syndrome (ACS) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with ACS 180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min 180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min \u2022 Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours \u2022 If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy \u2022 Aspirin, 160 mg to 325 mg, should be given daily Eptifibatide injection should be given concomitantly with heparin dosed to achieve the following parameters: During Medical Management : Target aPTT 50 to 70 seconds \u2022 If weight greater than or equal to 70 kg, 5000-unit bolus followed by infusion of 1000 units/h. \u2022 If weight less than 70 kg, 60-units/kg bolus followed by infusion of 12 units/kg/h. During PCI : Target ACT 200 to 300 seconds \u2022 If heparin is initiated prior to PCI, additional boluses during PCI to maintain an ACT target of 200 to 300 seconds. \u2022 Heparin infusion after the PCI is discouraged. 2.2 Dosage in Percutaneous Coronary Intervention (PCI) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with PCI 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) \u2022 Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. \u2022 In patients who undergo CABG surgery, eptifibatde infusion should be discontinued prior to surgery. \u2022 Aspirin, 160 mg to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter. \u2022 Eptifibatide injection should be given concomitantly with heparin to achieve a target ACT of 200 to 300 seconds. Administer 60-units/kg bolus initially in patients not treated with heparin within 6 hours prior to PCI. \u2022 Additional boluses during PCI to maintain ACT within target. \u2022 Heparin infusion after the PCI is strongly discouraged. Patients requiring thrombolytic therapy should discontinue eptifibatide injection. 2.3 Important Administration Instructions 1. Inspect eptifibatide injection for particulate matter and discoloration prior to administration, whenever solution and container permit. 2. May administer eptifibatide injection in the same intravenous line as alteplase, atropine, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, or verapamil. Do not administer eptifibatide injection through the same intravenous line as furosemide. 3. May administer eptifibatide injection in the same IV line with 0.9% NaCl or 0.9% NaCl/5% dextrose. With either vehicle, the infusion may also contain up to 60 mEq/L of potassium chloride. 4. Withdraw the bolus dose(s) of eptifibatide injection from the 10 mL vial into a syringe. Administer the bolus dose(s) by IV push. 5. Immediately following the bolus dose administration, initiate a continuous infusion of eptifibatide injection. When using an intravenous infusion pump, administer eptifibatide injection undiluted directly from the 100 mL vial. Spike the 100 mL vial with a vented infusion set. Center the spike within the circle on the stopper top. 6. Discard any unused portion left in the vial. Administer eptifibatide injection by volume according to patient weight (see Table 1). Table 1: Eptifibatide Injection Dosing Charts by Weight Patient Weight 180 mcg/kg Bolus Volume 2 mcg/kg/min Infusion Volume (CrCl greater than or equal to 50 mL/min) 1 mcg/kg/min Infusion Volume (CrCl less than 50 mL/min) (kg) (lb) (from 2 mg/mL vial) (from 2 mg/mL 100 mL vial) (from 0.75 mg/mL 100 mL vial) (from 2 mg/mL 100 mL vial) (from 0.75 mg/mL 100 mL vial) 37 to 41 81 to 91 3.4 mL 2 mL/h 6 mL/h 1 mL/h 3 mL/h 42 to 46 92 to 102 4 mL 2.5 mL/h 7 mL/h 1.3 mL/h 3.5 mL/h 47 to 53 103 to 117 4.5 mL 3 mL/h 8 mL/h 1.5 mL/h 4 mL/h 54 to 59 118 to 130 5 mL 3.5 mL/h 9 mL/h 1.8 mL/h 4.5 mL/h 60 to 65 131 to 143 5.6 mL 3.8 mL/h 10 mL/h 1.9 mL/h 5 mL/h 66 to 71 144 to 157 6.2 mL 4 mL/h 11 mL/h 2 mL/h 5.5 mL/h 72 to 78 158 to 172 6.8 mL 4.5 mL/h 12 mL/h 2.3 mL/h 6 mL/h 79 to 84 173 to 185 7.3 mL 5 mL/h 13 mL/h 2.5 mL/h 6.5 mL/h 85 to 90 186 to 198 7.9 mL 5.3 mL/h 14 mL/h 2.7 mL/h 7 mL/h 91 to 96 199 to 212 8.5 mL 5.6 mL/h 15 mL/h 2.8 mL/h 7.5 mL/h 97 to 103 213 to 227 9 mL 6 mL/h 16 mL/h 3.0 mL/h 8 mL/h 104 to 109 228 to 240 9.5 mL 6.4 mL/h 17 mL/h 3.2 mL/h 8.5 mL/h 110 to 115 241 to 253 10.2 mL 6.8 mL/h 18 mL/h 3.4 mL/h 9 mL/h 116 to 121 254 to 267 10.7 mL 7 mL/h 19 mL/h 3.5 mL/h 9.5 mL/h >121 >267 11.3 mL 7.5 mL/h 20 mL/h 3.7 mL/h 10 mL/h"
    ],
    "dosage_and_administration_table": [
      "<table width=\"100%\"><col width=\"17%\"/><col width=\"40%\"/><col width=\"43%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Indication</content></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Normal Renal Function</content></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Creatinine Clearance less than 50 mL/min</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Patients with</paragraph><paragraph>ACS</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>180 mcg/kg intravenous (IV) bolus </paragraph><paragraph>as soon as possible after diagnosis, followed by continuous infusion of </paragraph><paragraph>2 mcg/kg/min</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>180 mcg/kg IV bolus as soon</paragraph><paragraph>as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"/><td colspan=\"2\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours</item><item><caption>&#x2022;</caption>If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy</item><item><caption>&#x2022;</caption>Aspirin, 160 mg to 325 mg, should be given daily </item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"17%\"/><col width=\"40%\"/><col width=\"43%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Indication</content></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Normal Renal Function</content></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Creatinine Clearance less than 50 mL/min</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Patients with</paragraph><paragraph>PCI</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus)</paragraph></td><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule \" valign=\"top\"/><td colspan=\"2\" styleCode=\"Rrule Botrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended.</item><item><caption>&#x2022;</caption>In patients who undergo CABG surgery, eptifibatde infusion should be discontinued prior to surgery.</item><item><caption>&#x2022;</caption>Aspirin, 160 mg to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter.</item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"10%\"/><col width=\"10%\"/><col width=\"15%\"/><col width=\"17%\"/><col width=\"17%\"/><col width=\"15%\"/><col width=\"17%\"/><tbody><tr><td colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">Patient Weight </content></item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">180 mcg/kg Bolus Volume </content></item></list></td><td colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">2 mcg/kg/min Infusion Volume (CrCl greater than or equal to 50 mL/min) </content></item></list></td><td colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">1 mcg/kg/min Infusion Volume (CrCl less than 50 mL/min) </content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">(kg) </content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">(lb)</content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">(from 2 mg/mL vial) </content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">(from 2 mg/mL 100 mL vial) </content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">(from 0.75 mg/mL 100 mL vial)</content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">(from 2 mg/mL 100 mL vial) </content></item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">(from 0.75 mg/mL 100 mL vial)</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>37 to 41 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>81 to 91 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>3.4 mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>2 mL/h </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>6 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>1 mL/h </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>3 mL/h</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>42 to 46</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>92 to 102 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>4 mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>2.5 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>7 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>1.3 mL/h </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>3.5 mL/h</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>47 to 53 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>103 to 117 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>4.5 mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>3 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>8 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>1.5 mL/h </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>4 mL/h</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>54 to 59 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>118 to 130 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>5 mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>3.5 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>9 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>1.8 mL/h </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>4.5 mL/h</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>60 to 65 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>131 to 143 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>5.6 mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>3.8 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>10 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>1.9 mL/h </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>5 mL/h</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>66 to 71 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>144 to 157 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>6.2 mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>4 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>11 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>2 mL/h </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>5.5 mL/h</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>72 to 78 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>158 to 172 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>6.8 mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>4.5 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>12 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>2.3 mL/h </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>6 mL/h</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>79 to 84 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>173 to 185 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>7.3 mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>5 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>13 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>2.5 mL/h </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>6.5 mL/h</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>85 to 90 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>186 to 198 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>7.9 mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>5.3 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>14 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>2.7 mL/h </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>7 mL/h</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>91 to 96 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>199 to 212 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>8.5 mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>5.6 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>15 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>2.8 mL/h </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>7.5 mL/h</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>97 to 103 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>213 to 227 </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>9 mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>6 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>16 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>3.0 mL/h </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>8 mL/h</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>104 to 109</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>228 to 240</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>9.5 mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>6.4 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>17 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>3.2 mL/h </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>8.5 mL/h</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>110 to 115</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>241 to 253</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>10.2 mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>6.8 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>18 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>3.4 mL/h </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>9 mL/h</item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>116 to 121</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>254 to 267</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>10.7 mL</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>7 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>19 mL/h</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>3.5 mL/h </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>9.5 mL/h</item></list></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>&gt;121</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>&gt;267</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>11.3 mL</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>7.5 mL/h</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>20 mL/h</item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>3.7 mL/h </item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>10 mL/h</item></list></td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS \u2022 Injection: 20 mg of eptifibatide in 10 mL (2 mg/mL), for intravenous bolus. \u2022 Injection: 75 mg of eptifibatide in 100 mL (0.75 mg/mL), for intravenous infusion. \u2022 Injection: 200 mg of eptifibatide in 100 mL (2 mg/mL), for intravenous infusion. \u2022 20 mg/10 mL (2 mg/mL) in a single-dose vial for bolus injection ( 3 ) \u2022 75 mg/100 mL (0.75 mg/mL) in a single-dose vial for infusion ( 3 ) \u2022 200 mg/100 mL (2 mg/mL) in a single-dose vial for infusion ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Treatment with eptifibatide is contraindicated in patients with: \u2022 A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days \u2022 Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy \u2022 Major surgery within the preceding 6 weeks \u2022 History of stroke within 30 days or any history of hemorrhagic stroke \u2022 Current or planned administration of another parenteral GP IIb/IIIa inhibitor \u2022 Dependency on renal dialysis \u2022 Hypersensitivity to eptifibatide or any component of the product (hypersensitivity reactions that occurred included anaphylaxis and urticaria). \u2022 Bleeding diathesis or bleeding within the previous 30 days ( 4 ) \u2022 Severe uncontrolled hypertension ( 4 ) \u2022 Major surgery within the preceding 6 weeks ( 4 ) \u2022 Stroke within 30 days or any history of hemorrhagic stroke ( 4 ) \u2022 Coadministration of another parenteral GP IIb/IIIa inhibitor ( 4 ) \u2022 Dependency on renal dialysis ( 4 ) \u2022 Known hypersensitivity to any component of the product ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS \u2022 Eptifibatide can cause serious bleeding. If bleeding cannot be controlled, discontinue eptifibatide immediately. Minimize vascular and other traumas. If heparin is given concomitantly, monitor aPTT or ACT. ( 5.1 ) \u2022 Thrombocytopenia: Discontinue eptifibatide and heparin. Monitor and treat condition appropriately. ( 5.2 ) 5.1 Bleeding Bleeding is the most common complication encountered during eptifibatide therapy. Administration of eptifibatide is associated with an increase in major and minor bleeding, as classified by the criteria of the Thrombolysis in Myocardial Infarction Study group (TIMI) [see Adverse Reactions (6.1) ] . Most major bleeding associated with eptifibatide has been at the arterial access site for cardiac catheterization or from the gastrointestinal or genitourinary tract. Minimize the use of arterial and venous punctures, intramuscular injections, and the use of urinary catheters, nasotracheal intubation, and nasogastric tubes. When obtaining intravenous access, avoid non-compressible sites (e.g., subclavian or jugular veins). Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Risk factors for bleeding include older age, a history of bleeding disorders, and concomitant use of drugs that increase the risk of bleeding (thrombolytics, oral anticoagulants, nonsteroidal anti-inflammatory drugs, and P2Y 12 inhibitors). Concomitant treatment with other inhibitors of platelet receptor glycoprotein (GP) IIb/IIIa should be avoided. In patient treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT [see Dosage and Administration (2) ] . Care of the Femoral Artery Access Site in Patients Undergoing Percutaneous Coronary Intervention (PCI) In patients undergoing PCI, treatment with eptifibatide is associated with an increase in major and minor bleeding at the site of arterial sheath placement. After PCI, eptifibatide infusion should be continued until hospital discharge or up to 18 to 24 hours, whichever comes first. Heparin use is discouraged after the PCI procedure. Early sheath removal is encouraged while eptifibatide is being infused. Prior to removing the sheath, it is recommended that heparin be discontinued for 3 to 4 hours and an aPTT of <45 seconds or ACT <150 seconds be achieved. In any case, both heparin and eptifibatide should be discontinued and sheath hemostasis should be achieved at least 2 to 4 hours before hospital discharge. If bleeding at access site cannot be controlled with pressure, infusion of eptifibatide and heparin should be discontinued immediately. 5.2 Thrombocytopenia There have been reports of acute, profound thrombocytopenia (immune-mediated and non-immune mediated) with eptifibatide. In the event of acute profound thrombocytopenia or a confirmed platelet decrease to <100,000/mm 3 , discontinue eptifibatide and heparin (unfractionated or low-molecular weight). Monitor serial platelet counts, assess the presence of drug-dependent antibodies, and treat as appropriate [see Adverse Reactions (6.1) ] . There has been no clinical experience with eptifibatide initiated in patients with a baseline platelet count <100,000/mm 3 . If a patient with low platelet counts is receiving eptifibatide, their platelet count should be monitored closely."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reaction is also discussed elsewhere in the labeling: \u2022 Bleeding [see Contraindications (4) and Warnings and Precautions (5.1) ] Bleeding and hypotension are the most commonly reported adverse reactions. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. A total of 16,782 patients were treated in the Phase III clinical trials (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Eptifibatide Therapy (PURSUET), Enhanced Suppression of the Platelet IIb/IIIa Receptor with Eptifibatide Therapy (ESPRET), and Eptifibatide to Minimize Platelet Aggregation and Prevent Coronary Thrombosis II (EMPACT II)) [see Clinical Studies (14) ] . These 16,782 patients had a mean age of 62 years (range: 20 to 94 years). Eighty-nine percent of the patients were Caucasian, with the remainder being predominantly Black (5%) and Hispanic (5%). Sixty-eight percent were men. Because of the different regimens used in PURSUET, EMPACT II, and ESPRET, data from the 3 studies were not pooled. Bleeding and hypotension were the most commonly reported adverse reactions (incidence \u22655% and greater than placebo) in the eptifibatide controlled clinical trial database. Bleeding The incidence of bleeding and transfusions in the PURSUET and ESPRET studies are shown in Table 2. Bleeding was classified as major or minor by the criteria of the TIMI study group. Major bleeding consisted of intracranial hemorrhage and other bleeding that led to decreases in hemoglobin greater than 5 g/dL. Minor bleeding included spontaneous gross hematuria, spontaneous hematemesis, other observed blood loss with a hemoglobin decrease of more than 3 g/dL, and other hemoglobin decreases that were greater than 4 g/dL but less than 5 g/dL. In patients who received transfusions, the corresponding loss in hemoglobin was estimated through an adaptation of the method of Landefeld et al. Table 2: Bleeding and Transfusions in the PURSUET and ESPRET Studies PURSUET (ACS) Placebo n (%) Eptifibatide Injection 180/2 n (%) Patients 4696 4679 Major bleeding* Minor bleeding* Requiring transfusions \u2020 425 (9.3%) 347 (7.6%) 490 (10.4%) 498 (10.8%) 604 (13.1%) 601 (12.8%) ESPRET (PCI) Placebo n (%) Eptifibatide Injection 180/2/180 n (%) Patients 1024 1040 Major bleeding* Minor bleeding* Requiring transfusions \u2020 4 (0.4%) 18 (2%) 11 (1.1%) 13 (1.3%) 29 (3%) 16 (1.5%) Note: Denominator is based on patients for whom data are available. * For major and minor bleeding, patients are counted only once according to the most severe classification. \u2020 Includes transfusions of whole blood, packed red blood cells, fresh frozen plasma, cryoprecipitate, platelets, and autotransfusion during the initial hospitalization. The majority of major bleeding reactions in the ESPRET study occurred at the vascular access site (1 and 8 patients, or 0.1% and 0.8% in the placebo and eptifibatide groups, respectively). Bleeding at \u201cother\u201d locations occurred in 0.2% and 0.4% of patients, respectively. In the PURSUET study, the greatest increase in major bleeding in eptifibatide-treated patients compared to placebo-treated patients was also associated with bleeding at the femoral artery access site (2.8% versus 1.3%). Oropharyngeal (primarily gingival), genitourinary, gastrointestinal, and retroperitoneal bleeding were also seen more commonly in eptifibatide-treated patients compared to placebo-treated patients. Among patients experiencing a major bleed in the EMPACT II study, an increase in bleeding on eptifibatide versus placebo was observed only for the femoral artery access site (3.2% versus 2.8%). Table 3 displays the incidence of TIMI major bleeding according to the cardiac procedures carried out in the PURSUET study. The most common bleeding complications were related to cardiac revascularization (CABG-related or femoral artery access site bleeding). A corresponding table for ESPRET is not presented, as every patient underwent PCI in the ESPRET study and only 11 patients underwent CABG. Table 3: Major Bleeding by Procedures in the PURSUET Study Placebo n (%) Eptifibatide 180/2 n (%) Patients 4577 4604 Overall incidence of major bleeding 425 (9.3%) 498 (10.8%) Breakdown by procedure: CABG 375 (8.2%) 377 (8.2%) Angioplasty without CABG 27 (0.6%) 64 (1.4%) Angiography without angioplasty or CABG 11 (0.2%) 29 (0.6%) Medical therapy only 12 (0.3%) 28 (0.6%) Note: Denominators are based on the total number of patients whose TIMI classification was resolved. In the PURSUET and ESPRET studies, the risk of major bleeding with eptifibatide increased as patient weight decreased. This relationship was most apparent for patients weighing less than 70 kg. Bleeding resulting in discontinuation of the study drug was more frequent among patients receiving eptifibatide than placebo (4.6% versus 0.9% in ESPRET, 8% versus 1% in PURSUET, 3.5% versus 1.9% in EMPACT II). Intracranial Hemorrhage and Stroke Intracranial hemorrhage was rare in the PURSUET, EMPACT II, and ESPRET clinical studies. In the PURSUET study, 3 patients in the placebo group, 1 patient in the group treated with eptifibatide 180/1.3, and 5 patients in the group treated with eptifibatide 180/2 experienced a hemorrhagic stroke. The overall incidence of stroke was 0.5% in patients receiving eptifibatide 180/1.3, 0.7% in patients receiving eptifibatide 180/2, and 0.8% in placebo patients. In the EMPACT II study, intracranial hemorrhage was experienced by 1 patient treated with eptifibatide 135/0.5, 2 patients treated with eptifibatide 135/0.75, and 2 patients in the placebo group. The overall incidence of stroke was 0.5% in patients receiving 135/0.5 eptifibatide, 0.7% in patients receiving eptifibatide 135/0.75, and 0.7% in the placebo group. In the ESPRET study, there were 3 hemorrhagic strokes, 1 in the placebo group and 2 in the eptifibatide group. In addition there was 1 case of cerebral infarction in the eptifibatide group. Immunogenicity/Thrombocytopenia The potential for development of antibodies to eptifibatide has been studied in 433 subjects. Eptifibatide was nonantigenic in 412 patients receiving a single administration of eptifibatide (135 mcg/kg bolus followed by a continuous infusion of either 0.5 mcg/kg/min or 0.75 mcg/kg/min), and in 21 subjects to whom eptifibatide (135 mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min) was administered twice, 28 days apart. In both cases, plasma for antibody detection was collected approximately 30 days after each dose. The development of antibodies to eptifibatide at higher doses has not been evaluated. In patients with suspected eptifibatide-related immune-mediated thrombocytopenia, IgG antibodies that react with the GP IIb/IIIa complex were identified in the presence of eptifibatide and in eptifibatide injection-na\u00efve patients. These findings suggest acute thrombocytopenia after the administration of eptifibatide can develop as a result of naturally occurring drug-dependent antibodies or those induced by prior exposure to eptifibatide. Similar antibodies were identified with other GP IIb/IIIa ligand-mimetic agents. Immune-mediated thrombocytopenia with eptifibatide may be associated with hypotension and/or other signs of hypersensitivity. In the PURSUET and EMPACT II studies, the incidence of thrombocytopenia (<100,000/mm 3 or \u226550% reduction from baseline) and the incidence of platelet transfusions were similar between patients treated with eptifibatide and placebo. In the ESPRET study, the incidence was 0.6% in the placebo group and 1.2% in the eptifibatide group. Other Adverse Reactions In the PURSUET and ESPRET studies, the incidence of serious nonbleeding adverse reactions was similar in patients receiving placebo or eptifibatide (19% and 19%, respectively, in PURSUET; 6% and 7%, respectively, in ESPRET). In PURSUET, the only serious nonbleeding adverse reaction that occurred at a rate of at least 1% and was more common with eptifibatide than placebo (7% versus 6%) was hypotension. Most of the serious nonbleeding adverse reactions consisted of cardiovascular reactions typical of a UA population. In the EMPACT II study, serious nonbleeding adverse reactions that occurred in greater than 1% of patients were uncommon and similar in incidence between placebo- and eptifibatide-treated patients. Discontinuation of study drug due to adverse reactions other than bleeding was uncommon in the PURSUET, EMPACT II, and ESPRIT studies, with no single reaction occurring in >0.5% of the study population (except for \u201cother\u201d in the ESPRET study). 6.2 Postmarketing Experience The following adverse reactions have been reported in post-approval use of eptifibatide in combination with heparin and aspirin. Because the reactions below are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure: cerebral, GI, and pulmonary hemorrhage. Fatal bleeding reactions have been reported. Acute profound thrombocytopenia, as well as immune-mediated thrombocytopenia, have been reported [see Adverse Reactions (6.1) ] ."
    ],
    "adverse_reactions_table": [
      "<table width=\"100%\"><col width=\"35%\"/><col width=\"35%\"/><col width=\"30%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">PURSUET (ACS)</content></paragraph><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Eptifibatide Injection </content></paragraph><paragraph><content styleCode=\"bold\">180/2</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>Patients</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4696</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>4679</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Major bleeding*</paragraph><paragraph>Minor bleeding*</paragraph><paragraph>Requiring transfusions<sup>&#x2020;</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>425 (9.3%)</paragraph><paragraph>347 (7.6%)</paragraph><paragraph>490 (10.4%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>498 (10.8%)</paragraph><paragraph> 604 (13.1%) </paragraph><paragraph>601 (12.8%)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">ESPRET (PCI) </content></paragraph><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\"> n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Eptifibatide Injection </content></paragraph><paragraph><content styleCode=\"bold\">180/2/180</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph>Patients</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>1024</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"><paragraph>1040</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph>Major bleeding*</paragraph><paragraph>Minor bleeding*</paragraph><paragraph>Requiring transfusions<sup>&#x2020;</sup></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>4 (0.4%)</paragraph><paragraph>18 (2%)</paragraph><paragraph>11 (1.1%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>13 (1.3%)</paragraph><paragraph>29 (3%)</paragraph><paragraph>16 (1.5%)</paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"57%\"/><col width=\"25%\"/><col width=\"17%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide </content></paragraph><paragraph><content styleCode=\"bold\">180/2</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Patients </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>4577</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>4604</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Overall incidence of major bleeding </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>425 (9.3%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>498 (10.8%)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Breakdown by procedure:</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>CABG </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>375 (8.2%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>377 (8.2%)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Angioplasty without CABG </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>27 (0.6%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>64 (1.4%)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Angiography without angioplasty or CABG </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>11 (0.2%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>29 (0.6%)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph>Medical therapy only </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph>12 (0.3%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><paragraph>28 (0.6%)</paragraph></td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS \u2022 Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Avoid concomitant use with other glycoprotein (GP) IIb/IIIa inhibitors. ( 7.1 ) 7.1 Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Concomitant treatment with other inhibitors of platelet receptor GP IIb/IIIa should be avoided."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS \u2022 Geriatric Use: Risk of bleeding increases with age. ( 8.5 ) 8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus (see Clinical Considerations) . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide on the fetus. Data Animal Data Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide. 8.2 Lactation Risk Summary There are no available data on the presence of eptifibatide in human milk, the effects on the breastfed infant, or the effects on milk production. As eptifibatide is a peptide, it is likely to be destroyed in the infant\u2019s gastrointestinal tract and not absorbed orally by the breastfed infant. 8.4 Pediatric Use Safety and effectiveness of eptifibatide in pediatric patients have not been studied. 8.5 Geriatric Use The PURSUET and EMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUET study; no such limitation was stipulated in the ESPRET study [see Adverse Reactions (6.1) ]. 8.6 Renal Impairment Approximately 50% of eptifibatide is cleared by the kidney in patients with normal renal function. Total drug clearance is decreased by approximately 50% and steady-state plasma eptifibatide concentrations are doubled in patients with an estimated CrCl <50 mL/min (using the Cockcroft-Gault equation). Therefore, the infusion dose should be reduced to 1 mcg/kg/min in such patients [see Dosage and Administration (2) ] . The safety and efficacy of eptifibatide in patients dependent on dialysis has not been established."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus (see Clinical Considerations) . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide on the fetus. Data Animal Data Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety and effectiveness of eptifibatide in pediatric patients have not been studied."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use The PURSUET and EMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUET study; no such limitation was stipulated in the ESPRET study [see Adverse Reactions (6.1) ]."
    ],
    "overdosage": [
      "10 OVERDOSAGE There has been only limited experience with overdosage of eptifibatide. There were 8 patients in the EMPACT II study, 9 patients in the PURSUET study, and no patients in the ESPRET study who received bolus doses and/or infusion doses more than double those called for in the protocols. None of these patients experienced an intracranial bleed or other major bleeding. Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis). Symptoms of acute toxicity were loss of righting reflex, dyspnea, ptosis, and decreased muscle tone in rabbits and petechial hemorrhages in the femoral and abdominal areas of monkeys. From in vitro studies, eptifibatide is not extensively bound to plasma proteins and thus may be cleared from plasma by dialysis."
    ],
    "description": [
      "11 DESCRIPTION Eptifibatide is a cyclic heptapeptide containing 6 amino acids and 1 mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties. Chemically it is N 6 -(aminoiminomethyl)-N 2 -(3-mercapto-1-oxopropyl)-L\u2011lysylglycyl-L-\u03b1-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1\u21926)-disulfide. Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation. The eptifibatide peptide is produced by solution-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized. The structural formula is: Eptifibatide Injection is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use with an empirical formula of C 35 H 49 N 11 O 9 S 2 and molecular weight of 832. Each 10 mL vial contains 2 mg/mL of eptifibatide injection and each 100 mL vial contains either 0.75 mg/mL of eptifibatide injection or 2 mg/mL of eptifibatide injection. Each vial of either size also contains 5.25 mg/mL citric acid and sodium hydroxide to adjust the pH to 5.35. Figure 1"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet. 12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide was observed immediately after administration of a 180 mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide used in the EMPACT II and PURSUET studies on ex vivo platelet aggregation induced by 20 micromolar ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRET on platelet aggregation have not been studied. Table 4: Platelet Inhibition and Bleeding Time PURSUET 180/2* Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x *180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. The eptifibatide dosing regimen used in the ESPRET study included two 180 mcg/kg bolus doses given 10 minutes apart combined with a continuous 2 mcg/kg/min infusion. When administered alone, eptifibatide has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed. 12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180 mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4 to 6 hours). This decline can be prevented by administering a second 180 mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20 to 94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations (8.6) and Dosage and Administration (2) ] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "clinical_pharmacology_table": [
      "<table width=\"100%\"><col width=\"73%\"/><col width=\"27%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">PURSUET </content></paragraph><paragraph><content styleCode=\"bold\">180/2*</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Inhibition of platelet aggregation 15 min after bolus </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>84%</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Inhibition of platelet aggregation at steady state</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&gt;90%</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Bleeding-time prolongation at steady state</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&lt;5x</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Inhibition of platelet aggregation 4h after infusion discontinuation</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&lt;50%</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Bleeding-time prolongation 6h after infusion discontinuation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>1.4x</paragraph></td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide was observed immediately after administration of a 180 mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide used in the EMPACT II and PURSUET studies on ex vivo platelet aggregation induced by 20 micromolar ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRET on platelet aggregation have not been studied. Table 4: Platelet Inhibition and Bleeding Time PURSUET 180/2* Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x *180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. The eptifibatide dosing regimen used in the ESPRET study included two 180 mcg/kg bolus doses given 10 minutes apart combined with a continuous 2 mcg/kg/min infusion. When administered alone, eptifibatide has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed."
    ],
    "pharmacodynamics_table": [
      "<table width=\"100%\"><col width=\"73%\"/><col width=\"27%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">PURSUET </content></paragraph><paragraph><content styleCode=\"bold\">180/2*</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Inhibition of platelet aggregation 15 min after bolus </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>84%</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Inhibition of platelet aggregation at steady state</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&gt;90%</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Bleeding-time prolongation at steady state</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&lt;5x</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Inhibition of platelet aggregation 4h after infusion discontinuation</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&lt;50%</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Bleeding-time prolongation 6h after infusion discontinuation </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>1.4x</paragraph></td></tr></tbody></table>"
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180 mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4 to 6 hours). This decline can be prevented by administering a second 180 mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20 to 94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations (8.6) and Dosage and Administration (2) ] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Eptifibatide was studied in 3 placebo-controlled, randomized studies. PURSUET evaluated patients with acute coronary syndromes: UA or NSTEMI. Two other studies, ESPRET and EMPACT II, evaluated patients about to undergo a PCI. Patients underwent primarily balloon angioplasty in EMPACT II and intracoronary stent placement, with or without angioplasty, in ESPRET. 14.1 Non-ST-Segment Elevation Acute Coronary Syndrome Non-ST-segment elevation acute coronary syndrome is defined as prolonged (\u226510 minutes) symptoms of cardiac ischemia within the previous 24 hours associated with either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or positive CK-MB. This definition includes \"unstable angina\" and \"NSTEMI\" but excludes MI that is associated with Q waves or greater degrees of ST-segment elevation. PURSUET (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Eptifibatide Therapy) PURSUET was a 726-center, 27-country, double-blind, randomized, placebo-controlled study in 10,948 patients presenting with UA or NSTEMI. Patients could be enrolled only if they had experienced cardiac ischemia at rest (\u226510 minutes) within the previous 24 hours and had either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or increased CK-MB. Important exclusion criteria included a history of bleeding diathesis, evidence of abnormal bleeding within the previous 30 days, uncontrolled hypertension, major surgery within the previous 6 weeks, stroke within the previous 30 days, any history of hemorrhagic stroke, serum creatinine >2 mg/dL, dependency on renal dialysis, or platelet count <100,000/mm 3 . Patients were randomized to placebo, to eptifibatide 180 mcg/kg bolus followed by a 2 mcg/kg/min infusion (180/2), or to eptifibatide 180 mcg/kg bolus followed by a 1.3 mcg/kg/min infusion (180/1.3). The infusion was continued for 72 hours, until hospital discharge, or until the time of CABG, whichever occurred first, except that if PCI was performed, the eptifibatide infusion was continued for 24 hours after the procedure, allowing for a duration of infusion up to 96 hours. The lower-infusion-rate arm was stopped after the first interim analysis when the 2 active-treatment arms appeared to have the same incidence of bleeding. Patient age ranged from 20 to 94 (mean 63) years, and 65% were male. The patients were 89% Caucasian, 6% Hispanic, and 5% Black, recruited in the United States and Canada (40%), Western Europe (39%), Eastern Europe (16%), and Latin America (5%). This was a \"real world\" study; each patient was managed according to the usual standards of the investigational site; frequencies of angiography, PCI, and CABG therefore differed widely from site to site and from country to country. Of the patients in PURSUET, 13% were managed with PCI during drug infusion, of whom 50% received intracoronary stents; 87% were managed medically (without PCI during drug infusion). The majority of patients received aspirin (75 to 325 mg once daily). Heparin was administered intravenously or subcutaneously, at the physician's discretion, most commonly as an intravenous bolus of 5000 units followed by a continuous infusion of 1000 units/h. For patients weighing less than 70 kg, the recommended heparin bolus dose was 60 units/kg followed by a continuous infusion of 12 units/kg/h. A target aPTT of 50 to 70 seconds was recommended. A total of 1250 patients underwent PCI within 72 hours after randomization, in which case they received intravenous heparin to maintain an ACT of 300 to 350 seconds. The primary endpoint of the study was the occurrence of death from any cause or new MI (evaluated by a blinded Clinical Endpoints Committee) within 30 days of randomization. Compared to placebo, eptifibatide administered as a 180 mcg/kg bolus followed by a 2 mcg/kg/min infusion significantly (p=0.042) reduced the incidence of endpoint events (see Table 6). The reduction in the incidence of endpoint events in patients receiving eptifibatide was evident early during treatment, and this reduction was maintained through at least 30 days (see Figure 1). Table 5 also shows the incidence of the components of the primary endpoint, death (whether or not preceded by an MI) and new MI in surviving patients at 30 days. Table 5: Clinical Events in the PURSUET Study Death or MI Placebo (n=4739) n (%) Eptifibatide (180 mcg/kg bolus then 2 mcg/kg/min infusion) (n=4722) n (%) p-value 3 days 359 (7.6%) 279 (5.9%) 0.001 7 days 552 (11.6%) 477 (10.1%) 0.016 30 days Death or MI (primary endpoint) 745 (15.7%) 672 (14.2%) 0.042 Death 177 (3.7%) 165 (3.5%) Nonfatal MI 568 (12%) 507 (10.7%) Figure 1: Kaplan-Meier Plot of Time to Death or Myocardial Infarction Within 30 Days of Randomization in the PURSUET Study Treatment with eptifibatide prior to determination of patient management strategy reduced clinical events regardless of whether patients ultimately underwent diagnostic catheterization, revascularization (i.e., PCI or CABG surgery) or continued to receive medical management alone. Table 6 shows the incidence of death or MI within 72 hours. Table 6: Clinical Events (Death or MI) in the PURSUET Study Within 72 Hours of Randomization Placebo Eptifibatide (180 mcg/kg bolus then 2 mcg/kg/min infusion) Overall patient population n=4739 n=4722 \u2013 At 72 hours 7.6% 5.9% Patients undergoing early PCI n=631 n=619 \u2013 Pre-procedure (nonfatal MI only) 5.5% 1.8% \u2013 At 72 hours 14.4% 9% Patients not undergoing early PCI n=4108 n=4103 \u2013 At 72 hours 6.5% 5.4% All of the effect of eptifibatide was established within 72 hours (during the period of drug infusion), regardless of management strategy. Moreover, for patients undergoing early PCI, a reduction in events was evident prior to the procedure. An analysis of the results by sex suggests that women who would not routinely be expected to undergo PCI receive less benefit from eptifibatide (95% confidence limits for relative risk of 0.94 to 1.28) than do men (0.72 to 0.9). This difference may be a true treatment difference, the effect of other differences in these subgroups, or a statistical anomaly. No differential outcomes were seen between male and female patients undergoing PCI (see results for ESPRET) . Follow-up data were available through 165 days for 10,611 patients enrolled in the PURSUET trial (96.9% of the initial enrollment). This follow-up included 4566 patients who received eptifibatide at the 180/2 dose. As reported by the investigators, the occurrence of death from any cause or new MI for patients followed for at least 165 days was reduced from 13.6% with placebo to 12.1% with eptifibatide 180/2. Graph 1 14.2 Percutaneous Coronary Intervention (PCI) EMPACT II (Eptifibatide to Minimize Platelet Aggregation and Prevent Coronary Thrombosis II) EMPACT II was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States in 4010 patients undergoing PCI. Major exclusion criteria included a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 89 (mean 60) years, and 75% were male. The patients were 92% Caucasian, 5% Black, and 3% Hispanic. Forty-one percent of the patients underwent PCI for ongoing ACS. Patients were randomly assigned to 1 of 3 treatment regimens, each incorporating a bolus dose initiated immediately prior to PCI followed by a continuous infusion lasting 20 to 24 hours: 1) 135 mcg/kg bolus followed by a continuous infusion of 0.5 mcg/kg/min of eptifibatide (135/0.5); 2) 135 mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min of eptifibatide (135/0.75); or 3) a matching placebo bolus followed by a matching placebo continuous infusion. Each patient received aspirin and an intravenous heparin bolus of 100 units/kg, with additional bolus infusions of up to 2000 additional units of heparin every 15 minutes to maintain an ACT of 300 to 350 seconds. The primary endpoint was the composite of death, MI, or urgent revascularization, analyzed at 30 days after randomization in all patients who received at least 1 dose of study drug. As shown in Table 7, each eptifibatide regimen reduced the rate of death, MI, or urgent intervention, although at 30 days, this finding was statistically significant only in the lower-dose eptifibatide group. As in the PURSUET study, the effects of eptifibatide were seen early and persisted throughout the 30-day period. Table 7: Clinical Events in the EMPACT II Study Placebo n (%) Eptifibatide (135 mcg/kg bolus then 0.5 mcg/kg/min infusion) n (%) Eptifibatide (135 mcg/kg bolus then 0.75 mcg/kg/min infusion) n (%) Patients 1285 1300 1286 Abrupt Closure 65 (5.1%) 36 (2.8%) 43 (3.3%) p-value versus placebo 0.003 0.03 Death, MI, or Urgent Intervention 24 hours 123 (9.6%) 86 (6.6%) 89 (6.9%) p-value versus placebo 0.006 0.014 48 hours 131 (10.2%) 99 (7.6%) 102 (7.9%) p-value versus placebo 0.021 0.045 30 days (primary endpoint) 149 (11.6%) 118 (9.1%) 128 (10%) p-value versus placebo 0.035 0.179 Death or MI 30 days 110 (8.6%) 89 (6.8%) 95 (7.4%) p-value versus placebo 0.102 0.272 6 months 151 (11.9%)* 136 (10.6%)* 130 (10.3%)* p-value versus placebo 0.297 0.182 * Kaplan-Meier estimate of event rate. ESPRET (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Eptifibatide Therapy) The ESPRET study was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States and Canada that enrolled 2064 patients undergoing elective or urgent PCI with intended intracoronary stent placement. Exclusion criteria included MI within the previous 24 hours, ongoing chest pain, administration of any oral antiplatelet or oral anticoagulant other than aspirin within 30 days of PCI (although loading doses of thienopyridine on the day of PCI were encouraged), planned PCI of a saphenous vein graft or subsequent \u201cstaged\u201d PCI, prior stent placement in the target lesion, PCI within the previous 90 days, a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 93 (mean 62) years, and 73% of patients were male. The study enrolled 90% Caucasian, 5% African American, 2% Hispanic, and 1% Asian patients. Patients received a wide variety of stents. Patients were randomized either to placebo or eptifibatide administered as an intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2 mcg/kg/min, and a second bolus of 180 mcg/kg administered 10 minutes later (180/2/180). Eptifibatide infusion was continued for 18 to 24 hours after PCI or until hospital discharge, whichever came first. Each patient received at least 1 dose of aspirin (162 to 325 mg) and 60 units/kg of heparin as a bolus (not to exceed 6000 units) if not already receiving a heparin infusion. Additional boluses of heparin (10 to 40 units/kg) could be administered in order to reach a target ACT between 200 and 300 seconds. The primary endpoint of the ESPRET study was the composite of death, MI, urgent target vessel revascularization (UTVR), and \u201cbailout\u201d to open-label eptifibatide due to a thrombotic complication of PCI (TBO) (e.g., visible thrombus, \u201cno reflow,\u201d or abrupt closure) at 48 hours. MI, UTVR, and TBO were evaluated by a blinded Clinical Events Committee. As shown in Table 8, the incidence of the primary endpoint and selected secondary endpoints was significantly reduced in patients who received eptifibatide. A treatment benefit in patients who received eptifibatide was seen by 48 hours and at the end of the 30-day observation period. Table 8: Clinical Events in the ESPRET Study Placebo (n=1024) Eptifibatide* (n=1040) Relative Risk (95% CI) p-value Death, MI, UTVR, or Thrombotic \u201cBailout\u201d 48 hours (primary endpoint) 108 (10.5%) 69 (6.6%) 0.629 (0.471, 0.84) 0.0015 30 days 120 (11.7%) 78 (7.5%) 0.64 (0.488, 0.84) 0.0011 Death, MI, or UTVR 48 hours 95 (9.3%) 62 (6%) 0.643 (0.472, 0.875) 0.0045 30 days (key secondary endpoint) 107 (10.4%) 71 (6.8%) 0.653 (0.49, 0.871) 0.0034 Death or MI 48 hours 94 (9.2%) 57 (5.5%) 0.597 (0.435, 0.82) 0.0013 30 days 104 (10.2%) 66 (6.3%) 0.625 (0.465, 0.84) 0.0016 * Eptifibatide was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min. The need for thrombotic \u201cbailout\u201d was significantly reduced with eptifibatide at 48 hours (2.1% for placebo, 1% for eptifibatide; p=0.029). Consistent with previous studies of GP IIb/IIIa inhibitors, most of the benefit achieved acutely with eptifibatide was in the reduction of MI. Eptifibatide reduced the occurrence of MI at 48 hours from 9% for placebo to 5.4% (p=0.0015) and maintained that effect with significance at 30 days. There was no treatment difference with respect to sex in ESPRET. Eptifibatide reduced the incidence of the primary endpoint in both men (95% confidence limits for relative risk: 0.54, 1.07) and women (0.24, 0.72) at 48 hours. Follow-up (12-month) mortality data were available for 2024 patients (1017 on eptifibatide) enrolled in the ESPRET trial (98.1% of the initial enrollment). Twelve-month clinical event data were available for 1964 patients (988 on eptifibatide), representing 95.2% of the initial enrollment. As shown in Table 9, the treatment effect of eptifibatide seen at 48 hours and 30 days appeared preserved at 6 months and 1 year. Most of the benefit was in reduction of MI. Table 9: Clinical Events at 6 Months and 1 Year in the ESPRET Study Placebo (n=1024) Eptifibatide (n=1040) Hazard Ratio (95% CI) Death, MI, or Target Vessel Revascularization 6 months 187 (18.5%) 146 (14.3%) 0.744 (0.599, 0.924) 1 year 222 (22.1%) 178 (17.5%) 0.762 (0.626, 0.929) Death, MI 6 months 117 (11.5%) 77 (7.4%) 0.631 (0.473, 0.841) 1 year 126 (12.4%) 83 (8%) 0.63 (0.478, 0.832) Percentages are Kaplan-Meier event rates."
    ],
    "clinical_studies_table": [
      "<table width=\"100%\"><col width=\"37%\"/><col width=\"20%\"/><col width=\"30%\"/><col width=\"13%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Death or MI </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo (n=4739) </content></paragraph><paragraph><content styleCode=\"bold\">n (%) </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide</content></paragraph><paragraph><content styleCode=\"bold\">(180 mcg/kg bolus then 2 mcg/kg/min infusion) </content></paragraph><paragraph><content styleCode=\"bold\">(n=4722) </content></paragraph><paragraph><content styleCode=\"bold\">n (%) </content></paragraph></td><td align=\"right\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">p-value </content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>3 days </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>359 (7.6%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>279 (5.9%) </paragraph></td><td align=\"right\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.001 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>7 days </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>552 (11.6%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>477 (10.1%) </paragraph></td><td align=\"right\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.016 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>30 days</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>Death or MI (primary endpoint) </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>745 (15.7%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>672 (14.2%) </paragraph></td><td align=\"right\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.042 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>Death </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>177 (3.7%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>165 (3.5%) </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>Nonfatal MI </item></list></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>568 (12%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>507 (10.7%) </paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"/></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"56%\"/><col width=\"19%\"/><col width=\"25%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide </content></paragraph><paragraph><content styleCode=\"bold\">(180 mcg/kg bolus then 2</content> <content styleCode=\"bold\">mcg/kg/min infusion)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Overall patient population </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>n=4739 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>n=4722 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>&#x2013; At 72 hours </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>7.6% </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>5.9% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Patients undergoing early PCI </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>n=631 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>n=619 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>&#x2013; Pre-procedure (nonfatal MI only) </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>5.5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>1.8% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>&#x2013; At 72 hours </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>14.4% </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>9% </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Patients not undergoing early PCI </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>n=4108 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>n=4103 </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"bottom\"><list listType=\"ordered\"><item><caption> </caption>&#x2013; At 72 hours </item></list></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>6.5% </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>5.4% </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"38%\"/><col width=\"17%\"/><col width=\"22%\"/><col width=\"23%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide (135 mcg/kg bolus then 0.5 mcg/kg/min infusion)</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide </content></paragraph><paragraph><content styleCode=\"bold\">(135 mcg/kg bolus then 0.75 mcg/kg/min infusion) </content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Patients </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>1285</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>1300 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>1286 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Abrupt Closure </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>65 (5.1%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>36 (2.8%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>43 (3.3%) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>p-value versus placebo</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.003 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.03 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Death, MI, or Urgent Intervention</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>24 hours </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>123 (9.6%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>86 (6.6%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>89 (6.9%) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>p-value versus placebo </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.006 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.014 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>48 hours </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>131 (10.2%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>99 (7.6%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>102 (7.9%) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>p-value versus placebo </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.021 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.045 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>30 days (primary endpoint) </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>149 (11.6%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>118 (9.1%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>128 (10%) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>p-value versus placebo </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.035 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.179 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Death or MI </paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>30 days </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>110 (8.6%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>89 (6.8%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>95 (7.4%) </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>p-value versus placebo </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.102 </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.272 </paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>6 months </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>151 (11.9%)*</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>136 (10.6%)* </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>130 (10.3%)* </paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>p-value versus placebo </item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>0.297 </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>0.182 </paragraph></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"34%\"/><col width=\"16%\"/><col width=\"21%\"/><col width=\"16%\"/><col width=\"12%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"/><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">Placebo </content></item><item><caption> </caption><content styleCode=\"bold\">(n=1024) </content></item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">Eptifibatide* </content></item><item><caption> </caption><content styleCode=\"bold\">(n=1040) </content></item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">Relative Risk </content></item><item><caption> </caption><content styleCode=\"bold\">(95% CI) </content></item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption><content styleCode=\"bold\">p-value</content></item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>Death, MI, UTVR, or Thrombotic &#x201C;Bailout&#x201D; </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"bottom\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>48 hours (primary endpoint) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>108 (10.5%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>69 (6.6%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>0.629 (0.471, 0.84) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>0.0015 </item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>30 days </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>120 (11.7%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>78 (7.5%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>0.64 (0.488, 0.84) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>0.0011 </item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>Death, MI, or UTVR</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>48 hours </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>95 (9.3%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>62 (6%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>0.643 (0.472, 0.875) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>0.0045 </item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>30 days (key secondary endpoint) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>107 (10.4%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>71 (6.8%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>0.653 (0.49, 0.871) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>0.0034 </item></list></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>Death or MI</item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>48 hours </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>94 (9.2%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>57 (5.5%) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>0.597 (0.435, 0.82) </item></list></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>0.0013 </item></list></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>30 days </item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>104 (10.2%) </item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>66 (6.3%) </item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>0.625 (0.465, 0.84) </item></list></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>0.0016 </item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"39%\"/><col width=\"18%\"/><col width=\"21%\"/><col width=\"22%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo </content></paragraph><paragraph><content styleCode=\"bold\">(n=1024) </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Eptifibatide </content></paragraph><paragraph><content styleCode=\"bold\">(n=1040) </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Hazard Ratio</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Death, MI, or Target Vessel Revascularization</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>6 months </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>187 (18.5%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>146</paragraph><paragraph>(14.3%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.744</paragraph><paragraph>(0.599, 0.924)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>1 year </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>222 (22.1%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>178 (17.5%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.762 (0.626, 0.929)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Death, MI</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><list listType=\"ordered\"><item><caption> </caption>6 months </item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>117 (11.5%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>77 (7.4%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.631 (0.473, 0.841)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption>1 year </item></list></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>126 (12.4%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>83 (8%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0.63 (0.478, 0.832)</paragraph></td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Eptifibatide injection is supplied as a sterile solution as follows: NDC Eptifibatide Injection Package Factor 72078-025-10 20 mg/10 mL vial 1\u2019s 72078-027-10 200 mg/100 mL vial 1\u2019s 72078-026-10 75 mg/100 mL vial 1\u2019s 16.2 Storage Vials should be stored refrigerated at 2\u00b0 to 8\u00b0C (36\u00b0 to 46\u00b0F). Vials may be transferred to room temperature storage* for a period not to exceed 2 months. Upon transfer, vial cartons must be marked by the dispensing pharmacist with a \u201cDISCARD BY\u201d date (2 months from the transfer date or the labeled expiration date, whichever comes first). Protect from light until administration. * Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]."
    ],
    "how_supplied_table": [
      "<table width=\"100%\"><col width=\"46%\"/><col width=\"26%\"/><col width=\"28%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>NDC</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>Eptifibatide Injection</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>Package Factor</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>72078-025-10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>20 mg/10 mL vial</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1&#x2019;s</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>72078-027-10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>200 mg/100 mL vial</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>1&#x2019;s</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>72078-026-10</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>75 mg/100 mL vial</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>1&#x2019;s</paragraph></td></tr></tbody></table>"
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to inform the doctor or healthcare provider about any medical conditions, medications, and allergies. Manufactured for: Mylan Institutional LLC Morgantown, WV 26505 U.S.A Made in India Manufactured by: Mylan Laboratories Limited Bangalore, India MAY 2021 Novaplus is a registered trademark of Vizient, Inc."
    ],
    "package_label_principal_display_panel": [
      "Package/Label Display Panel NDC 72078-025-10 Eptibatide Injection 20 mg/10 mL (2 mg/mL) (20 mg/10 mL vial for weight-adjusted bolus dosing) FOR INTRAVENOUS USE ONLY Single-Dose Vial Sterile Rx ONLY novaplus Carton 20",
      "Package/Label Display Panel NDC 72078-026-10 Eptibatide Injection 75 mg/100 mL (0.75 mg/mL) (75 mg/100 mL for weight-adjusted infusion) FOR INTRAVENOUS USE ONLY Single-Dose Vial Sterile Rx ONLY novaplus Carton 75",
      "Package/Label Display Panel NDC 72078-027-10 Eptibatide Injection 200 mg/100 mL (2 mg/mL) (200 mg/100 mL for weight-adjusted infusion) FOR INTRAVENOUS USE ONLY Single-Dose Vial Sterile Rx ONLY novaplus Carton 200"
    ],
    "set_id": "a7a89c59-22fb-41fd-b70a-ac2395717db1",
    "id": "7af20acf-ba9f-4387-9729-85d3c137f41e",
    "effective_time": "20210528",
    "version": "3",
    "openfda": {
      "application_number": [
        "ANDA203258"
      ],
      "brand_name": [
        "Eptifibatide"
      ],
      "generic_name": [
        "EPTIFIBATIDE"
      ],
      "manufacturer_name": [
        "Mylan Institutional LLC"
      ],
      "product_ndc": [
        "72078-025",
        "72078-026",
        "72078-027"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "INTRAVENOUS"
      ],
      "substance_name": [
        "EPTIFIBATIDE"
      ],
      "rxcui": [
        "200349",
        "1736470",
        "1736477"
      ],
      "spl_id": [
        "7af20acf-ba9f-4387-9729-85d3c137f41e"
      ],
      "spl_set_id": [
        "a7a89c59-22fb-41fd-b70a-ac2395717db1"
      ],
      "package_ndc": [
        "72078-025-10",
        "72078-026-10",
        "72078-027-10"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0372078026108",
        "0372078027105"
      ],
      "nui": [
        "N0000008832",
        "N0000175578"
      ],
      "pharm_class_pe": [
        "Decreased Platelet Aggregation [PE]"
      ],
      "pharm_class_epc": [
        "Platelet Aggregation Inhibitor [EPC]"
      ],
      "unii": [
        "NA8320J834"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Eptifibatide eptifibatide eptifibatide eptifibatide citric acid monohydrate sodium hydroxide Eptifibatide eptifibatide eptifibatide eptifibatide citric acid monohydrate sodium hydroxide"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Eptifibatide injection is a platelet aggregation inhibitor indicated for: Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI). ( 1.1 ) Treatment of patients undergoing PCI (including intracoronary stenting). ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). 1.2 Percutaneous Coronary Intervention (PCI) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting [see Clinical Studies ( 14.1 , 14.2 )] ."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION Before infusion of eptifibatide injection, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured. The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT. ACS or PCI: 180 mcg/kg IV bolus as soon as possible after diagnosis followed by infusion at 2 mcg/kg/min. ( 2.1 , 2.2 ) PCI: Add a second 180 mcg/kg bolus at 10 minutes. ( 2.2 ) In patients with creatinine clearance less than 50 mL/min, reduce the infusion to 1 mcg/kg/min. ( 2.1 , 2.2 , 2.3 ) 2.1 Dosage in Acute Coronary Syndrome (ACS) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with ACS 180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min 180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy Aspirin, 160 to 325 mg, should be given daily Eptifibatide injection should be given concomitantly with heparin dosed to achieve the following parameters: During Medical Management : Target aPTT 50 to 70 seconds If weight greater than or equal to 70 kg, 5000-unit bolus followed by infusion of 1000 units/h. If weight less than 70 kg, 60-units/kg bolus followed by infusion of 12 units/kg/h. During PCI : Target ACT 200 to 300 seconds If heparin is initiated prior to PCI, additional boluses during PCI to maintain an ACT target of 200 to 300 seconds. Heparin infusion after the PCI is discouraged. 2.2 Dosage in Percutaneous Coronary Intervention (PCI) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with PCI 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. In patients who undergo CABG surgery, eptifibatide injection infusion should be discontinued prior to surgery. Aspirin, 160 to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter. Eptifibatide injection should be given concomitantly with heparin to achieve a target ACT of 200 to 300 seconds. Administer 60-units/kg bolus initially in patients not treated with heparin within 6 hours prior to PCI. Additional boluses during PCI to maintain ACT within target. Heparin infusion after the PCI is strongly discouraged. Patients requiring thrombolytic therapy should discontinue eptifibatide injection. 2.3 Important Administration Instructions Inspect eptifibatide injection for particulate matter and discoloration prior to administration, whenever solution and container permit. May administer eptifibatide injection in the same intravenous line as alteplase, atropine, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, or verapamil. Do not administer eptifibatide injection through the same intravenous line as furosemide. May administer eptifibatide injection in the same IV line with 0.9% NaCl or 0.9% NaCl/5% dextrose. With either vehicle, the infusion may also contain up to 60 mEq/L of potassium chloride. Withdraw the bolus dose(s) of eptifibatide injection from the 10-mL vial into a syringe. Administer the bolus dose(s) by IV push. Immediately following the bolus dose administration, initiate a continuous infusion of eptifibatide injection. When using an intravenous infusion pump, administer eptifibatide injection undiluted directly from the 100-mL vial. Spike the 100-mL vial with a vented infusion set. Center the spike within the circle on the stopper top. Discard any unused portion left in the vial. Administer eptifibatide injection by volume according to patient weight (see Table 1 ). Table 1: Eptifibatide Injection Dosing Charts by Weight Patient Weight 180-mcg/kg Bolus Volume 2-mcg/kg/min Infusion Volume (CrCl greater than or equal to 50 mL/min) 1-mcg/kg/min Infusion Volume (CrCl less than 50 mL/min) (kg) (lb) (from 2-mg/mL vial) (from 2-mg/mL 100-mL vial) (from 0.75-mg/mL 100-mL vial) (from 2-mg/mL 100-mL vial) (from 0.75-mg/mL 100-mL vial) 37-41 81-91 3.4 mL 2 mL/h 6 mL/h 1 mL/h 3 mL/h 42-46 92-102 4 mL 2.5 mL/h 7 mL/h 1.3 mL/h 3.5 mL/h 47-53 103-117 4.5 mL 3 mL/h 8 mL/h 1.5 mL/h 4 mL/h 54-59 118-130 5 mL 3.5 mL/h 9 mL/h 1.8 mL/h 4.5 mL/h 60-65 131-143 5.6 mL 3.8 mL/h 10 mL/h 1.9 mL/h 5 mL/h 66-71 144-157 6.2 mL 4 mL/h 11 mL/h 2 mL/h 5.5 mL/h 72-78 158-172 6.8 mL 4.5 mL/h 12 mL/h 2.3 mL/h 6 mL/h 79-84 173-185 7.3 mL 5 mL/h 13 mL/h 2.5 mL/h 6.5 mL/h 85-90 186-198 7.9 mL 5.3 mL/h 14 mL/h 2.7 mL/h 7 mL/h 91-96 199-212 8.5 mL 5.6 mL/h 15 mL/h 2.8 mL/h 7.5 mL/h 97-103 213-227 9 mL 6 mL/h 16 mL/h 3.0 mL/h 8 mL/h 104-109 228-240 9.5 mL 6.4 mL/h 17 mL/h 3.2 mL/h 8.5 mL/h 110-115 241-253 10.2 mL 6.8 mL/h 18 mL/h 3.4 mL/h 9 mL/h 116-121 254-267 10.7 mL 7 mL/h 19 mL/h 3.5 mL/h 9.5 mL/h >121 >267 11.3 mL 7.5 mL/h 20 mL/h 3.7 mL/h 10 mL/h"
    ],
    "dosage_and_administration_table": [
      "<table width=\"100%\"><col width=\"12.862%\" align=\"left\"/><col width=\"45.718%\" align=\"left\"/><col width=\"41.420%\" align=\"left\"/><tbody><tr><td align=\"justify\" valign=\"middle\" styleCode=\"Toprule Botrule Lrule Rrule\"><content styleCode=\"bold\">Indication</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule Rrule\"><content styleCode=\"bold\">Normal Renal Function</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule Rrule\"><content styleCode=\"bold\">Creatinine Clearance less than 50 mL/min</content></td></tr><tr><td align=\"left\" valign=\"middle\" styleCode=\"Botrule Lrule Rrule\">Patients with ACS </td><td align=\"justify\" valign=\"middle\" styleCode=\"Botrule Rrule\">180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min </td><td align=\"justify\" valign=\"middle\" styleCode=\"Botrule Rrule\">180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min </td></tr><tr><td align=\"justify\" valign=\"middle\" styleCode=\"Botrule Lrule Rrule\"/><td colspan=\"2\" align=\"left\" valign=\"middle\" styleCode=\"Botrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours </item><item>If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy </item><item>Aspirin, 160 to 325 mg, should be given daily </item></list></td></tr></tbody></table>",
      "<table width=\"100%\"><col width=\"11.867%\" align=\"left\"/><col width=\"44.067%\" align=\"left\"/><col width=\"44.067%\" align=\"left\"/><tbody><tr><td align=\"justify\" valign=\"middle\" styleCode=\"Toprule Botrule Lrule Rrule\"><content styleCode=\"bold\">Indication</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule Rrule\"><content styleCode=\"bold\">Normal Renal Function</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule Rrule\"><content styleCode=\"bold\">Creatinine Clearance less than 50 mL/min</content></td></tr><tr><td align=\"left\" valign=\"middle\" styleCode=\"Botrule Lrule Rrule\">Patients with PCI </td><td align=\"justify\" valign=\"middle\" styleCode=\"Botrule Rrule\">180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) </td><td align=\"justify\" valign=\"middle\" styleCode=\"Botrule Rrule\">180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) </td></tr><tr><td align=\"justify\" valign=\"middle\" styleCode=\"Botrule Lrule Rrule\"/><td colspan=\"2\" align=\"left\" valign=\"middle\" styleCode=\"Botrule Rrule\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. </item><item>In patients who undergo CABG surgery, eptifibatide injection infusion should be discontinued prior to surgery. </item><item>Aspirin, 160 to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter. </item></list></td></tr></tbody></table>",
      "<table ID=\"t1\" width=\"100%\"><caption>Table 1: Eptifibatide Injection Dosing Charts by Weight </caption><col width=\"9.471%\" align=\"left\"/><col width=\"9.957%\" align=\"left\"/><col width=\"15.243%\" align=\"left\"/><col width=\"15.229%\" align=\"left\"/><col width=\"16.757%\" align=\"left\"/><col width=\"16.743%\" align=\"left\"/><col width=\"16.600%\" align=\"left\"/><tbody><tr><td colspan=\"2\" align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule Lrule Rrule\"><content styleCode=\"bold\">Patient Weight</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule Rrule\"><content styleCode=\"bold\">180-mcg/kg</content> <content styleCode=\"bold\">Bolus Volume</content></td><td colspan=\"2\" align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule Rrule\"><content styleCode=\"bold\">2-mcg/kg/min</content> <content styleCode=\"bold\">Infusion Volume</content> <content styleCode=\"bold\">(CrCl greater than or equal to 50 mL/min)</content></td><td colspan=\"2\" align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule Rrule\"><content styleCode=\"bold\">1-mcg/kg/min</content> <content styleCode=\"bold\">Infusion Volume</content> <content styleCode=\"bold\">(CrCl less than 50 mL/min)</content></td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Botrule Lrule Rrule\"><content styleCode=\"bold\">(kg)</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule Rrule\"><content styleCode=\"bold\">(lb)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule Rrule\"><content styleCode=\"bold\">(from 2-mg/mL vial)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule Rrule\"><content styleCode=\"bold\">(from 2-mg/mL 100-mL vial)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule Rrule\"><content styleCode=\"bold\">(from 0.75-mg/mL 100-mL vial)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule Rrule\"><content styleCode=\"bold\">(from 2-mg/mL 100-mL vial)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Botrule Rrule\"><content styleCode=\"bold\">(from 0.75-mg/mL 100-mL vial)</content></td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule Rrule\">37-41 </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">81-91 </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">3.4 mL </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">2 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">6 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">1 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">3 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule Rrule\">42-46 </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">92-102 </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">4 mL </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">2.5 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">7 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">1.3 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">3.5 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule Rrule\">47-53 </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">103-117 </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">4.5 mL </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">3 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">8 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">1.5 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">4 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule Rrule\">54-59 </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">118-130 </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">5 mL </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">3.5 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">9 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">1.8 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">4.5 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule Rrule\">60-65 </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">131-143 </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">5.6 mL </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">3.8 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">10 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">1.9 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">5 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule Rrule\">66-71 </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">144-157 </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">6.2 mL </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">4 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">11 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">2 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">5.5 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule Rrule\">72-78 </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">158-172 </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">6.8 mL </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">4.5 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">12 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">2.3 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">6 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule Rrule\">79-84 </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">173-185 </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">7.3 mL </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">5 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">13 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">2.5 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">6.5 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule Rrule\">85-90 </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">186-198 </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">7.9 mL </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">5.3 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">14 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">2.7 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">7 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule Rrule\">91-96 </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">199-212 </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">8.5 mL </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">5.6 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">15 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">2.8 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">7.5 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule Rrule\">97-103 </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">213-227 </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">9 mL </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">6 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">16 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">3.0 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">8 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule Rrule\">104-109 </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">228-240 </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">9.5 mL </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">6.4 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">17 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">3.2 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">8.5 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule Rrule\">110-115 </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">241-253 </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">10.2 mL </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">6.8 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">18 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">3.4 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">9 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Lrule Rrule\">116-121 </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">254-267 </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">10.7 mL </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">7 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">19 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Rrule\">3.5 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Rrule\">9.5 mL/h </td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Botrule Lrule Rrule\">&gt;121 </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule Rrule\">&gt;267 </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule Rrule\">11.3 mL </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule Rrule\">7.5 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule Rrule\">20 mL/h </td><td align=\"center\" valign=\"top\" styleCode=\"Botrule Rrule\">3.7 mL/h </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule Rrule\">10 mL/h </td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Injection: 20 mg of eptifibatide in 10 mL (2 mg per mL), for intravenous bolus. Injection: 75 mg of eptifibatide in 100 mL (0.75 mg per mL), for intravenous infusion. 20 mg per 10 mL (2 mg per mL) in a single-dose vial for bolus injection ( 3 ) 75 mg per 100 mL (0.75 mg per mL) in a single-dose vial for infusion ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Treatment with eptifibatide is contraindicated in patients with: A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another parenteral GP IIb/IIIa inhibitor Dependency on renal dialysis Hypersensitivity to eptifibatide or any component of the product (hypersensitivity reactions that occurred included anaphylaxis and urticaria) Bleeding diathesis or bleeding within the previous 30 days ( 4 ) Severe uncontrolled hypertension ( 4 ) Major surgery within the preceding 6 weeks ( 4 ) Stroke within 30 days or any history of hemorrhagic stroke ( 4 ) Coadministration of another parenteral GP IIb/IIIa inhibitor ( 4 ) Dependency on renal dialysis ( 4 ) Known hypersensitivity to any component of the product ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Eptifibatide can cause serious bleeding. If bleeding cannot be controlled, discontinue eptifibatide immediately. Minimize vascular and other traumas. If heparin is given concomitantly, monitor aPTT or ACT. ( 5.1 ) Thrombocytopenia: Discontinue eptifibatide and heparin. Monitor and treat condition appropriately. ( 5.2 ) 5.1 Bleeding Bleeding is the most common complication encountered during eptifibatide therapy. Administration of eptifibatide is associated with an increase in major and minor bleeding, as classified by the criteria of the Thrombolysis in Myocardial Infarction Study group (TIMI) [see Adverse Reactions ( 6.1 )] . Most major bleeding associated with eptifibatide has been at the arterial access site for cardiac catheterization or from the gastrointestinal or genitourinary tract. Minimize the use of arterial and venous punctures, intramuscular injections, and the use of urinary catheters, nasotracheal intubation, and nasogastric tubes. When obtaining intravenous access, avoid non-compressible sites (e.g., subclavian or jugular veins). Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Risk factors for bleeding include older age, a history of bleeding disorders, and concomitant use of drugs that increase the risk of bleeding (thrombolytics, oral anticoagulants, nonsteroidal anti-inflammatory drugs, and P2Y 12 inhibitors). Concomitant treatment with other inhibitors of platelet receptor glycoprotein (GP) IIb/IIIa should be avoided. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT [see Dosage and Administration ( 2 )] . Care of the Femoral Artery Access Site in Patients Undergoing Percutaneous Coronary Intervention (PCI) In patients undergoing PCI, treatment with eptifibatide is associated with an increase in major and minor bleeding at the site of arterial sheath placement. After PCI, eptifibatide infusion should be continued until hospital discharge or up to 18 to 24 hours, whichever comes first. Heparin use is discouraged after the PCI procedure. Early sheath removal is encouraged while eptifibatide is being infused. Prior to removing the sheath, it is recommended that heparin be discontinued for 3 to 4 hours and an aPTT of <45 seconds or ACT <150 seconds be achieved. In any case, both heparin and eptifibatide should be discontinued and sheath hemostasis should be achieved at least 2 to 4 hours before hospital discharge. If bleeding at access site cannot be controlled with pressure, infusion of eptifibatide and heparin should be discontinued immediately. 5.2 Thrombocytopenia There have been reports of acute, profound thrombocytopenia (immune-mediated and non-immune mediated) with eptifibatide. In the event of acute profound thrombocytopenia or a confirmed platelet decrease to <100,000/mm 3 , discontinue eptifibatide and heparin (unfractionated or low-molecular weight). Monitor serial platelet counts, assess the presence of drug-dependent antibodies, and treat as appropriate [see Adverse Reactions ( 6.1 )] . There has been no clinical experience with eptifibatide initiated in patients with a baseline platelet count <100,000/mm 3 . If a patient with low platelet counts is receiving eptifibatide, their platelet count should be monitored closely."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reaction is also discussed elsewhere in the labeling: Bleeding [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )] Bleeding and hypotension are the most commonly reported adverse reactions. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Avenacy Inc. at 1-855-283-6229 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. A total of 16,782 patients were treated in the Phase III clinical trials (PURSUIT, ESPRIT, and IMPACT II) [see Clinical Studies ( 14 )] . These 16,782 patients had a mean age of 62 years (range: 20 to 94 years). Eighty-nine percent of the patients were Caucasian, with the remainder being predominantly Black (5%) and Hispanic (5%). Sixty-eight percent were men. Because of the different regimens used in PURSUIT, IMPACT II, and ESPRIT, data from the 3 studies were not pooled. Bleeding and hypotension were the most commonly reported adverse reactions (incidence \u22655% and greater than placebo) in the eptifibatide controlled clinical trial database. Bleeding The incidence of bleeding and transfusions in the PURSUIT and ESPRIT studies are shown in Table 2 . Bleeding was classified as major or minor by the criteria of the TIMI study group. Major bleeding consisted of intracranial hemorrhage and other bleeding that led to decreases in hemoglobin greater than 5 g/dL. Minor bleeding included spontaneous gross hematuria, spontaneous hematemesis, other observed blood loss with a hemoglobin decrease of more than 3 g/dL, and other hemoglobin decreases that were greater than 4 g/dL but less than 5 g/dL. In patients who received transfusions, the corresponding loss in hemoglobin was estimated through an adaptation of the method of Landefeld et al. Table 2: Bleeding and Transfusions in the PURSUIT and ESPRIT Studies Note: Denominator is based on patients for whom data are available. * For major and minor bleeding, patients are counted only once according to the most severe classification. \u2020 Includes transfusions of whole blood, packed red blood cells, fresh frozen plasma, cryoprecipitate, platelets, and autotransfusion during the initial hospitalization. PURSUIT (ACS) Placebo Eptifibatide 180/2 n (%) n (%) Patients 4696 4679 Major bleeding * 425 (9.3%) 498 (10.8%) Minor bleeding * 347 (7.6%) 604 (13.1%) Requiring transfusions \u2020 490 (10.4%) 601 (12.8%) ESPRIT (PCI) Placebo Eptifibatide 180/2/180 n (%) n (%) Patients 1024 1040 Major bleeding * 4 (0.4%) 13 (1.3%) Minor bleeding * 18 (2%) 29 (3%) Requiring transfusions \u2020 11 (1.1%) 16 (1.5%) The majority of major bleeding reactions in the ESPRIT study occurred at the vascular access site (1 and 8 patients, or 0.1% and 0.8% in the placebo and eptifibatide groups, respectively). Bleeding at \u201cother\u201d locations occurred in 0.2% and 0.4% of patients, respectively. In the PURSUIT study, the greatest increase in major bleeding in eptifibatide-treated patients compared to placebo-treated patients was also associated with bleeding at the femoral artery access site (2.8% versus 1.3%). Oropharyngeal (primarily gingival), genitourinary, gastrointestinal, and retroperitoneal bleeding were also seen more commonly in eptifibatide-treated patients compared to placebo-treated patients. Among patients experiencing a major bleed in the IMPACT II study, an increase in bleeding on eptifibatide versus placebo was observed only for the femoral artery access site (3.2% versus 2.8%). Table 3 displays the incidence of TIMI major bleeding according to the cardiac procedures carried out in the PURSUIT study. The most common bleeding complications were related to cardiac revascularization (CABG-related or femoral artery access site bleeding). A corresponding table for ESPRIT is not presented, as every patient underwent PCI in the ESPRIT study and only 11 patients underwent CABG. Table 3: Major Bleeding by Procedures in the PURSUIT Study Note: Denominators are based on the total number of patients whose TIMI classification was resolved. Placebo Eptifibatide 180/2 n (%) n (%) Patients 4577 4604 Overall incidence of major bleeding 425 (9.3%) 498 (10.8%) Breakdown by procedure: CABG 375 (8.2%) 377 (8.2%) Angioplasty without CABG 27 (0.6%) 64 (1.4%) Angiography without angioplasty or CABG 11 (0.2%) 29 (0.6%) Medical therapy only 12 (0.3%) 28 (0.6%) In the PURSUIT and ESPRIT studies, the risk of major bleeding with eptifibatide increased as patient weight decreased. This relationship was most apparent for patients weighing less than 70 kg. Bleeding resulting in discontinuation of the study drug was more frequent among patients receiving eptifibatide than placebo (4.6% versus 0.9% in ESPRIT, 8% versus 1% in PURSUIT, 3.5% versus 1.9% in IMPACT II). Intracranial Hemorrhage and Stroke Intracranial hemorrhage was rare in the PURSUIT, IMPACT II, and ESPRIT clinical studies. In the PURSUIT study, 3 patients in the placebo group, 1 patient in the group treated with eptifibatide 180/1.3, and 5 patients in the group treated with eptifibatide 180/2 experienced a hemorrhagic stroke. The overall incidence of stroke was 0.5% in patients receiving eptifibatide 180/1.3, 0.7% in patients receiving eptifibatide 180/2, and 0.8% in placebo patients. In the IMPACT II study, intracranial hemorrhage was experienced by 1 patient treated with eptifibatide 135/0.5, 2 patients treated with eptifibatide 135/0.75, and 2 patients in the placebo group. The overall incidence of stroke was 0.5% in patients receiving 135/0.5 eptifibatide, 0.7% in patients receiving eptifibatide 135/0.75, and 0.7% in the placebo group. In the ESPRIT study, there were 3 hemorrhagic strokes, 1 in the placebo group and 2 in the eptifibatide group. In addition there was 1 case of cerebral infarction in the eptifibatide group. Immunogenicity/Thrombocytopenia The potential for development of antibodies to eptifibatide has been studied in 433 subjects. Eptifibatide was nonantigenic in 412 patients receiving a single administration of eptifibatide (135-mcg/kg bolus followed by a continuous infusion of either 0.5 mcg/kg/min or 0.75 mcg/kg/min), and in 21 subjects to whom eptifibatide (135-mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min) was administered twice, 28 days apart. In both cases, plasma for antibody detection was collected approximately 30 days after each dose. The development of antibodies to eptifibatide at higher doses has not been evaluated. In patients with suspected eptifibatide-related immune-mediated thrombocytopenia, IgG antibodies that react with the GP IIb/IIIa complex were identified in the presence of eptifibatide and in eptifibatide-na\u00efve patients. These findings suggest acute thrombocytopenia after the administration of eptifibatide can develop as a result of naturally occurring drug-dependent antibodies or those induced by prior exposure to eptifibatide. Similar antibodies were identified with other GP IIb/IIIa ligand-mimetic agents. Immune-mediated thrombocytopenia with eptifibatide may be associated with hypotension and/or other signs of hypersensitivity. In the PURSUIT and IMPACT II studies, the incidence of thrombocytopenia (<100,000/mm 3 or \u226550% reduction from baseline) and the incidence of platelet transfusions were similar between patients treated with eptifibatide and placebo. In the ESPRIT study, the incidence was 0.6% in the placebo group and 1.2% in the eptifibatide group. Other Adverse Reactions In the PURSUIT and ESPRIT studies, the incidence of serious nonbleeding adverse reactions was similar in patients receiving placebo or eptifibatide (19% and 19%, respectively, in PURSUIT; 6% and 7%, respectively, in ESPRIT). In PURSUIT, the only serious nonbleeding adverse reaction that occurred at a rate of at least 1% and was more common with eptifibatide than placebo (7% versus 6%) was hypotension. Most of the serious nonbleeding adverse reactions consisted of cardiovascular reactions typical of a UA population. In the IMPACT II study, serious nonbleeding adverse reactions that occurred in greater than 1% of patients were uncommon and similar in incidence between placebo- and eptifibatide-treated patients. Discontinuation of study drug due to adverse reactions other than bleeding was uncommon in the PURSUIT, IMPACT II, and ESPRIT studies, with no single reaction occurring in >0.5% of the study population (except for \"other\" in the ESPRIT study). 6.2 Postmarketing Experience The following adverse reactions have been reported in post-approval use of eptifibatide in combination with heparin and aspirin. Because the reactions below are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure: cerebral, GI, and pulmonary hemorrhage. Fatal bleeding reactions have been reported. Acute profound thrombocytopenia, as well as immune-mediated thrombocytopenia, have been reported [see Adverse Reactions ( 6.1 )] ."
    ],
    "adverse_reactions_table": [
      "<table ID=\"t2\" width=\"100%\"><caption>Table 2: Bleeding and Transfusions in the PURSUIT and ESPRIT Studies </caption><col width=\"44.600%\" align=\"left\"/><col width=\"25.133%\" align=\"left\"/><col width=\"30.267%\" align=\"left\"/><tfoot><tr><td colspan=\"3\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\">Note: Denominator is based on patients for whom data are available. </paragraph></td></tr><tr><td colspan=\"3\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\"><sup>*</sup> For major and minor bleeding, patients are counted only once according to the most severe classification. </paragraph></td></tr><tr><td colspan=\"3\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\"><sup>&#x2020;</sup> Includes transfusions of whole blood, packed red blood cells, fresh frozen plasma, cryoprecipitate, platelets, and autotransfusion during the initial hospitalization. </paragraph></td></tr></tfoot><tbody><tr><td colspan=\"3\" align=\"center\" valign=\"middle\" styleCode=\"Toprule\"><content styleCode=\"bold\">PURSUIT (ACS)</content></td></tr><tr><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"top\"><content styleCode=\"bold\">Placebo</content></td><td align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">180/2</content></td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\"><content styleCode=\"bold\">n (%)</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\"><content styleCode=\"bold\">n (%)</content></td></tr><tr><td align=\"left\" valign=\"middle\">Patients </td><td align=\"center\" valign=\"middle\">4696 </td><td align=\"center\" valign=\"middle\">4679 </td></tr><tr><td align=\"left\" valign=\"middle\">Major bleeding<sup>*</sup></td><td align=\"center\" valign=\"middle\">425 (9.3%) </td><td align=\"center\" valign=\"middle\">498 (10.8%) </td></tr><tr><td align=\"left\" valign=\"middle\">Minor bleeding<sup>*</sup></td><td align=\"center\" valign=\"middle\">347 (7.6%) </td><td align=\"center\" valign=\"middle\">604 (13.1%) </td></tr><tr><td align=\"left\" valign=\"middle\" styleCode=\"Botrule\">Requiring transfusions<sup>&#x2020;</sup></td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">490 (10.4%) </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">601 (12.8%) </td></tr><tr><td colspan=\"3\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">ESPRIT (PCI)</content></td></tr><tr><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Placebo</content></td><td align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">180/2/180</content></td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\"><content styleCode=\"bold\">n (%)</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\"><content styleCode=\"bold\">n (%)</content></td></tr><tr><td align=\"left\" valign=\"middle\">Patients </td><td align=\"center\" valign=\"middle\">1024 </td><td align=\"center\" valign=\"middle\">1040 </td></tr><tr><td align=\"left\" valign=\"middle\">Major bleeding<sup>*</sup></td><td align=\"center\" valign=\"middle\">4 (0.4%) </td><td align=\"center\" valign=\"middle\">13 (1.3%) </td></tr><tr><td align=\"left\" valign=\"middle\">Minor bleeding<sup>*</sup></td><td align=\"center\" valign=\"middle\">18 (2%) </td><td align=\"center\" valign=\"middle\">29 (3%) </td></tr><tr><td align=\"left\" valign=\"middle\" styleCode=\"Botrule\">Requiring transfusions<sup>&#x2020;</sup></td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">11 (1.1%) </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">16 (1.5%) </td></tr></tbody></table>",
      "<table ID=\"t3\" width=\"100%\"><caption>Table 3: Major Bleeding by Procedures in the PURSUIT Study </caption><col width=\"62.767%\" align=\"left\"/><col width=\"17.533%\" align=\"left\"/><col width=\"19.700%\" align=\"left\"/><tfoot><tr><td colspan=\"3\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\">Note: Denominators are based on the total number of patients whose TIMI classification was resolved. </paragraph></td></tr></tfoot><tbody><tr><td align=\"center\" valign=\"middle\" styleCode=\"Toprule\"/><td align=\"center\" valign=\"middle\" styleCode=\"Toprule\"><content styleCode=\"bold\">Placebo</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Toprule\"><content styleCode=\"bold\">Eptifibatide</content></td></tr><tr><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\"><content styleCode=\"bold\">180/2</content></td></tr><tr><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\"><content styleCode=\"bold\">n (%)</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\"><content styleCode=\"bold\">n (%)</content></td></tr><tr><td align=\"left\" valign=\"middle\">Patients </td><td align=\"center\" valign=\"middle\">4577 </td><td align=\"center\" valign=\"middle\">4604 </td></tr><tr><td align=\"left\" valign=\"middle\">Overall incidence of major bleeding </td><td align=\"center\" valign=\"middle\">425 (9.3%) </td><td align=\"center\" valign=\"middle\">498 (10.8%) </td></tr><tr><td align=\"left\" valign=\"middle\">Breakdown by procedure: </td><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\"/></tr><tr><td align=\"left\" valign=\"middle\"> CABG </td><td align=\"center\" valign=\"middle\">375 (8.2%) </td><td align=\"center\" valign=\"middle\">377 (8.2%) </td></tr><tr><td align=\"left\" valign=\"middle\"> Angioplasty without CABG </td><td align=\"center\" valign=\"middle\">27 (0.6%) </td><td align=\"center\" valign=\"middle\">64 (1.4%) </td></tr><tr><td align=\"left\" valign=\"middle\"> Angiography without angioplasty or CABG </td><td align=\"center\" valign=\"middle\">11 (0.2%) </td><td align=\"center\" valign=\"middle\">29 (0.6%) </td></tr><tr><td align=\"left\" valign=\"middle\" styleCode=\"Botrule\"> Medical therapy only </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">12 (0.3%) </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">28 (0.6%) </td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Avoid concomitant use with other glycoprotein (GP) IIb/IIIa inhibitors. ( 7.1 ) 7.1 Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Concomitant treatment with other inhibitors of platelet receptor GP IIb/IIIa should be avoided."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Geriatric Use : Risk of bleeding increases with age. ( 8.5 ) 8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus (see Clinical Considerations ) . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide on the fetus. Data Animal Data Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide. 8.2 Lactation Risk Summary There are no available data on the presence of eptifibatide in human milk, the effects on the breastfed infant, or the effects on milk production. As eptifibatide is a peptide, it is likely to be destroyed in the infant's gastrointestinal tract and not absorbed orally by the breastfed infant. 8.4 Pediatric Use Safety and effectiveness of eptifibatide in pediatric patients have not been studied. 8.5 Geriatric Use The PURSUIT and IMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUIT study; no such limitation was stipulated in the ESPRIT study [see Adverse Reactions ( 6.1 )] . 8.6 Renal Impairment Approximately 50% of eptifibatide is cleared by the kidney in patients with normal renal function. Total drug clearance is decreased by approximately 50% and steady-state plasma eptifibatide concentrations are doubled in patients with an estimated CrCl <50 mL/min (using the Cockcroft-Gault equation). Therefore, the infusion dose should be reduced to 1 mcg/kg/min in such patients [see Dosage and Administration ( 2 )] . The safety and efficacy of eptifibatide in patients dependent on dialysis has not been established."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus (see Clinical Considerations ) . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide on the fetus. Data Animal Data Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety and effectiveness of eptifibatide in pediatric patients have not been studied."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use The PURSUIT and IMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUIT study; no such limitation was stipulated in the ESPRIT study [see Adverse Reactions ( 6.1 )] ."
    ],
    "overdosage": [
      "10 OVERDOSAGE There has been only limited experience with overdosage of eptifibatide. There were 8 patients in the IMPACT II study, 9 patients in the PURSUIT study, and no patients in the ESPRIT study who received bolus doses and/or infusion doses more than double those called for in the protocols. None of these patients experienced an intracranial bleed or other major bleeding. Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis). Symptoms of acute toxicity were loss of righting reflex, dyspnea, ptosis, and decreased muscle tone in rabbits and petechial hemorrhages in the femoral and abdominal areas of monkeys. From in vitro studies, eptifibatide is not extensively bound to plasma proteins and thus may be cleared from plasma by dialysis."
    ],
    "description": [
      "11 DESCRIPTION Eptifibatide is a cyclic heptapeptide containing 6 amino acids and 1 mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties. Chemically it is N 6 -(aminoiminomethyl)-N 2 -(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-\u03b1-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1\u21926)-disulfide. Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation. The eptifibatide peptide is produced by solid-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized. The structural formula is: Eptifibatide Injection is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use with an empirical formula of C 35 H 49 N 11 O 9 S 2 and a molecular weight of 831.96. Each 10 mL vial contains 2 mg per mL of eptifibatide and each 100 mL vial contains 0.75 mg per mL of eptifibatide. Each vial of either size also contains 5.25 mg per mL citric acid and sodium hydroxide to adjust the pH to 5.35. Structural Formula"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet. 12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide was observed immediately after administration of a 180-mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide used in the IMPACT II and PURSUIT studies on ex vivo platelet aggregation induced by 20 \u03bcM ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRIT on platelet aggregation have not been studied. Table 4: Platelet Inhibition and Bleeding Time * 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. PURSUIT 180/2 * Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x The eptifibatide dosing regimen used in the ESPRIT study included two 180-mcg/kg bolus doses given 10 minutes apart combined with a continuous 2-mcg/kg/min infusion. When administered alone, eptifibatide has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed. 12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180-mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4 to 6 hours). This decline can be prevented by administering a second 180-mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20 to 94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations ( 8.6 ) and Dosage and Administration ( 2 )] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "clinical_pharmacology_table": [
      "<table ID=\"t4\" width=\"100%\"><caption>Table 4: Platelet Inhibition and Bleeding Time </caption><col width=\"84.650%\" align=\"left\"/><col width=\"15.350%\" align=\"left\"/><tfoot><tr><td colspan=\"2\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\"><sup>*</sup> 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. </paragraph></td></tr></tfoot><tbody><tr><td align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule\"/><td align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">PURSUIT</content> <content styleCode=\"bold\">180/2</content><sup>*</sup></td></tr><tr><td align=\"left\" valign=\"middle\">Inhibition of platelet aggregation 15 min after bolus </td><td align=\"center\" valign=\"middle\">84% </td></tr><tr><td align=\"left\" valign=\"middle\">Inhibition of platelet aggregation at steady state </td><td align=\"center\" valign=\"middle\">&gt;90% </td></tr><tr><td align=\"left\" valign=\"middle\">Bleeding-time prolongation at steady state </td><td align=\"center\" valign=\"middle\">&lt;5x </td></tr><tr><td align=\"left\" valign=\"middle\">Inhibition of platelet aggregation 4h after infusion discontinuation </td><td align=\"center\" valign=\"middle\">&lt;50% </td></tr><tr><td align=\"left\" valign=\"middle\" styleCode=\"Botrule\">Bleeding-time prolongation 6h after infusion discontinuation </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">1.4x </td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide was observed immediately after administration of a 180-mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide used in the IMPACT II and PURSUIT studies on ex vivo platelet aggregation induced by 20 \u03bcM ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRIT on platelet aggregation have not been studied. Table 4: Platelet Inhibition and Bleeding Time * 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. PURSUIT 180/2 * Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x The eptifibatide dosing regimen used in the ESPRIT study included two 180-mcg/kg bolus doses given 10 minutes apart combined with a continuous 2-mcg/kg/min infusion. When administered alone, eptifibatide has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed."
    ],
    "pharmacodynamics_table": [
      "<table ID=\"t4\" width=\"100%\"><caption>Table 4: Platelet Inhibition and Bleeding Time </caption><col width=\"84.650%\" align=\"left\"/><col width=\"15.350%\" align=\"left\"/><tfoot><tr><td colspan=\"2\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\"><sup>*</sup> 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. </paragraph></td></tr></tfoot><tbody><tr><td align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule\"/><td align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">PURSUIT</content> <content styleCode=\"bold\">180/2</content><sup>*</sup></td></tr><tr><td align=\"left\" valign=\"middle\">Inhibition of platelet aggregation 15 min after bolus </td><td align=\"center\" valign=\"middle\">84% </td></tr><tr><td align=\"left\" valign=\"middle\">Inhibition of platelet aggregation at steady state </td><td align=\"center\" valign=\"middle\">&gt;90% </td></tr><tr><td align=\"left\" valign=\"middle\">Bleeding-time prolongation at steady state </td><td align=\"center\" valign=\"middle\">&lt;5x </td></tr><tr><td align=\"left\" valign=\"middle\">Inhibition of platelet aggregation 4h after infusion discontinuation </td><td align=\"center\" valign=\"middle\">&lt;50% </td></tr><tr><td align=\"left\" valign=\"middle\" styleCode=\"Botrule\">Bleeding-time prolongation 6h after infusion discontinuation </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">1.4x </td></tr></tbody></table>"
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180-mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4 to 6 hours). This decline can be prevented by administering a second 180-mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20 to 94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations ( 8.6 ) and Dosage and Administration ( 2 )] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Eptifibatide was studied in 3 placebo-controlled, randomized studies. PURSUIT evaluated patients with acute coronary syndromes: UA or NSTEMI. Two other studies, ESPRIT and IMPACT II, evaluated patients about to undergo a PCI. Patients underwent primarily balloon angioplasty in IMPACT II and intracoronary stent placement, with or without angioplasty, in ESPRIT. 14.1 Non-ST-Segment Elevation Acute Coronary Syndrome Non-ST-segment elevation acute coronary syndrome is defined as prolonged (\u226510 minutes) symptoms of cardiac ischemia within the previous 24 hours associated with either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or positive CK-MB. This definition includes \"unstable angina\" and \"NSTEMI\" but excludes MI that is associated with Q waves or greater degrees of ST-segment elevation. PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Eptifibatide Therapy) PURSUIT was a 726-center, 27-country, double-blind, randomized, placebo-controlled study in 10,948 patients presenting with UA or NSTEMI. Patients could be enrolled only if they had experienced cardiac ischemia at rest (\u226510 minutes) within the previous 24 hours and had either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or increased CK-MB. Important exclusion criteria included a history of bleeding diathesis, evidence of abnormal bleeding within the previous 30 days, uncontrolled hypertension, major surgery within the previous 6 weeks, stroke within the previous 30 days, any history of hemorrhagic stroke, serum creatinine >2 mg/dL, dependency on renal dialysis, or platelet count <100,000/mm 3 . Patients were randomized to placebo, to eptifibatide 180-mcg/kg bolus followed by a 2-mcg/kg/min infusion (180/2), or to eptifibatide 180-mcg/kg bolus followed by a 1.3-mcg/kg/min infusion (180/1.3). The infusion was continued for 72 hours, until hospital discharge, or until the time of CABG, whichever occurred first, except that if PCI was performed, the eptifibatide infusion was continued for 24 hours after the procedure, allowing for a duration of infusion up to 96 hours. The lower-infusion-rate arm was stopped after the first interim analysis when the 2 active-treatment arms appeared to have the same incidence of bleeding. Patient age ranged from 20 to 94 (mean 63) years, and 65% were male. The patients were 89% Caucasian, 6% Hispanic, and 5% Black, recruited in the United States and Canada (40%), Western Europe (39%), Eastern Europe (16%), and Latin America (5%). This was a \"real world\" study; each patient was managed according to the usual standards of the investigational site; frequencies of angiography, PCI, and CABG therefore differed widely from site to site and from country to country. Of the patients in PURSUIT, 13% were managed with PCI during drug infusion, of whom 50% received intracoronary stents; 87% were managed medically (without PCI during drug infusion). The majority of patients received aspirin (75 to 325 mg once daily). Heparin was administered intravenously or subcutaneously, at the physician's discretion, most commonly as an intravenous bolus of 5000 units followed by a continuous infusion of 1000 units/h. For patients weighing less than 70 kg, the recommended heparin bolus dose was 60 units/kg followed by a continuous infusion of 12 units/kg/h. A target aPTT of 50 to 70 seconds was recommended. A total of 1250 patients underwent PCI within 72 hours after randomization, in which case they received intravenous heparin to maintain an ACT of 300 to 350 seconds. The primary endpoint of the study was the occurrence of death from any cause or new MI (evaluated by a blinded Clinical Endpoints Committee) within 30 days of randomization. Compared to placebo, eptifibatide administered as a 180-mcg/kg bolus followed by a 2-mcg/kg/min infusion significantly (p=0.042) reduced the incidence of endpoint events (see Table 6 ). The reduction in the incidence of endpoint events in patients receiving eptifibatide was evident early during treatment, and this reduction was maintained through at least 30 days (see Figure 1 ). Table 5 also shows the incidence of the components of the primary endpoint, death (whether or not preceded by an MI) and new MI in surviving patients at 30 days. Table 5: Clinical Events in the PURSUIT Study Placebo Eptifibatide p-value Death or MI (n=4739) n (%) (180 mcg/kg bolus then 2 mcg/kg/min infusion) (n=4722) n (%) 3 days 359 (7.6%) 279 (5.9%) 0.001 7 days 552 (11.6%) 477 (10.1%) 0.016 30 days Death or MI (primary endpoint) 745 (15.7%) 672 (14.2%) 0.042 Death 177 (3.7%) 165 (3.5%) Nonfatal MI 568 (12%) 507 (10.7%) Figure 1: Kaplan-Meier Plot of Time to Death or Myocardial Infarction Within 30 Days of Randomization in the PURSUIT Study Treatment with eptifibatide prior to determination of patient management strategy reduced clinical events regardless of whether patients ultimately underwent diagnostic catheterization, revascularization (i.e., PCI or CABG surgery) or continued to receive medical management alone. Table 6 shows the incidence of death or MI within 72 hours. Table 6: Clinical Events (Death or MI) in the PURSUIT Study Within 72 Hours of Randomization Placebo Eptifibatide (180 mcg/kg bolus then 2 mcg/kg/min infusion) Overall patient population N=4739 N=4722 \u2013 At 72 hours 7.6% 5.9% Patients undergoing early PCI n=631 n=619 \u2013 Pre-procedure (nonfatal MI only) 5.5% 1.8% \u2013 At 72 hours 14.4% 9% Patients not undergoing early PCI n=4108 n=4103 \u2013 At 72 hours 6.5% 5.4% All of the effect of eptifibatide was established within 72 hours (during the period of drug infusion), regardless of management strategy. Moreover, for patients undergoing early PCI, a reduction in events was evident prior to the procedure. An analysis of the results by sex suggests that women who would not routinely be expected to undergo PCI receive less benefit from eptifibatide (95% confidence limits for relative risk of 0.94 to 1.28) than do men (0.72 to 0.9). This difference may be a true treatment difference, the effect of other differences in these subgroups, or a statistical anomaly. No differential outcomes were seen between male and female patients undergoing PCI (see results for ESPRIT) . Follow-up data were available through 165 days for 10,611 patients enrolled in the PURSUIT trial (96.9% of the initial enrollment). This follow-up included 4566 patients who received eptifibatide at the 180/2 dose. As reported by the investigators, the occurrence of death from any cause or new MI for patients followed for at least 165 days was reduced from 13.6% with placebo to 12.1% with eptifibatide 180/2. Figure 1 14.2 Percutaneous Coronary Intervention (PCI) IMPACT II (Eptifibatide to Minimize Platelet Aggregation and Prevent Coronary Thrombosis II) IMPACT II was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States in 4010 patients undergoing PCI. Major exclusion criteria included a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 89 (mean 60) years, and 75% were male. The patients were 92% Caucasian, 5% Black, and 3% Hispanic. Forty-one percent of the patients underwent PCI for ongoing ACS. Patients were randomly assigned to 1 of 3 treatment regimens, each incorporating a bolus dose initiated immediately prior to PCI followed by a continuous infusion lasting 20 to 24 hours: 1) 135-mcg/kg bolus followed by a continuous infusion of 0.5 mcg/kg/min of eptifibatide (135/0.5); 2) 135-mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min of eptifibatide (135/0.75); or 3) a matching placebo bolus followed by a matching placebo continuous infusion. Each patient received aspirin and an intravenous heparin bolus of 100 units/kg, with additional bolus infusions of up to 2000 additional units of heparin every 15 minutes to maintain an ACT of 300 to 350 seconds. The primary endpoint was the composite of death, MI, or urgent revascularization, analyzed at 30 days after randomization in all patients who received at least 1 dose of study drug. As shown in Table 7 , each eptifibatide regimen reduced the rate of death, MI, or urgent intervention, although at 30 days, this finding was statistically significant only in the lower-dose eptifibatide group. As in the PURSUIT study, the effects of eptifibatide were seen early and persisted throughout the 30-day period. Table 7: Clinical Events in the IMPACT II Study * Kaplan-Meier estimate of event rate. Placebo n (%) Eptifibatide (135 mcg/kg bolus then 0.5 mcg/kg/min infusion) n (%) Eptifibatide (135 mcg/kg bolus then 0.75 mcg/kg/min infusion) n (%) Patients 1285 1300 1286 Abrupt Closure 65 (5.1%) 36 (2.8%) 43 (3.3%) p-value versus placebo 0.003 0.03 Death, MI, or Urgent Intervention 24 hours 123 (9.6%) 86 (6.6%) 89 (6.9%) p-value versus placebo 0.006 0.014 48 hours 131 (10.2%) 99 (7.6%) 102 (7.9%) p-value versus placebo 0.021 0.045 30 days (primary endpoint) 149 (11.6%) 118 (9.1%) 128 (10%) p-value versus placebo 0.035 0.179 Death or MI 30 days 110 (8.6%) 89 (6.8%) 95 (7.4%) p-value versus placebo 0.102 0.272 6 months 151 (11.9%) * 136 (10.6%) * 130 (10.3%) * p-value versus placebo 0.297 0.182 ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Eptifibatide Therapy) The ESPRIT study was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States and Canada that enrolled 2064 patients undergoing elective or urgent PCI with intended intracoronary stent placement. Exclusion criteria included MI within the previous 24 hours, ongoing chest pain, administration of any oral antiplatelet or oral anticoagulant other than aspirin within 30 days of PCI (although loading doses of thienopyridine on the day of PCI were encouraged), planned PCI of a saphenous vein graft or subsequent \"staged\" PCI, prior stent placement in the target lesion, PCI within the previous 90 days, a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 93 (mean 62) years, and 73% of patients were male. The study enrolled 90% Caucasian, 5% African American, 2% Hispanic, and 1% Asian patients. Patients received a wide variety of stents. Patients were randomized either to placebo or eptifibatide administered as an intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2 mcg/kg/min, and a second bolus of 180 mcg/kg administered 10 minutes later (180/2/180). Eptifibatide infusion was continued for 18 to 24 hours after PCI or until hospital discharge, whichever came first. Each patient received at least 1 dose of aspirin (162 to 325 mg) and 60 units/kg of heparin as a bolus (not to exceed 6000 units) if not already receiving a heparin infusion. Additional boluses of heparin (10 to 40 units/kg) could be administered in order to reach a target ACT between 200 and 300 seconds. The primary endpoint of the ESPRIT study was the composite of death, MI, urgent target vessel revascularization (UTVR), and \"bailout\" to open-label eptifibatide due to a thrombotic complication of PCI (TBO) (e.g., visible thrombus, \"no reflow,\" or abrupt closure) at 48 hours. MI, UTVR, and TBO were evaluated by a blinded Clinical Events Committee. As shown in Table 8 , the incidence of the primary endpoint and selected secondary endpoints was significantly reduced in patients who received eptifibatide. A treatment benefit in patients who received eptifibatide was seen by 48 hours and at the end of the 30-day observation period. Table 8: Clinical Events in the ESPRIT Study * Eptifibatide was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min. Placebo (n=1024) Eptifibatide * (n=1040) Relative Risk (95% CI) p-value Death, MI, UTVR, or Thrombotic \"Bailout\" 48 hours (primary endpoint) 108 (10.5%) 69 (6.6%) 0.629 (0.471, 0.84) 0.0015 30 days 120 (11.7%) 78 (7.5%) 0.64 (0.488, 0.84) 0.0011 Death, MI, or UTVR 48 hours 95 (9.3%) 62 (6%) 0.643 (0.472, 0.875) 0.0045 30 days (key secondary endpoint) 107 (10.4%) 71 (6.8%) 0.653 (0.49, 0.871) 0.0034 Death or MI 48 hours 94 (9.2%) 57 (5.5%) 0.597 (0.435, 0.82) 0.0013 30 days 104 (10.2%) 66 (6.3%) 0.625 (0.465, 0.84) 0.0016 The need for thrombotic \"bailout\" was significantly reduced with eptifibatide at 48 hours (2.1% for placebo, 1% for eptifibatide; p=0.029). Consistent with previous studies of GP IIb/IIIa inhibitors, most of the benefit achieved acutely with eptifibatide was in the reduction of MI. Eptifibatide reduced the occurrence of MI at 48 hours from 9% for placebo to 5.4% (p=0.0015) and maintained that effect with significance at 30 days. There was no treatment difference with respect to sex in ESPRIT. Eptifibatide reduced the incidence of the primary endpoint in both men (95% confidence limits for relative risk: 0.54, 1.07) and women (0.24, 0.72) at 48 hours. Follow-up (12-month) mortality data were available for 2024 patients (1017 on eptifibatide) enrolled in the ESPRIT trial (98.1% of the initial enrollment). Twelve-month clinical event data were available for 1964 patients (988 on eptifibatide), representing 95.2% of the initial enrollment. As shown in Table 9 , the treatment effect of eptifibatide seen at 48 hours and 30 days appeared preserved at 6 months and 1 year. Most of the benefit was in reduction of MI. Table 9: Clinical Events at 6 Months and 1 Year in the ESPRIT Study Percentages are Kaplan-Meier event rates. Placebo (n=1024) Eptifibatide (n=1040) Hazard Ratio (95% CI) Death, MI, or Target Vessel Revascularization 6 months 187 (18.5%) 146 (14.3%) 0.744 (0.599, 0.924) 1 year 222 (22.1%) 178 (17.5%) 0.762 (0.626, 0.929) Death, MI 6 months 117 (11.5%) 77 (7.4%) 0.631 (0.473, 0.841) 1 year 126 (12.4%) 83 (8%) 0.63 (0.478, 0.832)"
    ],
    "clinical_studies_table": [
      "<table ID=\"t5\" width=\"100%\"><caption>Table 5: Clinical Events in the PURSUIT Study </caption><col width=\"30.683%\" align=\"left\"/><col width=\"15.079%\" align=\"left\"/><col width=\"40.610%\" align=\"left\"/><col width=\"13.628%\" align=\"left\"/><tbody><tr><td align=\"center\" valign=\"middle\" styleCode=\"Toprule\"/><td align=\"center\" valign=\"middle\" styleCode=\"Toprule\"><content styleCode=\"bold\">Placebo</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Toprule\"><content styleCode=\"bold\">Eptifibatide</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Toprule\"><content styleCode=\"bold\">p-value</content></td></tr><tr><td align=\"left\" valign=\"middle\" styleCode=\"Botrule\"><content styleCode=\"bold\">Death or MI</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\"><content styleCode=\"bold\">(n=4739)</content> <content styleCode=\"bold\">n (%)</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\"><content styleCode=\"bold\">(180 mcg/kg bolus then</content> <content styleCode=\"bold\">2 mcg/kg/min infusion)</content> <content styleCode=\"bold\">(n=4722)</content> <content styleCode=\"bold\">n (%)</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\"/></tr><tr><td align=\"left\" valign=\"middle\">3 days </td><td align=\"center\" valign=\"middle\">359 (7.6%) </td><td align=\"center\" valign=\"middle\">279 (5.9%) </td><td align=\"center\" valign=\"middle\">0.001 </td></tr><tr><td align=\"left\" valign=\"middle\">7 days </td><td align=\"center\" valign=\"middle\">552 (11.6%) </td><td align=\"center\" valign=\"middle\">477 (10.1%) </td><td align=\"center\" valign=\"middle\">0.016 </td></tr><tr><td align=\"left\" valign=\"middle\">30 days </td><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\"/></tr><tr><td align=\"left\" valign=\"middle\"> Death or MI (primary endpoint) </td><td align=\"center\" valign=\"middle\">745 (15.7%) </td><td align=\"center\" valign=\"middle\">672 (14.2%) </td><td align=\"center\" valign=\"middle\">0.042 </td></tr><tr><td align=\"left\" valign=\"middle\"> Death </td><td align=\"center\" valign=\"middle\">177 (3.7%) </td><td align=\"center\" valign=\"middle\">165 (3.5%) </td><td align=\"center\" valign=\"middle\"/></tr><tr><td align=\"left\" valign=\"middle\" styleCode=\"Botrule\"> Nonfatal MI </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">568 (12%) </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">507 (10.7%) </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\"/></tr></tbody></table>",
      "<table ID=\"t6\" width=\"100%\"><caption>Table 6: Clinical Events (Death or MI) in the PURSUIT Study Within 72 Hours of Randomization </caption><col width=\"46.333%\" align=\"left\"/><col width=\"14.400%\" align=\"left\"/><col width=\"39.267%\" align=\"left\"/><tbody><tr><td align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule\"/><td align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Placebo</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(180 mcg/kg bolus then</content> <content styleCode=\"bold\">2 mcg/kg/min infusion)</content></td></tr><tr><td align=\"left\" valign=\"top\">Overall patient population </td><td align=\"center\" valign=\"middle\">N=4739 </td><td align=\"center\" valign=\"middle\">N=4722 </td></tr><tr><td align=\"left\" valign=\"top\"> &#x2013; At 72 hours </td><td align=\"center\" valign=\"middle\">7.6% </td><td align=\"center\" valign=\"middle\">5.9% </td></tr><tr><td align=\"left\" valign=\"middle\">Patients undergoing early PCI </td><td align=\"center\" valign=\"middle\">n=631 </td><td align=\"center\" valign=\"middle\">n=619 </td></tr><tr><td align=\"left\" valign=\"top\"> &#x2013; Pre-procedure (nonfatal MI only) </td><td align=\"center\" valign=\"middle\">5.5% </td><td align=\"center\" valign=\"middle\">1.8% </td></tr><tr><td align=\"left\" valign=\"middle\"> &#x2013; At 72 hours </td><td align=\"center\" valign=\"middle\">14.4% </td><td align=\"center\" valign=\"middle\">9% </td></tr><tr><td align=\"left\" valign=\"middle\">Patients not undergoing early PCI </td><td align=\"center\" valign=\"middle\">n=4108 </td><td align=\"center\" valign=\"middle\">n=4103 </td></tr><tr><td align=\"left\" valign=\"top\" styleCode=\"Botrule\"> &#x2013; At 72 hours </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">6.5% </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">5.4% </td></tr></tbody></table>",
      "<table ID=\"t7\" width=\"100%\"><caption>Table 7: Clinical Events in the IMPACT II Study </caption><col width=\"26.718%\" align=\"left\"/><col width=\"16.721%\" align=\"left\"/><col width=\"28.318%\" align=\"left\"/><col width=\"28.243%\" align=\"left\"/><tfoot><tr><td colspan=\"4\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\"><sup>*</sup> Kaplan-Meier estimate of event rate. </paragraph></td></tr></tfoot><tbody><tr><td align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule\"/><td align=\"center\" valign=\"bottom\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">n (%)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(135 mcg/kg bolus then 0.5 mcg/kg/min infusion)</content> <content styleCode=\"bold\">n (%)</content></td><td align=\"center\" valign=\"top\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(135 mcg/kg bolus then 0.75 mcg/kg/min infusion)</content> <content styleCode=\"bold\">n (%)</content></td></tr><tr><td align=\"left\" valign=\"top\">Patients </td><td align=\"center\" valign=\"middle\">1285 </td><td align=\"center\" valign=\"middle\">1300 </td><td align=\"center\" valign=\"middle\">1286 </td></tr><tr><td align=\"left\" valign=\"top\">Abrupt Closure </td><td align=\"center\" valign=\"middle\">65 (5.1%) </td><td align=\"center\" valign=\"middle\">36 (2.8%) </td><td align=\"center\" valign=\"middle\">43 (3.3%) </td></tr><tr><td align=\"left\" valign=\"top\"> p-value versus placebo </td><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\">0.003 </td><td align=\"center\" valign=\"middle\">0.03 </td></tr><tr><td colspan=\"4\" align=\"left\" valign=\"top\">Death, MI, or Urgent Intervention </td></tr><tr><td align=\"left\" valign=\"top\"> 24 hours </td><td align=\"center\" valign=\"middle\">123 (9.6%) </td><td align=\"center\" valign=\"middle\">86 (6.6%) </td><td align=\"center\" valign=\"middle\">89 (6.9%) </td></tr><tr><td align=\"left\" valign=\"top\"> p-value versus placebo </td><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\">0.006 </td><td align=\"center\" valign=\"middle\">0.014 </td></tr><tr><td align=\"left\" valign=\"top\"> 48 hours </td><td align=\"center\" valign=\"middle\">131 (10.2%) </td><td align=\"center\" valign=\"middle\">99 (7.6%) </td><td align=\"center\" valign=\"middle\">102 (7.9%) </td></tr><tr><td align=\"left\" valign=\"top\"> p-value versus placebo </td><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\">0.021 </td><td align=\"center\" valign=\"middle\">0.045 </td></tr><tr><td align=\"left\" valign=\"top\"> 30 days (primary endpoint) </td><td align=\"center\" valign=\"middle\">149 (11.6%) </td><td align=\"center\" valign=\"middle\">118 (9.1%) </td><td align=\"center\" valign=\"middle\">128 (10%) </td></tr><tr><td align=\"left\" valign=\"top\"> p-value versus placebo </td><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\">0.035 </td><td align=\"center\" valign=\"middle\">0.179 </td></tr><tr><td colspan=\"4\" align=\"left\" valign=\"top\">Death or MI </td></tr><tr><td align=\"left\" valign=\"top\"> 30 days </td><td align=\"center\" valign=\"middle\">110 (8.6%) </td><td align=\"center\" valign=\"middle\">89 (6.8%) </td><td align=\"center\" valign=\"middle\">95 (7.4%) </td></tr><tr><td align=\"left\" valign=\"top\"> p-value versus placebo </td><td align=\"center\" valign=\"middle\"/><td align=\"center\" valign=\"middle\">0.102 </td><td align=\"center\" valign=\"middle\">0.272 </td></tr><tr><td align=\"left\" valign=\"top\"> 6 months </td><td align=\"center\" valign=\"middle\">151 (11.9%)<sup>*</sup></td><td align=\"center\" valign=\"middle\">136 (10.6%)<sup>*</sup></td><td align=\"center\" valign=\"middle\">130 (10.3%)<sup>*</sup></td></tr><tr><td align=\"left\" valign=\"top\" styleCode=\"Botrule\"> p-value versus placebo </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\"/><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">0.297 </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">0.182 </td></tr></tbody></table>",
      "<table ID=\"t8\" width=\"100%\"><caption>Table 8: Clinical Events in the ESPRIT Study </caption><col width=\"20.000%\" align=\"left\"/><col width=\"20.000%\" align=\"left\"/><col width=\"20.000%\" align=\"left\"/><col width=\"20.000%\" align=\"left\"/><col width=\"20.000%\" align=\"left\"/><tfoot><tr><td colspan=\"5\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\"><sup>*</sup> Eptifibatide was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min. </paragraph></td></tr></tfoot><tbody><tr><td align=\"left\" valign=\"top\" styleCode=\"Toprule Botrule\"/><td align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(n=1024)</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Eptifibatide</content><sup>*</sup> <content styleCode=\"bold\">(n=1040)</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Relative Risk</content> <content styleCode=\"bold\">(95% CI)</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">p-value</content></td></tr><tr><td colspan=\"5\" align=\"left\" valign=\"top\">Death, MI, UTVR, or Thrombotic &quot;Bailout&quot; </td></tr><tr><td align=\"left\" valign=\"top\"> 48 hours (primary   endpoint) </td><td align=\"center\" valign=\"middle\">108 (10.5%) </td><td align=\"center\" valign=\"middle\">69 (6.6%) </td><td align=\"center\" valign=\"middle\">0.629 (0.471, 0.84) </td><td align=\"center\" valign=\"middle\">0.0015 </td></tr><tr><td align=\"left\" valign=\"top\"> 30 days </td><td align=\"center\" valign=\"middle\">120 (11.7%) </td><td align=\"center\" valign=\"middle\">78 (7.5%) </td><td align=\"center\" valign=\"middle\">0.64 (0.488, 0.84) </td><td align=\"center\" valign=\"middle\">0.0011 </td></tr><tr><td colspan=\"5\" align=\"left\" valign=\"top\">Death, MI, or UTVR </td></tr><tr><td align=\"left\" valign=\"top\"> 48 hours </td><td align=\"center\" valign=\"middle\">95 (9.3%) </td><td align=\"center\" valign=\"middle\">62 (6%) </td><td align=\"center\" valign=\"middle\">0.643 (0.472, 0.875) </td><td align=\"center\" valign=\"middle\">0.0045 </td></tr><tr><td align=\"left\" valign=\"top\"> 30 days (key   secondary endpoint) </td><td align=\"center\" valign=\"middle\">107 (10.4%) </td><td align=\"center\" valign=\"middle\">71 (6.8%) </td><td align=\"center\" valign=\"middle\">0.653 (0.49, 0.871) </td><td align=\"center\" valign=\"middle\">0.0034 </td></tr><tr><td colspan=\"5\" align=\"left\" valign=\"top\">Death or MI </td></tr><tr><td align=\"left\" valign=\"top\"> 48 hours </td><td align=\"center\" valign=\"middle\">94 (9.2%) </td><td align=\"center\" valign=\"middle\">57 (5.5%) </td><td align=\"center\" valign=\"middle\">0.597 (0.435, 0.82) </td><td align=\"center\" valign=\"middle\">0.0013 </td></tr><tr><td align=\"left\" valign=\"top\" styleCode=\"Botrule\"> 30 days </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">104 (10.2%) </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">66 (6.3%) </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">0.625 (0.465, 0.84) </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">0.0016 </td></tr></tbody></table>",
      "<table ID=\"t9\" width=\"100%\"><caption>Table 9: Clinical Events at 6 Months and 1 Year in the ESPRIT Study </caption><col width=\"25.350%\" align=\"left\"/><col width=\"24.875%\" align=\"left\"/><col width=\"24.900%\" align=\"left\"/><col width=\"24.875%\" align=\"left\"/><tfoot><tr><td colspan=\"4\" align=\"left\" valign=\"top\"><paragraph styleCode=\"footnote\">Percentages are Kaplan-Meier event rates. </paragraph></td></tr></tfoot><tbody><tr><td align=\"left\" valign=\"top\" styleCode=\"Toprule Botrule\"/><td align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(n=1024)</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Eptifibatide</content> <content styleCode=\"bold\">(n=1040)</content></td><td align=\"center\" valign=\"middle\" styleCode=\"Toprule Botrule\"><content styleCode=\"bold\">Hazard Ratio</content> <content styleCode=\"bold\">(95% CI)</content></td></tr><tr><td colspan=\"4\" align=\"left\" valign=\"top\">Death, MI, or Target Vessel Revascularization </td></tr><tr><td align=\"left\" valign=\"top\"> 6 months </td><td align=\"center\" valign=\"middle\">187 (18.5%) </td><td align=\"center\" valign=\"middle\">146 (14.3%) </td><td align=\"center\" valign=\"middle\">0.744 (0.599, 0.924) </td></tr><tr><td align=\"left\" valign=\"top\"> 1 year </td><td align=\"center\" valign=\"middle\">222 (22.1%) </td><td align=\"center\" valign=\"middle\">178 (17.5%) </td><td align=\"center\" valign=\"middle\">0.762 (0.626, 0.929) </td></tr><tr><td colspan=\"4\" align=\"left\" valign=\"top\">Death, MI </td></tr><tr><td align=\"left\" valign=\"top\"> 6 months </td><td align=\"center\" valign=\"middle\">117 (11.5%) </td><td align=\"center\" valign=\"middle\">77 (7.4%) </td><td align=\"center\" valign=\"middle\">0.631 (0.473, 0.841) </td></tr><tr><td align=\"left\" valign=\"top\" styleCode=\"Botrule\"> 1 year </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">126 (12.4%) </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">83 (8%) </td><td align=\"center\" valign=\"middle\" styleCode=\"Botrule\">0.63 (0.478, 0.832) </td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Eptifibatide Injection is supplied as follows: NDC Eptifibatide Injection (2 mg per mL) Package Factor 83634-300-10 20 mg per 10 mL Single-Dose Vial 1 vial per carton NDC Eptifibatide Injection (0.75 mg per mL) Package Factor 83634-301-51 75 mg per 100 mL Single-Dose Vial 1 vial per carton 16.2 Storage Conditions Vials should be stored refrigerated between 2\u00b0 and 8\u00b0C (36\u00b0 and 46\u00b0F). Vials may be transferred to room temperature storage * for a period not to exceed 2 months. Upon transfer, vial cartons must be marked by the dispensing pharmacist with a \"DISCARD BY\" date (2 months from the transfer date or the labeled expiration date, whichever comes first). Protect from light. Retain in carton until time of use. Discard unused portion. * Store at 25\u00b0C (77\u00b0F); excursions permitted between 15\u00b0 and 30\u00b0C (59\u00b0 and 86\u00b0F). [See USP Controlled Room Temperature.] Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex."
    ],
    "how_supplied_table": [
      "<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"16.333%\" align=\"left\"/><col width=\"41.833%\" align=\"left\"/><col width=\"41.833%\" align=\"left\"/><tbody><tr><td align=\"justify\" valign=\"top\"><content styleCode=\"bold\">NDC</content></td><td align=\"justify\" valign=\"top\"><content styleCode=\"bold\">Eptifibatide Injection (2 mg per mL)</content></td><td align=\"justify\" valign=\"top\"><content styleCode=\"bold\">Package Factor</content></td></tr><tr><td align=\"justify\" valign=\"top\">83634-300-10 </td><td align=\"justify\" valign=\"top\">20 mg per 10 mL Single-Dose Vial </td><td align=\"justify\" valign=\"top\">1 vial per carton </td></tr><tr><td align=\"justify\" valign=\"top\"> </td><td align=\"justify\" valign=\"top\"/><td align=\"justify\" valign=\"top\"/></tr><tr><td align=\"justify\" valign=\"top\"><content styleCode=\"bold\">NDC</content></td><td align=\"justify\" valign=\"top\"><content styleCode=\"bold\">Eptifibatide Injection (0.75 mg per mL)</content></td><td align=\"justify\" valign=\"top\"><content styleCode=\"bold\">Package Factor</content></td></tr><tr><td align=\"justify\" valign=\"top\">83634-301-51 </td><td align=\"justify\" valign=\"top\">75 mg per 100 mL Single-Dose Vial </td><td align=\"justify\" valign=\"top\">1 vial per carton </td></tr></tbody></table>"
    ],
    "storage_and_handling": [
      "16.2 Storage Conditions Vials should be stored refrigerated between 2\u00b0 and 8\u00b0C (36\u00b0 and 46\u00b0F). Vials may be transferred to room temperature storage * for a period not to exceed 2 months. Upon transfer, vial cartons must be marked by the dispensing pharmacist with a \"DISCARD BY\" date (2 months from the transfer date or the labeled expiration date, whichever comes first). Protect from light. Retain in carton until time of use. Discard unused portion. * Store at 25\u00b0C (77\u00b0F); excursions permitted between 15\u00b0 and 30\u00b0C (59\u00b0 and 86\u00b0F). [See USP Controlled Room Temperature.] Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to inform the doctor or healthcare provider about any medical conditions, medications, and allergies. AVENACY Mfd. for Avenacy Schaumburg, IL 60173 (USA) Made in China \u00a92023 Avenacy Inc. October 2023"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL - PRINCIPAL DISPLAY PANEL \u2013 Vial Label NDC 83634-300-10 Eptifibatide Injection 20 mg per 10 mL (2 mg per mL) Rx only For Weight-Adjusted Bolus Dosing For Intravenous Use Only 10 mL Single-Dose Vial PACKAGE LABEL - PRINCIPAL DISPLAY PANEL \u2013 Vial Label",
      "PACKAGE LABEL - PRINCIPAL DISPLAY PANEL \u2013 Vial Label NDC 83634-301-51 Eptifibatide Injection 75 mg per 100 mL (0.75 mg per mL) Rx only For Weight-Adjusted Infusion For Intravenous Use Only 100 mL Single-Dose Vial PACKAGE LABEL - PRINCIPAL DISPLAY PANEL \u2013 Vial Label"
    ],
    "set_id": "c0781dae-3ef6-4cab-b084-01d2e45f3764",
    "id": "74e580c1-7f30-49cf-8e83-968bc05c5559",
    "effective_time": "20240815",
    "version": "2",
    "openfda": {
      "application_number": [
        "ANDA213081"
      ],
      "brand_name": [
        "Eptifibatide"
      ],
      "generic_name": [
        "EPTIFIBATIDE"
      ],
      "manufacturer_name": [
        "Avenacy Inc."
      ],
      "product_ndc": [
        "83634-300",
        "83634-301"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "INTRAVENOUS"
      ],
      "substance_name": [
        "EPTIFIBATIDE"
      ],
      "rxcui": [
        "200349",
        "1736470"
      ],
      "spl_id": [
        "74e580c1-7f30-49cf-8e83-968bc05c5559"
      ],
      "spl_set_id": [
        "c0781dae-3ef6-4cab-b084-01d2e45f3764"
      ],
      "package_ndc": [
        "83634-300-10",
        "83634-301-51"
      ],
      "is_original_packager": [
        true
      ],
      "nui": [
        "N0000008832",
        "N0000175578"
      ],
      "pharm_class_pe": [
        "Decreased Platelet Aggregation [PE]"
      ],
      "pharm_class_epc": [
        "Platelet Aggregation Inhibitor [EPC]"
      ],
      "unii": [
        "NA8320J834"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Eptifibatide Eptifibatide Eptifibatide Eptifibatide Citric Acid Monohydrate Sodium Hydroxide Eptifibatide Eptifibatide Eptifibatide Eptifibatide Citric Acid Monohydrate Sodium Hydroxide"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Eptifibatide injection is a platelet aggregation inhibitor indicated for: Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI) ( 1.1 ) Treatment of patients undergoing PCI (including intracoronary stenting) ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). 1.2 Percutaneous Coronary Intervention (PCI) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting [see Clinical Studies (14.1 , 14.2) ] ."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION Before infusion of eptifibatide injection, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured. The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT. ACS or PCI: 180 mcg/kg IV bolus as soon as possible after diagnosis followed by infusion at 2 mcg/kg/min. ( 2.1 , 2.2 ) PCI: Add a second 180 mcg/kg bolus at 10 minutes. ( 2.2 ) In patients with creatinine clearance less than 50 mL/min, reduce the infusion to 1 mcg/kg/min. ( 2.1 , 2.2 , 2.3 ) 2.1 Dosage in Acute Coronary Syndrome (ACS) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with ACS 180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min 180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy Aspirin, 160 to 325 mg, should be given daily. Eptifibatide injection should be given concomitantly with heparin dosed to achieve the following parameters: During Medical Management : Target aPTT 50 to 70 seconds If weight greater than or equal to 70 kg, 5000-unit bolus followed by infusion of 1000 units/h. If weight less than 70 kg, 60-units/kg bolus followed by infusion of 12 units/kg/h. During PCI : Target ACT 200 to 300 seconds If heparin is initiated prior to PCI, additional boluses during PCI to maintain an ACT target of 200 to 300 seconds. Heparin infusion after the PCI is discouraged. 2.2 Dosage in Percutaneous Coronary Intervention (PCI) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with PCI 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. In patients who undergo CABG surgery, eptifibatide injection infusion should be discontinued prior to surgery. Aspirin, 160 to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter. Eptifibatide injection should be given concomitantly with heparin to achieve a target ACT of 200 to 300 seconds. Administer 60-units/kg bolus initially in patients not treated with heparin within 6 hours prior to PCI. Additional boluses during PCI to maintain ACT within target. Heparin infusion after the PCI is strongly discouraged. Patients requiring thrombolytic therapy should discontinue eptifibatide injection. 2.3 Important Administration Instructions Inspect eptifibatide injection for particulate matter and discoloration prior to administration, whenever solution and container permit. May administer eptifibatide injection in the same intravenous line as alteplase, atropine, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, or verapamil. Do not administer eptifibatide injection through the same intravenous line as furosemide. May administer eptifibatide injection in the same IV line with 0.9% NaCl or 0.9% NaCl/5% dextrose. With either vehicle, the infusion may also contain up to 60 mEq/L of potassium chloride. Withdraw the bolus dose(s) of eptifibatide injection from the 10-mL vial into a syringe. Administer the bolus dose(s) by IV push. Immediately following the bolus dose administration, initiate a continuous infusion of eptifibatide injection. When using an intravenous infusion pump, administer eptifibatide injection undiluted directly from the 100-mL vial. Spike the 100-mL vial with a vented infusion set. Center the spike within the circle on the stopper top. Discard any unused portion left in the vial. Administer eptifibatide injection by volume according to patient weight (see Table 1 ). Table 1: Eptifiatide Injection Dosing Charts by Weight Patient Weight 180-mcg/kg Bolus Volume 2-mcg/kg/min Infusion Volume (CrCl greater than or equal to 50 mL/min) 1-mcg/kg/min Infusion Volume (CrCl less than 50 mL/min) (kg) (lb) (from 2-mg/mL vial) (from 2-mg/mL 100-mL vial) (from 0.75-mg/mL 100-mL vial) (from 2-mg/mL 100-mL vial) (from 0.75-mg/mL 100-mL vial) 37-41 81-91 3.4 mL 2 mL/h 6 mL/h 1 mL/h 3 mL/h 42-46 92-102 4 mL 2.5 mL/h 7 mL/h 1.3 mL/h 3.5 mL/h 47-53 103-117 4.5 mL 3 mL/h 8 mL/h 1.5 mL/h 4 mL/h 54-59 118-130 5 mL 3.5 mL/h 9 mL/h 1.8 mL/h 4.5 mL/h 60-65 131-143 5.6 mL 3.8 mL/h 10 mL/h 1.9 mL/h 5 mL/h 66-71 144-157 6.2 mL 4 mL/h 11 mL/h 2 mL/h 5.5 mL/h 72-78 158-172 6.8 mL 4.5 mL/h 12 mL/h 2.3 mL/h 6 mL/h 79-84 173-185 7.3 mL 5 mL/h 13 mL/h 2.5 mL/h 6.5 mL/h 85-90 186-198 7.9 mL 5.3 mL/h 14 mL/h 2.7 mL/h 7 mL/h 91-96 199-212 8.5 mL 5.6 mL/h 15 mL/h 2.8 mL/h 7.5 mL/h 97-103 213-227 9 mL 6 mL/h 16 mL/h 3.0 mL/h 8 mL/h 104-109 228-240 9.5 mL 6.4 mL/h 17 mL/h 3.2 mL/h 8.5 mL/h 110-115 241-253 10.2 mL 6.8 mL/h 18 mL/h 3.4 mL/h 9 mL/h 116-121 254-267 10.7 mL 7 mL/h 19 mL/h 3.5 mL/h 9.5 mL/h >121 >267 11.3 mL 7.5 mL/h 20 mL/h 3.7 mL/h 10 mL/h"
    ],
    "dosage_and_administration_table": [
      "<table width=\"80%\"><colgroup><col width=\"20%\" align=\"left\" valign=\"top\"/><col width=\"40%\" align=\"left\" valign=\"top\"/><col width=\"40%\" align=\"left\" valign=\"top\"/></colgroup><thead><tr styleCode=\"First Last\"><th styleCode=\"Lrule Rrule\" align=\"left\">Indication</th><th styleCode=\"Rrule\" align=\"left\">Normal Renal Function</th><th styleCode=\"Rrule\" align=\"left\">Creatinine Clearance less than 50 mL/min</th></tr></thead><tbody><tr styleCode=\"Botrule First\"><td styleCode=\"Lrule Rrule\" align=\"left\">Patients with ACS</td><td styleCode=\"Rrule\" align=\"left\">180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min</td><td styleCode=\"Rrule\" align=\"left\">180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min</td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"left\"/><td styleCode=\"Rrule\" colspan=\"2\" align=\"left\"><list listType=\"unordered\"><item>Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours</item><item>If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy</item><item>Aspirin, 160 to 325 mg, should be given daily.</item></list></td></tr></tbody></table>",
      "<table width=\"80%\"><colgroup><col width=\"20%\" align=\"left\" valign=\"top\"/><col width=\"40%\" align=\"left\" valign=\"top\"/><col width=\"40%\" align=\"left\" valign=\"top\"/></colgroup><thead><tr styleCode=\"First Last\"><th styleCode=\"Lrule Rrule\" align=\"left\">Indication</th><th styleCode=\"Rrule\" align=\"left\">Normal Renal Function</th><th styleCode=\"Rrule\" align=\"left\">Creatinine Clearance less than 50 mL/min</th></tr></thead><tbody><tr styleCode=\"Botrule First\"><td styleCode=\"Lrule Rrule\" align=\"left\">Patients with PCI</td><td styleCode=\"Rrule\" align=\"left\">180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus)</td><td styleCode=\"Rrule\" align=\"left\">180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus)</td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"left\"/><td styleCode=\"Rrule\" colspan=\"2\" align=\"left\"><list listType=\"unordered\" styleCode=\"Disc\"><item>Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended.</item><item>In patients who undergo CABG surgery, eptifibatide injection infusion should be discontinued prior to surgery.</item><item>Aspirin, 160 to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter.</item></list></td></tr></tbody></table>",
      "<table ID=\"table1\" width=\"100%\"><caption>Table 1: Eptifiatide Injection Dosing Charts by Weight</caption><colgroup><col width=\"16%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/></colgroup><thead><tr styleCode=\"First Last\"><th styleCode=\"Lrule\" colspan=\"2\" align=\"center\">Patient Weight</th><th align=\"center\">180-mcg/kg Bolus Volume</th><th colspan=\"2\" align=\"center\">2-mcg/kg/min Infusion Volume (CrCl greater than or equal to 50 mL/min)</th><th styleCode=\"Rrule\" colspan=\"2\" align=\"center\">1-mcg/kg/min Infusion Volume (CrCl less than 50 mL/min)</th></tr></thead><tbody><tr styleCode=\"Botrule First\"><td styleCode=\"Lrule\" align=\"center\"><content styleCode=\"bold\">(kg)</content></td><td align=\"center\"><content styleCode=\"bold\">(lb)</content></td><td align=\"center\"><content styleCode=\"bold\">(from 2-mg/mL vial)</content></td><td align=\"center\"><content styleCode=\"bold\">(from 2-mg/mL 100-mL vial)</content></td><td align=\"center\"><content styleCode=\"bold\">(from 0.75-mg/mL 100-mL vial)</content></td><td align=\"center\"><content styleCode=\"bold\">(from 2-mg/mL 100-mL vial)</content></td><td styleCode=\"Rrule\" align=\"center\"><content styleCode=\"bold\">(from 0.75-mg/mL 100-mL vial)</content></td></tr><tr><td styleCode=\"Lrule\" align=\"center\">37-41</td><td align=\"center\">81-91</td><td align=\"center\">3.4 mL</td><td align=\"center\">2 mL/h</td><td align=\"center\">6 mL/h</td><td align=\"center\">1 mL/h</td><td styleCode=\"Rrule\" align=\"center\">3 mL/h</td></tr><tr><td styleCode=\"Lrule\" align=\"center\">42-46</td><td align=\"center\">92-102</td><td align=\"center\">4 mL</td><td align=\"center\">2.5 mL/h</td><td align=\"center\">7 mL/h</td><td align=\"center\">1.3 mL/h</td><td styleCode=\"Rrule\" align=\"center\">3.5 mL/h</td></tr><tr><td styleCode=\"Lrule\" align=\"center\">47-53</td><td align=\"center\">103-117</td><td align=\"center\">4.5 mL</td><td align=\"center\">3 mL/h</td><td align=\"center\">8 mL/h</td><td align=\"center\">1.5 mL/h</td><td styleCode=\"Rrule\" align=\"center\">4 mL/h</td></tr><tr><td styleCode=\"Lrule\" align=\"center\">54-59</td><td align=\"center\">118-130</td><td align=\"center\">5 mL</td><td align=\"center\">3.5 mL/h</td><td align=\"center\">9 mL/h</td><td align=\"center\">1.8 mL/h</td><td styleCode=\"Rrule\" align=\"center\">4.5 mL/h</td></tr><tr><td styleCode=\"Lrule\" align=\"center\">60-65</td><td align=\"center\">131-143</td><td align=\"center\">5.6 mL</td><td align=\"center\">3.8 mL/h</td><td align=\"center\">10 mL/h</td><td align=\"center\">1.9 mL/h</td><td styleCode=\"Rrule\" align=\"center\">5 mL/h</td></tr><tr><td styleCode=\"Lrule\" align=\"center\">66-71</td><td align=\"center\">144-157</td><td align=\"center\">6.2 mL</td><td align=\"center\">4 mL/h</td><td align=\"center\">11 mL/h</td><td align=\"center\">2 mL/h</td><td styleCode=\"Rrule\" align=\"center\">5.5 mL/h</td></tr><tr><td styleCode=\"Lrule\" align=\"center\">72-78</td><td align=\"center\">158-172</td><td align=\"center\">6.8 mL</td><td align=\"center\">4.5 mL/h</td><td align=\"center\">12 mL/h</td><td align=\"center\">2.3 mL/h</td><td styleCode=\"Rrule\" align=\"center\">6 mL/h</td></tr><tr><td styleCode=\"Lrule\" align=\"center\">79-84</td><td align=\"center\">173-185</td><td align=\"center\">7.3 mL</td><td align=\"center\">5 mL/h</td><td align=\"center\">13 mL/h</td><td align=\"center\">2.5 mL/h</td><td styleCode=\"Rrule\" align=\"center\">6.5 mL/h</td></tr><tr><td styleCode=\"Lrule\" align=\"center\">85-90</td><td align=\"center\">186-198</td><td align=\"center\">7.9 mL</td><td align=\"center\">5.3 mL/h</td><td align=\"center\">14 mL/h</td><td align=\"center\">2.7 mL/h</td><td styleCode=\"Rrule\" align=\"center\">7 mL/h</td></tr><tr><td styleCode=\"Lrule\" align=\"center\">91-96</td><td align=\"center\">199-212</td><td align=\"center\">8.5 mL</td><td align=\"center\">5.6 mL/h</td><td align=\"center\">15 mL/h</td><td align=\"center\">2.8 mL/h</td><td styleCode=\"Rrule\" align=\"center\">7.5 mL/h</td></tr><tr><td styleCode=\"Lrule\" align=\"center\">97-103</td><td align=\"center\">213-227</td><td align=\"center\">9 mL</td><td align=\"center\">6 mL/h</td><td align=\"center\">16 mL/h</td><td align=\"center\">3.0 mL/h</td><td styleCode=\"Rrule\" align=\"center\">8 mL/h</td></tr><tr><td styleCode=\"Lrule\" align=\"center\">104-109</td><td align=\"center\">228-240</td><td align=\"center\">9.5 mL</td><td align=\"center\">6.4 mL/h</td><td align=\"center\">17 mL/h</td><td align=\"center\">3.2 mL/h</td><td styleCode=\"Rrule\" align=\"center\">8.5 mL/h</td></tr><tr><td styleCode=\"Lrule\" align=\"center\">110-115</td><td align=\"center\">241-253</td><td align=\"center\">10.2 mL</td><td align=\"center\">6.8 mL/h</td><td align=\"center\">18 mL/h</td><td align=\"center\">3.4 mL/h</td><td styleCode=\"Rrule\" align=\"center\">9 mL/h</td></tr><tr><td styleCode=\"Lrule\" align=\"center\">116-121</td><td align=\"center\">254-267</td><td align=\"center\">10.7 mL</td><td align=\"center\">7 mL/h</td><td align=\"center\">19 mL/h</td><td align=\"center\">3.5 mL/h</td><td styleCode=\"Rrule\" align=\"center\">9.5 mL/h</td></tr><tr><td styleCode=\"Lrule\" align=\"center\">&gt;121</td><td align=\"center\">&gt;267</td><td align=\"center\">11.3 mL</td><td align=\"center\">7.5 mL/h</td><td align=\"center\">20 mL/h</td><td align=\"center\">3.7 mL/h</td><td styleCode=\"Rrule\" align=\"center\">10 mL/h</td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Injection: 20 mg of eptifibatide in 10 mL (2 mg/mL), for intravenous bolus. Injection: 75 mg of eptifibatide in 100 mL (0.75 mg/mL), for intravenous infusion. 20 mg/10 mL (2 mg/mL) in a single-dose vial for bolus injection ( 3 ) 75 mg/100 mL (0.75 mg/mL) in a single-dose vial for infusion (3)"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Treatment with eptifibatide is contraindicated in patients with: A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another parenteral GP IIb/IIIa inhibitor Dependency on renal dialysis Hypersensitivity to eptifibatide or any component of the product (hypersensitivity reactions that occurred included anaphylaxis and urticaria) Bleeding diathesis or bleeding within the previous 30 days ( 4 ) Severe uncontrolled hypertension ( 4 ) Major surgery within the preceding 6 weeks ( 4 ) Stroke within 30 days or any history of hemorrhagic stroke ( 4 ) Coadministration of another parenteral GP IIb/IIIa inhibitor ( 4 ) Dependency on renal dialysis ( 4 ) Known hypersensitivity to any component of the product ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Eptifibatide can cause serious bleeding. If bleeding cannot be controlled, discontinue eptifibatide immediately. Minimize vascular and other traumas. If heparin is given concomitantly, monitor aPTT or ACT. ( 5.1 ) Thrombocytopenia: Discontinue eptifibatide and heparin. Monitor and treat condition appropriately. ( 5.2 ) 5.1 Bleeding Bleeding is the most common complication encountered during eptifibatide therapy. Administration of eptifibatide is associated with an increase in major and minor bleeding, as classified by the criteria of the Thrombolysis in Myocardial Infarction Study group (TIMI) [see Adverse Reactions (6.1) ] . Most major bleeding associated with eptifibatide has been at the arterial access site for cardiac catheterization or from the gastrointestinal or genitourinary tract. Minimize the use of arterial and venous punctures, intramuscular injections, and the use of urinary catheters, nasotracheal intubation, and nasogastric tubes. When obtaining intravenous access, avoid non-compressible sites (e.g., subclavian or jugular veins). Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Risk factors for bleeding include older age, a history of bleeding disorders, and concomitant use of drugs that increase the risk of bleeding (thrombolytics, oral anticoagulants, nonsteroidal anti-inflammatory drugs, and P2Y 12 inhibitors). Concomitant treatment with other inhibitors of platelet receptor glycoprotein (GP) IIb/IIIa should be avoided. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT [see Dosage and Administration (2) ] . Care of the Femoral Artery Access Site in Patients Undergoing Percutaneous Coronary Intervention (PCI) In patients undergoing PCI, treatment with eptifibatide is associated with an increase in major and minor bleeding at the site of arterial sheath placement. After PCI, eptifibatide infusion should be continued until hospital discharge or up to 18 to 24 hours, whichever comes first. Heparin use is discouraged after the PCI procedure. Early sheath removal is encouraged while eptifibatide is being infused. Prior to removing the sheath, it is recommended that heparin be discontinued for 3 to 4 hours and an aPTT of <45 seconds or ACT <150 seconds be achieved. In any case, both heparin and eptifibatide should be discontinued and sheath hemostasis should be achieved at least 2 to 4 hours before hospital discharge. If bleeding at access site cannot be controlled with pressure, infusion of eptifibatide and heparin should be discontinued immediately. 5.2 Thrombocytopenia There have been reports of acute, profound thrombocytopenia (immune-mediated and non-immune mediated) with eptifibatide. In the event of acute profound thrombocytopenia or a confirmed platelet decrease to <100,000/mm 3 , discontinue eptifibatide and heparin (unfractionated or low-molecular weight). Monitor serial platelet counts, assess the presence of drug-dependent antibodies, and treat as appropriate [see Adverse Reactions (6.1) ] . There has been no clinical experience with eptifibatide initiated in patients with a baseline platelet count <100,000/mm 3 . If a patient with low platelet counts is receiving eptifibatide, their platelet count should be monitored closely."
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Avoid concomitant use with other glycoprotein (GP) IIb/IIIa inhibitors. ( 7.1 ) 7.1 Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Concomitant treatment with other inhibitors of platelet receptor GP IIb/IIIa should be avoided."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Geriatric Use: Risk of bleeding increases with age. ( 8.5 ) 8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus (see Clinical Considerations ) . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide on the fetus Data Animal Data Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide. 8.2 Lactation Risk Summary There are no available data on the presence of eptifibatide in human milk, the effects on the breastfed infant, or the effects on milk production. As eptifibatide is a peptide, it is likely to be destroyed in the infant\u2019s gastrointestinal tract and not absorbed orally by the breastfed infant. 8.4 Pediatric Use Safety and effectiveness of eptifibatide in pediatric patients have not been studied. 8.5 Geriatric Use The PURSUIT and IMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUIT study; no such limitation was stipulated in the ESPRIT study [see Adverse Reactions (6.1) ] . 8.6 Renal Impairment Approximately 50% of eptifibatide is cleared by the kidney in patients with normal renal function. Total drug clearance is decreased by approximately 50% and steady-state plasma eptifibatide concentrations are doubled in patients with an estimated CrCl <50 mL/min (using the Cockcroft-Gault equation). Therefore, the infusion dose should be reduced to 1 mcg/kg/min in such patients [see Dosage and Administration (2) ] . The safety and efficacy of eptifibatide in patients dependent on dialysis has not been established."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus (see Clinical Considerations ) . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide on the fetus Data Animal Data Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety and effectiveness of eptifibatide in pediatric patients have not been studied."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use The PURSUIT and IMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUIT study; no such limitation was stipulated in the ESPRIT study [see Adverse Reactions (6.1) ] ."
    ],
    "overdosage": [
      "10 OVERDOSAGE There has been only limited experience with overdosage of eptifibatide. There were 8 patients in the IMPACT II study, 9 patients in the PURSUIT study, and no patients in the ESPRIT study who received bolus doses and/or infusion doses more than double those called for in the protocols. None of these patients experienced an intracranial bleed or other major bleeding. Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis). Symptoms of acute toxicity were loss of righting reflex, dyspnea, ptosis, and decreased muscle tone in rabbits and petechial hemorrhages in the femoral and abdominal areas of monkeys. From in vitro studies, eptifibatide is not extensively bound to plasma proteins and thus may be cleared from plasma by dialysis."
    ],
    "description": [
      "11 DESCRIPTION Eptifibatide is a cyclic heptapeptide containing 6 amino acids and 1 mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties. Chemically it is N 6 -(aminoiminomethyl)-N 2 -(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-\u03b1-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1\u21926)-disulfide. Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation. The eptifibatide peptide is produced by solid-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized. The structural formula is: Eptifibatide Injection is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use with an empirical formula of C 35 H 49 N 11 O 9 S 2 and a molecular weight of 831.96. Each 10-mL vial contains 2 mg/mL of eptifibatide and each 100-mL vial contains 0.75 mg/mL of eptifibatide. Each vial of either size also contains 5.25 mg/mL citric acid and sodium hydroxide to adjust the pH to 5.35. image description"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet. 12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide was observed immediately after administration of a 180-mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide used in the IMPACT II and PURSUIT studies on ex vivo platelet aggregation induced by 20 \u00b5M ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRIT on platelet aggregation have not been studied. Table 4: Platelet Inhibition and Bleeding Time PURSUIT 180/2 180-mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x The eptifibatide dosing regimen used in the ESPRIT study included two 180-mcg/kg bolus doses given 10 minutes apart combined with a continuous 2-mcg/kg/min infusion. When administered alone, eptifibatide has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed. 12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180-mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4-6 hours). This decline can be prevented by administering a second 180-mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20-94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations (8.6) and Dosage and Administration (2) ] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "clinical_pharmacology_table": [
      "<table width=\"80%\"><caption>Table 4: Platelet Inhibition and Bleeding Time</caption><colgroup><col width=\"75%\" align=\"left\" valign=\"top\"/><col width=\"25%\" align=\"left\" valign=\"top\"/></colgroup><thead><tr styleCode=\"First Last\"><th align=\"left\"/><th align=\"left\">PURSUIT 180/2<footnote ID=\"table4a\">180-mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min.</footnote></th></tr></thead><tbody><tr><td align=\"left\">Inhibition of platelet aggregation 15 min after bolus</td><td align=\"left\">84%</td></tr><tr><td align=\"left\">Inhibition of platelet aggregation at steady state</td><td align=\"left\">&gt;90%</td></tr><tr><td align=\"left\">Bleeding-time prolongation at steady state</td><td align=\"left\">&lt;5x</td></tr><tr><td align=\"left\">Inhibition of platelet aggregation 4h after infusion discontinuation</td><td align=\"left\">&lt;50%</td></tr><tr><td align=\"left\">Bleeding-time prolongation 6h after infusion discontinuation</td><td align=\"left\">1.4x</td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide was observed immediately after administration of a 180-mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide used in the IMPACT II and PURSUIT studies on ex vivo platelet aggregation induced by 20 \u00b5M ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRIT on platelet aggregation have not been studied. Table 4: Platelet Inhibition and Bleeding Time PURSUIT 180/2 180-mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x The eptifibatide dosing regimen used in the ESPRIT study included two 180-mcg/kg bolus doses given 10 minutes apart combined with a continuous 2-mcg/kg/min infusion. When administered alone, eptifibatide has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed."
    ],
    "pharmacodynamics_table": [
      "<table width=\"80%\"><caption>Table 4: Platelet Inhibition and Bleeding Time</caption><colgroup><col width=\"75%\" align=\"left\" valign=\"top\"/><col width=\"25%\" align=\"left\" valign=\"top\"/></colgroup><thead><tr styleCode=\"First Last\"><th align=\"left\"/><th align=\"left\">PURSUIT 180/2<footnote ID=\"table4a\">180-mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min.</footnote></th></tr></thead><tbody><tr><td align=\"left\">Inhibition of platelet aggregation 15 min after bolus</td><td align=\"left\">84%</td></tr><tr><td align=\"left\">Inhibition of platelet aggregation at steady state</td><td align=\"left\">&gt;90%</td></tr><tr><td align=\"left\">Bleeding-time prolongation at steady state</td><td align=\"left\">&lt;5x</td></tr><tr><td align=\"left\">Inhibition of platelet aggregation 4h after infusion discontinuation</td><td align=\"left\">&lt;50%</td></tr><tr><td align=\"left\">Bleeding-time prolongation 6h after infusion discontinuation</td><td align=\"left\">1.4x</td></tr></tbody></table>"
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180-mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4-6 hours). This decline can be prevented by administering a second 180-mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20-94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations (8.6) and Dosage and Administration (2) ] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Eptifibatide was studied in 3 placebo-controlled, randomized studies. PURSUIT evaluated patients with acute coronary syndromes: UA or NSTEMI. Two other studies, ESPRIT and IMPACT II, evaluated patients about to undergo a PCI. Patients underwent primarily balloon angioplasty in IMPACT II and intracoronary stent placement, with or without angioplasty, in ESPRIT. 14.1 Non-ST-Segment Elevation Acute Coronary Syndrome Non-ST-segment elevation acute coronary syndrome is defined as prolonged (\u226510 minutes) symptoms of cardiac ischemia within the previous 24 hours associated with either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or positive CK-MB. This definition includes \"unstable angina\" and \"NSTEMI\" but excludes MI that is associated with Q waves or greater degrees of ST-segment elevation. PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Eptifibatide Therapy) PURSUIT was a 726-center, 27-country, double-blind, randomized, placebo-controlled study in 10,948 patients presenting with UA or NSTEMI. Patients could be enrolled only if they had experienced cardiac ischemia at rest (\u226510 minutes) within the previous 24 hours and had either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or increased CK-MB. Important exclusion criteria included a history of bleeding diathesis, evidence of abnormal bleeding within the previous 30 days, uncontrolled hypertension, major surgery within the previous 6 weeks, stroke within the previous 30 days, any history of hemorrhagic stroke, serum creatinine >2 mg/dL, dependency on renal dialysis, or platelet count <100,000/mm 3 . Patients were randomized to placebo, to eptifibatide 180-mcg/kg bolus followed by a 2-mcg/kg/min infusion (180/2), or to eptifibatide 180-mcg/kg bolus followed by a 1.3-mcg/kg/min infusion (180/1.3). The infusion was continued for 72 hours, until hospital discharge, or until the time of CABG, whichever occurred first, except that if PCI was performed, the eptifibatide infusion was continued for 24 hours after the procedure, allowing for a duration of infusion up to 96 hours. The lower-infusion-rate arm was stopped after the first interim analysis when the 2 active-treatment arms appeared to have the same incidence of bleeding. Patient age ranged from 20 to 94 (mean 63) years, and 65% were male. The patients were 89% Caucasian, 6% Hispanic, and 5% Black, recruited in the United States and Canada (40%), Western Europe (39%), Eastern Europe (16%), and Latin America (5%). This was a \"real world\" study; each patient was managed according to the usual standards of the investigational site; frequencies of angiography, PCI, and CABG therefore differed widely from site to site and from country to country. Of the patients in PURSUIT, 13% were managed with PCI during drug infusion, of whom 50% received intracoronary stents; 87% were managed medically (without PCI during drug infusion). The majority of patients received aspirin (75-325 mg once daily). Heparin was administered intravenously or subcutaneously, at the physician's discretion, most commonly as an intravenous bolus of 5000 units followed by a continuous infusion of 1000 units/h. For patients weighing less than 70 kg, the recommended heparin bolus dose was 60 units/kg followed by a continuous infusion of 12 units/kg/h. A target aPTT of 50 to 70 seconds was recommended. A total of 1250 patients underwent PCI within 72 hours after randomization, in which case they received intravenous heparin to maintain an ACT of 300 to 350 seconds. The primary endpoint of the study was the occurrence of death from any cause or new MI (evaluated by a blinded Clinical Endpoints Committee) within 30 days of randomization. Compared to placebo, eptifibatide administered as a 180-mcg/kg bolus followed by a 2-mcg/kg/min infusion significantly (p=0.042) reduced the incidence of endpoint events (see Table 6 ). The reduction in the incidence of endpoint events in patients receiving eptifibatide was evident early during treatment, and this reduction was maintained through at least 30 days (see Figure 1 ). Table 5 also shows the incidence of the components of the primary endpoint, death (whether or not preceded by an MI) and new MI in surviving patients at 30 days. Table 5: Clinical Events in the PURSUIT Study Placebo Eptifibatide p-value Death or MI (n=4739) n (%) (180 mcg/kg bolus then 2 mcg/kg/min infusion) (n=4722) n (%) 3 days 359 (7.6%) 279 (5.9%) 0.001 7 days 552 (11.6%) 477 (10.1%) 0.016 30 days Death or MI (primary endpoint) 745 (15.7%) 672 (14.2%) 0.042 Death 177 (3.7%) 165 (3.5%) Nonfatal MI 568 (12%) 507 (10.7%) Figure 1: Kaplan-Meier Plot of Time to Death or Myocardial Infarction Within 30 Days of Randomization in the PURSUIT Study Treatment with eptifibatide prior to determination of patient management strategy reduced clinical events regardless of whether patients ultimately underwent diagnostic catheterization, revascularization (i.e., PCI or CABG surgery) or continued to receive medical management alone. Table 6 shows the incidence of death or MI within 72 hours. Table 6: Clinical Events (Death or MI) in the PURSUIT Study Within 72 Hours of Randomization Placebo Eptifibatide (180 mcg/kg bolus then 2 mcg/kg/min infusion) Overall patient population n=4739 n=4722 \u2013 At 72 hours 7.6% 5.9% Patients undergoing early PCI n=631 n=619 \u2013 Pre-procedure (nonfatal MI only) 5.5% 1.8% \u2013 At 72 hours 14.4% 9% Patients not undergoing early PCI n=4108 n=4103 \u2013 At 72 hours 6.5% 5.4% All of the effect of eptifibatide was established within 72 hours (during the period of drug infusion), regardless of management strategy. Moreover, for patients undergoing early PCI, a reduction in events was evident prior to the procedure. An analysis of the results by sex suggests that women who would not routinely be expected to undergo PCI receive less benefit from eptifibatide (95% confidence limits for relative risk of 0.94 - 1.28) than do men (0.72 - 0.9). This difference may be a true treatment difference, the effect of other differences in these subgroups, or a statistical anomaly. No differential outcomes were seen between male and female patients undergoing PCI (see results for ESPRIT) . Follow-up data were available through 165 days for 10,611 patients enrolled in the PURSUIT trial (96.9% of the initial enrollment). This follow-up included 4566 patients who received eptifibatide at the 180/2 dose. As reported by the investigators, the occurrence of death from any cause or new MI for patients followed for at least 165 days was reduced from 13.6% with placebo to 12.1% with eptifibatide 180/2. image description 14.2 Percutaneous Coronary Intervention (PCI) IMPACT II (Eptifibatide to Minimize Platelet Aggregation and Prevent Coronary Thrombosis II) IMPACT II was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States in 4010 patients undergoing PCI. Major exclusion criteria included a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 89 (mean 60) years, and 75% were male. The patients were 92% Caucasian, 5% Black, and 3% Hispanic. Forty-one percent of the patients underwent PCI for ongoing ACS. Patients were randomly assigned to 1 of 3 treatment regimens, each incorporating a bolus dose initiated immediately prior to PCI followed by a continuous infusion lasting 20 to 24 hours: 1)135-mcg/kg bolus followed by a continuous infusion of 0.5 mcg/kg/min of eptifibatide (135/0.5); 2)135-mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min of eptifibatide (135/0.75); or 3)a matching placebo bolus followed by a matching placebo continuous infusion. Each patient received aspirin and an intravenous heparin bolus of 100 units/kg, with additional bolus infusions of up to 2000 additional units of heparin every 15 minutes to maintain an ACT of 300 to 350 seconds. The primary endpoint was the composite of death, MI, or urgent revascularization, analyzed at 30 days after randomization in all patients who received at least 1 dose of study drug. As shown in Table 7 , each eptifibatide regimen reduced the rate of death, MI, or urgent intervention, although at 30 days, this finding was statistically significant only in the lower-dose eptifibatide group. As in the PURSUIT study, the effects of eptifibatide were seen early and persisted throughout the 30-day period. Table 7: Clinical Events in the IMPACT II Study Placebo n (%) Eptifibatide (135 mcg/kg bolus then 0.5 mcg/kg/min infusion) n (%) Eptifibatide (135 mcg/kg bolus then 0.75 mcg/kg/min infusion) n (%) Patients 1285 1300 1286 Abrupt Closure 65 (5.1%) 36 (2.8%) 43 (3.3%) p-value versus placebo 0.003 0.03 Death, MI, or Urgent Intervention 24 hours 123 (9.6%) 86 (6.6%) 89 (6.9%) p-value versus placebo 0.006 0.014 48 hours 131 (10.2%) 99 (7.6%) 102 (7.9%) p-value versus placebo 0.021 0.045 30 days (primary endpoint) 149 (11.6%) 118 (9.1%) 128 (10%) p-value versus placebo 0.035 0.179 Death or MI 30 days 110 (8.6%) 89 (6.8%) 95 (7.4%) p-value versus placebo 0.102 0.272 6 months 151 (11.9%) Kaplan-Meier estimate of event rate. 136 (10.6%) 130 (10.3%) p-value versus placebo 0.297 0.182 ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Eptifibatide Therapy) The ESPRIT study was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States and Canada that enrolled 2064 patients undergoing elective or urgent PCI with intended intracoronary stent placement. Exclusion criteria included MI within the previous 24 hours, ongoing chest pain, administration of any oral antiplatelet or oral anticoagulant other than aspirin within 30 days of PCI (although loading doses of thienopyridine on the day of PCI were encouraged), planned PCI of a saphenous vein graft or subsequent \"staged\" PCI, prior stent placement in the target lesion, PCI within the previous 90 days, a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 93 (mean 62) years, and 73% of patients were male. The study enrolled 90% Caucasian, 5% African American, 2% Hispanic, and 1% Asian patients. Patients received a wide variety of stents. Patients were randomized either to placebo or Eptifibatide administered as an intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2 mcg/kg/min, and a second bolus of 180 mcg/kg administered 10 minutes later (180/2/180). Eptifibatide infusion was continued for 18 to 24 hours after PCI or until hospital discharge, whichever came first. Each patient received at least 1 dose of aspirin (162-325 mg) and 60 units/kg of heparin as a bolus (not to exceed 6000 units) if not already receiving a heparin infusion. Additional boluses of heparin (10 to 40 units/kg) could be administered in order to reach a target ACT between 200 and 300 seconds. The primary endpoint of the ESPRIT study was the composite of death, MI, urgent target vessel revascularization (UTVR), and \"bailout\" to open-label eptifibatide due to a thrombotic complication of PCI (TBO) (e.g., visible thrombus, \"no reflow,\" or abrupt closure) at 48 hours. MI, UTVR, and TBO were evaluated by a blinded Clinical Events Committee. As shown in Table 8 , the incidence of the primary endpoint and selected secondary endpoints was significantly reduced in patients who received eptifibatide. A treatment benefit in patients who received eptifibatide was seen by 48 hours and at the end of the 30-day observation period. Table 8: Clinical Events in the ESPRIT Study Placebo Eptifibatide Eptifibatide was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min. Relative Risk (95% CI) p-value (n=1024) (n=1040) Death, MI, UTVR, or Thrombotic \"Bailout\" 48 hours (primary endpoint) 108 (10.5%) 69 (6.6%) 0.629 (0.471, 0.84) 0.0015 30 days 120 (11.7%) 78 (7.5%) 0.64 (0.488, 0.84) 0.0011 Death, MI, or UTVR 48 hours 95 (9.3%) 62 (6%) 0.643 (0.472, 0.875) 0.0045 30 days (key secondary endpoint) 107 (10.4%) 71 (6.8%) 0.653 (0.49, 0.871) 0.0034 Death or MI 48 hours 94 (9.2%) 57 (5.5%) 0.597 (0.435, 0.82) 0.0013 30 days 104 (10.2%) 66 (6.3%) 0.625 (0.465, 0.84) 0.0016 The need for thrombotic \"bailout\" was significantly reduced with eptifibatide at 48 hours (2.1% for placebo, 1% for eptifibatide; p=0.029). Consistent with previous studies of GP IIb/IIIa inhibitors, most of the benefit achieved acutely with eptifibatide was in the reduction of MI. Eptifibatide reduced the occurrence of MI at 48 hours from 9% for placebo to 5.4% (p=0.0015) and maintained that effect with significance at 30 days. There was no treatment difference with respect to sex in ESPRIT. Eptifibatide reduced the incidence of the primary endpoint in both men (95% confidence limits for relative risk: 0.54, 1.07) and women (0.24, 0.72) at 48 hours. Follow-up (12-month) mortality data were available for 2024 patients (1017 on eptifibatide) enrolled in the ESPRIT trial (98.1% of the initial enrollment). Twelve-month clinical event data were available for 1964 patients (988 on eptifibatide), representing 95.2% of the initial enrollment. As shown in Table 9, the treatment effect of eptifibatide seen at 48 hours and 30 days appeared preserved at 6 months and 1 year. Most of the benefit was in reduction of MI. Table 9: Clinical Events at 6 Months and 1 Year in the ESPRIT Study Placebo Eptifibatide Hazard Ratio (n=1024) (n=1040) (95% CI) Percentages are Kaplan-Meier event rates. Death, MI, or Target Vessel Revascularization 6 months 187 (18.5%) 146 (14.3%) 0.744 (0.599, 0.924) 1 year 222 (22.1%) 178 (17.5%) 0.762 (0.626, 0.929) Death, MI 6 months 117 (11.5%) 77 (7.4%) 0.631 (0.473, 0.841) 1 year 126 (12.4%) 83 (8%) 0.63 (0.478, 0.832)"
    ],
    "clinical_studies_table": [
      "<table ID=\"table5\" width=\"80%\"><caption>Table 5: Clinical Events in the PURSUIT Study</caption><colgroup><col width=\"30%\" valign=\"top\" align=\"left\"/><col width=\"20%\" valign=\"top\" align=\"center\"/><col width=\"30%\" valign=\"top\" align=\"center\"/><col width=\"20%\" valign=\"top\" align=\"center\"/></colgroup><thead><tr><th align=\"left\"/><th align=\"center\">Placebo</th><th align=\"center\">Eptifibatide</th><th align=\"center\">p-value</th></tr><tr><th align=\"left\"> Death or MI</th><th align=\"center\"> (n=4739) n (%)</th><th align=\"center\">(180 mcg/kg bolus then 2 mcg/kg/min infusion) (n=4722) n (%)</th><th align=\"center\"/></tr></thead><tbody><tr><td align=\"left\">3 days</td><td align=\"center\">359 (7.6%)</td><td align=\"center\">279 (5.9%)</td><td align=\"center\">0.001</td></tr><tr><td align=\"left\">7 days</td><td align=\"center\">552 (11.6%)</td><td align=\"center\">477 (10.1%)</td><td align=\"center\">0.016</td></tr><tr><td align=\"left\">30 days</td><td align=\"center\"/><td align=\"center\"/><td align=\"center\"/></tr><tr><td align=\"left\"> Death or MI (primary endpoint)</td><td align=\"center\">745 (15.7%)</td><td align=\"center\">672 (14.2%)</td><td align=\"center\">0.042</td></tr><tr><td align=\"left\"> Death</td><td align=\"center\">177 (3.7%)</td><td align=\"center\">165 (3.5%)</td><td align=\"center\"/></tr><tr><td align=\"left\"> Nonfatal MI</td><td align=\"center\">568 (12%)</td><td align=\"center\">507 (10.7%)</td><td align=\"center\"/></tr></tbody></table>",
      "<table ID=\"fig1\" width=\"75%\"><colgroup><col width=\"100%\" valign=\"top\" align=\"left\"/></colgroup><tbody><tr><td align=\"left\"><content styleCode=\"bold\">Figure 1: Kaplan-Meier Plot of Time to Death or Myocardial Infarction Within 30 Days of Randomization in the PURSUIT Study</content></td></tr><tr><td align=\"left\"><paragraph><renderMultiMedia referencedObject=\"L2608b59c-8aa9-4d1b-b037-b51aecbc5a91\"/></paragraph></td></tr></tbody></table>",
      "<table ID=\"table6\" width=\"80%\"><caption>Table 6: Clinical Events (Death or MI) in the PURSUIT Study Within 72 Hours of Randomization</caption><colgroup><col width=\"40%\" valign=\"top\" align=\"left\"/><col width=\"30%\" valign=\"top\" align=\"center\"/><col width=\"30%\" valign=\"top\" align=\"center\"/></colgroup><thead><tr styleCode=\"First Last\"><th align=\"left\"/><th align=\"center\">Placebo</th><th align=\"center\">Eptifibatide (180 mcg/kg bolus then 2 mcg/kg/min infusion)</th></tr></thead><tbody><tr><td align=\"left\">Overall patient population</td><td align=\"center\">n=4739</td><td align=\"center\">n=4722</td></tr><tr><td align=\"left\"> &#x2013; At 72 hours</td><td align=\"center\">7.6%</td><td align=\"center\">5.9%</td></tr><tr><td align=\"left\">Patients undergoing early PCI</td><td align=\"center\">n=631</td><td align=\"center\">n=619</td></tr><tr><td align=\"left\"> &#x2013; Pre-procedure (nonfatal MI only)</td><td align=\"center\">5.5%</td><td align=\"center\">1.8%</td></tr><tr><td align=\"left\"> &#x2013; At 72 hours</td><td align=\"center\">14.4%</td><td align=\"center\">9%</td></tr><tr><td align=\"left\">Patients not undergoing early PCI</td><td align=\"center\">n=4108</td><td align=\"center\">n=4103</td></tr><tr><td align=\"left\"> &#x2013; At 72 hours</td><td align=\"center\">6.5%</td><td align=\"center\">5.4%</td></tr></tbody></table>",
      "<table ID=\"table7\" width=\"80%\"><caption>Table 7: Clinical Events in the IMPACT II Study</caption><colgroup><col width=\"40%\" align=\"left\" valign=\"top\"/><col width=\"20%\" align=\"center\" valign=\"top\"/><col width=\"20%\" align=\"center\" valign=\"top\"/><col width=\"20%\" align=\"center\" valign=\"top\"/></colgroup><thead><tr styleCode=\"First Last\"><th align=\"left\"/><th align=\"center\">Placebo  n (%)</th><th align=\"center\">Eptifibatide (135 mcg/kg bolus then 0.5 mcg/kg/min infusion) n (%)</th><th align=\"center\">Eptifibatide (135 mcg/kg bolus then 0.75 mcg/kg/min infusion) n (%)</th></tr></thead><tbody><tr><td align=\"left\">Patients</td><td align=\"center\">1285</td><td align=\"center\">1300</td><td align=\"center\">1286</td></tr><tr><td align=\"left\">Abrupt Closure</td><td align=\"center\">65 (5.1%)</td><td align=\"center\">36 (2.8%)</td><td align=\"center\">43 (3.3%)</td></tr><tr><td align=\"left\"> p-value versus placebo</td><td align=\"center\"/><td align=\"center\">0.003</td><td align=\"center\">0.03</td></tr><tr><td align=\"left\">Death, MI, or Urgent Intervention</td><td align=\"center\"/><td align=\"center\"/><td align=\"center\"/></tr><tr><td align=\"left\"> 24 hours</td><td align=\"center\">123 (9.6%)</td><td align=\"center\">86 (6.6%)</td><td align=\"center\">89 (6.9%)</td></tr><tr><td align=\"left\"> p-value versus placebo</td><td align=\"center\"/><td align=\"center\">0.006</td><td align=\"center\">0.014</td></tr><tr><td align=\"left\"> 48 hours</td><td align=\"center\">131 (10.2%)</td><td align=\"center\">99 (7.6%)</td><td align=\"center\">102 (7.9%)</td></tr><tr><td align=\"left\"> p-value versus placebo</td><td align=\"center\"/><td align=\"center\">0.021</td><td align=\"center\">0.045</td></tr><tr><td align=\"left\"> 30 days (primary endpoint)</td><td align=\"center\">149 (11.6%)</td><td align=\"center\">118 (9.1%)</td><td align=\"center\">128 (10%)</td></tr><tr><td align=\"left\"> p-value versus placebo</td><td align=\"center\"/><td align=\"center\">0.035</td><td align=\"center\">0.179</td></tr><tr><td align=\"left\">Death or MI</td><td align=\"center\"/><td align=\"center\"/><td align=\"center\"/></tr><tr><td align=\"left\"> 30 days</td><td align=\"center\">110 (8.6%)</td><td align=\"center\">89 (6.8%)</td><td align=\"center\">95 (7.4%)</td></tr><tr><td align=\"left\"> p-value versus placebo</td><td align=\"center\"/><td align=\"center\">0.102</td><td align=\"center\">0.272</td></tr><tr><td align=\"left\"> 6 months</td><td align=\"center\">151 (11.9%)<footnote ID=\"table7a\">Kaplan-Meier estimate of event rate.</footnote></td><td align=\"center\">136 (10.6%)<footnoteRef IDREF=\"table7a\"/></td><td align=\"center\">130 (10.3%)<footnoteRef IDREF=\"table7a\"/></td></tr><tr><td align=\"left\"> p-value versus placebo</td><td align=\"center\"/><td align=\"center\">0.297</td><td align=\"center\">0.182</td></tr></tbody></table>",
      "<table ID=\"table8\" width=\"80%\"><caption>Table 8: Clinical Events in the ESPRIT Study</caption><colgroup><col width=\"40%\" align=\"left\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"14%\" align=\"center\" valign=\"top\"/><col width=\"20%\" align=\"center\" valign=\"top\"/><col width=\"12%\" align=\"center\" valign=\"top\"/></colgroup><thead><tr><th align=\"left\"/><th align=\"center\">Placebo</th><th align=\"center\">Eptifibatide<footnote ID=\"table8a\">Eptifibatide was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min.</footnote></th><th align=\"center\">Relative Risk (95% CI)</th><th align=\"center\"> p-value</th></tr><tr><th align=\"left\"/><th align=\"center\">(n=1024)</th><th align=\"center\">(n=1040)</th><th align=\"center\"/><th align=\"center\"/></tr></thead><tbody><tr><td align=\"left\">Death, MI, UTVR, or Thrombotic &quot;Bailout&quot;</td><td align=\"center\"/><td align=\"center\"/><td align=\"center\"/><td align=\"center\"/></tr><tr><td align=\"left\">48 hours (primary endpoint)</td><td align=\"center\">108 (10.5%)</td><td align=\"center\">69 (6.6%)</td><td align=\"center\">0.629 (0.471, 0.84)</td><td align=\"center\">0.0015</td></tr><tr><td align=\"left\">30 days</td><td align=\"center\">120 (11.7%)</td><td align=\"center\">78 (7.5%)</td><td align=\"center\">0.64 (0.488, 0.84)</td><td align=\"center\">0.0011</td></tr><tr><td align=\"left\">Death, MI, or UTVR</td><td align=\"center\"/><td align=\"center\"/><td align=\"center\"/><td align=\"center\"/></tr><tr><td align=\"left\">48 hours</td><td align=\"center\">95 (9.3%)</td><td align=\"center\">62 (6%)</td><td align=\"center\">0.643 (0.472, 0.875)</td><td align=\"center\">0.0045</td></tr><tr><td align=\"left\">30 days (key secondary endpoint)</td><td align=\"center\">107 (10.4%)</td><td align=\"center\">71 (6.8%)</td><td align=\"center\">0.653 (0.49, 0.871)</td><td align=\"center\">0.0034</td></tr><tr><td align=\"left\">Death or MI</td><td align=\"center\"/><td align=\"center\"/><td align=\"center\"/><td align=\"center\"/></tr><tr><td align=\"left\">48 hours</td><td align=\"center\">94 (9.2%)</td><td align=\"center\">57 (5.5%)</td><td align=\"center\">0.597 (0.435, 0.82)</td><td align=\"center\">0.0013</td></tr><tr><td align=\"left\">30 days</td><td align=\"center\">104 (10.2%)</td><td align=\"center\">66 (6.3%)</td><td align=\"center\">0.625 (0.465, 0.84)</td><td align=\"center\">0.0016</td></tr></tbody></table>",
      "<table ID=\"table9\" width=\"80%\"><caption>Table 9: Clinical Events at 6 Months and 1 Year in the ESPRIT Study</caption><colgroup><col width=\"40%\" align=\"left\" valign=\"top\"/><col width=\"20%\" align=\"center\" valign=\"top\"/><col width=\"20%\" align=\"center\" valign=\"top\"/><col width=\"20%\" align=\"center\" valign=\"top\"/></colgroup><thead><tr><th align=\"left\"/><th align=\"center\">Placebo</th><th align=\"center\">Eptifibatide</th><th align=\"center\">Hazard Ratio</th></tr><tr><th align=\"left\"/><th align=\"center\">(n=1024)</th><th align=\"center\">(n=1040)</th><th align=\"center\">(95% CI)</th></tr></thead><tfoot><tr styleCode=\"First Last\"><td colspan=\"4\" align=\"left\">Percentages are Kaplan-Meier event rates.</td></tr></tfoot><tbody><tr><td align=\"left\">Death, MI, or Target Vessel Revascularization</td><td align=\"center\"/><td align=\"center\"/><td align=\"center\"/></tr><tr><td align=\"left\"> 6 months</td><td align=\"center\">187 (18.5%)</td><td align=\"center\">146 (14.3%)</td><td align=\"center\">0.744 (0.599, 0.924)</td></tr><tr><td align=\"left\"> 1 year</td><td align=\"center\">222 (22.1%)</td><td align=\"center\">178 (17.5%)</td><td align=\"center\">0.762 (0.626, 0.929)</td></tr><tr><td align=\"left\">Death, MI</td><td align=\"center\"/><td align=\"center\"/><td align=\"center\"/></tr><tr><td align=\"left\"> 6 months</td><td align=\"center\">117 (11.5%)</td><td align=\"center\">77 (7.4%)</td><td align=\"center\">0.631 (0.473, 0.841)</td></tr><tr><td align=\"left\"> 1 year</td><td align=\"center\">126 (12.4%)</td><td align=\"center\">83 (8%)</td><td align=\"center\">0.63 (0.478, 0.832)</td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Eptifibatide injection is supplied as a sterile solution in 10-mL vials containing 20 mg of eptifibatide (NDC 52958-402-01) and 100-mL vials containing 75 mg of eptifibatide (NDC 52958-040-01). 16.2 Storage Vials should be stored refrigerated at 2-8\u00b0C (36-46\u00b0F). Vials may be transferred to room temperature storage * for a period not to exceed 2 months. Upon transfer, vial cartons must be marked by the dispensing pharmacist with a \"DISCARD BY\" date (2 months from the transfer date or the labeled expiration date, whichever comes first). Retain in carton to protect from light until administration. * Store at 25 o C (77 o F); excursions permitted to 15-30 o C (59- o F) [see USP Controlled Room Temperature]."
    ],
    "storage_and_handling": [
      "16.2 Storage Vials should be stored refrigerated at 2-8\u00b0C (36-46\u00b0F). Vials may be transferred to room temperature storage * for a period not to exceed 2 months. Upon transfer, vial cartons must be marked by the dispensing pharmacist with a \"DISCARD BY\" date (2 months from the transfer date or the labeled expiration date, whichever comes first). Retain in carton to protect from light until administration. * Store at 25 o C (77 o F); excursions permitted to 15-30 o C (59- o F) [see USP Controlled Room Temperature]."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to inform the doctor or healthcare provider about any medical conditions, medications, and allergies."
    ],
    "spl_unclassified_section": [
      "Manufactured by: Hainan Shuangcheng Pharmaceuticals Co., Ltd. Haikou, 570314, China for Avenacy. Schaumburg, IL 60173, USA"
    ],
    "package_label_principal_display_panel": [
      "NDC 52958-402-01 20 mg/10 mL vial for weight-adjusted bolus dosing Eptifibatide Injection 20 mg/10 mL (2 mg/mL) For Intravenous Use Only 1\u00d710 mL Single-dose Vial Rx only Shuangcheng Pharma image description",
      "NDC 52958-040-01 75 mg/100 mL vial for weight-adjusted infusion Eptifibatide Injection 75 mg/100 mL (0.75 mg/mL) For Intravenous Use Only 1\u00d7100 mL Single-dose Vial Rx only Shuangcheng Pharma image description"
    ],
    "set_id": "c488f1af-a82c-4360-8886-79520635561a",
    "id": "6f3dec26-ea9b-4e6e-8e5b-0fa6fb430598",
    "effective_time": "20251020",
    "version": "9",
    "openfda": {
      "application_number": [
        "ANDA213081"
      ],
      "brand_name": [
        "Eptifibatide"
      ],
      "generic_name": [
        "EPTIFIBATIDE"
      ],
      "manufacturer_name": [
        "Hainan Shuangcheng Pharmaceuticals Co., Ltd."
      ],
      "product_ndc": [
        "52958-040",
        "52958-402"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "INTRAVENOUS"
      ],
      "substance_name": [
        "EPTIFIBATIDE"
      ],
      "rxcui": [
        "200349",
        "1736470"
      ],
      "spl_id": [
        "6f3dec26-ea9b-4e6e-8e5b-0fa6fb430598"
      ],
      "spl_set_id": [
        "c488f1af-a82c-4360-8886-79520635561a"
      ],
      "package_ndc": [
        "52958-402-01",
        "52958-040-01"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0352958402017"
      ],
      "nui": [
        "N0000008832",
        "N0000175578"
      ],
      "pharm_class_pe": [
        "Decreased Platelet Aggregation [PE]"
      ],
      "pharm_class_epc": [
        "Platelet Aggregation Inhibitor [EPC]"
      ],
      "unii": [
        "NA8320J834"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Eptifibatide eptifibatide CITRIC ACID MONOHYDRATE SODIUM HYDROXIDE EPTIFIBATIDE EPTIFIBATIDE Eptifibatide eptifibatide CITRIC ACID MONOHYDRATE SODIUM HYDROXIDE EPTIFIBATIDE EPTIFIBATIDE"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Eptifibatide injection is a platelet aggregation inhibitor indicated for: Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI) ( 1.1 ) Treatment of patients undergoing PCI (including intracoronary stenting) ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). 1.2 Percutaneous Coronary Intervention (PCI) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting [see Clinical Studies ( 14.1 , 14.2 )] ."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION Before infusion of eptifibatide injection, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured. The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT. ACS or PCI: 180 mcg/kg IV bolus as soon as possible after diagnosis followed by infusion at 2 mcg/kg/min. ( 2.1 , 2.2 ) PCI: Add a second 180 mcg/kg bolus at 10 minutes. ( 2.2 ) In patients with creatinine clearance less than 50 mL/min, reduce the infusion to 1 mcg/kg/min. 2.1 , 2.2 , 2.3 ) 2.1 Dosage in Acute Coronary Syndrome (ACS) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with ACS 180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min 180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours. If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy. Aspirin, 160 to 325 mg, should be given daily. Eptifibatide injection should be given concomitantly with heparin dosed to achieve the following parameters: During Medical Management : Target aPTT 50 to 70 seconds If weight greater than or equal to 70 kg, 5000-unit bolus followed by infusion of 1000 units/h. If weight less than 70 kg, 60-units/kg bolus followed by infusion of 12 units/kg/h. During PCI : Target ACT 200 to 300 seconds If heparin is initiated prior to PCI, additional boluses during PCI to maintain an ACT target of 200 to 300 seconds. Heparin infusion after the PCI is discouraged. 2.2 Dosage in Percutaneous Coronary Intervention (PCI) Indication Normal Renal Function Creatinine Clearance less than 50 mL/min Patients with PCI 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) 180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of 1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus) Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. In patients who undergo CABG surgery, eptifibatide infusion should be discontinued prior to surgery. Aspirin, 160 to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter. Eptifibatide injection should be given concomitantly with heparin to achieve a target ACT of 200 to 300 seconds. Administer 60-units/kg bolus initially in patients not treated with heparin within 6 hours prior to PCI. Additional boluses during PCI to maintain ACT within target. Heparin infusion after the PCI is strongly discouraged. Patients requiring thrombolytic therapy should discontinue eptifibatide injection. 2.3 Important Administration Instructions Inspect eptifibatide injection for particulate matter and discoloration prior to administration, whenever solution and container permit. May administer eptifibatide injection in the same intravenous line as alteplase, atropine, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, or verapamil. Do not administer eptifibatide injection through the same intravenous line as furosemide. May administer eptifibatide injection in the same IV line with 0.9% NaCl or 0.9% NaCl/5% dextrose. With either vehicle, the infusion may also contain up to 60 mEq/L of potassium chloride. Withdraw the bolus dose(s) of eptifibatide injection from the 10 mL vial into a syringe. Administer the bolus dose(s) by IV push. Immediately following the bolus dose administration, initiate a continuous infusion of eptifibatide injection. When using an intravenous infusion pump, administer eptifibatide injection undiluted directly from the 100-mL vial. Spike the 100 mL vial with a vented infusion set. Center the spike within the circle on the stopper top. Discard any unused portion left in the vial. Administer eptifibatide injection by volume according to patient weight (see Table 1 ). Table 1. Eptifibatide Injection Dosing Charts by Weight Patient Weight 180 mcg/kg Bolus Volume 2 mcg/kg/min Infusion Volume (CrCl greater than or equal to 50 mL/min) 1 mcg/kg/min Infusion Volume (CrCl less than 50 mL/min) (kg) (lb) (from 2 mg/mL vial) (from 2 mg/mL 100 mL vial) (from 0.75 mg/mL 100 mL vial) (from 2 mg/mL 100 mL vial) (from 0.75 mg/mL 100 mL vial) 37-41 81-91 3.4 mL 2 mL/h 6 mL/h 1 mL/h 3 mL/h 42-46 92-102 4 mL 2.5 mL/h 7 mL/h 1.3 mL/h 3.5 mL/h 47-53 103-117 4.5 mL 3 mL/h 8 mL/h 1.5 mL/h 4 mL/h 54-59 118-130 5 mL 3.5 mL/h 9 mL/h 1.8 mL/h 4.5 mL/h 60-65 131-143 5.6 mL 3.8 mL/h 10 mL/h 1.9 mL/h 5 mL/h 66-71 144-157 6.2 mL 4 mL/h 11 mL/h 2 mL/h 5.5 mL/h 72-78 158-172 6.8 mL 4.5 mL/h 12 mL/h 2.3 mL/h 6 mL/h 79-84 173-185 7.3 mL 5 mL/h 13 mL/h 2.5 mL/h 6.5 mL/h 85-90 186-198 7.9 mL 5.3 mL/h 14 mL/h 2.7 mL/h 7 mL/h 91-96 199-212 8.5 mL 5.6 mL/h 15 mL/h 2.8 mL/h 7.5 mL/h 97-103 213-227 9 mL 6 mL/h 16 mL/h 3.0 mL/h 8 mL/h 104-109 228-240 9.5 mL 6.4 mL/h 17 mL/h 3.2 mL/h 8.5 mL/h 110-115 241-253 10.2 mL 6.8 mL/h 18 mL/h 3.4 mL/h 9 mL/h 116-121 254-267 10.7 mL 7 mL/h 19 mL/h 3.5 mL/h 9.5 mL/h >121 >267 11.3 mL 7.5 mL/h 20 mL/h 3.7 mL/h 10 mL/h"
    ],
    "dosage_and_administration_table": [
      "<table cellpadding=\"3.6pt\" width=\"100%\"><col width=\"21%\"/><col width=\"39%\"/><col width=\"39%\"/><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Indication</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Normal Renal Function</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Creatinine Clearance less than 50 mL/min</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>Patients with ACS</paragraph></td><td valign=\"top\"><paragraph>180 mcg/kg intravenous (IV) bolus as soon as possible after diagnosis, followed by continuous infusion of 2 mcg/kg/min</paragraph></td><td valign=\"top\"><paragraph>180 mcg/kg IV bolus as soon as possible after diagnosis, followed by continuous infusion of 1 mcg/kg/min</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"/><td colspan=\"2\" styleCode=\"Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Infusion should continue until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours.</item><item>If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy.</item><item>Aspirin, 160 to 325 mg, should be given daily.</item></list></td></tr></tbody></table>",
      "<table cellpadding=\"3.6pt\" width=\"100%\"><col width=\"21%\"/><col width=\"39%\"/><col width=\"39%\"/><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Indication</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Normal Renal Function</content></paragraph></td><td styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Creatinine Clearance less than 50 mL/min</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>Patients with PCI</paragraph></td><td valign=\"top\"><paragraph>180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of</paragraph><paragraph>2 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus)</paragraph></td><td valign=\"top\"><paragraph>180 mcg/kg IV bolus immediately before PCI followed by continuous infusion of</paragraph><paragraph>1 mcg/kg/min and a second bolus of 180 mcg/kg (given 10 minutes after the first bolus)</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"/><td colspan=\"2\" styleCode=\"Botrule \" valign=\"top\"><list listType=\"unordered\"><item>Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended.</item><item>In patients who undergo CABG surgery, eptifibatide infusion should be discontinued prior to surgery.</item><item>Aspirin, 160 to 325 mg, should be given 1 to 24 hours prior to PCI and daily thereafter.</item></list></td></tr></tbody></table>",
      "<table ID=\"_Ref468720797\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 1. Eptifibatide Injection Dosing Charts by Weight</caption><col width=\"14%\"/><col width=\"14%\"/><col width=\"16%\"/><col width=\"14%\"/><col width=\"14%\"/><col width=\"14%\"/><col width=\"14%\"/><tbody><tr><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Patient Weight</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">180 mcg/kg Bolus Volume</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">2 mcg/kg/min Infusion Volume (CrCl greater than or equal to 50 mL/min)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Lrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">1 mcg/kg/min Infusion Volume (CrCl less than 50 mL/min)</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">(kg)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">(lb)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">(from 2 mg/mL vial)</content></paragraph></td><td align=\"center\" styleCode=\"Lrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">(from</content></paragraph><paragraph><content styleCode=\"bold\">2 mg/mL</content></paragraph><paragraph><content styleCode=\"bold\">100 mL vial)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">(from</content></paragraph><paragraph><content styleCode=\"bold\">0.75 mg/mL 100 mL vial)</content></paragraph></td><td align=\"center\" styleCode=\"Lrule Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">(from</content></paragraph><paragraph><content styleCode=\"bold\">2 mg/mL</content></paragraph><paragraph><content styleCode=\"bold\">100 mL vial)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">(from</content></paragraph><paragraph><content styleCode=\"bold\">0.75 mg/mL 100 mL vial)</content></paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>37-41</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>81-91</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>3.4 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>2 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>6 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>1 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>3 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>42-46</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>92-102</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>4 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>2.5 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>7 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>1.3 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>3.5 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>47-53</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>103-117</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>4.5 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>3 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>8 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>1.5 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>4 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>54-59</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>118-130</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>5 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>3.5 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>9 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>1.8 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>4.5 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>60-65</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>131-143</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>5.6 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>3.8 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>10 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>1.9 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>66-71</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>144-157</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>6.2 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>4 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>11 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>2 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>5.5 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>72-78</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>158-172</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>6.8 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>4.5 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>12 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>2.3 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>6 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>79-84</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>173-185</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>7.3 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>5 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>13 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>2.5 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>6.5 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>85-90</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>186-198</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>7.9 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>5.3 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>14 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>2.7 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>7 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>91-96</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>199-212</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>8.5 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>5.6 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>15 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>2.8 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>7.5 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>97-103</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>213-227</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>9 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>6 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>16 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>3.0 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>8 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>104-109</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>228-240</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>9.5 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>6.4 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>17 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>3.2 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>8.5 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>110-115</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>241-253</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>10.2 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>6.8 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>18 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>3.4 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>9 mL/h</paragraph></td></tr><tr><td align=\"center\" valign=\"middle\"><paragraph>116-121</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>254-267</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>10.7 mL</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>7 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule \" valign=\"middle\"><paragraph>19 mL/h</paragraph></td><td align=\"center\" styleCode=\"Lrule \" valign=\"middle\"><paragraph>3.5 mL/h</paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>9.5 mL/h</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Botrule \" valign=\"middle\"><paragraph>&gt;121</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>&gt;267</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule \" valign=\"middle\"><paragraph>11.3 mL</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule \" valign=\"middle\"><paragraph>7.5 mL/h</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule \" valign=\"middle\"><paragraph>20 mL/h</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule \" valign=\"middle\"><paragraph>3.7 mL/h</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"middle\"><paragraph>10 mL/h</paragraph></td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Injection: 20 mg of eptifibatide injection in 10 mL (2 mg/mL), for intravenous bolus. Injection: 75 mg of eptifibatide injection in 100 mL (0.75 mg/mL), for intravenous infusion. 20 mg/10 mL (2 mg/mL) in a single-dose vial for bolus injection. ( 3 ) 75 mg/100 mL (0.75 mg/mL) in a single-dose vial for infusion. ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Treatment with eptifibatide injection is contraindicated in patients with: A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another parenteral GP IIb/IIIa inhibitor Dependency on renal dialysis Hypersensitivity to eptifibatide injection or any component of the product (hypersensitivity reactions that occurred included anaphylaxis and urticaria). Bleeding diathesis or bleeding within the previous 30 days. ( 4 ) Severe uncontrolled hypertension. ( 4 ) Major surgery within the preceding 6 weeks. ( 4 ) Stroke within 30 days or any history of hemorrhagic stroke. ( 4 ) Coadministration of another parenteral GP IIb/IIIa inhibitor. ( 4 ) Dependency on renal dialysis. ( 4 ) Known hypersensitivity to any component of the product. ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Eptifibatide injection can cause serious bleeding. If bleeding cannot be controlled, discontinue eptifibatide injection immediately. Minimize vascular and other traumas. If heparin is given concomitantly, monitor aPTT or ACT. ( 5.1 ) Thrombocytopenia: Discontinue eptifibatide injection and heparin. Monitor and treat condition appropriately. ( 5.2 ) 5.1 Bleeding Bleeding is the most common complication encountered during eptifibatide injection therapy. Administration of eptifibatide injection is associated with an increase in major and minor bleeding, as classified by the criteria of the Thrombolysis in Myocardial Infarction Study group (TIMI) [see Adverse Reactions ( 6.1 )] . Most major bleeding associated with eptifibatide injection has been at the arterial access site for cardiac catheterization or from the gastrointestinal or genitourinary tract. Minimize the use of arterial and venous punctures, intramuscular injections, and the use of urinary catheters, nasotracheal intubation, and nasogastric tubes. When obtaining intravenous access, avoid non-compressible sites (e.g., subclavian or jugular veins). Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Risk factors for bleeding include older age, a history of bleeding disorders, and concomitant use of drugs that increase the risk of bleeding (thrombolytics, oral anticoagulants, nonsteroidal anti-inflammatory drugs, and P2Y 12 inhibitors). Concomitant treatment with other inhibitors of platelet receptor glycoprotein (GP) IIb/IIIa should be avoided. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT [see Dosage and Administration ( 2 )] . Care of the Femoral Artery Access Site in Patients Undergoing Percutaneous Coronary Intervention (PCI) In patients undergoing PCI, treatment with eptifibatide injection is associated with an increase in major and minor bleeding at the site of arterial sheath placement. After PCI, eptifibatide infusion should be continued until hospital discharge or up to 18 to 24 hours, whichever comes first. Heparin use is discouraged after the PCI procedure. Early sheath removal is encouraged while eptifibatide injection is being infused. Prior to removing the sheath, it is recommended that heparin be discontinued for 3 to 4 hours and an aPTT of <45 seconds or ACT <150 seconds be achieved. In any case, both heparin and eptifibatide injection should be discontinued and sheath hemostasis should be achieved at least 2 to 4 hours before hospital discharge. If bleeding at access site cannot be controlled with pressure, infusion of eptifibatide injection and heparin should be discontinued immediately. 5.2 Thrombocytopenia There have been reports of acute, profound thrombocytopenia (immune-mediated and non-immune mediated) with eptifibatide injection. In the event of acute profound thrombocytopenia or a confirmed platelet decrease to <100,000/mm 3 , discontinue eptifibatide injection and heparin (unfractionated or low-molecular weight). Monitor serial platelet counts, assess the presence of drug-dependent antibodies, and treat as appropriate [see Adverse Reactions ( 6.1 )] . There has been no clinical experience with eptifibatide injection initiated in patients with a baseline platelet count <100,000/mm 3 . If a patient with low platelet counts is receiving eptifibatide injection, their platelet count should be monitored closely."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reaction is also discussed elsewhere in the labeling: Bleeding [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )] Bleeding and hypotension are the most commonly reported adverse reactions. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Slate Run Pharmaceuticals, LLC at 1-888-341-9214 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. A total of 16,782 patients were treated in the Phase III clinical trials (PURSUIT, ESPRIT, and IMPACT II) [see Clinical Studies ( 14 )] . These 16,782 patients had a mean age of 62 years (range: 20-94 years). Eighty-nine percent of the patients were Caucasian, with the remainder being predominantly Black (5%) and Hispanic (5%). Sixty-eight percent were men. Because of the different regimens used in PURSUIT, IMPACT II, and ESPRIT, data from the 3 studies were not pooled. Bleeding and hypotension were the most commonly reported adverse reactions (incidence \u22655% and greater than placebo) in the eptifibatide injection controlled clinical trial database. Bleeding The incidence of bleeding and transfusions in the PURSUIT and ESPRIT studies are shown in Table 2 . Bleeding was classified as major or minor by the criteria of the TIMI study group. Major bleeding consisted of intracranial hemorrhage and other bleeding that led to decreases in hemoglobin greater than 5 g/dL. Minor bleeding included spontaneous gross hematuria, spontaneous hematemesis, other observed blood loss with a hemoglobin decrease of more than 3 g/dL, and other hemoglobin decreases that were greater than 4 g/dL but less than 5 g/dL. In patients who received transfusions, the corresponding loss in hemoglobin was estimated through an adaptation of the method of Landefeld et al. Table 2. Bleeding and Transfusions in the PURSUIT and ESPRIT Studies Note: Denominator is based on patients for whom data are available. * For major and minor bleeding, patients are counted only once according to the most severe classification. \u2020 Includes transfusions of whole blood, packed red blood cells, fresh frozen plasma, cryoprecipitate, platelets, and autotransfusion during the initial hospitalization. PURSUIT (ACS) Placebo n (%) Eptifibatide Injection 180/2 n (%) Patients 4696 4679 Major bleeding* 425 (9.3%) 498 (10.8%) Minor bleeding* 347 (7.6%) 604 (13.1%) Requiring transfusions\u2020 490 (10.4%) 601 (12.8%) ESPRIT (PCI) Placebo n (%) Eptifibatide Injection 180/2/180 n (%) Patients 1024 1040 Major bleeding* 4 (0.4%) 13 (1.3%) Minor bleeding* 18 (2%) 29 (3%) Requiring transfusions\u2020 11 (1.1%) 16 (1.5%) The majority of major bleeding reactions in the ESPRIT study occurred at the vascular access site (1 and 8 patients, or 0.1% and 0.8% in the placebo and eptifibatide injection groups, respectively). Bleeding at \u201cother\u201d locations occurred in 0.2% and 0.4% of patients, respectively. In the PURSUIT study, the greatest increase in major bleeding in eptifibatide-treated patients compared to placebo-treated patients was also associated with bleeding at the femoral artery access site (2.8% versus 1.3%). Oropharyngeal (primarily gingival), genitourinary, gastrointestinal, and retroperitoneal bleeding were also seen more commonly in eptifibatide-treated patients compared to placebo-treated patients. Among patients experiencing a major bleed in the IMPACT II study, an increase in bleeding on eptifibatide injection versus placebo was observed only for the femoral artery access site (3.2% versus 2.8%). Table 3 displays the incidence of TIMI major bleeding according to the cardiac procedures carried out in the PURSUIT study. The most common bleeding complications were related to cardiac revascularization (CABG-related or femoral artery access site bleeding). A corresponding table for ESPRIT is not presented, as every patient underwent PCI in the ESPRIT study and only 11 patients underwent CABG. Table 3. Major Bleeding by Procedures in the PURSUIT Study Note: Denominators are based on the total number of patients whose TIMI classification was resolved. Placebo n (%) Eptifibatide Injection 180/2 n (%) Patients 4577 4604 Overall incidence of major bleeding 425 (9.3%) 498 (10.8%) Breakdown by procedure: CABG 375 (8.2%) 377 (8.2%) Angioplasty without CABG 27 (0.6%) 64 (1.4%) Angiography without angioplasty or CABG 11 (0.2%) 29 (0.6%) Medical therapy only 12 (0.3%) 28 (0.6%) In the PURSUIT and ESPRIT studies, the risk of major bleeding with eptifibatide injection increased as patient weight decreased. This relationship was most apparent for patients weighing less than 70 kg. Bleeding resulting in discontinuation of the study drug was more frequent among patients receiving eptifibatide injection than placebo (4.6% versus 0.9% in ESPRIT, 8% versus 1% in PURSUIT, 3.5% versus 1.9% in IMPACT II). Intracranial Hemorrhage and Stroke Intracranial hemorrhage was rare in the PURSUIT, IMPACT II, and ESPRIT clinical studies. In the PURSUIT study, 3 patients in the placebo group, 1 patient in the group treated with eptifibatide injection 180/1.3, and 5 patients in the group treated with eptifibatide injection 180/2 experienced a hemorrhagic stroke. The overall incidence of stroke was 0.5% in patients receiving eptifibatide injection 180/1.3, 0.7% in patients receiving eptifibatide injection 180/2, and 0.8% in placebo patients. In the IMPACT II study, intracranial hemorrhage was experienced by 1 patient treated with eptifibatide injection 135/0.5, 2 patients treated with eptifibatide injection 135/0.75, and 2 patients in the placebo group. The overall incidence of stroke was 0.5% in patients receiving 135/0.5 eptifibatide injection, 0.7% in patients receiving eptifibatide injection 135/0.75, and 0.7% in the placebo group. In the ESPRIT study, there were 3 hemorrhagic strokes, 1 in the placebo group and 2 in the eptifibatide injection group. In addition there was 1 case of cerebral infarction in the eptifibatide injection group. Immunogenicity/Thrombocytopenia The potential for development of antibodies to eptifibatide has been studied in 433 subjects. Eptifibatide injection was nonantigenic in 412 patients receiving a single administration of eptifibatide injection (135 mcg/kg bolus followed by a continuous infusion of either 0.5 mcg/kg/min or 0.75 mcg/kg/min), and in 21 subjects to whom eptifibatide injection (135 mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min) was administered twice, 28 days apart. In both cases, plasma for antibody detection was collected approximately 30 days after each dose. The development of antibodies to eptifibatide at higher doses has not been evaluated. In patients with suspected eptifibatide-related immune-mediated thrombocytopenia, IgG antibodies that react with the GP IIb/IIIa complex were identified in the presence of eptifibatide and in eptifibatide-na\u00efve patients. These findings suggest acute thrombocytopenia after the administration of eptifibatide injection can develop as a result of naturally occurring drug-dependent antibodies or those induced by prior exposure to eptifibatide injection. Similar antibodies were identified with other GP IIb/IIIa ligand-mimetic agents. Immune-mediated thrombocytopenia with eptifibatide injection may be associated with hypotension and/or other signs of hypersensitivity. In the PURSUIT and IMPACT II studies, the incidence of thrombocytopenia (<100,000/mm 3 or \u226550% reduction from baseline) and the incidence of platelet transfusions were similar between patients treated with eptifibatide injection and placebo. In the ESPRIT study, the incidence was 0.6% in the placebo group and 1.2% in the eptifibatide injection group. Other Adverse Reactions In the PURSUIT and ESPRIT studies, the incidence of serious nonbleeding adverse reactions was similar in patients receiving placebo or eptifibatide injection (19% and 19%, respectively, in PURSUIT; 6% and 7%, respectively, in ESPRIT). In PURSUIT, the only serious nonbleeding adverse reaction that occurred at a rate of at least 1% and was more common with eptifibatide injection than placebo (7% versus 6%) was hypotension. Most of the serious nonbleeding adverse reactions consisted of cardiovascular reactions typical of a UA population. In the IMPACT II study, serious nonbleeding adverse reactions that occurred in greater than 1% of patients were uncommon and similar in incidence between placebo- and eptifibatide-treated patients. Discontinuation of study drug due to adverse reactions other than bleeding was uncommon in the PURSUIT, IMPACT II, and ESPRIT studies, with no single reaction occurring in >0.5% of the study population (except for \u201cother\u201d in the ESPRIT study). 6.2 Postmarketing Experience The following adverse reactions have been reported in post-approval use of eptifibatide injection in combination with heparin and aspirin. Because the reactions below are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure: cerebral, GI, and pulmonary hemorrhage. Fatal bleeding reactions have been reported. Acute profound thrombocytopenia, as well as immune-mediated thrombocytopenia, has been reported [see Adverse Reactions ( 6.1 )] ."
    ],
    "adverse_reactions_table": [
      "<table ID=\"_Ref468720999\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 2. Bleeding and Transfusions in the PURSUIT and ESPRIT Studies</caption><col width=\"34%\"/><col width=\"33%\"/><col width=\"33%\"/><tfoot><tr><td align=\"left\" colspan=\"3\" valign=\"top\">Note: Denominator is based on patients for whom data are available.   * For major and minor bleeding, patients are counted only once according to the most severe classification.   &#x2020; Includes transfusions of whole blood, packed red blood cells, fresh frozen plasma, cryoprecipitate, platelets, and autotransfusion during the initial hospitalization. </td></tr></tfoot><tbody><tr><td align=\"center\" colspan=\"3\" styleCode=\"Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">PURSUIT (ACS)</content></paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Eptifibatide Injection</content></paragraph><paragraph><content styleCode=\"bold\">180/2</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>Patients</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>4696</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>4679</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Major bleeding*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>425 (9.3%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>498 (10.8%)</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Minor bleeding*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>347 (7.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>604 (13.1%)</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph>Requiring transfusions&#x2020;</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>490 (10.4%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>601 (12.8%)</paragraph></td></tr><tr><td align=\"center\" colspan=\"3\" valign=\"bottom\"><paragraph><content styleCode=\"bold\">ESPRIT (PCI)</content></paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Eptifibatide Injection</content></paragraph><paragraph><content styleCode=\"bold\">180/2/180</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>Patients</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1024</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1040</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Major bleeding*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>4 (0.4%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>13 (1.3%)</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Minor bleeding*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>18 (2%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>29 (3%)</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph>Requiring transfusions&#x2020;</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>11 (1.1%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>16 (1.5%)</paragraph></td></tr></tbody></table>",
      "<table ID=\"_Ref468721021\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 3. Major Bleeding by Procedures in the PURSUIT Study</caption><col width=\"43%\"/><col width=\"29%\"/><col width=\"29%\"/><tfoot><tr><td align=\"left\" colspan=\"3\" valign=\"top\">Note: Denominators are based on the total number of patients whose TIMI classification was resolved.</td></tr></tfoot><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Eptifibatide Injection</content></paragraph><paragraph><content styleCode=\"bold\">180/2</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>Patients</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>4577</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>4604</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Overall incidence of major bleeding</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>425 (9.3%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>498 (10.8%)</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Breakdown by procedure:</paragraph></td><td valign=\"top\"/><td valign=\"top\"/></tr><tr><td valign=\"top\"><paragraph> CABG</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>375 (8.2%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>377 (8.2%)</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Angioplasty without CABG</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>27 (0.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>64 (1.4%)</paragraph></td></tr><tr><td valign=\"top\"><paragraph> Angiography without angioplasty or CABG</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>11 (0.2%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>29 (0.6%)</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph> Medical therapy only</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>12 (0.3%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>28 (0.6%)</paragraph></td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Avoid concomitant use with other glycoprotein (GP) IIb/IIIa inhibitors. ( 7.1 ) 7.1 Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Concomitant treatment with other inhibitors of platelet receptor GP IIb/IIIa should be avoided."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Geriatric Use: Risk of bleeding increases with age. ( 8.5 ) 8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus [see Clinical Considerations ] . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk: Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide injection on the fetus. Data Animal Data: Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide. 8.2 Lactation Risk Summary There are no available data on the presence of eptifibatide in human milk, the effects on the breastfed infant, or the effects on milk production. As eptifibatide is a peptide, it is likely to be destroyed in the infant\u2019s gastrointestinal tract and not absorbed orally by the breastfed infant. 8.4 Pediatric Use Safety and effectiveness of eptifibatide injection in pediatric patients have not been studied. 8.5 Geriatric Use The PURSUIT and IMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide injection. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide injection groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUIT study; no such limitation was stipulated in the ESPRIT study [see Adverse Reactions ( 6.1 )] . 8.6 Renal Impairment Approximately 50% of eptifibatide is cleared by the kidney in patients with normal renal function. Total drug clearance is decreased by approximately 50% and steady-state plasma eptifibatide injection concentrations are doubled in patients with an estimated CrCl <50 mL/min (using the Cockcroft-Gault equation). Therefore, the infusion dose should be reduced to 1 mcg/kg/min in such patients [see Dosage and Administration ( 2 )] . The safety and efficacy of eptifibatide injection in patients dependent on dialysis has not been established."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus [see Clinical Considerations ] . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk: Myocardial infarction is a medical emergency in pregnancy which can be fatal to the pregnant woman and fetus if left untreated. Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of eptifibatide injection on the fetus. Data Animal Data: Embryo-fetal development studies have been performed by continuous intravenous infusion of eptifibatide in pregnant rats during the period of organogenesis at total daily doses of up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis) and in pregnant rabbits during the period of organogenesis at total daily doses of up to 36 mg/kg/day (also about 4 times the recommended maximum daily human dose on a body surface area basis). These studies revealed no evidence of harm to the fetus due to eptifibatide."
    ],
    "risks": [
      "Risk Summary Available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Untreated myocardial infarction can be fatal to the pregnant woman and fetus [see Clinical Considerations ] . In animal reproduction studies, there was no evidence of adverse developmental effects when eptifibatide was administered intravenously to pregnant rats and rabbits at approximately 4 times the recommended maximum daily human dose. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety and effectiveness of eptifibatide injection in pediatric patients have not been studied."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use The PURSUIT and IMPACT II clinical studies enrolled patients up to the age of 94 years (45% were age 65 and over; 12% were age 75 and older). There was no apparent difference in efficacy between older and younger patients treated with eptifibatide injection. The incidence of bleeding complications was higher in the elderly in both placebo and eptifibatide injection groups, and the incremental risk of eptifibatide-associated bleeding was greater in the older patients. No dose adjustment was made for elderly patients, but patients over 75 years of age had to weigh at least 50 kg to be enrolled in the PURSUIT study; no such limitation was stipulated in the ESPRIT study [see Adverse Reactions ( 6.1 )] ."
    ],
    "overdosage": [
      "10 OVERDOSAGE There has been only limited experience with overdosage of eptifibatide injection. There were 8 patients in the IMPACT II study, 9 patients in the PURSUIT study, and no patients in the ESPRIT study who received bolus doses and/or infusion doses more than double those called for in the protocols. None of these patients experienced an intracranial bleed or other major bleeding. Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis). Symptoms of acute toxicity were loss of righting reflex, dyspnea, ptosis, and decreased muscle tone in rabbits and petechial hemorrhages in the femoral and abdominal areas of monkeys. From in vitro studies, eptifibatide is not extensively bound to plasma proteins and thus may be cleared from plasma by dialysis."
    ],
    "description": [
      "11 DESCRIPTION Eptifibatide is a cyclic heptapeptide containing 6 amino acids and 1 mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties. Chemically it is N 6 -(aminoiminomethyl)-N 2 -(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-\u03b1-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1\u21926)-disulfide. Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation. The eptifibatide peptide is produced by solution-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized. The structural formula is: Eptifibatide Injection is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use with an empirical formula of C 35 H 49 N 11 O 9 S 2 and a molecular weight of 831.96. Each 10 mL vial contains 2 mg/mL of eptifibatide injection and each 100 mL vial contains 0.75 mg/mL of eptifibatide injection. Each vial of either size also contains 5.25 mg/mL citric acid and sodium hydroxide to adjust the pH to 5.35. structural formula"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet. 12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide injection inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide injection was observed immediately after administration of a 180 mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide injection used in the IMPACT II and PURSUIT studies on ex vivo platelet aggregation induced by 20 \u00b5M ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRIT on platelet aggregation have not been studied. Table 4. Platelet Inhibition and Bleeding Time * 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. PURSUIT 180/2* Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x The eptifibatide injection dosing regimen used in the ESPRIT study included two 180 mcg/kg bolus doses given 10 minutes apart combined with a continuous 2 mcg/kg/min infusion. When administered alone, eptifibatide injection has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed. 12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180 mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4-6 hours). This decline can be prevented by administering a second 180 mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20-94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations ( 8.6 ) and Dosage and Administration ( 2 )] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "clinical_pharmacology_table": [
      "<table ID=\"_Ref468721121\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 4. Platelet Inhibition and Bleeding Time</caption><col width=\"73%\"/><col width=\"27%\"/><tfoot><tr><td align=\"left\" colspan=\"2\" valign=\"top\">* 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min.</td></tr></tfoot><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">PURSUIT</content></paragraph><paragraph><content styleCode=\"bold\">180/2*</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>Inhibition of platelet aggregation 15 min after bolus</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>84%</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Inhibition of platelet aggregation at steady state</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>&gt;90%</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Bleeding-time prolongation at steady state</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>&lt;5x</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Inhibition of platelet aggregation 4h after infusion discontinuation</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>&lt;50%</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph>Bleeding-time prolongation 6h after infusion discontinuation</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>1.4x</paragraph></td></tr></tbody></table>"
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5 mcg/kg/min. In a baboon model that is refractory to aspirin and heparin, doses of eptifibatide that inhibit aggregation prevented acute thrombosis with only a modest prolongation (2- to 3-fold) of the bleeding time. Platelet aggregation in dogs was also inhibited by infusions of eptifibatide, with complete inhibition at 2 mcg/kg/min. This infusion dose completely inhibited canine coronary thrombosis induced by coronary artery injury (Folts model). Human pharmacodynamic data were obtained in healthy subjects and in patients presenting with UA or NSTEMI and/or undergoing percutaneous coronary intervention. Studies in healthy subjects enrolled only males; patient studies enrolled approximately one-third women. In these studies, eptifibatide injection inhibited ex vivo platelet aggregation induced by adenosine diphosphate (ADP) and other agonists in a dose- and concentration-dependent manner. The effect of eptifibatide injection was observed immediately after administration of a 180 mcg/kg intravenous bolus. Table 4 shows the effects of dosing regimens of eptifibatide injection used in the IMPACT II and PURSUIT studies on ex vivo platelet aggregation induced by 20 \u00b5M ADP in PPACK-anticoagulated platelet-rich plasma and on bleeding time. The effects of the dosing regimen used in ESPRIT on platelet aggregation have not been studied. Table 4. Platelet Inhibition and Bleeding Time * 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min. PURSUIT 180/2* Inhibition of platelet aggregation 15 min after bolus 84% Inhibition of platelet aggregation at steady state >90% Bleeding-time prolongation at steady state <5x Inhibition of platelet aggregation 4h after infusion discontinuation <50% Bleeding-time prolongation 6h after infusion discontinuation 1.4x The eptifibatide injection dosing regimen used in the ESPRIT study included two 180 mcg/kg bolus doses given 10 minutes apart combined with a continuous 2 mcg/kg/min infusion. When administered alone, eptifibatide injection has no measurable effect on PT or aPTT. There were no important differences between men and women or between age groups in the pharmacodynamic properties of eptifibatide. Differences among ethnic groups have not been assessed."
    ],
    "pharmacodynamics_table": [
      "<table ID=\"_Ref468721121\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 4. Platelet Inhibition and Bleeding Time</caption><col width=\"73%\"/><col width=\"27%\"/><tfoot><tr><td align=\"left\" colspan=\"2\" valign=\"top\">* 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min.</td></tr></tfoot><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">PURSUIT</content></paragraph><paragraph><content styleCode=\"bold\">180/2*</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>Inhibition of platelet aggregation 15 min after bolus</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>84%</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Inhibition of platelet aggregation at steady state</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>&gt;90%</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Bleeding-time prolongation at steady state</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>&lt;5x</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Inhibition of platelet aggregation 4h after infusion discontinuation</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>&lt;50%</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph>Bleeding-time prolongation 6h after infusion discontinuation</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>1.4x</paragraph></td></tr></tbody></table>"
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of eptifibatide are linear and dose-proportional for bolus doses ranging from 90 to 250 mcg/kg and infusion rates from 0.5 to 3 mcg/kg/min. Plasma elimination half-life is approximately 2.5 hours. Administration of a single 180 mcg/kg bolus combined with an infusion produces an early peak level, followed by a small decline prior to attaining steady state (within 4-6 hours). This decline can be prevented by administering a second 180 mcg/kg bolus 10 minutes after the first. The extent of eptifibatide binding to human plasma protein is about 25%. Clearance in patients with coronary artery disease is about 55 mL/kg/h. In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. No major metabolites have been detected in human plasma. Special Populations Geriatric Patients in clinical studies were older (range: 20-94 years) than those in the clinical pharmacology studies. Elderly patients with coronary artery disease demonstrated higher plasma levels and lower total body clearance of eptifibatide when given the same dose as younger patients. Limited data are available on lighter weight (<50 kg) patients over 75 years of age. Renal Impairment In patients with moderate to severe renal insufficiency (CrCl <50 mL/min using the Cockcroft-Gault equation), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels approximately doubled [see Use in Specific Populations ( 8.6 ) and Dosage and Administration ( 2 )] . Hepatic Impairment No studies have been conducted in patients with hepatic impairment. Gender Males and females have not demonstrated any clinically significant differences in the pharmacokinetics of eptifibatide."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate the carcinogenic potential of eptifibatide. Eptifibatide was not genotoxic in the Ames test, the mouse lymphoma cell (L 5178Y, TK+/-) forward mutation test, the human lymphocyte chromosome aberration test, or the mouse micronucleus test. Administered by continuous intravenous infusion at total daily doses up to 72 mg/kg/day (about 4 times the recommended maximum daily human dose on a body surface area basis), eptifibatide had no effect on fertility and reproductive performance of male and female rats."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Eptifibatide injection was studied in 3 placebo-controlled, randomized studies. PURSUIT evaluated patients with acute coronary syndromes: UA or NSTEMI. Two other studies, ESPRIT and IMPACT II, evaluated patients about to undergo a PCI. Patients underwent primarily balloon angioplasty in IMPACT II and intracoronary stent placement, with or without angioplasty, in ESPRIT. 14.1 Non-ST-Segment Elevation Acute Coronary Syndrome Non-ST-segment elevation acute coronary syndrome is defined as prolonged (\u226510 minutes) symptoms of cardiac ischemia within the previous 24 hours associated with either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or positive CK-MB. This definition includes \u201cunstable angina\u201d and \u201cNSTEMI\u201d but excludes MI that is associated with Q waves or greater degrees of ST-segment elevation. PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Eptifibatide Injection Therapy) PURSUIT was a 726-center, 27-country, double-blind, randomized, placebo-controlled study in 10,948 patients presenting with UA or NSTEMI. Patients could be enrolled only if they had experienced cardiac ischemia at rest (\u226510 minutes) within the previous 24 hours and had either ST-segment changes (elevations between 0.6 mm and 1 mm or depression >0.5 mm), T-wave inversion (>1 mm), or increased CK-MB. Important exclusion criteria included a history of bleeding diathesis, evidence of abnormal bleeding within the previous 30 days, uncontrolled hypertension, major surgery within the previous 6 weeks, stroke within the previous 30 days, any history of hemorrhagic stroke, serum creatinine >2 mg/dL, dependency on renal dialysis, or platelet count <100,000/mm 3 . Patients were randomized to placebo, to eptifibatide injection 180 mcg/kg bolus followed by a 2 mcg/kg/min infusion (180/2), or to eptifibatide injection 180 mcg/kg bolus followed by a 1.3 mcg/kg/min infusion (180/1.3). The infusion was continued for 72 hours, until hospital discharge, or until the time of CABG, whichever occurred first, except that if PCI was performed, the eptifibatide infusion was continued for 24 hours after the procedure, allowing for a duration of infusion up to 96 hours. The lower-infusion-rate arm was stopped after the first interim analysis when the 2 active-treatment arms appeared to have the same incidence of bleeding. Patient age ranged from 20 to 94 (mean 63) years, and 65% were male. The patients were 89% Caucasian, 6% Hispanic, and 5% Black, recruited in the United States and Canada (40%), Western Europe (39%), Eastern Europe (16%), and Latin America (5%). This was a \u201creal world\u201d study; each patient was managed according to the usual standards of the investigational site; frequencies of angiography, PCI, and CABG therefore differed widely from site to site and from country to country. Of the patients in PURSUIT, 13% were managed with PCI during drug infusion, of whom 50% received intracoronary stents; 87% were managed medically (without PCI during drug infusion). The majority of patients received aspirin (75-325 mg once daily). Heparin was administered intravenously or subcutaneously, at the physician's discretion, most commonly as an intravenous bolus of 5000 units followed by a continuous infusion of 1000 units/h. For patients weighing less than 70 kg, the recommended heparin bolus dose was 60 units/kg followed by a continuous infusion of 12 units/kg/h. A target aPTT of 50 to 70 seconds was recommended. A total of 1250 patients underwent PCI within 72 hours after randomization, in which case they received intravenous heparin to maintain an ACT of 300 to 350 seconds. The primary endpoint of the study was the occurrence of death from any cause or new MI (evaluated by a blinded Clinical Endpoints Committee) within 30 days of randomization. Compared to placebo, eptifibatide injection administered as a 180 mcg/kg bolus followed by a 2 mcg/kg/min infusion significantly (p=0.042) reduced the incidence of endpoint events (see Table 6 ). The reduction in the incidence of endpoint events in patients receiving eptifibatide injection was evident early during treatment, and this reduction was maintained through at least 30 days (see). Table 5 also shows the incidence of the components of the primary endpoint, death (whether or not preceded by an MI) and new MI in surviving patients at 30 days. Table 5. Clinical Events in the PURSUIT Study Death or MI Placebo (n=4739) n (%) Eptifibatide Injection (180 mcg/kg bolus then 2 mcg/kg/min infusion) (n=4722) n (%) p-value 3 days 359 (7.6%) 279 (5.9%) 0.001 7 days 552 (11.6%) 477 (10.1%) 0.016 30 days Death or MI (primary endpoint) 745 (15.7%) 672 (14.2%) 0.042 Death 177 (3.7%) 165 (3.5%) Nonfatal MI 568 (12%) 507 (10.7%) Figure 1: Kaplan-Meier Plot of Time to Death or Myocardial Infarction Within 30 Days of Randomization in the PURSUIT Study Treatment with eptifibatide injection prior to determination of patient management strategy reduced clinical events regardless of whether patients ultimately underwent diagnostic catheterization, revascularization (i.e., PCI or CABG surgery) or continued to receive medical management alone. Table 6 shows the incidence of death or MI within 72 hours. Table 6. Clinical Events (Death or MI) in the PURSUIT Study Within 72 Hours of Randomization Placebo Eptifibatide Injection (180 mcg/kg bolus then 2 mcg/kg/min infusion) Overall patient population n=4739 n=4722 \u2013 At 72 hours 7.6% 5.9% Patients undergoing early PCI n=631 n=619 \u2013 Pre-procedure (nonfatal MI only) 5.5% 1.8% \u2013 At 72 hours 14.4% 9% Patients not undergoing early PCI n=4108 n=4103 \u2013 At 72 hours 6.5% 5.4% All of the effect of eptifibatide injection was established within 72 hours (during the period of drug infusion), regardless of management strategy. Moreover, for patients undergoing early PCI, a reduction in events was evident prior to the procedure. An analysis of the results by sex suggests that women who would not routinely be expected to undergo PCI receive less benefit from eptifibatide injection (95% confidence limits for relative risk of 0.94 - 1.28) than do men (0.72 - 0.9). This difference may be a true treatment difference, the effect of other differences in these subgroups, or a statistical anomaly. No differential outcomes were seen between male and female patients undergoing PCI (see results for ESPRIT) . Follow-up data were available through 165 days for 10,611 patients enrolled in the PURSUIT trial (96.9% of the initial enrollment). This follow-up included 4566 patients who received eptifibatide injection at the 180/2 dose. As reported by the investigators, the occurrence of death from any cause or new MI for patients followed for at least 165 days was reduced from 13.6% with placebo to 12.1% with eptifibatide injection 180/2. Figure 1 14.2 Percutaneous Coronary Intervention (PCI) IMPACT II (Eptifibatide Injection to Minimize Platelet Aggregation and Prevent Coronary Thrombosis II) IMPACT II was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States in 4010 patients undergoing PCI. Major exclusion criteria included a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 89 (mean 60) years, and 75% were male. The patients were 92% Caucasian, 5% Black, and 3% Hispanic. Forty-one percent of the patients underwent PCI for ongoing ACS. Patients were randomly assigned to 1 of 3 treatment regimens, each incorporating a bolus dose initiated immediately prior to PCI followed by a continuous infusion lasting 20 to 24 hours: 1) 135 mcg/kg bolus followed by a continuous infusion of 0.5 mcg/kg/min of eptifibatide injection (135/0.5); 2) 135 mcg/kg bolus followed by a continuous infusion of 0.75 mcg/kg/min of eptifibatide injection (135/0.75); or 3) a matching placebo bolus followed by a matching placebo continuous infusion. Each patient received aspirin and an intravenous heparin bolus of 100 units/kg, with additional bolus infusions of up to 2000 additional units of heparin every 15 minutes to maintain an ACT of 300 to 350 seconds. The primary endpoint was the composite of death, MI, or urgent revascularization, analyzed at 30 days after randomization in all patients who received at least 1 dose of study drug. As shown in Table 7 , each eptifibatide injection regimen reduced the rate of death, MI, or urgent intervention, although at 30 days, this finding was statistically significant only in the lower-dose eptifibatide injection group. As in the PURSUIT study, the effects of eptifibatide injection were seen early and persisted throughout the 30-day period. Table 7. Clinical Events in the IMPACT II Study Placebo n (%) Eptifibatide Injection (135 mcg/kg bolus then 0.5 mcg/kg/min infusion) n (%) Eptifibatide Injection (135 mcg/kg bolus then 0.75 mcg/kg/min infusion) n (%) * Kaplan-Meier estimate of event rate. Patients 1285 1300 1286 Abrupt Closure 65 (5.1%) 36 (2.8%) 43 (3.3%) p-value versus placebo 0.003 0.03 Death, MI, or Urgent Intervention 24 hours 123 (9.6%) 86 (6.6%) 89 (6.9%) p-value versus placebo 0.006 0.014 48 hours 131 (10.2%) 99 (7.6%) 102 (7.9%) p-value versus placebo 0.021 0.045 30 days (primary endpoint) 149 (11.6%) 118 (9.1%) 128 (10%) p-value versus placebo 0.035 0.179 Death or MI 30 days 110 (8.6%) 89 (6.8%) 95 (7.4%) p-value versus placebo 0.102 0.272 6 months 151 (11.9%)* 136 (10.6%)* 130 (10.3%)* p-value versus placebo 0.297 0.182 ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Eptifibatide Injection Therapy) The ESPRIT study was a multicenter, double-blind, randomized, placebo-controlled study conducted in the United States and Canada that enrolled 2064 patients undergoing elective or urgent PCI with intended intracoronary stent placement. Exclusion criteria included MI within the previous 24 hours, ongoing chest pain, administration of any oral antiplatelet or oral anticoagulant other than aspirin within 30 days of PCI (although loading doses of thienopyridine on the day of PCI were encouraged), planned PCI of a saphenous vein graft or subsequent \u201cstaged\u201d PCI, prior stent placement in the target lesion, PCI within the previous 90 days, a history of bleeding diathesis, major surgery within 6 weeks of treatment, gastrointestinal bleeding within 30 days, any stroke or structural CNS abnormality, uncontrolled hypertension, PT >1.2 times control, hematocrit <30%, platelet count <100,000/mm 3 , and pregnancy. Patient age ranged from 24 to 93 (mean 62) years, and 73% of patients were male. The study enrolled 90% Caucasian, 5% African American, 2% Hispanic, and 1% Asian patients. Patients received a wide variety of stents. Patients were randomized either to placebo or eptifibatide injection administered as an intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2 mcg/kg/min, and a second bolus of 180 mcg/kg administered 10 minutes later (180/2/180). Eptifibatide infusion was continued for 18 to 24 hours after PCI or until hospital discharge, whichever came first. Each patient received at least 1 dose of aspirin (162-325 mg) and 60 units/kg of heparin as a bolus (not to exceed 6000 units) if not already receiving a heparin infusion. Additional boluses of heparin (10-40 units/kg) could be administered in order to reach a target ACT between 200 and 300 seconds. The primary endpoint of the ESPRIT study was the composite of death, MI, urgent target vessel revascularization (UTVR), and \u201cbailout\u201d to open-label eptifibatide injection due to a thrombotic complication of PCI (TBO) (e.g., visible thrombus, \u201cno reflow,\u201d or abrupt closure) at 48 hours. MI, UTVR, and TBO were evaluated by a blinded Clinical Events Committee. As shown in Table 8 , the incidence of the primary endpoint and selected secondary endpoints was significantly reduced in patients who received eptifibatide injection. A treatment benefit in patients who received eptifibatide injection was seen by 48 hours and at the end of the 30-day observation period. Table 8. Clinical Events in the ESPRIT Study * Eptifibatide injection was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min. Placebo (n=1024) Eptifibatide Injection* (n=1040) Relative Risk (95% CI) p-value Death, MI, UTVR, or Thrombotic \u201cBailout\u201d 48 hours (primary endpoint) 108 (10.5%) 69 (6.6%) 0.629 (0.471, 0.84) 0.0015 30 days 120 (11.7%) 78 (7.5%) 0.64 (0.488, 0.84) 0.0011 Death, MI, or UTVR 48 hours 95 (9.3%) 62 (6%) 0.643 (0.472, 0.875) 0.0045 30 days (key secondary endpoint) 107 (10.4%) 71 (6.8%) 0.653 (0.49, 0.871) 0.0034 Death or MI 48 hours 94 (9.2%) 57 (5.5%) 0.597 (0.435, 0.82) 0.0013 30 days 104 (10.2%) 66 (6.3%) 0.625 (0.465, 0.84) 0.0016 The need for thrombotic \u201cbailout\u201d was significantly reduced with eptifibatide injection at 48 hours (2.1% for placebo, 1% for eptifibatide injection; p=0.029). Consistent with previous studies of GP IIb/IIIa inhibitors, most of the benefit achieved acutely with eptifibatide injection was in the reduction of MI. Eptifibatide injection reduced the occurrence of MI at 48 hours from 9% for placebo to 5.4% (p=0.0015) and maintained that effect with significance at 30 days. There was no treatment difference with respect to sex in ESPRIT. Eptifibatide injection reduced the incidence of the primary endpoint in both men (95% confidence limits for relative risk: 0.54, 1.07) and women (0.24, 0.72) at 48 hours. Follow-up (12-month) mortality data were available for 2024 patients (1017 on eptifibatide injection) enrolled in the ESPRIT trial (98.1% of the initial enrollment). Twelve-month clinical event data were available for 1964 patients (988 on eptifibatide injection), representing 95.2% of the initial enrollment. As shown in Table 9 , the treatment effect of eptifibatide injection seen at 48 hours and 30 days appeared preserved at 6 months and 1 year. Most of the benefit was in reduction of MI. Table 9. Clinical Events at 6 Months and 1 Year in the ESPRIT Study Percentages are Kaplan-Meier event rates. Placebo (n=1024) Eptifibatide Injection (n=1040) Hazard Ratio (95% CI) Death, MI, or Target Vessel Revascularization 6 months 187 (18.5%) 146 (14.3%) 0.744 (0.599, 0.924) 1 year 222 (22.1%) 178 (17.5%) 0.762 (0.626, 0.929) Death, MI 6 months 117 (11.5%) 77 (7.4%) 0.631 (0.473, 0.841) 1 year 126 (12.4%) 83 (8%) 0.63 (0.478, 0.832)"
    ],
    "clinical_studies_table": [
      "<table ID=\"_Ref468721221\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 5. Clinical Events in the PURSUIT Study</caption><col width=\"37%\"/><col width=\"20%\"/><col width=\"22%\"/><col width=\"20%\"/><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Death or MI</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(n=4739)</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Eptifibatide Injection</content></paragraph><paragraph><content styleCode=\"bold\">(180 mcg/kg bolus then 2 mcg/kg/min infusion)</content></paragraph><paragraph><content styleCode=\"bold\">(n=4722)</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>3 days</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>359 (7.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>279 (5.9%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.001</paragraph></td></tr><tr><td valign=\"top\"><paragraph>7 days</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>552 (11.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>477 (10.1%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.016</paragraph></td></tr><tr><td valign=\"top\"><paragraph>30 days</paragraph></td><td valign=\"top\"/><td valign=\"top\"/><td valign=\"top\"/></tr><tr><td valign=\"top\"><paragraph> Death or MI (primary endpoint)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>745 (15.7%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>672 (14.2%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.042</paragraph></td></tr><tr><td valign=\"top\"><paragraph> Death</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>177 (3.7%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>165 (3.5%)</paragraph></td><td valign=\"top\"/></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph> Nonfatal MI</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>568 (12%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>507 (10.7%)</paragraph></td><td styleCode=\"Botrule \" valign=\"top\"/></tr></tbody></table>",
      "<table ID=\"_Ref468721193\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 6. Clinical Events (Death or MI) in the PURSUIT Study Within 72 Hours of Randomization</caption><col width=\"42%\"/><col width=\"29%\"/><col width=\"29%\"/><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Eptifibatide Injection</content></paragraph><paragraph><content styleCode=\"bold\">(180 mcg/kg bolus then 2 mcg/kg/min infusion)</content></paragraph></td></tr><tr><td valign=\"top\"><paragraph>Overall patient population</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>n=4739</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>n=4722</paragraph></td></tr><tr><td valign=\"top\"><paragraph> &#x2013; At 72 hours</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>7.6%</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5.9%</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Patients undergoing early PCI</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>n=631</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>n=619</paragraph></td></tr><tr><td valign=\"top\"><paragraph> &#x2013; Pre-procedure (nonfatal MI only)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>5.5%</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>1.8%</paragraph></td></tr><tr><td valign=\"top\"><paragraph> &#x2013; At 72 hours</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>14.4%</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>9%</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Patients not undergoing early PCI</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>n=4108</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>n=4103</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph> &#x2013; At 72 hours</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>6.5%</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>5.4%</paragraph></td></tr></tbody></table>",
      "<table ID=\"_Ref468721254\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 7. Clinical Events in the IMPACT II Study</caption><col width=\"36%\"/><col width=\"20%\"/><col width=\"22%\"/><col width=\"22%\"/><thead><tr><th align=\"left\" styleCode=\"Botrule Toprule \" valign=\"bottom\"/><th align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">n (%)</content></th><th align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><content styleCode=\"bold\">Eptifibatide Injection</content> <content styleCode=\"bold\">(135 mcg/kg bolus then 0.5 mcg/kg/min infusion)</content> <content styleCode=\"bold\">n (%)</content></th><th align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><content styleCode=\"bold\">Eptifibatide Injection</content> <content styleCode=\"bold\">(135 mcg/kg bolus then 0.75 mcg/kg/min infusion)</content> <content styleCode=\"bold\">n (%)</content></th></tr></thead><tfoot><tr><td align=\"left\" colspan=\"4\" valign=\"top\">* Kaplan-Meier estimate of event rate.</td></tr></tfoot><tbody><tr><td styleCode=\"Toprule \" valign=\"top\"><paragraph>Patients</paragraph></td><td align=\"center\" styleCode=\"Toprule \" valign=\"top\"><paragraph>1285</paragraph></td><td align=\"center\" styleCode=\"Toprule \" valign=\"top\"><paragraph>1300</paragraph></td><td align=\"center\" styleCode=\"Toprule \" valign=\"top\"><paragraph>1286</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Abrupt Closure</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>65 (5.1%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>36 (2.8%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>43 (3.3%)</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph> p-value versus placebo</paragraph></td><td styleCode=\"Botrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.003</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.03</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Death, MI, or Urgent Intervention</paragraph></td><td valign=\"top\"/><td valign=\"top\"/><td valign=\"top\"/></tr><tr><td valign=\"top\"><paragraph> 24 hours</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>123 (9.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>86 (6.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>89 (6.9%)</paragraph></td></tr><tr><td valign=\"top\"><paragraph> p-value versus placebo</paragraph></td><td valign=\"top\"/><td align=\"center\" valign=\"top\"><paragraph>0.006</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.014</paragraph></td></tr><tr><td valign=\"top\"><paragraph> 48 hours</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>131 (10.2%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>99 (7.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>102 (7.9%)</paragraph></td></tr><tr><td valign=\"top\"><paragraph> p-value versus placebo</paragraph></td><td valign=\"top\"/><td align=\"center\" valign=\"top\"><paragraph>0.021</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.045</paragraph></td></tr><tr><td valign=\"top\"><paragraph> 30 days (primary endpoint)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>149 (11.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>118 (9.1%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>128 (10%)</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph> p-value versus placebo</paragraph></td><td styleCode=\"Botrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.035</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.179</paragraph></td></tr><tr><td valign=\"top\"><paragraph>Death or MI</paragraph></td><td valign=\"top\"/><td valign=\"top\"/><td valign=\"top\"/></tr><tr><td valign=\"top\"><paragraph> 30 days</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>110 (8.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>89 (6.8%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>95 (7.4%)</paragraph></td></tr><tr><td valign=\"top\"><paragraph> p-value versus placebo</paragraph></td><td valign=\"top\"/><td align=\"center\" valign=\"top\"><paragraph>0.102</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.272</paragraph></td></tr><tr><td valign=\"top\"><paragraph> 6 months</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>151 (11.9%)*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>136 (10.6%)*</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>130 (10.3%)*</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph> p-value versus placebo</paragraph></td><td styleCode=\"Botrule \" valign=\"top\"/><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.297</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.182</paragraph></td></tr></tbody></table>",
      "<table ID=\"_Ref468721274\" cellpadding=\"3.6pt\" width=\"97.88%\"><caption>Table 8. Clinical Events in the ESPRIT Study</caption><col width=\"26%\"/><col width=\"15%\"/><col width=\"22%\"/><col width=\"19%\"/><col width=\"18%\"/><tfoot><tr><td align=\"left\" colspan=\"5\" valign=\"top\">* Eptifibatide injection was administered as 180 mcg/kg boluses at times 0 and 10 minutes and an infusion at 2 mcg/kg/min.</td></tr></tfoot><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(n=1024)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Eptifibatide Injection*</content></paragraph><paragraph><content styleCode=\"bold\">(n=1040)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Relative Risk</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">p-value</content></paragraph></td></tr><tr><td colspan=\"5\" valign=\"top\"><paragraph>Death, MI, UTVR, or Thrombotic &#x201C;Bailout&#x201D;</paragraph></td></tr><tr><td valign=\"top\"><paragraph>48 hours (primary endpoint)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>108 (10.5%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>69 (6.6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.629 (0.471, 0.84)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.0015</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph>30 days</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>120 (11.7%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>78 (7.5%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.64 (0.488, 0.84)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.0011</paragraph></td></tr><tr><td colspan=\"5\" valign=\"top\"><paragraph>Death, MI, or UTVR</paragraph></td></tr><tr><td valign=\"top\"><paragraph>48 hours</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>95 (9.3%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>62 (6%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.643 (0.472, 0.875)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.0045</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph>30 days (key secondary endpoint)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>107 (10.4%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>71 (6.8%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.653 (0.49, 0.871)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.0034</paragraph></td></tr><tr><td colspan=\"5\" valign=\"top\"><paragraph>Death or MI</paragraph></td></tr><tr><td valign=\"top\"><paragraph>48 hours</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>94 (9.2%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>57 (5.5%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.597 (0.435, 0.82)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.0013</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph>30 days</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>104 (10.2%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>66 (6.3%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.625 (0.465, 0.84)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.0016</paragraph></td></tr></tbody></table>",
      "<table ID=\"_Ref468721295\" cellpadding=\"3.6pt\" width=\"100%\"><caption>Table 9. Clinical Events at 6 Months and 1 Year in the ESPRIT Study</caption><col width=\"26%\"/><col width=\"25%\"/><col width=\"25%\"/><col width=\"25%\"/><tfoot><tr><td align=\"left\" colspan=\"4\" valign=\"top\">Percentages are Kaplan-Meier event rates.</td></tr></tfoot><tbody><tr><td styleCode=\"Botrule Toprule \" valign=\"bottom\"/><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(n=1024)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Eptifibatide Injection</content></paragraph><paragraph><content styleCode=\"bold\">(n=1040)</content></paragraph></td><td align=\"center\" styleCode=\"Botrule Toprule \" valign=\"bottom\"><paragraph><content styleCode=\"bold\">Hazard Ratio</content></paragraph><paragraph><content styleCode=\"bold\">(95% CI)</content></paragraph></td></tr><tr><td colspan=\"4\" valign=\"top\"><paragraph>Death, MI, or Target Vessel Revascularization</paragraph></td></tr><tr><td valign=\"top\"><paragraph> 6 months</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>187 (18.5%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>146 (14.3%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.744 (0.599, 0.924)</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph> 1 year</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>222 (22.1%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>178 (17.5%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.762 (0.626, 0.929)</paragraph></td></tr><tr><td colspan=\"4\" valign=\"top\"><paragraph>Death, MI</paragraph></td></tr><tr><td valign=\"top\"><paragraph> 6 months</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>117 (11.5%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>77 (7.4%)</paragraph></td><td align=\"center\" valign=\"top\"><paragraph>0.631 (0.473, 0.841)</paragraph></td></tr><tr><td styleCode=\"Botrule \" valign=\"top\"><paragraph> 1 year</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>126 (12.4%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>83 (8%)</paragraph></td><td align=\"center\" styleCode=\"Botrule \" valign=\"top\"><paragraph>0.63 (0.478, 0.832)</paragraph></td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Eptifibatide injection is supplied as a sterile solution in 10 mL vials containing 20 mg of eptifibatide (NDC 70436-026-80) and 100 mL vials containing 75 mg of eptifibatide (NDC 70436-027-80). 16.2 Storage Vials should be stored refrigerated at 2\u00b0 to 8\u00b0C (36\u00b0 to 46\u00b0F). Vials may be transferred to room temperature storage* for a period not to exceed 2 months. Upon transfer, vial cartons must be marked by the dispensing pharmacist with a \u201cDISCARD BY\u201d date (2 months from the transfer date or the labeled expiration date, whichever comes first). Protect from light until administration. *Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to inform the doctor or healthcare provider about any medical conditions, medications, and allergies. Rx only Manufactured by: Hainan Poly Pharm. Co., Ltd. Guilinyang Economic Development Area, Haikou, Hainan Province, China 571127 Distributed by: Slate Run Pharmaceuticals, LLC Columbus, Ohio 43215 10000060/04 Revised: 04/2021"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL - 20 mg CARTON LABEL NDC 70436-026-80 Eptifibatide Injection, 20 mg/10 mL (2 mg/mL) 20mg carton",
      "PRINCIPAL DISPLAY PANEL - 75 mg CARTON LABEL NDC 70436-027-80 Eptifibatide Injection, 75 mg/100 mL (0.75 mg/mL) 70436-027-80"
    ],
    "set_id": "da421d88-6c00-428a-82a6-b3b4f7a68b85",
    "id": "4a613f2d-85b3-d45c-e063-6294a90adb93",
    "effective_time": "20260209",
    "version": "6",
    "openfda": {
      "application_number": [
        "ANDA209864"
      ],
      "brand_name": [
        "Eptifibatide"
      ],
      "generic_name": [
        "EPTIFIBATIDE"
      ],
      "manufacturer_name": [
        "Slate Run Pharmaceuticals, LLC"
      ],
      "product_ndc": [
        "70436-026",
        "70436-027"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "INTRAVENOUS"
      ],
      "substance_name": [
        "EPTIFIBATIDE"
      ],
      "rxcui": [
        "200349",
        "1736470"
      ],
      "spl_id": [
        "4a613f2d-85b3-d45c-e063-6294a90adb93"
      ],
      "spl_set_id": [
        "da421d88-6c00-428a-82a6-b3b4f7a68b85"
      ],
      "package_ndc": [
        "70436-026-80",
        "70436-027-80"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0370436027804"
      ],
      "nui": [
        "N0000008832",
        "N0000175578"
      ],
      "pharm_class_pe": [
        "Decreased Platelet Aggregation [PE]"
      ],
      "pharm_class_epc": [
        "Platelet Aggregation Inhibitor [EPC]"
      ],
      "unii": [
        "NA8320J834"
      ]
    }
  }
]